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ABSTRACT 
Ellen Foot Perkowski: Development of a Novel Method for Genome-wide Identification of 
Proteins Exported during Infection and Functional Studies of One in vivo Exported Protein in 
Mycobacterium tuberculosis 
(Under the direction of Miriam Braunstein) 
Intracellular pathogens manipulate and outwit the host’s immune defenses and reprogram 
the hostile intracellular environment into a hospitable replicative niche. The intracellular 
pathogen Mycobacterium tuberculosis is responsible for the disease tuberculosis, which kills 
approximately 1.5 million people per year. M. tuberculosis produces many proteins that are 
exported: transported out of the bacterial cytoplasm to the bacterial cell surface and out into the 
host environment. Exported proteins are located at the host-pathogen interface, in an ideal 
location to manipulate the host response and allow for intracellular growth, and exported proteins 
contribute significantly to virulence. Unfortunately, approaches used to identify proteins 
exported by the bacteria are limited to bacteria growing in laboratory media (in vitro). Because in 
vitro conditions cannot mimic the complexity of the host environment, there are likely critical 
exported virulence factors that have been missed because they are only exported in the context of 
infection. The main objective of the research described in this dissertation was to develop a 
method to identify proteins that are exported by bacterial pathogens during infection of a host (in 
vivo). We developed a novel method that we refer to as EXIT, EXported In vivo Technology, 
and applied it to identify M. tuberculosis proteins exported during murine infection. EXIT 
identified 593 in vivo exported proteins, 100 that were experimentally shown to be exported for 
the first time, and 32 proteins with no in silico predicted export signals. EXIT identified 38 
iv 
proteins exported significantly more in vivo than in vitro, suggesting that temporal or spatial 
control of their export is important to infection. 21 of these 38 proteins have unknown function, 
making them particularly interesting for future functional characterization. We focused on one of 
the EXIT identified in vivo exported proteins, OmasA, a protein of unknown function for further 
study. We demonstrated that OmasA was required for M. tuberculosis virulence in a mouse 
model of tuberculosis. We further demonstrated a function for OmasA in stabilizing multi-
protein Mce transporters required for lipid import. Future studies will focus on assigning 
function to new EXIT identified exported proteins, in particular proteins whose export is 
significantly induced during infection.  
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May our next journey be as wonderful as the last. 
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CHAPTER 1: INTRODUCTION 
In 1882 Robert Koch described the bacterium Mycobacterium tuberculosis as the 
causative agent of the disease then known as “consumption” and now better known as 
tuberculosis (Sakula, 1983). M. tuberculosis fulfilled “Koch’s postulates”, cultures of M. 
tuberculosis could be isolated from patients, purified, and used to infect laboratory animals 
(Koch, 1932). These animals would then develop characteristic tuberculosis disease, and M. 
tuberculosis bacilli could be isolated from their lung lesions (Koch, 1932). Prior to Koch’s 
discovery, Jean-Antoine Villimen had demonstrated that a rabbit could develop tuberculosis after 
inoculation of material from a human granuloma; however, many still attributed the disease to 
poor environmental conditions or genetics (Daniel, 2006). Koch’s discovery led to a more broad 
understanding of the infectious nature of tuberculosis (Daniel, 2006). One of the key symptoms 
of tuberculosis, prolonged coughing, is now know to be instrumental in allowing the bacteria to 
escape the lungs of an infected individual and be transmitted through the air to surrounding 
people. This transmission is so effective that one-third of the world’s population (two billion 
people), are thought to be infected with M. tuberculosis (World Health Organization, 2014).  
The development of the antibiotic streptomycin in the 1940s led to the first treatment for 
tuberculosis (Schatz et al., 1944). Even early on, it was clear that tuberculosis was harder to treat 
than many other bacterial pathogens. Treatment regimens had to be very long or else patients 
would quickly relapse, often with drug resistant strains (Sakula, 1983). Despite 70 years since 
the first anti-mycobacterial drug was introduced, we are still struggling with effective treatments 
for tuberculosis. The World Health Organization estimates that, of the nine million individuals 
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presenting active tuberculosis each year, approximately 480,000 patients are infected with multi-
drug resistant strains (World Health Organization, 2014). In the absence of effective antibiotic 
treatment tuberculosis is usually fatal (Tiemersma et al., 2011). Today, despite the advances of 
modern medicine, 1.5 million people continue to die from tuberculosis every year (World Health 
Organization, 2014).  
Upon inhaling M. tuberculosis, the bacteria are transferred down into the lungs and into 
the alveolar spaces, where they can be engulfed by resident alveolar macrophages (Russell et al., 
2010). These macrophages are normally the immune system’s first line of defense against 
inhaled material, and will usually engulf and destroy invading bacteria. M. tuberculosis, 
however, has developed many strategies to avoid destruction, and is able to grow inside 
macrophages, in a compartment called the phagosome (Russell et al., 2010). M. tuberculosis 
reconstructs the phagosome into a hospitable environment, blocking phagosomal maturation and 
preventing fusion with lysosomes, which would normally lead to destruction of the phagosomal 
contents (Rohde et al., 2007; Armstrong & Hart, 1971). M. tuberculosis will undergo many 
rounds of replication inside macrophages. Although these macrophages fail to eliminate the M. 
tuberculosis bacilli, they will produce chemoattractant molecules resulting in an influx of 
inflammatory cells including macrophages, dendritic cells, and neutrophils (Russell et al., 2010; 
Orme & Basaraba, 2014). Macrophages present antigens to dendritic cells at the site of infection, 
and these dendritic cells migrate to lymph nodes where they prime T-cells. Antigen specific T 
cells are then recruited to the site of lung infection where they recognize and activate M. 
tuberculosis infected macrophages, which serves to limit further intracellular bacterial 
replication, and they organize the inflammatory cells (Russell et al., 2010; Orme & Basaraba, 
2014). Eventually, formation of a fibrous and calcified barrier will wall off the inflammatory 
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focus (Russell et al., 2010; Orme & Basaraba, 2014). This process ultimately leads to formation 
of a highly specialized structure called a granuloma (Figure 1.1).  
Once granulomas have formed, most infected individuals will have no symptoms, a 
condition known as latent tuberculosis. Although the immune system contains M. tuberculosis 
within granulomas, the bacteria are not fully eradicated and for approximately 10% of infected 
individuals this containment will ultimately fail during their lifetime (Flynn & Chan, 2001). 
Individuals who fail to contain the M. tuberculosis bacilli will develop active tuberculosis. 
Although certain risk factors are known, such as immune dysfunction, the cause of this 
reactivation and the factors determining when it will occur are still mysterious (Flynn & Chan, 
2001). The underlying ability for M. tuberculosis to cause disease, survive in the macrophage 
environment and avoid complete destruction by the immune system remains poorly understood.  
M. tuberculosis is challenging to treat with antibiotics for several reasons. Drugs must 
penetrate granulomas and host cells to reach intracellular M. tuberculosis bacilli. M. tuberculosis 
bacilli can persist in a non-replicating state, which is resistant to most antibiotics. Additionally, 
the M. tuberculosis cellular structure is unique, and poses further complications to drug 
treatment. M. tuberculosis has both a cytoplasmic membrane and a specialized outer membrane 
referred to as the myco-membrane (Figure 1.2). The outermost layer of M. tuberculosis is a thick 
capsule surrounding the myco-membrane. The myco-membrane is composed of specialized long 
chain lipids including mycolic acids. The myco-membrane is covalently linked to 
arabinogalactan, which is attached to peptidoglycan within the periplasm (Figure 1.2). As well as 
presenting a challenge to drug entry, the complex cell wall of M. tuberculosis would seem to 
present a challenge to protein exit as occurs during protein secretion.  
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Figure 1.1. Structure of a classic Human Granuloma. Adapted from (Barry et al., 2009). Granulomas 
consist of a large number of macrophages surrounded by lymphocytes (B cells, CD4
+ 
T cells, CD8
+ 
T 
cells). Macrophages within granulomas can appear epithelioid or foamy. Mature granulomas in humans 
become necrotic and hypoxic at the core, which is referred to as the caseum.  
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Figure 1.2. Cellular structure of M. tuberculosis. M. tuberculosis is an acid-fast organism with an 
cytoplasmic membrane consisting of a phospholipid bilayer (represented in blue) surrounded by a layer of 
peptidoglycan (yellow). Unique features of the M. tuberculosis cell wall include arabinogalactan (orange) 
which covalently crosslinks the outer myco-membrane to the peptidoglycan. The myco-membrane 
primarily consists of specialized lipids composed of mycolic acids (Marchand et al., 2012). The 
mycobacterial capsule is poorly characterized, however, it recently has been visualized by cryo-electron 
microscopy (Sani et al., 2010). 
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Bacterial exported proteins are critical to the virulence of intracellular pathogens 
 We are beginning to understand the important role that exported proteins play in 
virulence for many bacterial pathogens. This dissertation will refer to exported proteins as any 
protein produced in the bacterial cytoplasm and actively transported to the bacterial cytoplasmic 
membrane, cell wall, or out into the host environment (Figure 1.3). Exported proteins lie at the 
host-pathogen interface, and thus are in an ideal location to interact with the host and contribute 
to virulence. Many of the best studied virulence factors are exported proteins. For example, 
virulence of the bacterial pathogen Legionella pneumophila requires a type IV secretion system 
(ICM/Dot), which delivers nearly 300 proteins out of the bacterium and directly into the 
cytoplasm of host cells (Isaac & Isberg, 2014). Effectors of the ICM/Dot system mediate 
construction of the Legionella-containing vacuole, intracellular replication, and evasion of 
lysosome fusion (Isaac & Isberg, 2014). Salmonella enterica, another well studied bacterial 
pathogen, relies on exported proteins to attach to host cells, invade, program the fate of its 
intracellular vacuole, and ultimately replicate to cause infection (Agbor & McCormick, 2011). 
Given the importance of exported proteins to intracellular pathogens, it is not surprising that M. 
tuberculosis also relies on numerous exported proteins to survive and grow in macrophages and 
cause disease in a host. The goal of this dissertation was to identify proteins that are exported in 
the host, and begin the process of assigning function to in vivo exported proteins of M. 
tuberculosis.  
Mechanisms of protein export in M. tuberculosis 
Currently there are four types of systems known to export proteins out of the cytoplasm 
of M. tuberculosis: the general Sec pathway, the SecA2-dependent pathway, the Tat (Twin-
Arginine Translocation) pathway, and the ESX (Type VII) pathways (Ligon et al., 2012). The   
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Figure 1.3. Exported Proteins of M. tuberculosis. M. tuberculosis bacilli (represented in green) 
grow within the phagosome (yellow) of macrophages (blue). Exported proteins are located at the 
bacterial-host interface and are in an ideal position to be virulence factors. Exported proteins 
include those which are fully secreted into the host environment (stars) as well as membrane or 
cell wall associated proteins.  
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transport mechanism as currently understood for each of these export pathways, and a review of 
the general importance of each export pathway to M. tuberculosis is described below. Because 
each of these systems exports multiple proteins, when mutants defective in any one of these 
pathways are studied the cumulative effect of many exported proteins not being properly 
localized is observed. Much of what we currently know about the role of M. tuberculosis 
exported proteins in virulence comes not from studying and identifying the role of individual 
proteins, rather from studying genetic deletions disrupting entire export systems.  
The General Secretion System: SecA1 dependent protein export 
The general secretion system (Sec) is the housekeeping system that carries out the bulk of 
export/secretion, as recently reviewed (Ligon et al., 2012). The Sec pathway is essential and is 
required for the majority of protein export that occurs in all bacteria. Sec exported proteins are 
synthesized as precursors containing N-terminal signal peptides, which direct them to be post-
translationally exported by the Sec pathway (Ligon et al., 2012). SecA1 is an ATPase which 
recognizes signal peptides of proteins for export, delivers them to the SecYEG membrane 
channel, and undergoes successive rounds of ATP hydrolysis to transport the protein across the 
cytoplasmic membrane (Ligon et al., 2012). After export, a signal peptidase cleaves the signal 
peptide and releases the mature domain of the protein into the periplasm. Sec exported proteins 
can remain in the cell wall or get fully secreted out of the bacterial cell by a poorly defined 
second mechanism. As in other bacteria, the Sec system is predicted to export the majority of 
proteins in M. tuberculosis, including proteins required for basic cellular physiology, cell 
maintenance, and virulence (Ligon et al., 2012). Lipoproteins are a subset of Sec exported 
proteins that have a lipid moiety attached to their N-terminus responsible for localizing 
lipoproteins within the cytoplasmic membrane or cell wall. Lipoproteins contain a distinct signal 
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peptide and are cleaved by a specialized lipoprotein signal peptidase (Ligon et al., 2012). The 
lipoprotein signal peptidase is required for virulence, highlighting the importance of exported 
lipoproteins to M. tuberculosis (Sander et al., 2004). SecA1, SecYE, and the general signal 
peptidase of mycobacteria are all essential for bacterial cell viability (Ligon et al., 2012).  
Co-translational Export of Transmembrane Proteins 
The SecYEG channel is additionally important to the export of integral membrane 
proteins, through a recently reviewed mechanism (Facey & Kuhn, 2010; Ligon et al., 2012). As 
polypeptide chains emerge from the ribosome they are scanned for hydrophobic domains that 
may constitute transmembrane domains by the signal recognition particle (SRP). Upon detection 
of a hydrophobic domain, SRP will bind and transport the growing polypeptide chain and 
ribosome complex to the SRP receptor FtsY. FtsY will pass the protein to the SecYEG complex, 
where the protein will undergo co-translational export. Transmembrane domains can pass 
sideways through a gate in the SecY channel with the help of YidC to stably integrate into the 
membrane. A subset of transmembrane proteins can be inserted by YidC alone (Facey & Kuhn, 
2010). Transmembrane proteins are required for basic cellular physiology, cell maintenance, and 
virulence; therefore, SRP, FtsY, and YidC are all essential to bacterial cell viability (Ligon et al., 
2012).  
Accessory Sec Export Pathway: SecA2 dependent protein export 
An unusual property of mycobacteria is that they have two non-redundant SecA 
homologues (SecA1 and SecA2) (Braunstein et al., 2001). The SecA2 protein of mycobacteria is 
thought to function much like SecA1, binding to SecA2 substrates, transporting them to the 
SecYEG complex, and transporting preproteins through SecY with rounds of ATP hydrolysis 
(Ligon et al., 2013; Feltcher & Braunstein, 2012). Some SecA2 substrates have Sec-like signal 
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peptides, and these signal peptides are required for export (Gibbons et al., 2007). Surprisingly, 
the signal peptide alone does not confer SecA2 specificity (Feltcher et al., 2013). Undefined 
elements within the mature domain determine export through the SecA2 pathway, and the 
leading hypothesis is that the SecA2 pathway in mycobacteria may exist to export proteins that 
tend to fold prior to export (Feltcher et al., 2013). Furthermore, not all SecA2 substrates have 
signal peptides, highlighting the importance of additional targeting domains within the mature 
domain of SecA2 exported proteins (Braunstein et al., 2001; Braunstein et al., 2003).  
SecA2 is not essential for M. tuberculosis growth in vitro, but mutants lacking a 
functional SecA2 dependent protein export pathway are significantly attenuated (Braunstein et 
al., 2003; Kurtz et al., 2006). Mice infected with a ΔsecA2 mutant of M. tuberculosis  have lower 
bacterial burden and survive longer than WT M. tuberculosis infected mice (Braunstein et al., 
2003). Additionally, the ΔsecA2 mutant is unable to grow in macrophages (Kurtz et al., 2006). 
These results indicate that one or more proteins exported through the SecA2 dependent protein 
export pathway are required for virulence. Recent evidence suggests that SecA2 exported 
proteins play roles in preventing phagosomal maturation (Sullivan et al., 2012) and promoting 
nutrient acquisition (Feltcher et al., 2015), although the contribution of individual SecA2 
exported proteins to attenuation of the ΔsecA2 mutant has yet to be determined.  
Export of Pre-folded Substrates: The Twin-Arginine Translocation Pathway 
Mycobacteria use the Twin-Arginine Translocation (Tat) pathway to export pre-folded 
proteins in a Sec-independent pathway, which has been recently reviewed (Ligon et al., 2012). 
Tat exported proteins contain distinct N-terminal signal peptides which direct them for export 
through the TatABC complex. The TatBC membrane protein complex binds Tat precursors and 
determines whether they are properly folded for export. TatA is recruited to the complex and 
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forms homo-oligomers of varying sizes to form a channel large enough to transport the pre-
folded substrate. Transport of pre-proteins through the TatABC complex is energized by the 
proton motive force. After export, the signal peptides of Tat exported proteins can be cleaved by 
signal peptidases (Ligon et al., 2012).  
The Tat export pathway has been studied in many bacterial pathogens and is frequently 
required for export of virulence factors and, thus, contributes to pathogenesis (Ligon et al., 
2012). The prediction of Tat exported proteins is clouded by the limited agreement between 
prediction algorithms; however, as many as 95 proteins may be exported by the Tat pathway in 
M. tuberculosis (McDonough et al., 2008). Characterized Tat substrates include proteins 
important to both drug resistance and virulence. The Tat pathway is not essential for the in vitro 
viability of most bacterial, thus it is surprising that the Tat pathway is essential to M. tuberculosis 
viability in vitro (Saint-Joanis et al., 2006).  
Type VII secretion: ESX Specialized Secretion Systems 
M. tuberculosis encodes five Type VII secretion systems, named ESX-1 to ESX-5, which 
are named for the first known exported substrate of these systems, ESAT-6. ESX secretion was 
recently reviewed in (Houben et al., 2014). ESX gene clusters contain genes encoding ESX 
conserved components (Ecc), ESX specific proteins (Esp), and mycosins (MycP) which form the 
export machinery. Some genes encoding ESX substrates are also located within these genomic 
regions, including genes encoding the classical ESAT-6 like proteins and Pro-Glu and Pro-Pro-
Glu repeat containing proteins (PE/PPE) (Houben et al., 2014). The export mechanism of Type 
VII systems is under active investigation. These systems appear to form multi-protein transport 
complexes with components in the cytoplasm and cytoplasmic membrane (Houben et al., 2014). 
Most mycobacterial ESX systems contain cytoplasmic proteins that bind to exported substrates 
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prior to export and are predicted to function as chaperones (Houben et al., 2014). The exported 
substrates are thought to be targeted, possibly with the assistance of chaperones, to the large ESX 
membrane complex consisting of conserved components EccBCDE, all of which are required for 
ESX secretion; however, the individual role of each protein within the complex remains unclear 
(Houben et al., 2014). EccD is a multi-membrane spanning protein predicted to form a channel 
for protein transport (Houben et al., 2014). EccC contains three nucleotide binding domains, and 
is predicted to energize transport of exported substrates through the complex by ATP hydrolysis 
(Houben et al., 2014). The subtilisin-like protease, MycP, cleaves at least one ESX substrate and 
may additionally regulate export in a protease-independent process. Because many ESX 
substrates are fully secreted into the culture filtrate, it has been hypothesized that the ESX 
secretion system spans both the cytoplasmic membrane and the outer myco-membrane, to direct 
proteins out of the bacterium in a single step from the cytoplasm to the extracellular environment 
(Houben et al., 2014). However, so far, no ESX secretion components have been identified 
within the myco-membrane.  
The full repertoire of exported substrates of each ESX system is still undefined. ESX 
exported proteins do not contain classical signal peptides; rather, a YxxxD/E conserved motif has 
been shown to be required for export (Daleke et al., 2012). Surprisingly, the classical substrate 
ESAT-6 does not contain this motif. ESX substrates are often exported as heterodimers, and 
often it is only one of the proteins in the complex that contains the YxxxD/E motif (Houben et 
al., 2014). ESX-1 is the best characterized ESX system in M. tuberculosis. ESX-1 has been 
shown to export a small number of proteins, including EsxA (ESAT-6), EsxB (CFP-10), and 
EspB (Houben et al., 2014). Mycobacterium marinum, a pathogenic mycobacterial species 
naturally infecting fish, has been used as a model system to study ESX secretion. Approximately 
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7% of the M. tuberculosis proteome are Pro-Glu or Pro-Glu Glu repeat containing proteins 
(PE/PPE proteins), most of which are thought to be surface localized (Goldberg et al., 2014; 
Banu et al., 2002; Brennan et al., 2001). In M. marinum, the ESX-5 system was shown to export 
a large number of PE/PPE proteins, including those encoded outside of the ESX-5 locus 
(Abdallah et al., 2009). However, only a subset of PE/PPE proteins in M. tuberculosis are 
exported through ESX-5, although proteins in M. tuberculosis containing PE domains do have 
the YxxxD/E motif (Bottai et al., 2012). Future studies are necessary to characterize exported 
substrates of the additional ESX systems.  
ESX-1 plays a clear role in M. tuberculosis virulence, as shown by attenuation of esx-1 
mutants during mouse and macrophage infection (Pym et al., 2002; Lewis et al., 2003). ESX-2 
and ESX-4 have not been previously studied. ESX-3 is essential for M. tuberculosis growth in 
vitro due to a role in iron acquisition (Siegrist et al., 2009). Additionally, ESX-5 has recently 
been shown to be important during M. tuberculosis infection, as shown by attenuation of esx-5 
mutants during mouse and macrophage infection (Bottai et al., 2012).  
Identification of M. tuberculosis exported proteins 
 Comprehensive study of the role of exported proteins in M. tuberculosis virulence first 
requires a fundamental understanding of which proteins are exported. Currently, in silico 
predictions are most frequently used to predict the exported nature of a protein; however, in 
silico predictions require experimental validation. The approaches currently used to assign a 
protein as being exported by M. tuberculosis are reviewed below, and Chapter 2 of this 
dissertation describes a novel method we developed to experimentally identify proteins that are 
exported by M. tuberculosis in the context of host infection. 
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Prediction of Exported Proteins by Bioinformatics (in silico)  
 The use of computational, or in silico, predictions to identify exported proteins is by far 
the easiest and most common approach. Exported proteins comprise approximately 20% of 
bacterial proteomes, and include proteins exported by a large diversity of systems. There are a 
wide variety of programs designed to predict the cellular location of proteins through identifying 
signal peptides and transmembrane domains, common features of exported proteins. One 
consistent difficulty with using these prediction programs is that the prediction algorithms have 
been trained on datasets from Gram positive and/or Gram negative bacteria; none have been 
trained on GC rich acid-fast mycobacteria. Despite the fact that no protein export prediction tools 
are optimized for mycobacteria, in silico analyses remain the most common method used to 
predict the subcellular location of a protein in M. tuberculosis. However, prediction algorithms 
are far from perfect, and in silico predictions must be followed up with experimentally 
validation.  
Prediction programs for Sec exported proteins inspect the N-terminus of a protein for a 
signal peptide.  Signatures of a Sec signal peptide include a positively charged N-terminus, a 
hydrophobic core, and a polar region C-terminal domain containing the cleavage site (Feltcher et 
al., 2013). Programs designed to predict Sec signal peptides include SignalP (Petersen et al., 
2011), Psort (Nakai & Horton, 1999), and PrediSi (Hiller et al., 2004). Recent data suggests that 
Signal P is the most accurate of the available algorithms when predicting signal peptides in 
mycobacteria (Leversen et al., 2009). Lipoproteins, a subset of Sec exported proteins, contain 
distinct lipoprotein signal peptides with a lipobox motif, often L-A-G/A-↓C where ↓ represents 
the signal peptide cleavage site (Juncker et al., 2003). The conserved cysteine residue 
immediately following the signal peptide cleavage site becomes lipid modified upon export. 
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Lipoproteins can be predicted using LipoP (Juncker et al., 2003), and a comprehensive in silico 
analysis of lipoproteins in mycobacteria has recently been published (Sutcliffe & Harrington, 
2004).  
Several programs are designed to specifically predict signal peptides for the Tat pathway 
including Tatfind (Rose et al., 2002), TatPred (Taylor et al., 2006), TatP (Bendtsen et al., 2005), 
and TigrFAM (Selengut et al., 2007). These Tat prediction algorithms are built on slight 
variations of the twin arginine motif, commonly expressed as R-R-X-- ( = hydrophobic) 
(Ligon et al., 2012), and some incorporate additional requirements for the signal peptide regions 
surrounding the Tat motif (Bendtsen et al., 2005; Rose et al., 2002). As previously described 
(McDonough et al., 2008), variations between Tat prediction algorithms results in disagreement 
as to which M. tuberculosis proteins are predicted to contain a Tat signal peptide.  
Programs specific to identification of membrane proteins include TMHMM (Krogh et al., 
2001; Sonnhammer et al., 1998) TMPRED (Hofmann & Stoffel, 1993), TopPred (Claros & von 
Heijne, 1994), and MEMSAT2 (Jones et al., 1994) which predict transmembrane domains 
through the identification of large regions of hydrophobic residues forming alpha-helices (Krogh 
et al., 2001; Sonnhammer et al., 1998; Hofmann & Stoffel, 1993; Jones et al., 1994; Claros & 
von Heijne, 1994), as well as charge analysis based on positively charged residues on the 
cytoplasmic face of the membrane (von Heijne, 1992; Krogh et al., 2001). Studies generally 
predict that 20-30% of proteins in most genomes contain transmembrane domains (Punta et al., 
2007). Transmembrane prediction algorithms which rely only on hydrophobicity analysis lead to 
a false identification of hydrophobic regions in globular proteins as transmembrane domains, and 
care should be taken when choosing a program to identify membrane proteins (Punta et al., 
2007). Of available programs, TMHMM was one identified as having a low incidence of false 
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positive prediction of globular proteins (Punta et al., 2007). Consistent with previously analyzed 
bacterial genomes, TMHMM predicts 802 proteins (20% of all proteins) in M. tuberculosis to be 
membrane proteins (Perkowski, unpublished data). All transmembrane prediction algorithms 
falsely identify N-terminal signal peptides as transmembrane domains due to their inherent 
hydrophobicity (Punta et al., 2007). Therefore, predicted transmembrane domains at the far N-
terminus of proteins should be further inspected for cleavage sites to discriminate between N-
terminal transmembrane domains and signal peptides.  
Transmembrane prediction programs will also predict the final topology of the integral 
membrane proteins and the protein domains that will be localized to the cytoplasm or periplasm. 
Unfortunately, these predictions frequently disagree, and currently no method is accurate at 
predicting topology from sequence information alone (Punta et al., 2007). Prediction algorithms 
are built based on high resolution protein structure information; however, very few membrane 
proteins have solved crystal structures (Punta et al., 2007). Additionally, transmembrane 
topology may be determined not only by sequence, but also by interactions with the export 
machinery (Punta et al., 2007). For these reasons, it is essential that in silico predicted topologies 
of transmembrane proteins be experimentally validated.  
 For the SecA2 and ESX protein export systems of mycobacteria there currently exist no 
bioinformatics prediction programs, primarily due to the fact that the precise requirements for 
export through these pathways are only beginning to be discovered. Of the known SecA2 
exported proteins many contain signal peptides that are identified with the existing signal peptide 
bioinformatics prediction programs mentioned above (Gibbons et al., 2007; Feltcher et al., 
2015). However, some proteins thought to be exported by the SecA2 pathway in M. tuberculosis 
and M. marinum, such as SodA and PknG, do not have canonical signal peptides (Braunstein et 
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al., 2003; van der Woude et al., 2014; Feltcher et al., 2015). Additionally, there are features of 
the mature domain of SecA2 exported proteins that are currently poorly defined and required for 
export, and the leading hypothesis is that the mature domain of SecA2 exported proteins tends to 
fold in the cytoplasm (Feltcher et al., 2013). Export through ESX Type VII secretion systems 
requires a YxxxD/E secretion motif within the exported protein or a partner co-secreted protein 
(Daleke et al., 2012). However, the YxxxD/E motif is not sufficient for export because undefined 
elements outside of this motif determine which ESX system a protein is exported through 
(Daleke et al., 2012). Overall, while bioinformatics programs play an important role in 
predicting exported proteins in M. tuberculosis, they have limitations and should not be the only 
method used to determine if a given protein is exported.  
Experimental Identification of Exported Proteins: Mass Spectrometry 
Mass spectrometry based methods can be used to identify the proteins localized to 
exported fractions of M. tuberculosis (cytoplasmic membrane, cell wall or fully secreted culture 
filtrate) as recently reviewed (de Souza & Wiker, 2011). For these studies, M. tuberculosis is 
grown in vitro and then fractionated by various methods to isolate subcellular compartments. The 
power of mass spectrometry based approaches lies in the sheer quantity of proteins that are 
identified and the potential to acquire information about protein abundance (Solis & Cordwell, 
2011; de Souza & Wiker, 2011). Quantitative mass spectrometry, in particular, is a powerful 
method for identifying substrates of specific export systems, by comparing the abundance of 
proteins in exported fractions between wild-type and export system mutants (Feltcher et al., 
2015; Champion et al., 2014; Altindis et al., 2015; Fritsch et al., 2013). However, there are 
limitations to mass spectrometry of subcellular fractions as a means of comprehensive 
identification of exported proteins (Solis & Cordwell, 2011; de Souza & Wiker, 2011; Yang et 
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al., 2015; Schmidt & Volker, 2011). While enrichment of exported proteins is successfully 
accomplished with subcellular fractionation methods, contamination with cytoplasmic material 
can never be fully avoided. This often leads to the identification of highly expressed cytoplasmic 
protein contaminants in exported fractions (Table 1.1) (de Souza & Wiker, 2011). Furthermore, 
as mass spectrometry has become increasingly sensitive, the potential for false positive 
identification of cytoplasmic contaminants as exported proteins has grown. In recent mass 
spectrometry proteomics studies, only 30% of proteins identified in exported fractions have a 
predicted export signal, highlighting the abundance of non-exported proteins being detected 
(Table 1.1). Further, in one of the most comprehensive proteomics studies of M. tuberculosis to 
date, of 1,050 M. tuberculosis proteins identified 98% of the proteins were detected in both 
cytoplasmic and exported fractions (Bell et al., 2012). Thus, caution should be exercised when a 
protein is identified as being exported solely on the basis of mass spectrometry based 
proteomics. 
An additional challenge facing exported protein identification by mass spectrometry is 
the use of this technology to identify proteins exported by a pathogen during in vivo growth in a 
host (Schmidt & Volker, 2011; Yang et al., 2015). Mass spectrometry based approaches are 
biased by abundance, and low abundance proteins in a sample are difficult to identify. This 
becomes particularly difficult when attempting to identify relatively rare bacterial proteins from 
among host cells proteins in an infection model (Schmidt & Volker, 2011; Yang et al., 2015; 
Kruh et al., 2010). Isolation and purification of bacterial cells out of the host tissue, as well as 
very high bacterial cell numbers is generally required (Xia et al., 2007; Twine et al., 2006; 
Becker et al., 2006; Schmidt et al., 2010; Liu et al., 2012; Pieper et al., 2009). Further, it is hard 
to determine if a bacterial protein identified in the context of infection was cytoplasmic or 
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exported. Analysis of crude extracts of infected organs does not allow for discrimination between 
exported and non-exported proteins (Schmidt & Volker, 2011; Yang et al., 2015). Isolation of 
bacterial cells from infected host cells could be useful for identifying proteins exported to the 
bacterial cytoplasmic membrane and cell wall, but current methods will not provide sufficient 
material for subcellular fractionation and further analysis (Schmidt & Volker, 2011; Yang et al., 
2015). An alternative approach is to search for bacterial proteins secreted away from the bacteria 
into the host cytosol. However, due to the sensitivity of mass spectrometry this demands an 
efficient method to eliminate intracellular bacteria from the host cytosol which represents 
another technical challenge. As a result, the exported proteomes of pathogens during infection 
remain to be defined.  
Metabolic labeling and biorthogonal chemistry promises to improve many fields, 
including the study of bacterial exported proteins (Ngo et al., 2009; Horisawa, 2014; Mahdavi et 
al., 2014; Siegrist et al., 2015). Incorporating labels amenable to click-chemistry can allow for 
downstream chemical reactions which can tag labeled compounds with fluorescent markers, or 
allow for isolation of tagged molecules out of complex mixtures (Mahdavi et al., 2014; Dieterich 
et al., 2007; Siegrist et al., 2015). Recently, bio-orthogonal noncanonical amino acid tagging, 
BONCAT (Dieterich et al., 2007), has been used in Escherichia coli, Salmonella enterica 
serovar Typhimurium and Yersinia pseudotuberculosis to incorporate azidonorleucine (ANL) 
into proteins (Tanrikulu et al., 2009; Grammel et al., 2010; Mahdavi et al., 2014). In one study, 
S. Typhimurium was used to infect mammalian cells in vitro, cells were pulsed with ANL to 
label all bacterial proteins, and then click chemistry was used to selectively tag bacterial ANL 
labeled proteins with biotin for isolation (Grammel et al., 2010). A second study used the same 
technology to isolate proteins secreted by the type three secretion system (T3SS) of extracellular 
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Y. pseudotuberculosis into in vitro cultured cells (Mahdavi et al., 2014). Exported proteins 
delivered into the host cell were identified through the comparison of wild type Y. 
pseudotuberculosis to a T3SS mutant unable to translocate effectors (Mahdavi et al., 2014). 
Unfortunately, a large number of background cytoplasmic bacterial proteins were also identified 
in the host cell, which prevented applying this technology to the identification of new exported 
proteins (Mahdavi et al., 2014). Overall, while this technology holds promise for facilitating 
studies of proteins exported in the context of infection, there remain significant technical hurdles. 
In addition, incorporation of unnatural amino acids by bacteria has yet to be performed during in 
vivo infection.  
Experimental Identification of Exported Proteins: Genetic Reporters 
An alternative strategy to biochemical identification of exported proteins is the use of 
genetic reporters of protein export. A protein export reporter is an enzyme whose activity or 
function depends on the reporter being exported/localized out of the cytoplasm. Protein export 
reporters are missing their native signal for export and, consequently, they require in-frame 
fusion with a protein capable of exporting the reporter to be active. Genetic reporters require a 
genetically tractable organism and they need to be compatible with the specific export system 
under investigation. Genetic reporter approaches for identifying exported proteins have the 
benefit over mass spectrometry of identifying fewer false positives and thus cytoplasmic proteins 
are less of a concern with export reporters. Over 90% of proteins identified with a genetic 
reporter contain a predicted export signal (Table 1.1, Figure 1.4), which reinforces their 
identification as being exported. This is compared to by mass spectrometry based methods which 
only identify approximately 30% of proteins with predicted export signals. Comparing studies of 
exported proteins in M. tuberculosis using mass spectrometry or genetic reporter based   
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Figure 1.4. Genetic Reporters Identify a High Proportion of Proteins with Export Signals. Data 
calculated in Table 1.1 was graphed to demonstrate that technologies utilizing a genetic reporter result in 
identification of primarily exported proteins, as defined by containing an export signal. Export signals 
including transmembrane domains and Sec and Tat signal peptides were predicted by SignalP, TatP, 
TMHMM, (Sutcliffe & Harrington, 2004), and (McDonough et al., 2008). 
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approaches reveals high abundance cytoplasmic proteins (as identified by PaxDB (Wang et al., 
2015; Wang et al., 2012)) as frequently identified as exported by mass spectrometry but not by 
genetic reporter approaches (Table 1.1, Figure 1.5).  
The classic genetic reporter of bacterial protein export is the enzyme alkaline phosphatase 
(PhoA) (Taylor et al., 1987; Kaufman & Taylor, 1994; Cleavinger et al., 1995; Lim et al., 1995; 
Manoil & Beckwith, 1985; Manoil et al., 1990). Bacterial colonies exporting PhoA can be 
detected as blue colonies when plate on agar containing a colorimetric PhoA substrate. 
Consequently, a truncated ‘PhoA reporter lacking its native signal for export can “report” on the 
presence of an export signal in a protein to which it is fused, by producing  blue colored colonies.  
In the first study to identify M. tuberculosis exported proteins using a ‘PhoA reporter, ‘PhoA was 
encoded on a plasmid, and random fragments of M. tuberculosis genomic DNA were fused 
upstream of the reporter (Lim et al., 1995). The resulting plasmids were screened in 
Mycobacterium smegmatis, a non-pathogenic model species of M. tuberculosis, and blue 
colonies were identified when the transformants were plated on the PhoA colorimetric substrate 
(Lim et al., 1995). This first study identified three M. tuberculosis proteins as exported (Lim et 
al., 1995). Further studies utilized the ‘PhoA reporter combined with in vitro transposition into 
M. tuberculosis cosmids. These transposon mutagenized cosmids were transformed into M. 
smegmatis to screen for active PhoA fusions, resulting in the identification of 31 M. tuberculosis 
exported proteins (Braunstein et al., 2000). Unfortunately, due to endogenous phosphatase 
activity, the ‘PhoA reporter is not compatible with use in M. tuberculosis, and thus all ‘PhoA 
screens have to be carried out in the non-pathogenic M. smegmatis (Lim et al., 1995). 
Generation of a β-lactam sensitive ΔblaC mutant of M. tuberculosis (Flores et al., 2005; 
McDonough et al., 2005) opened up the possibility of using β-lactamase reporters to identify   
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Figure 1.5. MS based methods Identify (ID) High Abundance Cytoplasmic Proteins as Exported. 
Percentage of high abundance cytoplasmic proteins identified in exported fractions as described in Table 
1.1. The Top 50 most abundant cytoplasmic proteins were identified by PaxDB (Wang et al., 2015; Wang 
et al., 2012). Proteins identified as abundant in PaxDB but containing predicted export signals, or known 
to be exported (i.e. EsxA and EsxB) were excluded, to generate a list of the top 50 most abundant 
cytoplasmic proteins in M. tuberculosis. 
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exported proteins directly in pathogenic M. tuberculosis. The E. coli β-lactamase, BlaTEM, 
cleaves β-lactam antibiotics and is able to produce β-lactam resistance. Like ‘PhoA, removal of 
the native signal peptide of ‘BlaTEM prevents export but when fused to a signal peptide, or the 
extracytoplasmic portion of an exported protein, the exported ‘Bla reporter confers β-lactam 
resistance (Figure 1.6). This was first worked out in Escherichia coli (Broome-Smith & Spratt, 
1986), and holds true when the ‘BlaTEM reporter is used in the ΔblaC mutant of M. tuberculosis 
(McCann et al., 2007).  The ‘BlaTEM reporter is compatible with both Sec and Tat export 
systems of M. tuberculosis (McCann et al., 2007). An additional β-lactamase reporter (‘BlaC) 
has been developed for M. tuberculosis that is specific for export by the Tat pathway 
(McDonough et al., 2005; McDonough et al., 2008). For the ‘BlaC reporter, only fusion to Tat 
exported proteins (and not signals for other export systems) works to confer resistance to β-
lactams (McDonough et al., 2008). Generation of a library of plasmids containing the ‘blaC 
reporter fused downstream of random fragments of M. tuberculosis genomic DNA led to the 
identification of 13 proteins exported by the Tat pathway in M. tuberculosis (McDonough et al., 
2008). The ‘blaC reporter has additionally been used to directly test individual proteins for Tat 
dependent export (Ligon et al., 2012). 
In other bacterial pathogens, transposons carrying the ‘PhoA reporter proved a powerful 
means to identify exported proteins with roles in virulence (Taylor et al., 1987; Kaufman & 
Taylor, 1994; Manoil & Beckwith, 1985; Manoil et al., 1990). With the development of -
lactamase reporters that work in mycobacteria, this approach could be directly applied to the 
identification of exported virulence factors of M. tuberculosis Using a Himar1-based mariner 
transposon carrying the ‘BlaTEM reporter in M. tuberculosis and plating on β-lactam containing 
agar, transposon insertions in genes encoding 111 unique M. tuberculosis exported proteins were   
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Figure 1.6. ‘BlaTEM Reporter Activity is Dependent on Export. The β-lactamase BlaTEM from E. 
coli (blue) contains a native signal peptide that directs it to be exported out of the cytoplasm, where it 
breaks down β-lactam antibiotics (yellow) and confers β-lactam resistance (left). The ‘BlaTEM reporter is 
composed of a truncated protein where the native signal peptide has been removed, and thus the reporter 
is not exported. This results in β-lactam sensitivity, when β-lactam antibiotics break down the cell wall 
(right). Fusion of the reporter to a signal peptide or the extra-cytoplasmic portion of an exported protein 
will rescue export and confer resistance to β-lactam antibiotics (left).  
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identified (McCann et al., 2011). The same in-frame transposon insertion that identifies an 
exported protein will, in most cases, also disrupt the function of that exported protein.  By 
subsequent screening of 111 transposon insertion mutants in genes encoding exported proteins 
for virulence defects in a macrophage intracellular growth assay a total of six exported proteins 
with roles in virulence were identified (McCann et al., 2011). One of these proteins, Rv0199, had 
no previously predicted function. Chapter 3 will focus on further characterization of the rv0199 
transposon mutant culminating in assigning function to Rv0199, and shedding light on the 
function of a previously uncharacterized exported protein family.  
There are advantages to using a β-lactamase based genetic reporter over other genetic 
reporters. First, β-lactamases are selectable markers, dramatically reducing the otherwise 
laborious nature of screening for reporter positive colonies (McCann et al., 2011). Second, β-
lactamases have the potential of overcoming the requirement for using in vitro grown bacteria 
when identifying exported proteins. Many β-lactam antibiotics are available and safe for use in 
cell culture and animal models. Proof of principle studies demonstrated, that the ΔblaC M. 
tuberculosis mutant is susceptible to β-lactams during intracellular growth in a cultured 
macrophage cell line (McCann et al., 2007). Furthermore, McCann et al. demonstrated that the 
‘BlaTEM reporter can report on the export of a protein to which it is fused during intracellular 
growth. Model strains were constructed that produce the ‘BlaTEM reporter with no export signal 
(‘BlaTEM, β-lactam sensitive) or the ‘BlaTEM reporter fused to a signal peptide (sp-‘BlaTEM, 
β-lactam resistant) in M. tuberculosis  (McCann et al., 2007). Macrophages were infected with 
each strain, and treated by addition of the β-lactam carbenicillin to the media. In the absence of 
treatment both strains could replicate in macrophages; however, carbenicillin treatment restricted 
the intracellular growth of the ‘BlaTEM β-lactam sensitive strain. The strain with an exported sp-
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‘BlaTEM reporter was protected from carbenicillin treatment, and grew normally in the 
macrophage. This demonstrated that the ‘BlaTEM reporter can report on export during growth in 
macrophages (McCann et al., 2007). These studies with macrophages, suggested the possibility 
of using the ‘BlaTEM reporter in screening for M. tuberculosis proteins exported during 
infection in -lactam treated mice. Chapter 2 will focus on the development of a method called 
EXIT (EXported In vivo Technology) which we developed to specifically identify proteins 
exported by M. tuberculosis during murine infection.  
Exported proteins play important roles in M. tuberculosis virulence 
Exported proteins are vital to the survival of intracellular pathogens, such as M. 
tuberculosis, where they not only maintain cellular physiology, but also provide protection from 
intracellular stresses, control the host cell response, and allow for nutrient acquisition in a 
purposefully nutrient poor environment (McCann, 2009). Several examples of exported virulence 
factors are highlighted below.  
Exported proteins important to M. tuberculosis virulence 
M. tuberculosis encodes several classical exported virulence factors, for example, 
proteins involved in detoxification of radical oxygen and radical nitrogen species (McCann, 
2009). Additionally, some of the best studied virulence factors in M. tuberculosis are exported 
proteins required for the biosynthesis specialized lipids within the highly complex and 
impermeable mycobacterial cell wall and outer membrane (myco-membrane). The myco-
membrane consists of several specialized lipid structures, many including long chain fatty acids 
called mycolic acids. Synthesis and transport of many lipids within the myco-membrane of M. 
tuberculosis is required for bacterial cell viability; however, some lipids are not required for in 
vitro growth, including phthiocerol dimycocerosate (PDIM). Mutations in genes required for the 
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synthesis and transport of PDIM to the myco-membrane results in attenuation of M. tuberculosis 
during infection of macrophages and mice (Forrellad et al., 2013). Interestingly, PDIM appears 
to be important for immune modulation, and the attenuation of PDIM mutants appears to result 
from reduced control of the host (Forrellad et al., 2013).  
M. tuberculosis has not only had to develop strategies to evade destruction by the host 
immune system, but also to acquire nutrients for survival. The phagosome is nutritionally 
restricted as a way to prevent growth of intracellular bacteria (Appelberg, 2006). Perhaps the 
most well studied nutritional restriction, the host’s ability to restrict iron is overcome by M. 
tuberculosis through the production of siderophores, molecules with very high affinity for iron 
which are able to chelate it away from host iron stores (Fang et al., 2015). Disruption of 
siderophore biosynthesis or function attenuates the virulence of M. tuberculosis in cell culture 
and animal models of infection (Fang et al., 2015). 
Role of Lipid Import and Catabolism in M. tuberculosis virulence 
During infection, M. tuberculosis is thought to primarily consume lipids as a carbon 
source (Munoz-Elias & McKinney, 2006; Eisenreich et al., 2010). This lifestyle is reflected in 
the numerous enzymes required for catabolism of lipids in M. tuberculosis (Cole et al., 1998). 
Additionally, the M. tuberculosis genome encodes several specialized multi-protein transporters 
predicted to import lipids, four Mce transporters (Mce1, 2, 3, and 4). All of the mce operons are 
important to virulence in mice (Sassetti & Rubin, 2003; Shimono et al., 2003; Lima et al., 2007; 
Uchida et al., 2007; Senaratne et al., 2008; Marjanovic et al., 2010). Study of mce operons in M. 
tuberculosis has shown that one of them, mce4, imports cholesterol (Pandey & Sassetti, 2008; 
Klepp et al., 2012; Mohn et al., 2008). M. tuberculosis is fully able to catabolize cholesterol 
(Miner et al., 2009), and mutants have been generated in several steps of the cholesterol 
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metabolic pathway, and they are severely attenuated (Miner et al., 2009). The mce4 mutant is 
attenuated in a mouse model of infection, as demonstrated by reduced bacterial burden, increased 
survival time in mice, and decreased histopathology, demonstrating an importance for 
cholesterol import during infection (Senaratne et al., 2008; Pandey & Sassetti, 2008). The other 
mce operons are not as well studied as mce4, but they are also thought to be lipid transporters. 
Mce1 is required during infection of macrophages as well as during murine infection (McCann et 
al., 2011; Rengarajan et al., 2005). Recent evidence suggests that Mce1 imports mycolic acids, 
specialized lipids which are incorporated into many complex molecules in the myco-membrane 
(Forrellad et al., 2014; Cantrell et al., 2013). Mce1 functions potentially as a mechanism of 
recycling for control of the mycolic acid concentration within the mycobacterial outer 
membrane. The lipids transported by Mce2 or Mce3 have yet to be identified.  
Although the contribution of Mce systems to M. tuberculosis virulence has been 
characterized, the role of individual proteins within the Mce transport complex has yet to be 
characterized. Mce operons are thought to be analogous to ABC transporters, and the genes 
encoded in the operons have been assigned function based on our knowledge of ABC 
transporters (Casali & Riley, 2007). However, the sequence similarity to ABC transporters is 
limited, and Mce transporters are distinct from ABC transporters in that mce operons contain 
genes encoding multiple predicted permease and solute binding protein components. mce 
operons additionally contain genes encoding proteins with no homology to ABC transporter 
components that have been named Mce-associated (Mas) proteins. Therefore, the mechanism of 
Mce transport and the function of the individual Mce transporter components in lipid transport 
and virulence await direct study. In Chapter 3, we characterize Rv0199 (renamed OmasA) as an 
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in vivo exported protein of unknown function and assign it a role in the stabilization and function 
of Mce transporter systems.  
Summary 
While the technology for identifying exported proteins has improved dramatically, there 
are still technical hurdles to accurate genome-wide identification of exported proteins. 
Furthermore, current technologies remain limited to identifying exported proteins using in vitro 
grown bacteria. Transcriptional analysis has identified large shifts in the M. tuberculosis lifestyle 
during infection (Talaat et al., 2004; Schnappinger et al., 2006). While transcriptional analysis 
has informed our perspectives on M. tuberculosis metabolism, and the intracellular lifestyle, 
there is mounting evidence that transcriptional analysis alone is not representative of cellular 
protein changes (de Souza & Wiker, 2011). Thus, it is important to develop methods to 
specifically study protein behavior during infection.  
We propose that a subset of exported proteins may be selectively expressed or exported 
during infection, that are missed by current analyses focusing on in vitro grown M. tuberculosis. 
Such proteins could be incredibly important to pathogenesis, and define interactions between the 
host and pathogen. In this dissertation, we sought to comprehensively identify the in vivo 
exported proteome of M. tuberculosis. Accomplishment of this goal, which has not been 
attempted previously in any bacterial pathogen, required the development of a novel method, 
which we termed EXIT for EXported In vivo Technology. Chapter 2 will describe the process of 
developing and optimizing EXIT, as well as describing key results from analyzing the in vivo 
exported proteome of M. tuberculosis. We identified 593 proteins as exported during murine 
infection, including 32 proteins with no in silico predicted export signal which represent 
candidates for new exported proteins. We further identified 38 proteins whose export was 
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significantly upregulated during infection as compared to in vitro growth. Because these proteins 
are subject to regulation, they may have important functions during infection and could 
understand the host-pathogen interface. Finally, we applied our reporter fusion data to determine 
the topology of important M. tuberculosis virulence factors. The proteins identified in this study, 
and the vast resource of topology data, represent a valuable resource for the M. tuberculosis 
research community.  
Identification of exported proteins is a proximal goal. With the knowledge that exported 
proteins are critical to M. tuberculosis virulence we also seek to better understand the roles of 
individual exported proteins during infection. Previous studies analyzing transposon mutants 
lacking individual exported proteins during intracellular growth identified six attenuated mutants 
(McCann et al., 2011). Of these, one mutation was in a membrane protein of unknown function, 
Rv0199. Rv0199 was also identified by EXIT as exported in vivo. Chapter 3 describes further 
characterization of the rv0199 mutant, resulting in a functional assignment of rv0199 as an 
orphaned mce-associated gene (mas). Further study into the role of Rv0199 in Mce transport 
determined that Rv0199, and potentially all Mas family proteins, provides stability to the large 
multi-protein Mce transport complex.   
32 
Table 1.1Exported Protein Identification in M. tuberculosis 
First Author Year Method Fraction # ID 
Proteins 
% Export 
Signal 
% ID of Top 
50 Highly 
Expressed 
Cytoplasmic 
Proteins 
Gu 2003  MS MEM 737 15 82 
Rosenkrands 2000  MS CF 49 29 28 
Xiong 2005  MS MEM 342 44 40 
Mawuenyega 2005  MS MEM 105 21 6 
Mawuenyega 2005  MS CW 65 15 6 
Wolfe 2010  MS CW 540 26 76 
Malen 2007  MS MEM 255 58 28 
de Souza 2011  MS CF 458 33 40 
de Souza 2011  MS MEM 1439 30 90 
Bell 2012  MS CW 791 21 92 
Bell 2012  MS MEM 666 24 78 
Bell 2012  MS CF 508 29 82 
Gunawardena 2013  MS MEM 2203 28 88 
Feltcher 2015 MS CW 1729 29 82 
 
Braunstein 2000  GR Exported 31 94 0 
Gomez 2000  GR Exported 9 100 0 
McDonough 2008  GR Exported 13 100 0 
McCann 2011  GR Exported 111 95 0 
 
Table 1.1. Exported Protein Identification in M. tuberculosis. Exported proteins of M. tuberculosis 
have been identified by mass-spectrometry (MS) based methods as well as use of genetic reporters (GR) 
(Gu et al., 2003; Rosenkrands et al., 2000; Xiong et al., 2005; Mawuenyega et al., 2005; Wolfe et al., 
2010; Malen et al., 2007; de Souza et al., 2011; Bell et al., 2012; Gunawardena et al., 2013; Braunstein et 
al., 2000; Gomez et al., 2000; McDonough et al., 2008; McCann et al., 2011). MS based methods have 
analyzed proteins in exported fractions including the membrane (MEM), cell wall (CW), and extracellular 
or culture filtrate (CF) fractions. For comparison, all lists were analyzed using the H37Rv RefSeq genome 
annotation released January 9 2012. The total number of proteins identified (# ID Proteins) in the given 
fraction is reported and analyzed for percentage containing an export signal (% Export Signal) and the 
percentage of top 50 most abundant cytoplasmic proteins identified (% ID Top Cytoplasmic), as 
described below. Export signals including transmembrane domains and Sec and Tat signal peptides were 
predicted by SignalP, TatP, TMHMM, (Sutcliffe & Harrington, 2004), and (McDonough et al., 2008). 
The Top 50 most abundant cytoplasmic proteins were identified by PaxDB, a database calculating the 
relative abundance of proteins from published proteomics datasets (Wang et al., 2015; Wang et al., 2012). 
Proteins identified as abundant in PaxDB but containing predicted export signals, or known to be 
exported (i.e. EsxA and EsxB) were excluded, to generate a list of the top 50 most abundant cytoplasmic 
proteins in M. tuberculosis.  
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CHAPTER 2: PROBING FOR BACTERIAL PROTEINS AT THE HOST-PATHOGEN 
INTERFACE
1
 
Introduction 
Historically, studies of bacterial pathogens have largely relied on bacteria that are grown 
in the laboratory (i.e. under in vitro conditions); however, bacteria grown in the laboratory 
behave differently than they do in the host environment. Studying bacterial pathogens during 
infection has and will continue to help identify the virulence factors necessary for surviving in 
the host environment and establishing infection. One technological advance which proves the 
importance of studying pathogens directly in the host (i.e. under in vivo conditions) is IVET (in 
vivo expression technology). IVET uses a promoter trap approach to identify bacterial genes 
induced during infection. Fragments of genomic DNA are cloned into a plasmid, upstream of a 
reporter gene required for bacterial growth during infection (Mahan et al., 1993; Angelichio & 
Camilli, 2002). Plasmids containing promoters active during infection drive expression of the 
reporter and allow for survival of those select bacterial clones in vivo (Mahan et al., 1993). 
Clones that express active reporters during infection are then tested for reporter activity during in 
vitro growth, resulting in the successful identification of genes whose expression is specifically 
induced in vivo, many of which are virulence factors (Mahan et al., 1993; Mahan et al., 2000). 
Prominent examples of in vivo induced virulence factors include the Salmonella pathogenicity 
island 2 (SPI-2) encoded Type III secretion system, the Legionella ICM/Dot Type IV secretion 
                                                          
1
 Adapted for this dissertation from: Perkowski EF, Weerakoon D, Hayden JD, Ioerger TR, Oreper D, Gomez S, 
Sacchettini JC, Braunstein M. Probing for bacterial proteins at the host-pathogen interface. In preparation. 
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system, and the two component regulatory system PhoP in Salmonella (Mahan et al., 2000). 
IVET was called a “bellwether”, the first of new technologies to study pathogens directly in the 
host and improve our understanding of host-pathogen interactions (Barinaga, 1993). While 
decades have passed since the introduction of IVET and other in vivo technologies, critical 
questions remain about how pathogens establish disease, and new methods are required to further 
probe the host-pathogen interface in vivo.  
Exported proteins are the proteins that are transported out of the bacterial cytoplasm to 
the bacterial cytoplasmic membrane, cell envelope, or out into the host environment. These 
proteins are located in an ideal place to interact with or protect from the host and to influence 
infection. Consequently, many exported proteins have functions in virulence (Isaac & Isberg, 
2014; Agbor & McCormick, 2011; Ligon et al., 2012). For this reason, decades of research has 
been devoted to identifying exported proteins of bacterial pathogens as candidates for being new 
virulence factors. However, all such studies have been limited by the available technologies, 
which study laboratory (in vitro) grown bacteria (de Souza & Wiker, 2011). In this Chapter, we 
describe the development of a novel method that we refer to as EXIT (EXported In vivo 
Technology) to specifically identify proteins exported by a bacterial pathogens during in vivo 
infection. Here, we used EXIT to successfully identify proteins exported by the human pathogen 
Mycobacterium tuberculosis during mouse infection. In the future, this technology could be 
applied to study diverse bacteria-host interactions.  
Current Methods for Identifying Exported Proteins 
Many bioinformatics programs are available to predict exported proteins. These programs 
search protein sequences for hallmarks of exported proteins (putative transmembrane helices 
and/or signal peptides) (Krogh et al., 2001; Sonnhammer et al., 1998; Hofmann & Stoffel, 1993; 
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von Heijne, 1992; Petersen et al., 2011; Nakai & Horton, 1999; Hiller et al., 2004; Taylor et al., 
2006; Juncker et al., 2003; Sutcliffe & Russell, 1995; Rose et al., 2002; Bendtsen et al., 2005; 
Selengut et al., 2007). However, these in silico methods are not fail-proof. There is significant 
disagreement between algorithms (data not shown; McDonough et al., 2008) and the potential 
for incorrect assignment exists. In addition, these programs are limited to predicting conventional 
exported proteins and unable to identify exported substrates of specialized export systems. Thus, 
it is important to follow up in silico predictions of export with experimental validation. 
There are two methods commonly used to experimentally discover new exported 
proteins. One method involves identification of proteins in exported subcellular fractions, often 
using mass spectrometry (MS). For this analysis, subcellular fractions containing exported 
proteins (membrane, cell wall, or secreted fractions) must first be prepared by physical (e.g. 
ultracentrifugation) or chemical (e.g. detergent) separation. MS based approaches to identify 
exported proteins are not currently applicable to bacterial pathogens during in vivo host infection 
(Schmidt & Volker, 2011). MS analysis is biased by abundance, which is particularly 
problematic when attempting to identify relatively rare bacterial proteins secreted into the host 
cell (Schmidt & Volker, 2011; Yang et al., 2015; Kruh et al., 2010). In fact, analysis of crude 
lysates from infected organs results in a very limited number of bacterial proteins identified 
(Kruh et al., 2010). An alternate method is to first isolate/enrich bacteria from infected tissue, 
increasing the number of total bacterial proteins identified (Xia et al., 2007; Twine et al., 2006; 
Becker et al., 2006; Schmidt et al., 2010; Liu et al., 2012; Pieper et al., 2009). Isolation of 
bacterial cells from infected host cells could be useful for identifying proteins exported to the 
bacterial cell envelope. However, currently it cannot provide sufficient material for separation of 
exported fractions from cytoplasmic material (Schmidt & Volker, 2011; Yang et al., 2015). 
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Therefore, application of MS based approaches to identification of in vivo exported proteins is 
not currently feasible. 
An alternative strategy to biochemical identification of exported proteins is the use of 
genetic reporters (GR) of protein export. A protein export reporter is an enzyme whose activity 
or function depends on the reporter being exported/localized out of the cytoplasm. In the EXIT 
methodology developed in this study, we took advantage of the ‘BlaTEM reporter. The E. coli β-
lactamase BlaTEM cleaves β-lactam antibiotics and is able to confer β-lactam resistance on cells, 
as long as it gets exported out of the cytoplasm. The ‘BlaTEM reporter is advantageous because 
it can be used as a selectable marker. Removal of the native signal peptide of BlaTEM 
(‘BlaTEM) prevents export. However, when the truncated ‘BlaTEM reporter is fused to a signal 
peptide, or the extra-cytoplasmic portion of an exported protein, export of the reporter confers β-
lactam resistance (Figure 1.6). Thus, membrane, cell wall, or fully secreted proteins can be 
identified with the ‘BlaTEM reporter (Figure 2.1). Only fusions to the periplasmic domains of 
membrane proteins will produce β-lactam resistance (Figure 2.1). This was first worked out in 
Escherichia coli (Broome-Smith & Spratt, 1986), and holds true when the ‘BlaTEM reporter is 
used in the ΔblaC mutant of M. tuberculosis (McCann et al., 2007), which lacks the endogenous 
exported β-lactamase BlaC of Mycobacterium tuberculosis (McCann et al., 2007; McCann et al., 
2011). A transposon carrying the ‘BlaTEM reporter was previously used to identify 111 M. 
tuberculosis proteins that are exported when the bacteria are growing on β-lactam containing 
agar plates in vitro (McCann et al., 2011).  
In general, MS based methods tend to have high false positive rates (high numbers of 
non-exported proteins identified as exported) and GR based methods tend to have high false  
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Figure 2.1.The ‘BlaTEM reporter. The ‘BlaTEM reporter is compatible with proteins localized 
to the bacterial cell membrane, periplasm, cell wall, or fully exported/secreted out of the bacterial cell. On 
the left are three example proteins, one cytoplasmic, one integral membrane, and one fully exported 
protein. The right panel demonstrates ‘BlaTEM fusions that will be active or inactive dependent on fusion 
location. Fusions located in frame in extra-cytoplasmic, or exported, portions of proteins will produce 
active fusions (red) and will confer β-lactam resistance to a cell producing this fusion. Fusions located 
within cytoplasmic proteins, or the cytoplasmic face of membrane proteins, will be inactive (purple) and 
will not confer β-lactam resistance. 
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negative rates (much smaller number of proteins identified, and thus many real exported proteins 
not identified). GR based approaches are highly accurate at identifying exported proteins, with 
>95% of proteins identified by GRs containing predicted export signals (Braunstein et al., 2000; 
McDonough et al., 2008; McCann et al., 2011; Gomez et al., 2000). However, GR based 
approaches historically identify far fewer proteins overall, in part because they are more labor 
intensive, and thus have a higher rate of false negative predictions than MS based approaches. 
MS based approaches, in comparison, tend to identify far more proteins but they have much 
higher false positive rates than GR based approaches. MS based approaches are less accurate 
than GRs at identifying proteins with predicted export signals. In M. tuberculosis MS based 
studies, it is often the case that 30% or less of identified proteins in an exported fraction contain 
a predicted export signal because the high level of sensitivity leads to identification of abundant 
cytoplasmic contaminants in exported fractions (Gunawardena et al., 2013; Bell et al., 2012; 
Malen et al., 2011; de Souza & Wiker, 2011; Feltcher et al., 2015). Neither MS or GR based 
approaches have been used to identify proteins exported during infection. As a result, the 
exported proteomes of pathogens during infection remain to be defined. 
Protein Export in M. tuberculosis 
M. tuberculosis exports proteins through two conserved and several specialized accessory 
systems. The Sec system and the Twin Arginine Translocation (Tat) pathway are conserved 
systems that export the bulk of proteins (Ligon et al., 2012). Proteins exported by each of these 
systems are distinguished by the presence of N-terminal signal peptides which are cleaved off 
after export. Signal peptides directing proteins to the Tat system contain a RR motif (twin 
arginine) for which the system is named. Accessory systems (SecA2 and ESX1-5) export a 
smaller and not yet fully defined subset of proteins, and the precise requirements for export 
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through these pathways are only beginning to be discovered (Ligon et al., 2012). SecA2 
substrates fall into two groups, those that contain Sec-like N-terminal signal peptides and those 
that have no predicted N-terminal signal peptide (Gibbons et al., 2007; Feltcher et al., 2015; 
Braunstein et al., 2003; van der Woude et al., 2014). While the signal peptide is required for 
export of a SecA2 substrate if it exists, features of the mature domain of SecA2 exported proteins 
is what targets them for SecA2 dependent export (Feltcher et al., 2013). ESX export requires a 
YxxxD/E motif in the exported substrate or a co-secreted partner protein, although elements 
outside of this motif define which ESX system will export the substrate (Daleke et al., 2012). 
Overall, identifying the exported substrates of accessory systems has been challenging in M. 
tuberculosis, often due to our limited understanding of these systems.  
The ‘BlaTEM reporter is compatible with export through both the Sec and Tat systems, 
and it is compatible with integral membrane proteins (McCann et al., 2011; McCann et al., 
2007). The ‘BlaTEM reporter is also compatible with export through T3SS and T4SS (Ehsani et 
al., 2009), and while M. tuberculosis is not predicted to encode either system it may possess 
T4SS-like proteins encoding a potential Tight adherence-like (Tad-like) secretion system 
(Danelishvili et al., 2010; Tomich et al., 2007). It remains unknown whether the ‘BlaTEM 
reporter is compatible with the accessory systems of export in M. tuberculosis.  
Identification of Proteins Exported During Infection 
We hypothesized that possibly the most important exported proteins are those that are 
only exported in the host environment. Therefore, we set out to develop a way to study protein 
export in the host and identify new exported proteins that had been long overlooked. Proteins 
exported only during infection could be regulated at the level of transcription, post-transcription, 
or export. Because β-lactams are already used to treat bacterial infections in mice, we 
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hypothesized that the ‘BlaTEM reporter could be used in vivo in a mammalian host. Consistent 
with this hypothesis, proof of principle studies demonstrated that ‘BlaTEM reporter fusions can 
be used with M. tuberculosis to identify exported proteins during infection of cultured 
macrophages (McCann et al., 2007). We developed a selection strategy compatible with use of 
the ‘BlaTEM reporter during murine infection by optimizing β-lactam treatment for β-lactam 
sensitive M. tuberculosis, and analysis by next generation sequencing. In this study we applied 
this new method, EXported In vivo Technology (EXIT), to identify proteins exported by M. 
tuberculosis during murine infection.  
EXIT identified 593 proteins as being exported by M. tuberculosis during infection, 
representing 57% of the in silico predicted exported proteome of M. tuberculosis. 100 of these 
proteins were experimentally demonstrated as being exported for the first time. Analysis of the 
exported fusions provided insight into the topology of several known virulence factors in M. 
tuberculosis. Further, several interesting classes of proteins were identified, including proteins 
with no predicted export signal and exported fusions in previously unannotated genomic regions. 
Additionally, 38 of the proteins identified by EXIT were exported significantly more during in 
vivo infection than in vitro. Because M. tuberculosis regulates production/export of these 
proteins in a spatial or temporal way, we hypothesize that they may be previously unidentified 
virulence factors.  
Results 
Our goal was to develop a method to identify proteins that were exported by M. 
tuberculosis during murine infection. The EXIT strategy was composed of four fundamental 
steps (Figure 2.2). In Step 1, a comprehensive library of 5x10
6  
M. tuberculosis clones was 
constructed carrying plasmids with random fragments of M. tuberculosis genomic DNA fused to  
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Figure 2.2 The EXported In vivo Technology (EXIT) Strategy. The EXIT strategy was composed of 
four fundamental steps. In Step 1, a comprehensive library M. tuberculosis clones carrying plasmids with 
random fragments of M. tuberculosis genomic DNA was fused to the ‘blaTEM reporter. First, a multi-
copy plasmid was constructed containing origins of replication for mycobacteria and E. coli, a 
hygromycin resistance cassette, and a ClaI restriction enzyme cloning site upstream of the ‘blaTEM 
reporter gene. This plasmid contained no promoter upstream of the reporter, therefore an active reporter 
required in frame fusion to a protein that was actively expressed off its native promoter. Genomic DNA 
from a ΔblaC β-lactamase sensitive mutant of M. tuberculosis was fragmented by partial digestion four-
base cutters AciI and HpaII. Ligation of digested fragments into the ClaI site of the plasmid was used to 
generate a library of 5x10
6
plasmids with unique DNA fusions. The plasmid library was transformed into 
the ΔblaC β-lactamase sensitive mutant of M. tuberculosis and 5x106 transformants were pooled to 
generate the EXIT library. In Step 2, mice were infected with the EXIT library and treated with β-lactam 
antibiotics to select for EXIT clones exporting ‘BlaTEM fusion proteins. Mice were infected by tail vein 
injection with approximately 4x10
6 
colony forming units (cfu). The remaining inoculum was collected 
and subjected to sequencing for the input as described below. Oral gavage treatment twice daily with 
amoxicillin and probenecid (β-lactam treatment) began one day after infection, and continued to 2 weeks 
after infection. Mice were sacrificed, and spleens and lungs were harvested and homogenized. In Step 3, 
organ homogenates were plated on solid agar media and grown for three weeks to recover M. tuberculosis 
clones that had survived β-lactam treatment during infection. Plates were scraped and colonies were 
pooled separately for lungs and spleens. In Step 4, plasmids from the recovered bacteria and the input 
samples were isolated and the fusion junction was sequenced using Illumina sequencing. Sequencing 
primers were designed to read out of the ‘blaTEM reporter and sequence the immediately adjacent fusion 
site. Sequences were trimmed and aligned to the M. tuberculosis genome corresponding to known AciI 
and HpaII restriction sites. Unique sequences were counted to identify the abundance of each fusion 
junction site within the population. The most highly abundant genes after in vivo β-lactam treatment were 
identified, which corresponded to plasmids producing ‘BlaTEM reporters fused downstream of exported 
proteins.   
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the ‘BlaTEM reporter. In Step 2, mice were infected with the EXIT library and, starting one day 
after infection, treated by oral gavage with β-lactam antibiotics to select for clones exporting 
‘BlaTEM fusion proteins in vivo. After 2 weeks of treatment, mice were sacrificed and spleens  
and lungs were harvested and homogenized. In Step 3, organ homogenates were plated on solid 
agar media and grown for three weeks to recover M. tuberculosis clones that had survived β-
lactam treatment during infection. The recovered colonies were scraped from the agar plates and 
collected separately for lungs and spleens. In Step 4, library plasmids were isolated from the 
recovered bacteria surviving in vivo β-lactam treatment as well as from the input library and the 
fusion junctions were sequenced using Illumina sequencing. Sequencing primers were designed 
to read out of the ‘BlaTEM reporter and sequence the immediately adjacent M. tuberculosis 
fusion. Unique sequences were counted to identify the abundance of each fusion within the 
population. Finally, statistical modeling was used to identify highly abundant fusions recovered 
from the mice following in vivo β-lactam treatment. 
Construction of a comprehensive EXIT Library for M. tuberculosis 
In order to construct the comprehensive plasmid library with random fragments of M. 
tuberculosis genomic DNA fused to the ‘BlaTEM reporter we first constructed plasmid pDW31 
(Plasmid Table 2.1). Plasmid pDW31 is a multi-copy plasmid carrying an open reading frame 
(ORF) for the truncated ‘BlaTEM reporter along with a hygromycin resistance selectable marker, 
origins of replication for Escherichia coli and M. tuberculosis, and a ClaI restriction enzyme 
cloning site for cloning in random genomic fragments upstream of the reporter. There is no 
promoter sequence upstream of the reporter on plasmid pDW31; therefore, an active reporter 
requires an in frame fusion to a gene encoding an exported protein that is being expressed from 
its native promoter. Genomic DNA from a ΔblaC β-lactamase sensitive mutant of M. 
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tuberculosis was fragmented by partial digestion with 4 base pair cutters: AciI and HpaII 
restriction enzymes. Digestion was optimized for fragments between 500-5,000 base pairs in 
length, in an attempt to include native promoters for genes distally located in operons. Ligation 
of digested genomic DNA into the ClaI site of the plasmid followed by transformation into E. 
coli resulted in a plasmid library of 5 x10
6
 unique plasmids. The plasmid library was 
subsequently purified from E. coli and then transformed into the ΔblaC β-lactam sensitive 
mutant of M. tuberculosis, resulting in a total of 5 x10
6 
M. tuberculosis transformants (Strain 
Table 2.2).  
We used a cumulative binomial equation to determine how many plasmids would be 
needed to have the whole M. tuberculosis genome represented in the EXIT library by at least one 
in frame fusion to the ‘BlaTEM reporter. To achieve 99.9% confidence that any gene as small as 
100 bp in length would be represented by at least one in frame fusion in the library required a 
library of 2 x10
6
 unique plasmids (APPENDIX I). Therefore, the final EXIT library of 5 x10
6
 
plasmids theoretically had saturating coverage of the genome in frame with the reporter. The 
input EXIT library in M. tuberculosis was sequenced by next-generation sequencing using a 
primer at the fusion junction to the ‘BlaTEM reporter (Primer Table 2.3). Sequence data 
confirmed saturation of the predicted AciI and HpaII sites within the genome. On average, the 
library contained a fusion every 26 base pairs in the M. tuberculosis genome, with the maximum 
non-represented region of the genome in the library being only 110 nucleotides long (Figure 
2.3A).  
Because out of frame and opposite orientation fusions are not able to produce a properly 
translated fusion of the ‘BlaTEM reporter to a given Open Reading Frame (ORF), only one sixth 
of fusions are potentially informative. Despite this large reduction in usable fusions, the  
 55 
 
Figure 2.3 The EXIT library comprehensively represented the Mycobacterium tuberculosis 
proteome. A. The input library was sequenced by Illumina next-generation sequencing and analyzed to 
determine genome coverage of the EXIT library. Analysis of the frequency of fusion sites to the ‘BlaTEM 
reporter determined that the largest gap of M. tuberculosis DNA between two unique fusion sites was 110 
nucleotides. On average, there was a unique fusion site to the ‘BlaTEM reporter every 26 nucleotides, 
demonstrating comprehensive coverage of the M. tuberculosis genome fused to the ‘BlaTEM reporter. 
Percentiles are shown with dotted lines representing 25 and 75
th
 percentile and a solid line representing 
the 50
th
 percentile. B. Analysis of the frequency of in frame fusions identified an average of 16 in frame 
fusions per M. tuberculosis gene, with less than 1% of the genome not represented by an in frame fusion 
in the EXIT library. Percentiles are shown with dotted lines representing 25 and 75
th
 percentile and a solid 
line representing the 50
th
 percentile. C. The average size of annotated M. tuberculosis genes is 1006 
nucleotides or approximately 1 kilobase (kb). The number of in frame fusions in each gene was 
normalized to a size of 1kb, and a histogram showed the frequency of in frame fusions per gene 
normalized to 1kb. The small population with greater than 50 in frame fusions per 1kb size was composed 
of GC rich proteins which contain disproportionally high numbers of AciI and HpaII restriction enzyme 
sites. Percentiles are shown with dotted lines representing 25 and 75
th
 percentile and a solid line 
representing the 50
th
 percentile. 
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complexity of the library was such that each gene was still represented by an average of 16 in-
frame fusions, and some genes contained greater than 35 in-frame fusions (Figure 2.3B). 
Additionally, 99% of genes in the M. tuberculosis genome were represented by at least one in-
frame fusion. The number of in-frame fusions per gene was directly proportional to gene length. 
When the length of each gene was normalized to 1kb, there were, on average, 14 in-frame 
fusions per 1 kb length (Figure 2.3C). Interestingly, there was a population of genes represented 
by greater than 50 in-frame fusions per kb in length. These genes were highly GC rich and thus 
contained a disproportionate number of AciI and HpaII restriction enzyme sites (Figure 2.3C).  
Optimizing selection of exported ‘BlaTEM-fusions in β-lactam treated mice 
One of the major obstacles to developing EXIT was establishing the conditions for β-
lactam selection in a murine host. M. tuberculosis is naturally β-lactam resistant due to an 
endogenous β-lactamase BlaC (Flores et al., 2005). Because of this, EXIT was performed in a M. 
tuberculosis ΔblaC mutant background (Flores et al., 2005). There were no established methods 
for β-lactam treatment of either wild type or ΔblaC M. tuberculosis during murine infection. 
Common strategies for treatment of mice with β-lactams include supplementing water with the 
antibiotics, single intra-muscular injections, and delivery of antibiotics by oral gavage. Although 
effective for the treatment of many different pathogens, and potentially useful for application of 
EXIT to other pathogens, supplementation of the water supply with amoxicillin or ampicillin was 
not sufficient to inhibit growth of β-lactam sensitive M. tuberculosis strains (data not shown). 
Likewise, treatment by oral gavage with amoxicillin alone was not sufficient (data not shown). 
Probenecid has long been used in conjunction with antibiotics to reduce drug efflux in the 
kidneys, increasing the serum concentration with few side effects (Robbins et al., 2012). 
Addition of probenecid to an amoxicillin oral gavage treatment protocol (hereon referred to as β-
 57 
lactam treatment), and an increase in dosage frequency to twice daily oral gavage resulted in a 
successful treatment with evidence of killing the β-lactam sensitive M. tuberculosis strain.  
To test the efficacy of our protocol we performed a proof of principle experiment to 
demonstrate β-lactam sensitivity of a strain exporting a functional reporter compared to a strain 
producing a non-exported reporter. The β-lactam sensitive M. tuberculosis strain produced a non-
exported ‘BlaTEM reporter to control for any possible lysis and release of intracellular β-
lactamase that could have potentially promoted survival. The β-lactam resistant M. tuberculosis 
strain produced the ‘BlaTEM reporter fused downstream of a signal peptide for an exported M. 
tuberculosis protein. Mice were infected with the β-lactam sensitive or β-lactam resistant strain, 
and bacterial burden in the spleen was determined after 14 days. Proof of principle experiments 
demonstrated a significant reduction in bacterial burden of a β-lactam sensitive M. tuberculosis 
strain in β-lactam treated mice (Figure 2.4). However, unlike the β-lactam sensitive strain, the β-
lactam resistant strain grew normally despite β-lactam treatment (Figure 2.4). Importantly, both 
strains were fully virulent and grew to equal bacterial burden in untreated mice (Figure 2.4). 
These proof of principle experiments confirmed that the ‘BlaTEM reporter could be used in β-
lactam treated mice to distinguish an exported protein from a non-exported protein.  
Next we wanted to test if β-lactam resistant clones could be selectively enriched from 
complex mixture of β-lactam sensitive and β-lactam resistant clones, as would be the case with 
the EXIT library. In order to test this we infected mice with a mixture of β-lactam sensitive and 
β-lactam resistant M. tuberculosis (1% β-lactam resistant). After mice were infected with this 1% 
mixed population and treated with β-lactams for 14 days, 69% of the bacteria recovered from the 
spleen were β-lactam resistant (Table 2.4). This result was significant in demonstrating in vivo 
selection and enrichment of the β-lactam resistant fraction of the population while the β-lactam  
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Figure 2.4. The ‘BlaTEM Reporter is Compatible with β-lactam Treatment During Murine 
Infection. Mice were infected by tail vein injection with M. tuberculosis strains producing a ‘BlaTEM 
reporter fused in frame with an exported signal peptide (sp-‘BlaTEM, red) or producing non-exported the 
‘BlaTEM reporter alone (‘BlaTEM, black). One group of mice from each strain was sacrificed to 
determine initial bacterial burden in the spleens on day 1 after infection, and groups of mice were 
followed to day 14 after infection. Half of the mice were treated with the β-lactam antibiotic amoxicillin, 
and a synergistic drug probenecid twice daily by oral gavage, while half remained untreated. On day 14 
the remaining mice were sacrificed and spleens were homogenized and plated on agar media to determine 
bacterial burden (colony forming units/cfu) with and without treatment. * represents statistical 
significance (p<0.05).  
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sensitive population was depleted. When mice were infected with the 1% mixed population but 
not treated with β-lactams, no enrichment for the β-lactam resistant population was observed,  
confirming that the enrichment observed in the treated animals was due to selection for β-lactam 
resistant bacteria (Table 2.4). Importantly, this confirmed that β-lactam resistant clones could be 
selectively enriched from a mixed population. In the input M. tuberculosis EXIT library 1% of 
the bacteria were β-lactam resistant in vitro. As with the above experiment, when mice were 
infected with the EXIT library and treated for 2 weeks with β-lactams, in vivo enrichment of β-
lactam resistant clones was observed, going from 1% to 76% of the population, confirming our 
ability to select in vivo for β-lactam resistant clones.  
Performing EXIT in M. tuberculosis infected mice 
One day after intravenous infection, approximately 20% of the M. tuberculosis inoculum 
was found in the spleen and 1% in the lungs (data not shown), consistent with previous studies 
(Orme & Gonzalez-Juarrero, 2007). Prior to conducting large scale experiments, we calculated 
the number of animals that would be required in order to comprehensively screen the EXIT 
library in mice. Using a modified binomial calculation (APPENDIX I) we determined that 
infection of 24 mice with 5x10
6
 bacteria from the EXIT library would result in a 99.5% 
probability of any individual clone in the library establishing infection in the spleen of at least 
one mouse. With this knowledge, large scale EXIT experiments were conducted with 24 mice 
and were performed in duplicate on separate occasions. For each experiment, mice were 
intravenously infected with 5x10
6
 bacteria from the EXIT library and treatment with β-lactams 
started one day after infection. After two weeks, lungs and spleens were collected and organ 
homogenates were plated onto agar plates. Colonies for each organ were pooled separately, 
plasmids were isolated, and the fusion junctions were sequenced by Illumina next-generation 
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sequencing technology with a specific primer reading out of the ‘BlaTEM fusion junction. In 
parallel, the M. tuberculosis input library (inoculum) used to infect the mice was subjected to 
next-generation sequencing to determine the representation of individual fusions at the start of 
each experiment.  
 A unique pipeline was built for analysis of the sequencing data, which consisted of 136 
million paired-end sequenced reads (see Methods). Briefly, sequences were trimmed and fusion 
junctions between the genomic DNA and the reporter were mapped to the genome. Unique reads 
for each fusion site were counted and the abundance was determined individually for each organ 
and experiment. Lastly, the gene fused immediately upstream of the reporter was determined to 
be in frame with the reporter, out of frame with the reporter, or outside of an annotated gene. 
Results from the two independent experiments were highly correlated as determined by a 
Pearson’s Product Moment Correlation, input: r=0.818, output from treated mice: r=0.784 
(Figure 2.5A and 2.5B).  
The majority of individual fusions were less abundant when rescued from treated mice 
(i.e. following in vivo β-lactam treatment) than they were in the input library (Figure 2.6A). This 
depletion was expected as the library includes many out of frame fusions or fusions with 
cytoplasmic proteins. A smaller population of sequenced fusions was enriched (Figure 2.6A). An 
early sign that EXIT was working as expected came when we directly compared the enrichment 
of in frame fusions with the reporter to out of frame fusions. Out of frame fusions should not 
produce β-lactamase activity. Therefore, out of frame fusions should not support growth in the 
presence in β-lactam treated mice and they should not be enriched. As expected, out of frame 
fusions were highly depleted during in vivo β-lactam selection, and 95% of the highly enriched 
fusions were in frame with the reporter.  
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Figure 2.5. EXIT replicate experiments demonstrated high reproducibility and correlation. A. Raw 
count values in each input replicate experiment (A and B) were plotted for each fusion junction site on a 
log2 scale. A Pearson Product Moment correlation identified a significant correlation r value of 0.818. B. 
Raw count values in the mouse spleen output for each fusion junction site were plotted on a log2 scale for 
replicate experiments A and B. A Pearson Product Moment correlation identified a significant correlation 
r value of 0.784.  
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 M. tuberculosis clones that expressed in frame fusions to exported proteins were expected 
to survive and replicate during in vivo β-lactam treatment, and be the most abundant clones in the  
output from treated mice. Abundance values were assigned for each gene based on the number of 
sequenced reads identified in the output from β-lactam treated mice. To impose the highest level 
of stringency in identifying genes that were reliably more abundant, the lowest abundance value 
for a gene from the two experimental replicates was selected for the subsequent statistical 
analysis (for details see Methods). A Gaussian mixture model was constructed to describe the 
two populations: a large group of low abundance genes and a smaller group of high abundance 
genes (Figure 2.6B). The statistical model set a cutoff of log10 of 2.90, or an abundance of 
approximately 800 unique sequenced reads, above which a given gene was identified in the high 
abundance group. Using this statistical analysis, 593 genes were identified as highly abundant 
after in vivo β-lactam treatment, and thus predicted to encode exported proteins (Figure 2.6B, 
APPENDIX II).  
EXIT successfully identified exported proteins 
As a first assessment of the accuracy of EXIT, we searched for export signals (signal 
peptides and transmembrane domains) in the 593 proteins identified (APPENDIX II). To 
facilitate identification of export signals in proteins identified in EXIT, we first analyzed the 
whole M. tuberculosis H37Rv proteome for transmembrane domains using TMHMM (Krogh et 
al., 2001), signal peptides using Signal P (Petersen et al., 2011), and lipoproteins and Tat signal 
peptides (Sutcliffe & Harrington, 2004; McDonough et al., 2008) (APPENDIX III). There are 
many transmembrane and signal peptide prediction algorithms available. Our decision to the 
TMHMM program is based on the report of it having a lower frequency of false-positive 
predictions than other transmembrane prediction programs (Punta et al., 2007). We chose the  
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Figure 2.6. EXIT identified 593 proteins as exported during murine infection. A. The average 
abundance of each fusion site in the output from mice was divided by the average abundance in the input. 
Fusion sites with values of zero, occurring mostly in the output, were assigned a value of 1. A histogram 
was generated to compare the number of fusion sites enriched or depleted during in vivo β-lactam 
treatment. B. The most abundant fusion position within each annotated gene in the M. tuberculosis 
genome (3999 protein coding genes from H37Rv RefSeq genome annotation released January 9 2012) 
was identified individually within the output for each of two replicate experiments. The lower of these 
two numbers was plotted on a histogram. A two component Gaussian mixture model (black line overlay) 
was used to generate a statistical model distinguishing between high abundance genes (right) and low 
abundance genes (left), with a statistical cutoff of log10=2.90, or approximately 800 counts (red line). 593 
genes were identified in the high abundance population corresponding to EXIT exported proteins.  
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Signal P program because it performs better than other tools in identifying signal peptides in M. 
tuberculosis exported proteins (Leversen et al., 2009). Using these in silico programs to predict  
signal peptides and transmembrane domains, 26% (1040 proteins) of the M. tuberculosis 
proteome was predicted to be exported (APPENDIX III). This compares well to analyses across 
bacterial species, which usually predict 20-30% of the proteome to be exported (Saleh et al., 
2001).  
Only 26% of proteins containing in frame fusions in the input library contained in silico 
predicted export signals. However, nearly all (95%) of the 593 proteins identified by EXIT as 
exported in the mouse were in silico predicted exported proteins (Figure 2.7A, APPENDIX II). 
This demonstrated strong selection in vivo for fusion proteins possessing export signals. Overall, 
57% of the in silico predicted exported proteome of M. tuberculosis was identified as exported in 
vivo by EXIT. Proteins identified as exported in vivo included those with in silico predicted Sec 
signal peptides, Tat signal peptides, lipoproteins, and proteins with transmembrane domains, 
confirming broad compatibility with the ‘BlaTEM reporter (APPENDIX II). 
As an additional test of the ability of EXIT to correctly identify exported proteins, we 
compared the list of 593 to lists of known exported (Table 2.5) and known non-exported proteins 
(Table 2.6). Because we had no information about in vivo exported proteins, we relied on a list of 
proteins known to be exported in vitro, presuming that many or all would also be exported in 
vivo (Table 2.5). Therefore we compared EXIT identified proteins to proteins experimentally 
demonstrated as exported in vitro, including well-known M. tuberculosis exported antigenic 
proteins like Ag85B and 19 kDa/LpqH (McCann et al., 2011). 82% of these experimentally 
demonstrated exported proteins were identified as exported in vivo by EXIT. We also searched 
the list of 593 proteins for examples of known non-exported (cytoplasmic) proteins. Highly  
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Figure 2.7. EXIT successfully and reliably identified exported proteins. A. The input EXIT library 
was composed of fusions into 99% of M. tuberculosis genes, with 74% encoding proteins with no 
predicted export signal (green), 15% encoding predicted integral membrane proteins (red), and 11% 
encoding proteins containing predicted signal peptides (black). In contrast, 95% of proteins in the EXIT 
output contained an export signal. The 593 proteins identified as exported in EXIT were composed of 57 
% predicted integral membrane proteins (red), 38% of proteins containing a predicted signal peptide 
(black), and 5% of proteins with no predicted export signal (green).B. The top 50 most abundant 
cytoplasmic proteins were identified by PaxDB, a database calculating the relative abundance of proteins 
from published proteomics datasets (Wang et al., 2015; Wang et al., 2012). Proteins identified as 
abundant in PaxDB but containing predicted export signals (transmembrane domains and signal peptides 
were predicted by SignalP, TatP, TMHMM, (Sutcliffe & Harrington, 2004), and (McDonough et al., 
2008)), or proteins known to be exported (e.g. EsxA and EsxB) were excluded, to generate a list of the 
top 50 most abundant cytoplasmic proteins in M. tuberculosis. Exported proteins of M. tuberculosis have 
been identified on in vitro grown bacteria by mass-spectrometry (MS) based methods as well as use of 
genetic reporters (GR). MS based methods have analyzed proteins in exported fractions including the 
bacterial cell membrane, cell wall, and extracellular or culture filtrate fractions. For comparison, all lists 
were analyzed using the H37Rv RefSeq genome annotation released January 9 2012. The number of high 
abundance cytoplasmic proteins was determined for each MS and GR based study of exported proteins. 
C. Genes identified as encoding exported proteins were analyzed for the number of statistically enriched 
fusions after in vivo β-lactam treatment. On average, 4 unique fusion sites were enriched for each 
exported protein. Percentiles are shown with dotted lines representing 25 and 75
th
 percentile and a solid 
line representing the 50
th
 percentile. 
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abundant cytoplasmic proteins would be the most likely candidates for false positive 
identification by EXIT, as highly expressed intracellular BlaTEM fusions could potentially result  
in release of β-lactamase through a non-specific process. Using PaxDB, a database that mines in 
vitro proteomics datasets and estimates cellular abundance of proteins (Wang et al., 2015; Wang 
et al., 2012), we compiled a list of 50 of the most abundant cytoplasmic proteins in M. 
tuberculosis (Table 2.6). Not one of these 50 highly expressed cytoplasmic proteins were on the 
list of 593 proteins identified by EXIT (Figure 2.7B), thus we were very pleased at the apparent 
success of EXIT to identify a large number of exported proteins with a very low false positive 
rate. In comparison, MS based methodologies to identify proteins in exported subcellular 
fractions consistently identify more than 40 of the 50 most abundant cytoplasmic proteins 
identified by PaxDB (Figure 2.7B) (Gu et al., 2003; Rosenkrands et al., 2000a; Mawuenyega et 
al., 2005; Wolfe et al., 2010; Xiong et al., 2005; Malen et al., 2007; Malen et al., 2011; Bell et 
al., 2012; Gunawardena et al., 2013).  
 Finally, we wanted to compare different fusion sites within EXIT identified proteins, 
because identification of multiple unique fusion sites as independently enriched would provide 
extra confidence that EXIT reliably identified the same proteins as exported. We looked at cases 
of multiple unique ‘BlaTEM fusion sites in the same gene and compared the abundance of each 
fusion in the input and output samples to determine statistical enrichment. 2,516 unique fusion 
sites were identified as statistically enriched during in vivo β-lactam treatment, corresponding to 
the 593 proteins identified as exported. Each protein was represented by an average of four 
unique enriched fusion sites (Figure 2.7C). This provided additional confidence in the power of 
EXIT to identify exported proteins, because 82% of the 593 proteins were identified by multiple 
unique fusion sites within each experiment.  
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EXIT identified new exported proteins 
Proteins never previously experimentally shown as exported 
Many EXIT identified proteins had previously been identified as exported in vitro by MS 
and GR based methods (Figure 2.8A), further validating the EXIT method for identification of 
exported proteins. However, despite multiple previous in vitro studies using MS and GR based 
methods (Gu et al., 2003; Rosenkrands et al., 2000a; Mawuenyega et al., 2005; Wolfe et al., 
2010; Xiong et al., 2005; Malen et al., 2007; Malen et al., 2011; Bell et al., 2012; Gunawardena 
et al., 2013; Braunstein et al., 2000; McDonough et al., 2008; McCann et al., 2011; Gomez et 
al., 2000), EXIT still identified 100 proteins that had no previous experimental evidence of 
export (Figure 2.8A).  
Proteins not predicted in silico as exported 
Due to the very high percentage (95%) of proteins identified by EXIT that possess in 
silico predicted export signals and the evidence of multiple unique in vivo enriched fusions per 
EXIT identified protein (Figure 2.7A, Figure 2.7C), proteins that were identified as exported by 
EXIT with no conventional export signal are compelling candidates for non-conventional 
exported proteins. EXIT identified 32 proteins (5% of EXIT predicted proteins) which lack a 
predicted export signal, and could be true exported proteins overlooked by current bioinformatics 
programs (Table 2.7). To test whether these 32 proteins include examples of true exported 
proteins, three representative proteins were engineered with an HA tag at the C-terminus 
(Rv1728c, Rv3707c, and Rv3811) and these genes were expressed off a constitutive hsp60 
promoter in M. tuberculosis. Cells were lysed by French press to generate whole cell lysates 
(WCL), and subcellular fractions containing the cell wall (CW), membrane (MEM) and 
soluble/cytoplasmic (SOL) proteins were generated by differential ultracentrifugation. Western  
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Figure 2.8. EXIT identified new exported proteins. A. Proteins identified as exported by EXIT were 
compared with previous studies to determine how many previous studies had identified them as exported. 
100 proteins designated in red had not previously been identified as exported in vitro. Two proteins, 
LppX and PhoS1 were each identified in 10 studies. Percentiles are shown with dotted lines representing 
25 and 75
th
 percentile and a solid line representing the 50
th
 percentile. B. Three proteins with no in silico 
predicted export signal (Rv1728c, Rv3707c, and Rv3811) were engineered with C-terminal HA tags, and 
produced in M. tuberculosis. Cells were irradiated, lysed by French pressure cell into whole cell lysate 
(WCL), equalized by BCA protein quantification, and fractionated by differential ultracentrifugation into 
cell wall (CW), membrane (MEM), and soluble/cytoplasmic (SOL) fractions. Fractions containing equal 
cellular material were separated by SDS-PAGE and HA tagged proteins were detected by Western blot 
with anti-HA antibodies. Chemiluminescent signal was quantified individually for each subcellular 
fraction by the ChemiDoc MP (Biorad) with Image Lab software (Biorad) and reported as fraction of total 
from total signal (SOL+CW+MEM). Error bars represent standard deviation from duplicate biological 
replicates.  
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 blot analysis of the subcellular fractions demonstrated that all three of these proteins are 
exported to the cell wall fraction of M. tuberculosis (Figure 2.8B). These results speak to the 
ability of EXIT to identify exported proteins that are missed by the heavily relied upon in silico 
prediction tools for export signals. Nine of the proteins that EXIT identified as exported that lack 
predicted export signals have not previously been identified as exported by any available in silico 
or in vitro method (Table 2.7). This list of nine proteins included Rv3811, one protein we 
successfully validated as exported.  
Potential exported ORFs in unannotated regions 
 The vast majority of enriched fusions were in frame with annotated genes. However, 
EXIT also identified enriched fusions in a small subset of unannotated regions of the genome, 
spanning intergenic spaces, suggesting that these regions may contain unannotated/misannotated 
exported proteins. One such enriched exported fusion was immediately upstream of the gene 
rv3035, which encodes one of the 32 EXIT identified proteins with no predicted export signal. 
Interestingly, upstream of the predicted start site for rv3035 is an in-frame translational start site 
that would introduce a predicted N-terminal transmembrane domain and account for this 
additional fusion being identified by EXIT. This upstream sequence also provided a likely 
explanation for the export of rv3035.  
Unannotated regions which contained multiple enriched fusions in the same reading 
frame and within 100 base pairs of each other were identified as the most likely to represent 
currently unannotated ORFs encoding exported proteins (Table 2.8). One genomic region 
downstream of Rv2307A contained six highly enriched fusion sites that were all in the same 
reading frame. We used the Geneious software program (Kearse et al., 2012) to identify potential 
ORFs within this region, and a single ORF was consistent with all six enriched fusion sites. 
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Furthermore, there was an in silico predicted signal peptide at the N-terminus of the translated 
ORF. Future studies are required to better characterize these ORFs as new exported proteins. The 
identification of exported proteins lacking in silico predicted export signals and identification of 
unannotated exported proteins demonstrates the power of an unbiased genome-wide strategy as 
well as an unbiased sequencing platform. 
EXIT fusions identify proteins exported in the lungs 
 Because of low (1%) seeding of the lungs following intravenous infection and the 
associated bottleneck issues, we were unable to comprehensively test the EXIT library in the 
lungs of mice. This was evident in data analysis of the fusions present in bacteria recovered from 
lungs of treated mice, where there was not a sufficient number of high abundance fusions 
identified to develop statistical models. However, using a threshold of 3.5 fold enrichment of a 
gene in the lungs over abundance in the input in duplicate experiments there were 282 proteins, 
representing the strongest candidates for being exported in the lungs. Of these, 274 (97%) were 
identified by EXIT as exported in the spleen (APPENDIX II). These 282 proteins represent 46% 
of the 593 proteins identified as exported in the spleen (APPENDIX II). We predict that a higher 
proportion of the 593 proteins were actually exported in the lungs, but they were not identified 
due to bottleneck effects.  
There was an interesting group of eight proteins not identified by EXIT as exported in the 
spleen but predicted to be exported in the lungs (Table 2.9). Interestingly, 4 of these 8 proteins 
are PE_PGRS proteins, a poorly understood class of proline and glutamic acid repeat containing 
proteins unique to mycobacteria. The identification of these 4 PE_PGRS proteins in the lung data 
from EXIT but not in the more comprehensive spleen data is intriguing as it could reflect lung 
specific mechanisms of expression or export for these proteins. PE_PGRS proteins are a 
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subfamily of PE/PPE proteins (proteins containing Pro-Glu or Pro-Pro-Glu repeat domains) that 
additionally contain polymorphic guanosine-cytosine-rich sequences (PGRS) (Goldberg et al., 
2014). While the function of PE/PPE proteins remains uncertain, evidence suggests that they are 
surface localized, and members of the PE/PPE protein family have been shown to be important 
for M. tuberculosis virulence (Banu et al., 2002; Brennan et al., 2001; Forrellad et al., 2013b). 
Identification of four PE_PGRS proteins as exported only in the lungs identifies them as 
interesting candidate virulence factors 
EXIT exported fusions provide topology information for membrane proteins 
The specific insertion sites of the ‘BlaTEM fusion identified by EXIT provides its own 
useful information about exported protein domains located outside of the cytoplasm. Such 
information is particularly informative for understanding functional domains of integral 
membrane proteins. Only fusions located within periplasmic domains of membrane proteins can 
provide β-lactam resistance; therefore, enriched exported fusion sites can be used to determine 
exported domains and the topology of membrane proteins. Several bioinformatics algorithms 
exist to predict which domains of transmembrane proteins will be exported to the periplasm 
(Krogh et al., 2001; Hofmann & Stoffel, 1993; von Heijne, 1992; Claros & von Heijne, 1994; 
Jones et al., 1994). These algorithms are guided by the positive-inside rule (von Heijne & Gavel, 
1988); however, in terms of topology predictions for membrane proteins it is extremely common 
for different programs to disagree.  
Because the EXIT library had an average of 16 in-frame fusions per gene, it provided 
information on the exported domains of integral membrane proteins in unprecedented detail. All 
2,516 exported fusions sites for the 593 identified EXIT fusions are reported (APPENDIX II). 
There were several examples, discussed below, where the fusion sites provided key insight into 
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the topology of M. tuberculosis membrane proteins that are currently under extensive 
investigation for the important role(s) they play in virulence, physiology or drug resistance.  
MmpL3 and MmpL family members 
The MmpL (mycobacterial membrane protein Large) family of proteins is composed of 
polytopic integral membrane proteins, and M. tuberculosis H37Rv encodes 13 mmpL genes 
(Tekaia et al., 1999). Many MmpL proteins contribute to M. tuberculosis virulence (Domenech 
et al., 2005; Domenech et al., 2004; Converse et al., 2003) and MmpL3 is essential in 
mycobacteria (Domenech et al., 2005). The substrates of most MmpL transporters have yet to be 
identified; however, all the MmpL transporters characterized to date act to export lipids 
(Domenech et al., 2004; Varela et al., 2012; Rayasam, 2014; Converse et al., 2003). The 
essential MmpL3 exports mycolic acid precursors required for biosynthesis of the mycobacterial 
outer membrane (Rayasam, 2014). Resistance mutations to several new TB inhibitors  map to the 
gene encoding MmpL3 (Li et al., 2014; Rayasam, 2014; Remuinan et al., 2013; Poce et al., 
2013; Tahlan et al., 2012; La Rosa et al., 2012), which has attracted a great deal of attention for 
MmpL3 being a potential novel drug target. MmpL proteins usually possess 11-12 predicted 
transmembrane domains with two large loops and a large C-terminal domain. However, the 
membrane topology of MmpL3, and other MmpL members, is under debate (Li et al., 2014; 
Rayasam, 2014; Remuinan et al., 2013; Poce et al., 2013; Tahlan et al., 2012; La Rosa et al., 
2012; Sandhu & Akhter, 2015; Varela et al., 2012). Prediction programs disagree about the 
location (cytoplasmic or periplasmic) of the two large loops of the protein (Figure 2.9A), and 
multiple different topology predictions for this protein are published (Li et al., 2014; Rayasam, 
2014; Remuinan et al., 2013; Poce et al., 2013; Tahlan et al., 2012; La Rosa et al., 2012; Sandhu 
& Akhter, 2015; Varela et al., 2012). EXIT identified 13 different exported fusions in the two   
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Figure 2.9. EXIT Exported fusions clarify the topology of membrane protein MmpL3. A. MmpL3 
predictions for transmembrane domains prediction programs including TopPred, TMHMM, TMpred, and 
Memstat2 predict two large loops (red and blue) and a C-terminal domain (purple); however, disagree on 
the cellular location of these domains. B. Topology diagrams were created by choosing transmembrane 
predictions that best agreed with the exported fusion sites identified by EXIT. 37 unique fusions sites in 
MmpL3 were represented in the input library (blue triangles). Of these, 13 fusion sites were identified as 
exported in EXIT (red triangles top panel), corresponding to exported domains of the MmpL3 protein. 
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predicted large loops of MmpL3 (Figure 2.9B). These fusion sites serve to define the two large 
loops as being localized to the periplasm, which supports one of the topology predictions for 
MmpL3, generated by TopPred (Figure 2.9B) (Claros & von Heijne, 1994). We similarly 
analyzed the enriched fusions identified by EXIT for topological information for the remaining 
MmpL family members. Eleven MmpL family members were represented by 52 unique exported 
fusion sites within the large loops of the proteins, again indicating that MmpL family proteins 
have the two large loops positioned on the periplasmic side of the cytoplasmic membrane (Figure 
2.10). This topology is consistent with the expected topology for RND (Resistance, Nodulation, 
Division) family transporters, with which MmpL proteins share some homology (Domenech et 
al., 2005). The composite topology for MmpL proteins (Figure 2.10) did not include data for 
MmpL6, which was not identified as exported in EXIT. Additionally, the composite topology did 
not include MmpL10, because EXIT identified exported fusion sites contradicted all in silico 
predicted topologies based on in silico predicted transmembrane domains. MmpL10 may be 
structured differently than other MmpL proteins; however, further studies are necessary to 
determine the location of transmembrane domains in MmpL10 that may explain the exported 
fusion sites identified by EXIT.  
MmpL proteins are often encoded by genes in operons containing mmpS genes 
(mycobacterial membrane protein small) (Tekaia et al., 1999). Several MmpS proteins have 
recently been shown to function in MmpL mediated transport (Wells et al., 2013; Jones et al., 
2014). Most MmpS proteins are predicted to contain a single N-terminal transmembrane domain 
(Krogh et al., 2001). Analysis of unique MmpS fusions identified a consensus topology where 
the C-terminal domain was periplasmic (Figure 2.10). MmpS1 is predicted to have a second C-
terminal transmembrane domain, and an exported fusion localizes the loop between the two   
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Figure 2.10. EXIT Exported fusions support composite model of MmpL and MmpS proteins. A 
composite topology was generated by identifying fusions in the two large loops of each of the MmpL 
proteins. All MmpL proteins identified in EXIT except MmpL10 were identified with exported fusions 
(red triangles) in the two large loops, consistent with a shared topology for the MmpL family with the two 
large loops exported to the periplasm. No predicted topology for MmpL10 was consistent with the EXIT 
identified exported fusion sites, so topology of MmpL10 remains unclear. A composite topology was also 
generated for MmpS proteins by analysis of EXIT exported fusion sites in the C-terminal domain of 
MmpS2-5, and the loop of MmpS1.  
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transmembrane domains of MmpS1 to the periplasm (Figure 2.10). This topology is consistent 
with a recent study identifying interactions between the C-terminus of MmpS4/5 proteins and the 
first loop of MmpL4/5 proteins (Wells et al., 2013), both of which are predicted by EXIT to 
localize to the periplasm. 
Emb proteins 
Ethambutol (EMB) is a frontline anti-tuberculosis drug known to target mycobacterial 
cell wall synthesis. EMB resistance mutations are linked to expression and structure of 
mycobacterial arabinosyl transferases (EmbA,B,C proteins) (Telenti et al., 1997) that function in 
the biosynthesis of arabinogalactan and lipoarabinomannan, key components in the 
mycobacterial cell wall (Jackson et al., 2013). Like MmpL3, Emb proteins are essential for M. 
tuberculosis during in vitro growth (Goude et al., 2008), important to synthesis of the 
mycobacterial cell wall, and play important roles in M. tuberculosis drug resistance. Despite their 
significance to mycobacterial cellular physiology and drug resistance, the topology of M. 
tuberculosis Emb proteins has yet to be investigated experimentally. Emb proteins possess 
approximately 13 predicted transmembrane domains, a large N-terminal loop, and a large C-
terminal domain (Krogh et al., 2001). Prediction programs suggest that the topology of EmbB 
may be different than EmbA and EmbC (Krogh et al., 2001). However, analysis of the 25 unique 
exported fusion sites in EmbA, B, and C proteins identified in EXIT is consistent with a similar 
topology for all three proteins, with the N-terminal loop and C-terminal domain localized to the 
periplasm (Figure 2.11). This topology is in agreement with the published topology of the single 
Emb orthologue of Corynebacterium glutamicum, an acid fast organism related to mycobacteria, 
that was determined when heterologously expressed in Escherichia coli (Seidel et al., 2007).  
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Figure 2.11. EXIT exported fusions clarify topology of EMB proteins important to drug resistance 
in M. tuberculosis. Exported fusion sites in EmbABC proteins in M. tuberculosis were analyzed in 
combination with TMHMM predicted transmembrane domains to generate a composite family topology. 
Exported fusions in EmbA are depicted in red, EmbB in yellow, and EmbC in green. 
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ESX (Type VII Secretion System) components  
M. tuberculosis encodes five Type VII secretion system islands, named ESX-1 to ESX-5 
for the first known exported substrate, ESAT-6. ESX secretion is required for full virulence of 
M. tuberculosis, and deletion of the ESX-1 locus is one of the main attenuating mutations in the 
BCG vaccine strain (Ligon et al., 2012). ESX gene clusters display a high level of conservation, 
and encode ESX conserved components (Ecc), ESX specific proteins (Esp), and mycosins 
(MycP) which form the export machinery. The export mechanism of ESX systems is being 
actively investigated; however, all ESX systems are believed to form multi-protein transport 
complexes with components in the cytoplasm and inner membrane (Houben et al., 2014). It is 
proposed that substrates are targeted to an ESX membrane complex consisting of four conserved 
membrane proteins (EccBCDE), all of which are required for ESX secretion; however, the 
individual role of each protein within the complex remains unclear (Houben et al., 2014). 
EccBCDE and MycP have been localized to the cell envelope in M. marinum (Houben et al., 
2012). However, the topology for these five membrane proteins has yet to be determined 
experimentally. EXIT obtained 33 unique exported fusions in EccB, EccD, and MycP family 
members, representing components of four of the five Type VII secretion systems in M. 
tuberculosis (ESX-1, ESX-2, ESX-3, and ESX-5). Sites of exported fusions localized the large 
C-terminal domain of EccB and the large N-terminal globular domain of MycP to the periplasm 
(Figure 2.12). This data supports the proposed topology of EccB and MycP based on in silico 
modeling (Houben et al., 2014). Localization of the globular domain for MycP within the 
periplasm is significant because MycP has protease activity, and EXIT data demonstrates that the 
known active site for protease cleavage from crystallography data is localized to the periplasm 
(Ohol et al., 2010; Wagner et al., 2013). While the function of EccB remains unclear the finding   
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Figure 2.12. EXIT exported fusions clarify topology of ESX Type VII secretion system membrane 
proteins. Genomic clusters encoding ESX or Type VII secretion systems encode five known membrane 
proteins thought to compose the ESX secretion machinery. EXIT identified exported fusion sites in three 
components of these systems, EccB, EccD, and MycP for four of the five ESX secretion systems in M. 
tuberculosis. Transmembrane domain predictions were made by TMHMM and EXIT exported fusion 
sites were combined to generate a topology diagrams. Yellow triangles represented fusions in ESX-1 
membrane proteins, purple in ESX-2, green in ESX-3, and red in ESX-5. The EccD protein in ESX-1 was 
predicted to have one more transmembrane domain than other EccD proteins, and this extra predicted 
transmembrane domain was depicted in grey. 
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that the majority of the protein is localized in the periplasm can help guide future functional 
studies.  
The EccD proteins are predicted to have approximately 10 transmembrane domains (the 
ESX-1 member of the EccD family, EccD1, is predicted to have 11), with a large N-terminal 
domain and a large loop after the sixth transmembrane domain (Krogh et al., 2001). Because of 
their multiple transmembrane domains, EccD proteins are the best candidates for being the 
membrane channel used for transport (Ligon et al., 2012). However, the function of the EccD 
family proteins in ESX secretion has not been studied. EXIT did not obtain any exported fusions 
in the N-terminal domain or the large loop; however, exported fusions were identified in several 
small loops opposite of these domains (Figure 2.12). This data suggests that the large domains of 
EccD are cytoplasmic, which will be useful for further study of the function and mechanism of 
EccD proteins to ESX secretion.  
Identification of proteins exported significantly more in vivo than in vitro 
Our original hypothesis was that a subset of M. tuberculosis proteins are exported 
significantly more during in vivo infection than during in vitro growth. One mechanism by which 
a protein could be exported more in vivo than in vitro is if its expression levels are induced in 
vivo due to transcriptional or posttranscriptional effects. Several studies have identified genes in 
M. tuberculosis whose expression is upregulated in the host environment (Talaat et al., 2004; 
Dubnau & Smith, 2003; Rohde et al., 2007b; Timm et al., 2003; Talaat et al., 2007; Rachman et 
al., 2006b; Schnappinger et al., 2003). Alternatively, the responsible protein export system could 
be upregulated or only active in the host, resulting in substrates exported more in vivo than in 
vitro. There are examples of protein export systems of other bacterial pathogens that are turned 
on or induced during infection. For example, the Salmonella type III secretion system T3SS2  is 
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only expressed and active following cellular invasion, when exported effector proteins are 
required for maturation of the Salmonella containing vacuole (Malik-Kale et al., 2011). 
Similarly, the Yersinia T3SS is not normally expressed during in vitro growth; however, 
expression can be induced in vitro by temperature and calcium concentrations that mimic 
conditions encountered during infection (Dewoody et al., 2013). In this thesis we will use the 
terminology “in vivo induced” to refer to either category of proteins that are exported more in 
vivo versus in vitro. Regardless of mechanism, exported proteins that are induced in vivo are 
attractive candidates for being previously overlooked proteins with critical roles in M. 
tuberculosis virulence.  
In an attempt to identify in vivo induced exported proteins, the EXIT library bacteria 
surviving β-lactam treatment in mice were plated in parallel on regular agar media and β-lactam 
containing agar media (Figure 2.13). The clones recovered on regular media reported on the total 
population of fusion proteins exported during infection. As described above, these fusions were 
sequenced leading to the identification of 593 proteins as exported during infection. Clones that 
grow on media containing β-lactams express fusions that are additionally expressed and exported 
under in vitro conditions. The fusions recovered on β-lactam containing media were sequenced 
from duplicate experiments, and there was a high degree of correlation between replicates 
(Figure 2.14A).  
Fusion proteins that enabled survival in a -lactam treated mouse in vivo and on -lactam 
containing agar in vitro are considered examples of proteins that are exported both in vitro and in 
vivo. In comparison, any clones that expressed reporter fusions to proteins that are only 
expressed/exported during infection would survive β-lactam treatment in vivo but be unable to 
grow in vitro on media containing β-lactam antibiotics. The majority of in vivo exported proteins   
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Figure 2.13. Strategy for identification of proteins exported more in vivo than in vitro. Identification 
of proteins with export upregulated during infection used a modified EXIT approach. As described in 
Figure 2.2, mice were infected with the EXIT library, treated with β-lactam antibiotics, and spleens were 
harvested and homogenized two weeks after infection. Spleen homogenates were plated in parallel on 
solid agar media to recover all clones (red venn diagram), and solid agar media containing β-lactam 
antibiotics to recover clones exporting ‘BlaTEM fusion proteins during in vitro growth (purple venn 
diagram). The population of clones only identified, or identified in significantly greater abundance on 
media lacking β-lactams represented proteins whose export was upregulated during infection (blue). 
Statistical analysis identified 38 proteins. 
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Figure 2.14. Statistical modeling identified 38 proteins exported significantly more in vivo than in 
vitro. A. Raw sequenced read count values in the mouse output after β-lactam selection in vivo and in 
vitro for each fusion junction site were plotted for replicate experiments A and B. A Pearson Product 
Moment correlation identified a significant correlation r value of 0.858. B. Raw sequenced read count 
values for each fusion junction site were plotted to compare samples with only β-lactam selection in vivo, 
or those that were treated with β-lactams in vivo and in vitro. A Pearson Product Moment correlation 
identified a significant correlation r value of 0.857. C. Raw sequenced read count values for the 593 
proteins identified as exported in EXIT were plotted to compare β-lactam treatment in vivo, with dual β-
lactam treatment in vivo and in vitro. The majority of proteins identified as exported in vivo remained 
highly abundant after additional β-lactam treatment in vitro (black), representing most proteins which are 
exported similarly in vitro and in vivo. Genes highlighted in red were identified as statistically less 
abundant after in vitro β-lactam selection, representing proteins exported significantly more in vivo than 
in vitro. D. Abundance was determined individually for each gene based on sequenced read counts for the 
most highly abundant fusion site in each experiment. A ratio was determined for abundance after in vivo 
β-lactam treatment compared with abundance after dual β-lactam treatment in vivo and in vitro. Higher 
numbers correspond to genes that survived β-lactam treatment in mice but were killed during in vitro β-
lactam treatment. Statistics were used to identify 38 genes on the right shoulder that were significantly 
different than the normal population. These genes encoded proteins exported significantly more in vivo 
than in vitro.   
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identified were also exported in vitro as shown by a high level of correlation in the abundance of 
clones recovered on media containing or lacking β-lactams r=0.857 (Figure 2.14B). 
 As a starting point for comparing the abundance of each fusion after recovery on regular 
media (in vivo exported proteins) versus recovery on media containing β-lactam antibiotics (in 
vivo and in vitro exported proteins), we calculated an abundance ratio between the two 
conditions. The distribution of abundance ratios was uni-modal and normal, with a small right 
shoulder (Figure 2.14C). The null hypothesis was disproven, and a statistically significant 
difference was found for a subset of clones recovered on regular media versus those recovered 
on β-lactams containing media. Using a false discovery rate (FDR) set at 5%, after a correction 
for multiple comparisons, 38 genes (6% of the total 593 identified by EXIT) were identified as 
having significantly reduced abundance on β-lactam containing agar in vitro compared to regular 
media, and thus predicted to encode fusions that are exported significantly more in vivo than in 
vitro (Figure 2.14D, Table 2.10).  
 The exported proteins we identified as in vivo induced may represent a spectrum of 
effects, with some exported proteins being induced during infection and others being exclusively 
exported during infection. Consistent with this range of in vivo induced effects, five of the 38 in 
vivo induced exported proteins are predicted to be essential during in vitro growth by saturating 
mutagenesis approaches, meaning they most likely have a function during in vitro growth 
(Griffin et al., 2011; Sassetti et al., 2003). Thus, these proteins likely represent examples of 
proteins that are exported and functional during in vitro growth and induced during infection. Of 
the 38 in vivo induced proteins identified, 14 (37%) are known to be transcriptionally induced 
during infection (Dubnau et al., 2005; Dubnau et al., 2002; Schnappinger et al., 2003; Rachman 
et al., 2006b ; Talaat et al., 2007; Rohde et al., 2007a; Rohde et al., 2007b; Sharma et al., 2006; 
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Srivastava et al., 2007; Rodriguez et al., 2013). The precedent for these proteins being reported 
as in vivo induced provides strong support for the EXIT methodology to identify in vivo induced 
exported proteins. The mechanism of regulation for the remaining 23 proteins remains to be 
determined. 
Among the 38 in vivo induced exported proteins are proteins with functions in regulation, 
host defense, myco-membrane synthesis, and nutrient acquisition. 13 of the in vivo induced 
exported proteins (34%) have demonstrated or predicted roles in virulence (Reddy et al., 2013; 
Danelishvili et al., 2010; Chuang et al., 2015; Papavinasasundaram et al., 2005; Rifat et al., 
2014; Tischler et al., 2013; Marjanovic et al., 2010; McCann et al., 2011; Gioffre et al., 2005; 
Senaratne et al., 2008; Dutta et al., 2010; Hu et al., 2010; Sassetti & Rubin, 2003; Stewart et al., 
2005; Rengarajan et al., 2005). 21 of the 38 proteins (55%) have unknown function. Most of the 
function unknown proteins are not previously studied and they represent potentially unidentified 
and underappreciated virulence factors. Additionally, eight (21%) of the 38 proteins do not 
possess in silico predicted export signals, suggesting they may be exported by unique 
mechanisms.  Below we review some of the most notable in vivo induced exported proteins 
identified by the EXIT strategy. 
Regulation 
Two regulatory proteins were identified as being exported significantly more in vivo than 
in vitro. SenX3 is the sensor histidine kinase of the SenX3-RegX3 two component regulatory 
system implicated in phosphate responsive gene regulation (Rifat et al., 2009; Rifat & 
Karakousis, 2014; Glover et al., 2007). SenX3 is required for growth in phosphate limiting 
conditions, and important to virulence (Rifat et al., 2009; Glover et al., 2007; Rifat et al., 2014; 
Tischler et al., 2013). PknH is a serine/threonine protein kinase unique to pathogenic 
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mycobacterial strains and known to regulate production of phthiocerol dimycoceroserate (PDIM) 
(a complex lipid with a role in virulence) and expression of the dormancy regulon (Sharma et al., 
2006; Gomez-Velasco et al., 2013; Chao et al., 2010). Deletion of pknH results in 
hypervirulence, as the pknH mutant bacteria replicate to a higher bacterial load in mice than WT 
M. tuberculosis (Papavinasasundaram et al., 2005). Both SenX3 and PknH are membrane 
proteins with predicted transmembrane domains (Krogh et al., 2001).  
For these regulators identified by EXIT as in vivo induced, their induction is likely a 
reflection of a transcriptional effect during infection. Transcript levels of pknH are upregulated 
during intracellular growth in macrophages (Sharma et al., 2006; Srivastava et al., 2007). 
Further, while transcript levels of senX3 have not been directly tested during infection, senX3 
expression is induced by phosphate depletion (Rifat et al., 2014; Rifat & Karakousis, 2014). 
Identification of SenX3 as an in vivo induced exported protein suggests that M. tuberculosis may 
encounter phosphate limiting conditions during infection, similar to many other bacterial 
pathogens (Lamarche et al., 2008).  
Myco-membrane synthesis 
 Mycobacteria have a unique outer membrane structure, called the myco-membrane, 
which is composed of specialized lipids important to cellular physiology and virulence (Figure 
1.2). Biogenesis of the myco-membrane requires a series of biosynthetic enzymes and 
transporters, many of which are unique mycobacterial exported proteins. Two specialized lipid 
transporters (DrrC and MmpL8) important to myco-membrane synthesis were identified by 
EXIT as being exported significantly more in vivo than in vitro. DrrC is an exported membrane 
protein important for transport of PDIM to the myco-membrane (Camacho et al., 2001; Camacho 
et al., 1999; Forrellad et al., 2013b). MmpL8 is a multi-membrane spanning integral membrane 
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protein that plays a role in biosynthesis and transport of sulfolipid-1 (SL-1), an abundant lipid in 
the myco-membrane (Domenech et al., 2004; Converse et al., 2003). Previous studies are 
consistent with PDIM levels and mmpL8 expression increasing during infection (Jain et al., 
2007; Rodriguez et al., 2013). Our identification of DrrC and MmpL8 being exported at 
increased levels during infection may indicate a need for increased levels of specialized lipids 
within the myco-membrane during infection. 
Host Defense 
Two of the proteins identified as in vivo induced exported proteins play roles in defense 
from and manipulation of the host: Mmco and Rv3654c. Mmco is a periplasmic multi-copper 
oxidase, and one of several proteins that provide protection from copper toxicity, a newly 
described macrophage defense strategy (Rowland & Niederweis, 2013; Shi & Darwin, 2015). 
The expression of mmco is controlled by a copper responsive regulator, RicR (Festa et al., 2011), 
and Mmco protein levels increase after incubation with copper (Shi et al., 2014). Our 
identification of Mmco as exported more in vivo than in vitro confirms previous studies 
suggesting that M. tuberculosis encounters high copper concentrations during murine infection 
(Talaat et al., 2004; Ward et al., 2010; Neyrolles et al., 2015).  
A particularly interesting protein on the list of in vivo induced exported proteins is 
Rv3654c, which has a function suppressing macrophage apoptosis during infection (Danelishvili 
et al., 2010). In silico predictions do not predict Rv3654c to be an exported protein, and thus it is 
also on our list of 32 proteins identified by EXIT with no in silico export signal. However, 
Rv3654c was previously identified in macrophage lysates cleared of intracellular M. 
tuberculosis, suggesting it is exported out of the bacterial cell and into the macrophage during 
infection (Danelishvili et al., 2010). Our EXIT results provide important confirmation of 
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Rv3654c being an exported protein.  Further, the identification of Rv3654c on our list of 
exported proteins induced in vivo is consistent with previously described transcriptional 
induction of the rv3654c gene during macrophage infection (Danelishvili et al., 2010). 
Interestingly, rv3654c is located within an operon encoding proteins with homology to tight 
adherence (Tad) secretion system components (Tomich et al., 2007; Danelishvili et al., 2010), 
offering a potential export mechanism for this unconventional exported protein. Future studies 
are required to determine the contribution of Tad-like proteins to export of Rv3654c.  
Nutrient acquisition 
Seven (18%) of the 38 proteins EXIT identified as exported significantly more in vivo 
than in vitro are predicted to play a role in nutrient acquisition, reflecting altered nutritional 
requirements or availability during infection, compared to in vitro growth conditions. Iron, 
sulfur, and nitrogen are all fundamental inorganic nutrients required for life and examples of 
elements that bacteria must acquire to successfully grow in an intracellular environment. We 
identified multiple examples of proteins important for acquisition of these elements as being 
export induced during infection. Iron acquisition is a well-studied virulence mechanism for 
bacterial pathogens (Becker & Skaar, 2014). Biosynthesis of siderophores, iron chelating 
molecules designed to compete for and deliver host iron to bacteria, is induced during infection 
(Timm et al., 2003; Schnappinger et al., 2003). We identified MtbE, one essential component of 
the siderophore biosynthetic operon, as being induced during infection, which is consistent with 
transcriptional induction stimulated by low iron conditions in vivo (Reddy et al., 2013). NarK2 
and NarK3 are two of four predicted nitrate/nitrite transporters in M. tuberculosis, with NarK2 
being shown to be a H
+
:nitrate antiporter (Giffin et al., 2012). Expression of narK2 is induced in 
hypoxic conditions and during infection, and expression and nitrate transport occurs concurrently 
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with increased nitrate reductase activity, yielding large quantities of nitrite (Sohaskey & Wayne, 
2003; Shi et al., 2005). Although the assumption may have been that induction of narK2 is 
required for acquisition of nitrogen for nutrition during infection, nitrate imported by narK2 is 
thought to be used primarily as a terminal electron acceptor for respiration rather than 
assimilation (Sohaskey & Wayne, 2003; Gouzy et al., 2014). Thus, the source of nitrogen as a 
nutrient, the pathways responsible for nitrogen acquisition and assimilation during infection, and 
whether nitrogen acquisition pathways are required for virulence remain to be determined 
(Gouzy et al., 2014). Rv1739c is one of three predicted SulP family sulfate transporters in M. 
tuberculosis, and it is shown to transport sulfate when expressed in E. coli (Zolotarev et al., 
2008). However, the role of SulP family sulfate transporters to sulfate transport in vitro or during 
infection is currently unknown. Our identification of Rv1739c as exported in vivo suggests that 
this understudied group of proteins could be important during infection (Niederweis, 2008; 
Zolotarev et al., 2008).  
Mce lipid transporters 
 M. tuberculosis encodes four mce operons predicted to encode multi-protein complexes 
that import lipids (Casali & Riley, 2007). Mce4 is shown to import cholesterol (Pandey & 
Sassetti, 2008; Mohn et al., 2008), and recent evidence suggests that Mce1 plays a role in 
recycling mycolic acids, which are central components of the myco-membrane (Forrellad et al., 
2014; Cantrell et al., 2013). In contrast, the substrates for Mce2 and Mce3 transporter systems 
have yet to be characterized, although Mce2 and Mce3 are known to contribute to M. 
tuberculosis virulence (Marjanovic et al., 2010; McCann et al., 2011; Gioffre et al., 2005; 
Senaratne et al., 2008; Dutta et al., 2010). The operons encoding Mce2 and Mce3 appear to be 
repressed during in vitro growth (Santangelo et al., 2002; Santangelo Mde et al., 2009; Forrellad 
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et al., 2013a; Gioffre et al., 2005) but expressed during infection (Santangelo et al., 2002; 
Schnappinger et al., 2003). Consistent with these findings, several exported components of Mce2 
and Mce3 transporters were found to be significantly induced during infection (Mce2E, YrbE3B, 
and Mce3D). Direct investigation of the suite of exported components of the Mce2 and Mce3 
systems revealed a consistent trend in being exported more in vivo than in vitro, although some 
of these proteins did not meet our stringent statistical cutoffs of significance (Figure 2.15).  
 Eighteen percent of proteins identified by EXIT as exported more in vivo than in vitro 
belonged to the category of proteins required for nutrient acquisition, underscoring the 
differences in nutrient availability and acquisition between in vitro and in vivo growth. Many of 
these nutrient acquisition systems are understudied, and the nutrients they are responsible for 
acquiring have yet to be determined, highlighting the limitations of our knowledge about growth 
in vivo.  
In vivo induced exported proteins of unknown function 
One goal of EXIT was to provide information on function unknown proteins. 
Determining a given protein’s localization and regulation are two common strategies for learning 
about a protein of unknown function. Towards this goal, EXIT experimentally identified 21 
proteins of unknown function as being exported and induced in vivo. These proteins represent the 
most exciting category of proteins identified by EXIT. Two of these 21 proteins belong to the 
MmpL/S family of mycobacterial proteins, MmpS2 and MmpL13a. Like other MmpL/S family 
proteins these membrane proteins are likely to be transporters; however, they remain to be 
characterized (Domenech et al., 2005).  
  
 91 
 
Figure 2.15. Proteins of the Mce2 and Mce3 lipid transporters of M. tuberculosis are reliably 
exported more in vivo than in vitro. Genes in mce operons encoding multi-protein Mce lipid transporters 
were analyzed for evidence of being exported more in vivo than in vitro. While only three genes were 
statistically significant (mce2E, yrbE3B, and mce3D) multiple other genes in mce2 and mce3 operons 
were depleted more than two fold change after in vitro β-lactam treatment (green arrows). In contrast, 
genes in mce1 or mce4 operons showed no change in abundance after in vitro β-lactam treatment (grey 
arrows), demonstrating export in vitro as well as in vivo.  
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Three of the in vivo induced exported proteins of unknown function have no in silico 
predicted export signal: PPE54, PPE60, and Rv3707c. PE/PPE proteins are surface localized, and 
expression of ppe genes varies widely in different in vitro conditions (Voskuil et al., 2004; Banu 
et al., 2002; Brennan et al., 2001). Neither PPE54 or PPE60 have a YxxxD/E motif, described as 
being important for Type VII secretion of PE/PPE proteins (Daleke et al., 2012), and neither 
protein is located in an operon with a Type VII secretion system. Consequently, the mechanism 
of export of these proteins is currently unknown. Expression of ppe54 is induced during human 
infection (Rachman et al., 2006b), and PPE54 appears to play a role in preventing phagosomal 
maturation, an important process in M. tuberculosis virulence (Brodin et al., 2010). Rv3707c is 
important for preventing phagosomal maturation in the attenuated vaccine strain Mycobacterium 
bovis BCG, and for growth of BCG in macrophages (Stewart et al., 2005). The mechanism of 
export for Rv3707c is also unknown because it possesses no in silico predicted export signal.  
Importantly, in this thesis we confirmed that Rv3707c was exported to the cell wall in M. 
tuberculosis (Figure 2.8B).  
 Potentially the most interesting category of unknown function proteins we identified as in 
vivo induced exported proteins are those that are predicted to be fully secreted. Of all the 
categories of exported proteins, the fully secreted proteins are most likely to localize outside of 
the bacterial cell and interact with the host. Two proteins, Rv0559c and Rv0817, have predicted 
Sec signal peptides and, because they lack any additional predicted transmembrane domains, 
they may be fully secreted. Both of these proteins have been identified as core mycobacterial 
proteins, defined as proteins with homologues throughout mycobacteria but no homologues 
outside of actinomycetes (Marmiesse et al., 2004). The potential role of Rv0559c and Rv0817 in 
virulence has yet to be tested, but these proteins are particularly interesting virulence candidates.  
 93 
Future studies will help to understand how and why M. tuberculosis regulates export of 
these proteins, and their potential role in virulence and immunogenicity. Identifying these 
proteins as exported and further characterization of their role during disease could lead to a better 
understanding of M. tuberculosis infection and host-pathogen interactions.  
 
Discussion 
EXIT is the first genome-wide method for discovering bacterial proteins exported during 
infection. As such, it represents a powerful tool for identifying new proteins with roles in host-
pathogen interactions. Previous methodologies used to identify exported proteins of bacteria 
were limited to identifying proteins exported during growth in lab media, in vitro. With in vitro 
based systems, potentially interesting and important proteins exported only in vivo in an animal 
model of disease would have been overlooked.  
Besides EXIT there are recent studies of bacterial protein export in vivo; however, so far, 
these efforts are limited to direct testing of individual proteins. In several cases the studies utilize 
individual protein fusions to the ‘BlaTEM reporter, however, the fusions were detected using a 
cell-permeable fluorescent β-lactamase substrate (CCF2-AM) to monitor transport out of the 
bacterium and into host cells during infection (Pechous et al., 2013; Danelishvili et al., 2014; Ge 
et al., 2009; Broms et al., 2012). While this approach can be used to identify certain types of 
proteins exported in the context of host cells, it does not take advantage of ‘BlaTEM as a 
selectable marker and screening of individual clones is required. Thus, scaling up to a level of 
genome-wide discovery, as done in EXIT, would be difficult with this method. In a different 
approach, click-chemistry was recently used to study export of Type III secretion system (T3SS) 
proteins exported during infection (Mahdavi et al., 2014). This approach uses an engineered t-
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RNA to incorporate an unnatural amino acid (azidonorleucine, ANL) into proteins produced by 
Yersinia entercolitica (Tanrikulu et al., 2009; Mahdavi et al., 2014). ANL can be targeted by 
click-chemistry to selectively enrich for ANL-containing proteins, addressing one of the 
difficulties of using mass spectrometry to identify exported bacterial proteins amongst a mixture 
of predominately host proteins. The authors used this strategy to confirm the export and 
determine the timing of export for T3SS substrates injected by extracellular Y. entercolitica into 
cultured macrophages (Mahdavi et al., 2014). However, the authors were unable to conclusively 
identify any new exported proteins; the other proteins identified in this study are likely to be 
cytoplasmic contaminants (Mahdavi et al., 2014). Further refinement of the ANL methodology 
will be required before this method is broadly applicable to identifying in vivo exported proteins 
on a large-scale.  
The EXIT Strategy 
 The ‘BlaTEM reporter and EXIT methodology are theoretically compatible with any 
bacterium that is either naturally, or can be made genetically, β-lactam sensitive. This study 
focused on application of EXIT to the study of M. tuberculosis and identification of in vivo 
exported proteins during acute murine infection. However, EXIT could be used in the future to 
study the in vivo exported proteome for a variety of pathogens, in diverse models of infection, 
and could lead to a better understanding of host-pathogen interactions for multiple bacterial 
diseases.  
As a new method, there were several obstacles to overcome in the development of EXIT.  
We were initially concerned about the potential of having a high background of non-exported 
fusions due to trans-complementation and/or lysis of bacteria expressing non-exported fusions, 
which could release active β-lactamase and potentially promote the survival of surrounding 
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bacteria. However, proof of principle experiments in which in vivo β-lactam selection was tested 
with mixed populations of β-lactam sensitive and β-lactam resistant clones showed significant 
enrichment of β-lactam resistant clones, indicating that any background that possibly exists was 
insufficient to mask the power of the β-lactam selection (Figure 2.4, Table 2.4). We also had to 
optimize β-lactam dosage and route of infection to be compatible with screening the large EXIT 
library. Fortunately several different routes of infection are routinely used to model tuberculosis 
in mice (Orme & Gonzalez-Juarrero, 2007). A low dose aerosol model is most similar to natural 
infection, where humans are thought to be infected by inhalation of as few as one bacterium 
(Russell et al., 2010). However, a low aerosol dosage (100 bacteria) is not compatible with 
screening a large library and we were unsuccessful in our effort to establish conditions to achieve 
a sufficiently high pulmonary dose (~50,000 cfu/lungs) for surveying the EXIT library in a 
comprehensive manner. These difficulties in achieving a high lung burden by the aerosol route of 
infection explain why genome-wide saturating mutagenesis screens for M. tuberculosis (e.g. 
TraSH, DeADMAn) use mice that are infected by intravenous injection and analyzed the library 
recovered from the spleens (~ 1 x10
6
 cfu/spleen) (Sassetti & Rubin, 2003; Zhang et al., 2013; 
Lamichhane et al., 2005). Despite the focus on spleens instead of the lungs, these genome-wide 
screens have effectively identified a large number of virulence factors later confirmed to be 
important to growth and survival in both spleens and lungs (Sassetti & Rubin, 2003; Forrellad et 
al., 2013b; Zhang et al., 2013; Lamichhane et al., 2005). Thus, for EXIT we similarly utilized 
mice that were infected by intravenous injection and comprehensively surveyed the library in 
spleens. We also gathered and analyzed data from lungs to identify trends; however, the reported 
results of EXIT focus primarily on the robust dataset from the spleens.  
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Proteins identified as exported in vivo 
 EXIT identified 593 proteins as exported in vivo. Not only is this an impressive 
accomplishment because it is the first effort to identify proteins on a genome-wide level as 
exported in vivo, but it also represents a large number of exported proteins being identified at one 
time by a genetic reporter in a bacterial pathogen. The effectiveness of EXIT was a result of the 
following features of the system: 1) the highly comprehensive library (99% of the genome 
represented with at least one in frame fusion in the library), 2) the use of the ‘BlaTEM reporter 
as a selectable marker, and 3) the use of next-generation sequencing to identify enriched 
exported fusions. EXIT identified proteins known to localize within each exported compartment: 
cytoplasmic membrane (e.g. MmpL), periplasm (Mmco), cell wall (penicillin binding proteins, 
Ag85A/FbpA), myco-membrane (outer membrane protein A, OmpA), fully secreted proteins 
(Mpt32, Mpt63, Mpt64), and even proteins shown to be secreted out of the phagosome during 
intracellular M. tuberculosis growth (19kD/LpqH). 100 of the proteins identified by EXIT had 
not previously been experimentally demonstrated as exported by genetic reporter or mass 
spectrometry based methodologies (Gu et al., 2003; Rosenkrands et al., 2000a; Xiong et al., 
2005; Mawuenyega et al., 2005; Wolfe et al., 2010; Malen et al., 2007; de Souza et al., 2011; 
Bell et al., 2012; Gunawardena et al., 2013; Braunstein et al., 2000; Gomez et al., 2000; 
McDonough et al., 2008; McCann et al., 2011; Feltcher et al., 2015).  
EXIT identified 32 proteins with no in silico predicted export signals and six unannotated 
regions of the genome that appear to encode exported proteins. Three of the proteins with no 
predicted export signals were selected for further analysis and all three were successfully 
validated as exported and localized to the cell wall of M. tuberculosis (Figure 2.8B). Given this 
successful validation, it seems likely that there are additional examples of unconventional 
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exported proteins on this list of 32 exported proteins lacking in silico predicted export signals 
There is clear precedence for novel export systems in bacterial pathogens, and commonly these 
specialized export systems play important roles in virulence. However, it is often difficult to 
identify substrates of these export systems (Ligon et al., 2012). Therefore, we are excited about 
the potential for proteins identified by EXIT but lacking in silico predicted export signals to 
represent new exported substrates of currently unknown export pathways.  
There was an interesting group of eight proteins not identified by EXIT as exported in the 
spleen but predicted to be exported in the lungs, including four PE_PGRS proteins (Table 2.9). 
PE_PGRS proteins are a subfamily of PE/PPE proteins that additionally contain polymorphic 
guanosine-cytosine-rich sequences (PGRS) (Goldberg et al., 2014). Among the 4 PE_PGRS 
family we identified in the lung, but not the spleen, is PE_PGRS33. PE_PGRS33 is the best 
studied PE_PGRS protein, and it contributes to growth of the M. bovis BCG vaccine strain in 
macrophages (Brennan et al., 2001), Additionally, PE_PGRS33 may modulate the host cytokine 
response during M. tuberculosis infection (Bottai et al., 2014; Goldberg et al., 2014). The 
identification of these 4 PE_PGRS proteins in the lung data from EXIT but not in the more 
comprehensive spleen data is intriguing as it could reflect lung specific mechanisms of 
expression or export for these proteins. 
We had prior evidence that the ‘BlaTEM reporter is compatible with fusions containing 
large N-terminal segments of the native protein (McCann et al., 2007), and EXIT successfully 
identified exported fusions throughout many large exported proteins (Figure 2.9B, APPENDIX 
II). For every protein identified, the site of enriched fusions to the reporter is provided in 
APPENDIX II. There are many prediction programs available to predict transmembrane domains 
and membrane protein topology; however, the predictions of these programs often disagree 
 98 
(Krogh et al., 2001; Sonnhammer et al., 1998; Hofmann & Stoffel, 1993; Claros & von Heijne, 
1994; Jones et al., 1994). For example, different prediction programs led to multiple published 
topology predictions for MmpL3 (Li et al., 2014; Rayasam, 2014; Remuinan et al., 2013; Poce et 
al., 2013; Tahlan et al., 2012; La Rosa et al., 2012; Sandhu & Akhter, 2015; Varela et al., 2012). 
Fusion site information from EXIT provided strong evidence in favor of one of the predicted 
topologies, generated by TopPred (Figure 2.9B) (Claros & von Heijne, 1994). The EXIT 
database of exported fusion sites for 337 membrane proteins will help in selecting the correct 
topology prediction and the dataset could also be useful for building an improved prediction 
algorithm to define the location of extra-cytoplasmic domains.  
EXIT identified 57% of the in silico predicted exported proteome (1040 proteins) as 
exported in vivo (Krogh et al., 2001; Petersen et al., 2011; Sonnhammer et al., 1998; Sutcliffe & 
Harrington, 2004; McDonough et al., 2008). In silico algorithms remain the easiest and most 
used method of identifying a protein’s localization; however, some of the predictions may be 
wrong. It is interesting to note that 39% of the M. tuberculosis proteins predicted as exported in 
silico but NOT identified by EXIT have never been identified as exported by any method, 
including mass spectrometry based approaches (Gu et al., 2003; Rosenkrands et al., 2000a; 
Xiong et al., 2005; Mawuenyega et al., 2005; Wolfe et al., 2010; Malen et al., 2007; de Souza et 
al., 2011; Bell et al., 2012; Gunawardena et al., 2013; Braunstein et al., 2000; Gomez et al., 
2000; McDonough et al., 2008; McCann et al., 2011; Feltcher et al., 2015). This lack of 
identification by any experimental method could reflect these proteins not being truly exported, 
being present in very low abundance, or not expressed in the conditions tested. EXIT was limited 
to testing proteins expressed during the first two weeks (acute phase) of murine infection. 
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Testing for export during later stages of murine infection or in additional animal models could 
potentially identify additional exported proteins of M. tuberculosis.  
Lack of identification by EXIT is not sufficient evidence to conclude a protein is not 
exported. Genetic reporters for export can be limited by incompatibility with specialized export 
systems, the level of expression required for a positive export signal (β-lactam resistance), and 
instability of certain fusion proteins. For example, despite the representation of ESAT-6 like 
proteins by in frame fusions in the input library, none of these classic ESX secreted proteins 
were identified as exported by EXIT. This was initially surprising, as a recent paper 
demonstrated that the ‘BlaTEM reporter could report on ESX secreted proteins; however, this 
paper has since been fully retracted (2013; Rosenberger et al., 2012). It is currently unknown 
whether the lack of identifying ESAT-6 like proteins with the ‘BlaTEM reporter is due to 
incompatibility of this reporter with ESX secretion, instability of reporter fusions to this category 
of proteins, or interrupted binding of ESAT-6 like protein fusions to their co-secreted proteins. 
PE_PGRS proteins contain a predicted YxxxD/E motif, and are thought to be exported by ESX 
secretion (Daleke et al., 2012). Four PE_PGRS proteins were identified by EXIT in the lungs 
(Table 2.9), suggesting that ‘BlaTEM reporter may not be inherently incompatible with ESX 
secretion. However, it is notable that three of these four PE_PGRS proteins also had in silico 
predicted Sec signal peptides (Table 2.9) (Petersen et al., 2011), thus it will be important to 
determine which targeting domain (Sec signal peptide or YxxxD/E motif) is responsible for 
export of these PE_PGRS proteins.  
Proteins identified as exported significantly more in vivo than in vitro 
The original impetus for identifying proteins exported during infection was the 
hypothesis that some proteins would only be exported, and thus only identified as exported, in 
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vivo. EXIT provided evidence for 38 proteins being in vivo induced exported proteins (i.e. 
proteins that are exported to higher levels during infection), most of which have unknown 
function (Table 2.10). Determining whether these proteins are uniquely expressed and/or 
exported during infection will require further study. It is notable that 13 of these proteins (34%) 
have not been identified previously as exported in vitro, including by highly sensitive MS 
methods, and may represent proteins uniquely exported during infection (Gu et al., 2003; 
Rosenkrands et al., 2000a; Xiong et al., 2005; Mawuenyega et al., 2005; Wolfe et al., 2010; 
Malen et al., 2007; de Souza et al., 2011; Bell et al., 2012; Gunawardena et al., 2013; Braunstein 
et al., 2000; Gomez et al., 2000; McDonough et al., 2008; McCann et al., 2011; Feltcher et al., 
2015).  
The mechanism for in vivo induced export of each protein has yet to be determined, and 
there are several different possibilities. First, a subset of proteins with induced export during 
infection will be transcriptionally induced during infection. Secondly, some of these proteins 
may be post-transcriptionally regulated: translated or stabilized during infection. Finally, we 
hypothesize that the export of some proteins may be directly controlled, such that the protein is 
maintained within the bacterial cytoplasm until a signal is received to initiate export. This could 
occur through regulated expression and/or building of the export apparatus, or regulated 
triggering of the export process. Future studies will be necessary to define the mechanism of in 
vivo regulation for each of these proteins.  
 The identification of exported proteins lacking in silico predicted export signals and 
identification of unannotated exported proteins demonstrates the power of an unbiased genome-
wide strategy as well as an unbiased sequencing platform. The ability to assign an exported 
location to unpredicted exported proteins exemplifies how EXIT can provide functional genomic 
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information to open reading frames (ORFs) of unknown function. Identification of exported 
proteins is important because exported proteins often are virulence determinants for pathogens 
(Ligon et al., 2012). Additionally, exported proteins, and protein export in general are potentially 
good targets for anti-virulence treatments and antibiotics as antibiotics would not have to fully 
penetrate the bacterial cell to reach their target (Feltcher et al., 2010). Finally, because bacterial 
exported proteins are more exposed to the host environment they are more readily available for 
recognition by the host immune system than cytoplasmic proteins. Nearly all of the 
immunogenic antigens studied for M. tuberculosis are exported proteins that were identified by 
in silico prediction algorithms as well as analysis of fully secreted and cell wall fractions of in 
vitro grown M. tuberculosis (Boesen et al., 1995; Kurtz & Braunstein, 2005; Singh et al., 2001; 
Samanich et al., 1998; Samanich et al., 2000; Laal et al., 1997; Lyashchenko et al., 1998). 
Antigenic proteins in M. tuberculosis are being used to develop new targets for diagnostic 
development as well as new vaccine candidates. Thus, identification of new in vivo exported 
proteins has the added potential value for revealing novel antigens to be considered for 
diagnostic and vaccine development (Weiner & Kaufmann, 2014; Ivanyi, 2014).  
 
Methods: 
Bacterial growth. In this study, we used the bacterial strains listed in Table 2.2, and plasmids as 
listed in Table 2.1. M. tuberculosis strains were grown in Middlebrook 7H9 broth (Difco) 
supplemented with 1x albumin dextrose saline (ADS), 0.5% glycerol, and 0.025% Tween-80 
(7AGT) (Braunstein et al., 2002). As needed, growth media was supplemented with 20 µg/mL 
kanamycin (Acros), 50 µg/mL hygromycin (Roche), or 50 µg/mL carbenicillin (Sigma). E. coli 
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strains were grown on Luria-Bertani medium (Fisher) supplemented as necessary with 40 μg/ml 
kanamycin, 150 μg/ml hygromycin, and 100 μg/ml carbenicillin.  
Construction of the ‘BlaTEM reporter plasmid pDW31. Detailed plasmid information can be 
found on Table 2.1. pMB219 was digested with Van91I, overhangs were repaired with T4 DNA 
polymerase to generate blunt ends and the resulting fragment was digested with Nru1 to remove 
the kanamycin cassette. A hygromycin cassette derived from pYUB412 as a SmaI/EcoRV 
fragment was then ligated into the Van91I/NruI digested pMB219 to yield pDW1. In order to 
reduce the size of the plasmid backbone, pDW1 was digested with HpaI and Van91I, blunt ended 
with T4 DNA polymerase, and religated to obtain pDW10. 'blaTEM, liberated from pJES110 as 
a BamHI and ClaI fragment, was next cloned into BamHI and ClaI digested pDW10 to yield 
pDW14. Several additional steps lead to the introduction of a ‘sacB reporter downstream of the 
‘blaTEM reporter to generate the final library vector pDW31. The ‘sacB reporter was intended to 
be used as a counter-selectable marker; however, the counter-selection proved to be problematic 
and was not utilized in the final EXIT strategy.  
EXIT Library Construction. M. tuberculosis genomic DNA (gDNA) was prepared as previously 
described (Pavelka & Jacobs, 1999) from the M. tuberculosis ΔblaC mutant, PM638 (Flores et 
al., 2005). Genomic DNA fragments were generated by partial digestion with AciI and HpaII 
over a 2 hour digestion time optimized for generation of fragments between 500bp and 5kb. 
pDW31 was digested with ClaI, the restriction enzyme site immediately upstream of the 
‘BlaTEM reporter. The AciI and HpaII DNA fragments were then ligated into the ClaI site with 
T4 DNA ligase (Invitrogen). Ligated plasmids were transformed into MegaX DH10 
Electrocompetent cells (Invitrogen). 5.64x10
6 
E. coli transformants were pooled and plasmids 
were isolated using QiaFilter Plasmid Giga Kit (Qiagen).  Plasmids isolated from E. coli were 
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transformed into PM638, M. tuberculosis H37Rv ΔblaC, as previously described (Braunstein et 
al., 2002). 5.4x10
6
 M. tuberculosis transformants from 50 transformations were pooled to 
generate the final M. tuberculosis EXIT library.  
Mouse infection with the EXIT library. For identification of in vivo exported proteins, 8-10 week 
old female BALB/c mice were infected with 2x10
6
-4x10
6
 cfu of the M. tuberculosis EXIT 
library by tail vein injection, as previously described (Braunstein et al., 2003). For each of two 
separate experiments, 30 mice were infected. One day after infection, lungs, livers and spleens 
from six mice were harvested to determine initial dose and organ burden. 24 mice per experiment 
were maintained and treated with β-lactam antibiotics. One day after infection mice began 
treatment by oral gavage twice daily with 40 mg amoxicillin (MP Biomedicals 190145 or Sigma 
A8523) and 8mg probenecid (Sigma P8761) administered in 0.25M NaOH in PBS. 14 days post 
infection mice were CO2 euthanized and spleens and lungs were harvested to collect surviving 
bacteria.  
Recovery of bacteria that survived in vivo β-lactam treatment. Organ homogenates were plated 
undiluted onto solid agar media containing 7AGT and cyclohexamide (as described above in 
Bacterial growth). For determining fusions exported both in vivo and in vitro organ homogenates 
were plated in parallel onto solid agar media containing carbenecillin (a β-lactam antibiotic). 
Plates were incubated at 37C for three weeks, after which colonies were pooled for plasmid 
DNA isolation.  
Isolation of plasmid DNA from recovered M. tuberculosis. Library plasmids were isolated from 
M. tuberculosis using a modification of the QIAfilter Plasmid Maxi Kit (Qiagen). M. 
tuberculosis colonies were pooled from agar plates as described above, and incubated with 1% 
glycine at 37C for 24 hours prior to harvest, pelleted at room temperature and frozen at -20C 
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overnight. Pellets were resuspended in P1 buffer with RNase and 10 mg/mL lysozyme, and 
incubated at 37C for one hour. Buffer P2 was added and mixed by inverting, and incubated 5 
minutes. Buffer P3 was added and mixed by inverting. Lysate was poured into Qiafilter 
cartridge, and incubated 10 minutes. The lysate was filtered through the cartridge, and then 
filtered twice through 0.22µm Steriflip units (Millipore) to ensure sterility before removal from 
the BSL-3 facility. Filtered lysate was next added to Qiagen-tips that were pre-equilibrated with 
Buffer QBT. The column was washed with a 1:1 mixture of chloroform and methanol, washed 
twice with Buffer QC, and eluted with Buffer QF. DNA was precipitated with isopropanol and 
centrifugation. DNA pellets were washed with 70% ethanol, dried, and resuspended in TE 
buffer.  
Sample preparation for Illumina sequencing. Detailed primer information can be found on Table 
2.3. Plasmids were linearized by DraI digestion and then sheared by nebulization at 45 psi for 3 
minutes in a glycerol TE buffer (53% Glycerol, 37mM Tris-HCl, 5.5mM EDTA) as described in 
NimbleGen Arrays User’s Guide: Sequence Capture Array Delivery v3.1, generating fragments 
ranging from 200-800bp in length. The nebulized DNA was then purified with the QiaQuick 
PCR Purification kit (Qiagen). Purified DNA was prepared for sequencing as previously 
described (Long et al., 2015). Fragments were end repaired using Blunting kit (New England 
Biolabs E1201L), purified using PCR Purification kit and resuspended in DNase free dH20. 
Fragments were tailed with dATP (Roche) by Taq polymerase (Invitrogen) for 45 minutes at 
72C. A double stranded adaptor was constructed from Adaptor 1.1 and Adaptor 2.1 primers 
mixed with MgCl2 and incubated in a thermocycler at 1% ramp from 95C to 20C. Double 
stranded adaptors were ligated to the sheared plasmid fragments with T4 DNA ligase 
(Invitrogen) and incubated at 16C overnight. Using the adaptor ligated DNA as template, 
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amplification of ‘blaTEM fusion junctions was performed with adaptor and ‘blaTEM targeting 
primers (‘Bla IL, ‘Bla IL 3b, ‘Bla IL 4b, ‘Bla IL 5b and Adaptor 1 (containing multiplex barcode 
1), Adaptor 2 (containing multiplex barcode 2), and Adaptor 3 (containing multiplex barcode 3)) 
with Phusion High Fidelity Polymerase (New England Biolabs). 200-400 bp fragments were 
isolated from the PCR amplification and purified with QiaQuick Gel Purification kit (Qiagen). 
Samples were sequenced using a HiSeq (Illumina) generating paired end multiplexed sequencing 
reads. 
Computational analysis of sequencing data to identify ‘blaTEM reporter fusion sites. Paired end 
reads included adapter regions containing two barcodes: a multiplexing barcode, and a random 
barcode (NNANNANNN), as previously described with minor modifications (Long et al., 2015). 
The reads were first de-multiplexed. The adapter regions were identified using custom R code 
which used the Bioconductor biostrings package (H. Pages), along with the expected adapter 
sequence. The random barcodes were then extracted from these identified adapter regions, and 
the adapter regions were trimmed from each read. Following trimming, the right end read was 
~24bp, and the left end read was ~12bp.The trimmed reads were aligned to the H37Rv reference 
genome. The right end read was aligned by the BWA backtrack algorithm, using the “samse”, 
command. The left end read was aligned by a custom implementation of smith-waterman to 
locations within 500 bp of the right end read alignment. Reads in which at least one end failed to 
align, or in which the only alignment was disconcordant were discarded. Reads whose right end 
start could only be aligned more than 4bp away from a known enzyme restriction site were also 
discarded. The random barcode (NNANNANNN) were employed to control for artificially high 
counts generated by biased PCR amplification. Sequences with identical fusion positions and the 
same random barcode were counted as one unique sequence. Reads whose right end start was 
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aligned between 1 and 4 bp from a known enzyme restriction site were assumed to have been 
trimmed or aligned incorrectly, and were assigned to the known restriction enzyme site. The 
gene containing the alignment position of the right end start of each read was identified using the 
H37Rv RefSeq genome annotation released January 9 2012. Approximately 1% of all alignments 
landed in positions contained by more than one annotated gene, and the gene was assigned to the 
first gene in numerical order. Unambiguous unique sequences were each counted as a value of 1. 
Sequences that were ambiguous (could align to more than one location in the genome) were 
assigned to each of those fusion positions at a value of 1/# of potential alignment positions (e.g. 
for a sequence that could align to two potential fusion sites, each fusion was assigned a ½ read 
count). The Illumina HiSeq generated a different total number of reads per sample (average 
1.5x10
7
 reads). All read counts were normalized to the total number of sequenced reads in that 
sample.  
Statistical analysis used to identify in vivo exported proteins (spleen) Unique reads for each 
fusion site in the genome were counted in the output from the spleen of β-lactam treated mice, 
and the most abundant fusion site within each annotated gene was identified for each replicate. 
The lower abundance value between replicates was used as the representative abundance value 
for the gene in the subsequent statistical analysis to increase stringency and require that any 
identified gene was highly abundant in both samples. Log10 
 
values were used to generate a 
histogram, which was bi-modal. A Gaussian mixture model was used to identify the mean and 
variance for each population, and determine the probability that each value identified with the 
higher or lower abundance population. Genes with a higher probability of belonging to the 
higher abundance group were identified as in vivo exported proteins. Three genes in regions with 
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enriched out of frame fusions were excluded from the results, resulting in 593 genes identified as 
encoding in vivo exported proteins. 
Statistical analysis used to identify proteins exported significantly more in vivo than in vitro To 
identify M. tuberculosis clones that were β-lactam resistant both in vivo and in vitro, bacteria 
recovered from β-lactam treated mice were plated in parallel on agar media containing or lacking 
β-lactam antibiotics. From each in vitro plating condition, plasmids were isolated, sequenced, 
and unique reads for each fusion site counted, as described above. The most abundant fusion site 
within each annotated gene was identified for each condition and replicate. For in vivo β-lactam 
treated samples the lower abundance value between replicates was used as a representative 
abundance value for the gene, to identify the most stringent list of proteins exported in both 
experiments, as described above. For dual in vivo and in vitro β-lactam treated (recovered on β-
lactam containing agar media in vitro) samples the higher abundance value between replicates 
was used as a representative abundance value for the gene, to identify the most stringent list of 
proteins that were not exported in vitro in either experiment. Pseudo-counts of 100 were added to 
the in vivo and in vitro β-lactam treated dataset. The log10 value of the ratio between in vivo 
treatment and in vivo plus in vitro treatment was calculated. The top and bottom 5% were 
trimmed for robustness. This data fit a normal uni-modal distribution, where genes of interest fell 
on the right shoulder of the curve (with high ratios of in vivo vs. in vivo and in vitro reads). A 
normal fit distribution was used to identify outliers, with higher ratios than would be predicted 
by chance. The Benjamini-Hochberg procedure was used to correct for multiple comparisons, 
and identified 41 genes with p<0.0005 (False Discovery Rate <0.05). Three genes in regions 
with enriched out of frame fusions were excluded from the results, resulting in 38 genes 
identified to encode for proteins exported significantly more in vivo than in vitro.  
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Analysis used to identify in vivo exported proteins (lungs). The lower starting burden in the lungs 
after intravenous infection resulted in incomplete coverage of the EXIT library in lungs 
(APPENDIX I) and prevented us from applying statistical modeling to the data as was done with 
the spleens. Unique reads for each fusion site in the genome were counted in the output from the 
lungs of β-lactam treated mice, and the most abundant fusion site within each annotated gene 
was identified separately for each replicate. The lower abundance value between replicates was 
used as a representative abundance value for the gene. Genes that displayed 3.5 fold more unique 
reads in the output than the input (3.5 fold enrichment) were used to predict proteins exported in 
vivo in the lungs. 3.5 fold enrichment correlated well with the enrichment level identified for the 
593 statistically identified genes encoding proteins exported in the spleen.  
Statistical analysis used to identify individual enriched fusion junctions for topology 
determination. The number of sequenced reads for each fusion site in the output from β-lactam 
treated mice was divided by the number of sequenced reads in the corresponding input for each 
experiment, with pseudo-counts of 10 added across the board. Values of zero were excluded 
from analysis. Log10 enrichment values were used to generate histograms, which produced a 
uni-modal distribution with a right shoulder of enriched sites. A Gaussian mixture model was 
fitted to the distribution using Mclust in R (Fraley et al.). The resulting mixture models had two 
peaks, one representing the majority of the sites, and a second, smaller peak representing points 
in the right shoulder. The derived cutoffs for Experiment A corresponded to an enrichment of 
log10 1.756 fold above input, and Experiment B corresponded to an enrichment of log10 3.203 
fold. 2,516 individual fusion sites that were identified as being in the statistically enriched 
populations in both experiments were considered to be exported.  
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Construction of strains expressing HA tagged proteins for in vitro export analysis. Detailed 
plasmid information can be found on Table 2.1 and primer sequences are provided on Table 2.3. 
The rv3707c gene was PCR amplified using primers rv3707c_HA_F2 and  rv3707c_HA_R1, the 
rv1728c gene with primers rv1728c_HA_F1 and rv1728c_HA_R1, and the rv3811 gene with 
preimers rv3811_HA_F1 and rv3811_HA_R1, and PCR fragments were cloned into pCR2.1 
(Invitrogen). The resulting plasmids were sequenced and confirmed error-free. Plasmids 
containing rv3707c, rv1728c, and rv3811 were digested from pCR2.1 with XmnI and HindIII, 
gel purified, and ligated into MscI and HindIII digested pJSC77 (Glickman et al., 2000), 
containing an in-frame C-terminal HA tag. Plasmids were transformed into M. tuberculosis 
H37Rv as previously described (Braunstein et al., 2002).  
Subcellular fractionation and Western blotting. M. tuberculosis cells were pelleted by 
centrifugation (1,900 x g), sterilized by irradiation (JL Shephard Mark I 137Cs irradiator, 
Department of Radiobiology, University of North Carolina at Chapel Hill), and sterilized M. 
tuberculosis cells were removed from BSL-3 containment. Subcellular fractionation was 
performed as previously described (Gibbons et al., 2007). Cells were lysed by passage through a 
French pressure cell. Clarified whole cell lysates (WCL) were generated by centrifugation of 
lysed cellular material (1,900 x g) and then fractionated with differential ultracentrifugation. 
27,000 x g for 30 minutes for cell wall (CW), 100,000 x g for 2 hours for the membrane (MEM), 
and the remaining soluble (SOL) fraction containing the cytoplasm. Fractions from equivalent 
original cell material were separated by SDS-PAGE and transferred to nitrocellulose membranes. 
Proteins were detected using the primary anti-HA antibody (1:25,000 from Covance) and 
secondary anti-mouse conjugated HRP (Biorad). HRP signal was detected using an enhanced 
chemiluminescence (Clarity Western ECL, Biorad).  
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Identification of export signals. Sequences were analyzed for transmembrane domains and signal 
peptides using TMHMM (Krogh et al., 2001), Signal P (Petersen et al., 2011), (Sutcliffe & 
Harrington, 2004), and (McDonough et al., 2008). PE/PPE proteins were analyzed for YxxxD/E 
motifs as described in (Daleke et al., 2012).  
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Table 2.1 Plasmids used in this study 
Plasmid 
Antibiotic 
resistance Notes Source 
pMV261 kan 
Multi-copy mycobacterial vector with 
hsp60 promoter 
(Stover et al., 
1991) 
pJSC77 kan 
Multi-copy mycobacterial vector, HA tag 
cloned into pMV261 
(Glickman et al., 
2000) 
pEP207 kan Phsp60-rv3707c cloned into pJSC77 This study 
pEP210 kan Phsp60-rv1728 cloned into pJSC77 This study 
pEP213 kan Phsp60-rv3811 cloned into pJSC77 This study 
pMB219 kan Multi-copy mycobacterial vector 
(McCann et al., 
2007) 
pYUB412 hyg 
Single copy integrating mycobacterial 
vector 
(Bange et al., 
1999) 
pDW1 hyg 
Multi-copy mycobacterial vector 
containing backbone from pMB219 and 
hygromycin resistance cassette from 
pYUB412 This study 
pDW10 hyg pDW1 with extraneous sequence deleted This study 
pJES110 kan, amp 
'blaTEM reporter in cloning vector pCR2.1 
Topo (Invitrogen) This study 
pDW14 hyg 
Multi-copy mycobacterial vector, with 
'blaTEM reporter downstream of ClaI 
restriction site This study 
pDW31 hyg 
Multi-copy mycobacterial vector, with 
'blaTEM reporter downstream of ClaI 
restriction site This study 
 
Table 2.1. Plasmids used in this study.  
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Table 2.2 Bacterial strains used in this study 
M. tuberculosis 
strains Description Source 
PM638 M. tuberculosis H37Rv ΔblaC 
(Flores et al., 
2005) 
EXIT Library 
PM638 + pDW31 containing PM638 genomic DNA 
fragments (~500-5,000 bp) in ClaI site. Strain is hyg
R
 This study 
MBTB542 H37Rv + pEP207 (expressing rv3707c-HA). Strain is kan
R
 This study 
MBTB543 H37Rv + pEP210 (expressing rv1728-HA). Strain is kan
R
 This study 
MBTB544 H37Rv + pEP213 (expressing rv3811-HA). Strain is kan
R
 This study 
 
Table 2.2. Bacterial strains used in this study.  
  
 113 
Table 2.3 Primers used in this study 
Name Primer sequence Source 
Adaptor 1.1 TACCACGACCA-NH2 (Long et al., 
2015) 
Adaptor 2.1 ATGATGGCCGGTGGATTTGTGNNANNANNNTGGTCGTGGTAT (Long et al., 
2015) 
 'Bla IL AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCT
CTTCCGATCTTTTACTTTCACCAGCGTTTC 
This study 
 'Bla IL 3b AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCT
CTTCCGATCTTTTTACTTTCACCAGCGTTTC 
This study 
 'Bla IL 4b AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCT
CTTCCGATCTGATATTTACTTTCACCAGCGTTTC 
This study 
 'Bla IL 5b AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCT
CTTCCGATCTATCTATTTACTTTCACCAGCGTTTC 
This study 
Adaptor 1 CAAGCAGAAGACGGCATACGAGATAAGTAGAGGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATCTATGATGGCCGGTGGATTTGTG 
(Long et al., 
2015) 
Adaptor 2 CAAGCAGAAGACGGCATACGAGATACACGATCGTGACTGGAGTTCAG
ACGTGTGCTCTTCCGATCTATGATGGCCGGTGGATTTGTG 
(Long et al., 
2015) 
Adaptor 3 CAAGCAGAAGACGGCATACGAGATCGCGCGGTGTGACTGGAGTTCAG
ACGTGTGCTCTTCCGATCTATGATGGCCGGTGGATTTGTG 
(Long et al., 
2015) 
rv3707c_HA
_F2 
GAATGCCTTCCTGCGAATCGGTCCGACGGCCGGTAC This study 
rv3707c_HA
_R1 
AAGCTTGCGGGTCTGACCAGGGCTTGAAC This study 
rv1728c_HA
_F1 
CGAATGCCTTCATGAGCGTGAACGGCTTGC This study 
rv1728c_HA
_R1 
AAGCTTGTTCTGGCGGCGTAGGGCTC This study 
rv3811_HA_
F1 
GAATGCCTTCGCAGCGACCGTCGTCATCGTCGCGTGGATAG This study 
rv3811_HA_
R1 
AAGCTTGGGTGATCGGATGCGTTGGCAGCGTGAAG This study 
 
Table 2.3. Primers used in this study. Primers used to prepare fragments for Illumina sequencing are 
color coded for additional information. The adaptor ligation sites represent where the double stranded 
adaptor primers attach for Adaptor 1.1 and Adaptor 2.1 (pink), or where the PCR amplification primer has 
homology to the adaptor for PCR amplification (yellow, Adaptor 2.1 and Adaptor primers). Two barcodes 
were used, a random barcode integrated into the Adaptor 2.1 sequence (bright green) to be able to 
quantify PCR biases in amplification, and an index or multiplexing barcode to allow for multiple 
sequences to be simultaneously sequenced in Adaptor 1, 2, and 3 primers (purple). PCR amplification 
using ‘Bla IL and Adaptor 1,2,3 primers was used to attach the sequences necessary for attachment to the 
Illumina chip (blue) and for sequencing with the Illumina primers (red, Read 1 sequence in Bla IL primers 
Read 2 sequence in Adaptor primers). The ‘Bla IL primers additionally possessed homology to the 
‘BlaTEM reporter for PCR amplification (dark green), and a variable site for Illumina sequencing (grey).  
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Table 2.4 Proof of principle enrichment studies  
  Initial % β-lactamR 
% β-lactamR after 
infection with no 
treatment 
% β-lactamR after 
infection with  in vivo 
β-lactam treatment 
99:1 ‘BlaTEM: 
sp-‘BlaTEM 1% 1% 69% 
EXIT Library 1% 1% 76% 
 
Table 2.4. Proof of principle enrichment studies. Mice were infected by tail vein injection with a 
mixture of M. tuberculosis strains producing a non-exported ‘BlaTEM reporter (‘BlaTEM, black), or an 
exported signal peptide fused ‘BlaTEM reporter (sp-‘BlaTEM, red) or in a 99:1 ratio (‘BlaTEM:sp-
‘BlaTEM). The inoculum was plated in parallel on normal agar media and agar media containing β-
lactam antibiotics, to determine the initial β-lactam resistance frequency. Half of the mice were treated 
with the β-lactam antibiotic amoxicillin and a synergistic drug probenecid twice daily by oral gavage, 
while half remained untreated. On day 14 mice were sacrificed and spleens were homogenized and plated 
again in parallel on normal media and agar media containing β-lactam antibiotics, to determine the final 
β-lactam resistance frequency. This experiment was repeated with the EXIT library to determine initial β-
lactam resistance frequency as well as β-lactam resistance frequency following in vivo β-lactam resistance 
treatment. 
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Table 2.5 Known Exported Proteins (Adapted from McCann et al. 2011) 
Genome 
Designation gene standard_name function 
Rv0064     UNKNOWN 
Rv0072     
THOUGHT TO BE INVOLVED IN ACTIVE TRANSPORT OF 
GLUTAMINE ACROSS THE MEMBRANE (IMPORT). 
RESPONSIBLE FOR THE TRANSLOCATION OF THE 
SUBSTRATE ACROSS THE MEMBRANE. 
Rv0092 ctpA   
CATION-TRANSPORTING ATPASE; POSSIBLY 
CATALYZES THE TRANSPORT OF A CATION (POSSIBLY 
COPPER) WITH THE HYDROLYSE OF ATP [CATALYTIC 
ACTIVITY: ATP + H(2)O + CATION(IN) = ADP + 
PHOSPHATE + CATION(OUT)]. 
Rv0116c     UNKNOWN 
Rv0125 pepA mtb32a 
UNKNOWN; POSSIBLY HYDROLYZES PEPTIDES AND/OR 
PROTEINS (SEEMS TO CLEAVE PREFERENTIALLY AFTER 
SERINE RESIDUES). 
Rv0169 mce1A mce1 
UNKNOWN, BUT THOUGHT TO BE INVOLVED IN HOST 
CELL INVASION (ENTRY AND SURVIVAL INSIDE 
MACROPHAGES). 
Rv0170 mce1B mceD 
UNKNOWN, BUT THOUGHT TO BE INVOLVED IN HOST 
CELL INVASION. 
Rv0171 mce1C   
UNKNOWN, BUT THOUGHT TO BE INVOLVED IN HOST 
CELL INVASION. 
Rv0172 mce1D   
UNKNOWN, BUT THOUGHT TO BE INVOLVED IN HOST 
CELL INVASION. 
Rv0173 lprK mce1E 
UNKNOWN, BUT THOUGHT TO BE INVOLVED IN HOST 
CELL INVASION. 
Rv0174 mce1F   
UNKNOWN, BUT THOUGHT INVOLVED IN HOST CELL 
INVASION. 
Rv0175     UNKNOWN 
Rv0178     UNKNOWN 
Rv0199     UNKNOWN 
Rv0265c   fecB2 
THOUGHT TO BE INVOLVED IN IRON TRANSPORT 
ACROSS THE MEMBRANE (IMPORT). 
Rv0312     UNKNOWN 
Rv0346c ansP2 aroP2 
THOUGHT TO BE INVOLVED IN TRANSPORT OF L-
ASPARAGINE ACROSS THE MEMBRANE. RESPONSIBLE 
FOR THE TRANSLOCATION OF THE SUBSTRATE ACROSS 
THE MEMBRANE. 
Rv0361     UNKNOWN 
Rv0402c mmpL1   
UNKNOWN. THOUGHT TO BE INVOLVED IN FATTY ACID 
TRANSPORT. 
Rv0412c     UNKNOWN 
Rv0418 lpqL   UNKNOWN; HYDROLYZES PEPTIDES AND/OR PROTEINS. 
Rv0432 sodC   
DESTROYS RADICALS WHICH ARE NORMALLY 
PRODUCED WITHIN THE CELLS AND ARE TOXIC TO 
BIOLOGICAL SYSTEMS [CATALYTIC ACTIVITY: 2 
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superoxide + 2 H+ = O2 + H2O2]. 
Rv0450c mmpL4   
UNKNOWN. THOUGHT TO BE INVOLVED IN FATTY ACID 
TRANSPORT. 
Rv0453 PPE11   UNKNOWN 
Rv0483 lprQ   UNKNOWN 
Rv0506 mmpS2   UNKNOWN 
Rv0517     
UNKNOWN; PROBABLY INVOLVED IN CELLULAR 
METABOLISM. 
Rv0583c lpqN   UNKNOWN 
Rv0594 mce2F   
UNKNOWN, BUT THOUGHT INVOLVED IN HOST CELL 
INVASION. 
Rv0676c mmpL5   
UNKNOWN. THOUGHT TO BE INVOLVED IN FATTY ACID 
TRANSPORT. 
Rv0677c mmpS5   UNKNOWN 
Rv0783c emrB   
TRANSLOCASE THAT CONFERS RESISTANCE TO 
SUBSTANCES OF HIGH HYDROPHOBICITY. INVOLVED IN 
TRANSPORT OF MULTIDRUG ACROSS THE MEMBRANE 
(EXPORT): MULTIDRUG RESISTANCE BY AN EXPORT 
MECHANISM. RESPONSIBLE FOR THE TRANSLOCATION 
OF THE SUBSTRATE ACROSS THE MEMBRANE. 
Rv0837c     UNKNOWN 
Rv0876c     UNKNOWN 
Rv0917 betP   
HIGH-AFFINITY UPTAKE OF GLYCINE BETAINE. 
SUPPOSED RESPONSIBLE FOR THE TRANSLOCATION OF 
THE SUBSTRATE ACROSS THE MEMBRANE. 
Rv0931c pknD mbk 
INVOLVED IN SIGNAL TRANSDUCTION (VIA 
PHOSPHORYLATION). THOUGHT TO REGULATE 
PHOSPHATE TRANSPORT. CAN PHOSPHORYLATE THE 
PEPTIDE SUBSTRATE MYELIN BASIC PROTEIN (MBP) AT 
SERINE AND THREONINE RESIDUES. CAN BE 
AUTOPHOSPHORYLATED ON THREONINE RESIDUES 
[CATALYTIC ACTIVITY: ATP + A PROTEIN = ADP + A 
PHOSPHOPROTEIN]. 
Rv0934 pstS1 phoS1; phoS 
INVOLVED IN ACTIVE TRANSPORT OF INORGANIC 
PHOSPHATE ACROSS THE MEMBRANE (IMPORT). THIS IS 
ONE OF THE PROTEINS REQUIRED FOR BINDING-
PROTEIN-MEDIATED PHOSPHATE TRANSPORT. 
Rv0983 pepD mtb32b 
UNKNOWN; POSSIBLY HYDROLYZES PEPTIDES AND/OR 
PROTEINS (SEEMS TO CLEAVE PREFERENTIALLY AFTER 
SERINE RESIDUES). 
Rv1004c     UNKNOWN 
Rv1009 rpfB   
THOUGHT TO PROMOTE THE RESUSCITATION AND 
GROWTH OF DORMANT, NONGROWING CELL. COULD 
ALSO STIMULATES THE GROWTH OF SEVERAL OTHER 
HIGH G+C GRAM+ ORGANISMS, e.g. Mycobacterium avium, 
Mycobacterium bovis (BCG), Mycobacterium kansasii, 
Mycobacterium smegmatis. 
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Rv1078 pra   UNKNOWN 
Rv1096     
PROBABLY INVOLVED IN CARBOHYDRATE 
DEGRADATION. May Hydrolyse the glycosidic bond between 
two or more carbohydrates or between a carbohydrate and a non-
carbohydrate moiety. 
Rv1157c     UNKNOWN 
Rv1164 narI   
NITRATE REDUCTION [CATALYTIC ACTIVITY: Nitrite + 
acceptor = nitrate + reduced acceptor]. 
Rv1174c TB8.4   UNKNOWN FUNCTION (SECRETED PROTEIN) 
Rv1230c     UNKNOWN 
Rv1239c corA   
THOUGHT TO BE INVOLVED IN TRANSPORT OF 
MAGNESIUM AND COBALT IONS ACROSS THE 
MEMBRANE. RESPONSIBLE FOR THE TRANSLOCATION 
OF THE SUBSTRATE ACROSS THE MEMBRANE. 
Rv1319c     
THOUGHT TO PLAY AN ESSENTIAL ROLES IN 
REGULATION OF CELLULAR METABOLISM BY 
CATALYSING THE SYNTHESIS OF A SECOND 
MESSENGER, CAMP [CATALYTIC ACTIVITY: ATP = 3',5'-
CYCLIC AMP + PYROPHOSPHATE]. 
Rv1368 lprF   UNKNOWN 
Rv1419     UNKNOWN 
Rv1435c     UNKNOWN 
Rv1567c     UNKNOWN 
Rv1591     UNKNOWN 
Rv1635c     UNKNOWN 
Rv1648     UNKNOWN 
Rv1707     
UNKNOWN; POSSIBLY INVOLVED IN TRANSPORT OF 
SULFATE ACROSS THE MEMBRANE. 
Rv1728c     UNKNOWN 
Rv1743 pknE   
INVOLVED IN SIGNAL TRANSDUCTION (VIA 
PHOSPHORYLATION). THOUGHT TO BE INVOLVED IN 
MEMBRANE TRANSPORT [CATALYTIC ACTIVITY: ATP + 
A PROTEIN = ADP + A PHOSPHOPROTEIN]. 
Rv1779c     UNKNOWN 
Rv1819c     
THOUGHT TO BE INVOLVED IN ACTIVE TRANSPORT OF 
DRUGS ACROSS THE MEMBRANE (EXPORT): 
MULTIDRUGS RESISTANCE BY AN EXPORT 
MECHANISM. RESPONSIBLE FOR ENERGY COUPLING TO 
THE TRANSPORT SYSTEM AND FOR THE 
TRANSLOCATION OF THE SUBSTRATE ACROSS THE 
MEMBRANE. 
Rv1836c     UNKNOWN 
Rv1860 apa mpt32; modD 
UNKNOWN (COULD MEDIATE BACTERIAL 
ATTACHMENT TO HOST CELLS). 
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Rv1886c fbpB mpt59; 85B 
INVOLVED IN CELL WALL MYCOLOYLATION. PROTEINS 
OF THE ANTIGEN 85 COMPLEX ARE RESPONSIBLE FOR 
THE HIGH AFFINITY OF MYCOBACTERIA TO 
FIBRONECTIN. POSSESSES A MYCOLYLTRANSFERASE 
ACTIVITY REQUIRED FOR THE BIOGENESIS OF 
TREHALOSE DIMYCOLATE (CORD FACTOR), A 
DOMINANT STRUCTURE NECESSARY FOR MAINTAINING 
CELL WALL INTEGRITY. 
Rv1887     UNKNOWN 
Rv1891     UNKNOWN 
Rv1984c cfp21   HYDROLYZES CUTIN. 
Rv2040c     
Thought to be involved in active transport of sugar across the 
membrane (import). Responsible for the translocation of the 
substrate across the membrane. 
Rv2068c blaC   
hydrolyses beta-lactams to generate corresponding beta-amino 
acid [CATALYTIC ACTIVITY: A BETA-LACTAM + H(2)O = 
A SUBSTITUTED BETA-AMINO ACID]. 
Rv2080 lppJ   UNKNOWN 
Rv2113     UNKNOWN 
Rv2127 ansP1   Involved in L-asparagine transport. 
Rv2200c ctaC   
INVOLVED IN AEROBIC RESPIRATION. SUBUNIT I AND II 
FORM THE FUNCTIONAL CORE OF THE ENZYME 
COMPLEX. ELECTRONS ORIGINATING IN CYTOCHROME 
C ARE TRANSFERRED VIA HEME A AND CU(A) TO THE 
BINUCLEAR CENTER FORMED BY HEME A3 AND CU(B) 
(BY SIMILARITY). 
Rv2203     UNKNOWN 
Rv2240c     UNKNOWN 
Rv2264c     UNKNOWN 
Rv2284 lipM   Hydrolysis of lipids (bound ester). 
Rv2290 lppO   UNKNOWN 
Rv2301 cut2 cfp25 
HYDROLYSIS OF CUTIN (A POLYESTER THAT FORMS 
THE STRUCTURE OF PLANT CUTICLE). 
Rv2320c rocE   
THOUGHT TO BE INVOLVED IN TRANSPORT OF 
CATIONIC AMINO ACID (ESPECIALLY ARGININE AND 
ORNITHINE) ACROSS THE MEMBRANE. RESPONSIBLE 
FOR THE TRANSLOCATION OF THE SUBSTRATE ACROSS 
THE MEMBRANE. 
Rv2339 mmpL9   
UNKNOWN. THOUGHT TO BE INVOLVED IN FATTY ACID 
TRANSPORT. 
Rv2394 ggtB   
PLAYS A KEY ROLE IN THE GAMMA-GLUTAMYL CYCLE, 
A PATHWAY FOR THE SYNTHESIS AND DEGRADATION 
OF GLUTATHIONE [CATALYTIC ACTIVITY: 5-L-
GLUTAMYL)-PEPTIDE + AN AMINO ACID = PEPTIDE + 5-
L-GLUTAMYL-AMINO ACID]. 
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Rv2443 dctA   
INVOLVED IN THE TRANSPORT OF DICARBOXYLATES 
SUCH AS SUCCINATE, FUMARATE, AND MALATE FROM 
THE PERIPLASM ACROSS THE INNER MEMBRANE. 
RESPONSIBLE FOR THE TRANSLOCATION OF THE 
SUBSTRATE ACROSS THE MEMBRANE. 
Rv2585c     UNKNOWN 
Rv2599     UNKNOWN 
Rv2639c     UNKNOWN 
Rv2721c     UNKNOWN 
Rv2905 lppW   UNKNOWN 
Rv2938 drrC   
PROBABLY INVOLVED IN ACTIVE TRANSPORT OF 
ANTIBIOTIC AND PHTHIOCEROL DIMYCOCEROSATE 
(DIM) ACROSS THE MEMBRANE (EXPORT). 
DRRA|Rv2934|MTCY19H9.04, DRRB|Rv2937|MTCY19H9.05 
AND DRRC MAY ACT JOINTLY TO CONFER 
DAUNORUBICIN AND DOXORUBICIN RESISTANCE BY 
AN EXPORT MECHANISM. PROBABLY RESPONSIBLE FOR 
THE TRANSLOCATION OF THE SUBSTRATE ACROSS THE 
MEMBRANE AND LOCALIZATION OF DIM INTO THE 
CELL WALL. 
Rv2945c lppX   UNKNOWN 
Rv3036c TB22.2   UNKNOWN 
Rv3090     UNKNOWN 
Rv3103c     UNKNOWN 
Rv3209     UNKNOWN 
Rv3253c     
THOUGHT TO BE INVOLVED IN CATIONIC AMINO ACID 
TRANSPORT ACROSS THE MEMBRANE. RESPONSIBLE 
FOR THE TRANSLOCATION OF THE SUBSTRATE ACROSS 
THE MEMBRANE. 
Rv3267     UNKNOWN 
Rv3390 lpqD   UNKNOWN 
Rv3413c     UNKNOWN 
Rv3476c kgtP   
INVOLVED IN ACTIVE TRANSPORT OF DICARBOXYLIC 
ACID ACROSS THE MEMBRANE. RESPONSIBLE FOR THE 
TRANSLOCATION OF THE SUBSTRATE ACROSS THE 
MEMBRANE. 
Rv3484 cpsA   NOT KNOW. 
Rv3494c mce4F   
UNKNOWN, BUT THOUGHT INVOLVED IN HOST CELL 
INVASION. 
Rv3496c mce4D   
UNKNOWN, BUT THOUGHT TO BE INVOLVED IN HOST 
CELL INVASION. 
Rv3497c mce4C   
UNKNOWN, BUT THOUGHT TO BE INVOLVED IN HOST 
CELL INVASION. 
Rv3498c mce4B   
UNKNOWN, BUT THOUGHT TO BE INVOLVED IN HOST 
CELL INVASION. 
Rv3584 lpqE   UNKNOWN 
Rv3689     UNKNOWN 
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Rv3779     UNKNOWN 
Rv3802c     UNKNOWN 
Rv3835     UNKNOWN 
Rv3869     UNKNOWN 
Rv3901c     UNKNOWN 
Rv3910     UNKNOWN 
 
Table 2.5. Known exported proteins. 111 M. tuberculosis proteins were identified in (McCann et al., 
2011)to be exported in vitro. These proteins were used as known positives, or known exported proteins, to 
compare to EXIT identified exported proteins.  
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Table 2.6 50 Most abundant cytoplasmic proteins (adapted from PaxDB (Wang et al., 
2015; Wang et al., 2012)) 
Abundance 
rank 
Rv 
number Name 
Estimated 
PPM  Function 
1 Rv2031c acr 125706 heat shock protein HspX 
2 Rv3418c Rv3418c 96990 
co-chaperonin GroES; Binds to Cpn60 in the 
presence of Mg-ATP and suppresses the ATPase 
activity of the latter 
3 Rv0440 Rv0440 37230 
chaperonin GroEL; Prevents misfolding and 
promotes the refolding and proper assembly of 
unfolded polypeptides generated under stress 
conditions (By similarity) 
6 Rv0652 rplL 11450 
50S ribosomal protein L7/L12; Seems to be the 
binding site for several of the factors involved in 
protein synthesis and appears to be essential for 
accurate translation (By similarity) 
7 Rv1470 Rv1470 10999 
thioredoxin TrxC (TRX) (MPT46); Participates 
in various redox reactions through the reversible 
oxidation of its active center dithiol to a disulfide 
and catalyzes dithiol-disulfide exchange 
reactions (By similarity) 
8 Rv2244 acpM 10397 
acyl carrier protein; Acyl carrier protein involved 
in meromycolate extension (By similarity) 
9 Rv0350 dnaK 9967 
molecular chaperone DnaK; Acts as a chaperone 
(By similarity) 
11 Rv0685 tuf 7356 
elongation factor Tu; This protein promotes the 
GTP-dependent binding of aminoacyl-tRNA to 
the A-site of ribosomes during protein 
biosynthesis 
14 Rv3648c cspA 6541 cold shock protein A 
19 Rv3028c etfA 4429 
electron transfer flavoprotein subunit alpha; The 
electron transfer flavoprotein serves as a specific 
electron acceptor for other dehydrogenases. It 
transfers the electrons to the main respiratory 
chain via ETF-ubiquinone oxidoreductase (ETF 
dehydrogenase) (By similarity) 
20 Rv1133c metE 4164 
5-methyltetrahydropteroyltriglutamate-- 
homocysteine S-methyltransferase; Catalyzes the 
transfer of a methyl group from 5- 
methyltetrahydrofolate to homocysteine resulting 
in methionine formation (By similarity) 
22 Rv2623 TB31.7 3757 hypothetical protein 
23 Rv2220 glnA1 3713 
glutamine synthetase GLNA1 (glutamine 
synthase) (GS-I) 
25 Rv2145c ag84 3535 hypothetical protein 
26 Rv1872c lldD2 3477 L-lactate dehydrogenase (cytochrome) LldD2 
29 Rv3118 sseC1 3200 hypothetical protein 
30 Rv2744c Rv2744c 3194 hypothetical protein 
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31 Rv0475 hbhA 3091 
iron-regulated heparin binding hemagglutinin 
HbhA (adhesin); Required for extrapulmonary 
dissemination. Mediates adherence to epithelial 
cells by binding to sulfated glycoconjugates 
present at the surface of these cells; binds 
heparin, dextran sulfate, fucoidan and 
chondroitin sulfate. Promotes hemagglutination 
of erythrocytes of certain host species. Induces 
mycobacterial aggregation 
33 Rv2986c Rv2986c 2920 
DNA-binding protein HU; Histone-like DNA-
binding protein which is capable of wrapping 
DNA to stabilize it, and thus to prevent its 
denaturation under extreme environmental 
conditions (By similarity) 
34 Rv1827 Rv1827 2870 hypothetical protein 
35 Rv1498A Rv1498A 2851 hypothetical protein 
36 Rv3248c Rv3248c 2796 S-adenosyl-L-homocysteine hydrolase 
37 Rv3846 Rv3846 2772 
superoxide dismutase [Fe] SODA; Destroys 
radicals which are normally produced within the 
cells and which are toxic to biological systems 
40 Rv1392 metK 2683 
S-adenosylmethionine synthetase; Catalyzes the 
formation of S-adenosylmethionine from 
methionine and ATP. The overall synthetic 
reaction is composed of two sequential steps, 
AdoMet formation and the subsequent 
tripolyphosphate hydrolysis which occurs prior 
to release of AdoMet from the enzyme (By 
similarity) 
41 Rv1738 Rv1738 2671 hypothetical protein 
42 Rv3841 bfrB 2649 bacterioferritin BfrB 
44 Rv0379 secE2 2569 protein transport protein 
45 Rv3716c Rv3716c 2551 hypothetical protein 
46 Rv2159c Rv2159c 2540 hypothetical protein 
47 Rv1932 tpx 2519 
thiol peroxidase; Has antioxidant activity. Could 
remove peroxides or H(2)O(2) (By similarity) 
48 Rv1636 TB15.3 2469 hypothetical protein 
49 Rv3457c rpoA 2456 
DNA-directed RNA polymerase subunit alpha; 
DNA-dependent RNA polymerase catalyzes the 
transcription of DNA into RNA using the four 
ribonucleoside triphosphates as substrates 
50 Rv3029c etfB 2426 
electron transfer flavoprotein subunit beta; The 
electron transfer flavoprotein serves as a specific 
electron acceptor for other dehydrogenases. It 
transfers the electrons to the main respiratory 
chain via ETF-ubiquinone oxidoreductase (ETF 
dehydrogenase) (By similarity) 
52 Rv1310 atpD 2158 
F0F1 ATP synthase subunit beta; Produces ATP 
from ADP in the presence of a proton gradient 
across the membrane. The catalytic sites are 
hosted primarily by the beta subunits (By 
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similarity) 
53 Rv1177 fdxC 2140 ferredoxin FdxC 
54 Rv2461c clpP1 2124 
ATP-dependent Clp protease proteolytic subunit; 
Cleaves peptides in various proteins in a process 
that requires ATP hydrolysis. Has a 
chymotrypsin-like activity. Plays a major role in 
the degradation of misfolded proteins (By 
similarity) 
55 Rv0009 ppiA 2116 
iron-regulated peptidyl-prolyl cis-trans isomerase 
A; PPIases accelerate the folding of proteins. It 
catalyzes the cis-trans isomerization of proline 
imidic peptide bonds in oligopeptides (By 
similarity) 
56 Rv2111c Rv2111c 2109 
hypothetical protein; Protein modifier that is 
covalently attached to lysine residues of substrate 
proteins, thereby targeting them for proteasomal 
degradation. The tagging system is termed 
pupylation. Identified substrates are the fabD, 
panB and mpa proteins 
57 Rv2215 sucB 2095 
dihydrolipoamide acetyltransferase; The 2-
oxoglutarate dehydrogenase complex catalyzes 
the overall conversion of 2-oxoglutarate to 
succinyl-CoA and CO(2). It contains multiple 
copies of three enzymatic components: 2- 
oxoglutarate dehydrogenase (E1), 
dihydrolipoamide succinyltransferase (E2) and 
lipoamide dehydrogenase (E3) (By similarity) 
58 Rv3458c rpsD 2094 
30S ribosomal protein S4; One of the primary 
rRNA binding proteins, it binds directly to 16S 
rRNA where it nucleates assembly of the body of 
the 30S subunit (By similarity) 
59 Rv0569 Rv0569 2071 hypothetical protein 
60 Rv1308 atpA 2064 
F0F1 ATP synthase subunit alpha; Produces 
ATP from ADP in the presence of a proton 
gradient across the membrane. The alpha chain is 
a regulatory subunit 
61 Rv1436 gap 2035 glyceraldehyde-3-phosphate dehydrogenase 
62 Rv3417c Rv3417c 1978 
chaperonin GroEL; Prevents misfolding and 
promotes the refolding and proper assembly of 
unfolded polypeptides generated under stress 
conditions (By similarity) 
63 Rv1388 mihF 1970 putative integration host factor MIHF 
64 Rv0054 ssb 1942 
single-stranded DNA-binding protein; This 
protein is essential for replication of the 
chromosome. It is also involved in DNA 
recombination and repair (By similarity) 
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67 Rv0683 rpsG 1922 
30S ribosomal protein S7; One of the primary 
rRNA binding proteins, it binds directly to 16S 
rRNA where it nucleates assembly of the head 
domain of the 30S subunit. Is located at the 
subunit interface close to the decoding center, 
probably blocks exit of the E-site tRNA (By 
similarity) 
68 Rv1211 Rv1211 1910 hypothetical protein 
71 Rv0363c fba 1877 
fructose-bisphosphate aldolase; Catalyzes the 
aldol condensation of dihydroxyacetone 
phosphate (DHAP or glycerone-phosphate) with 
glyceraldehyde 3- phosphate (G3P) to form 
fructose 1,6-bisphosphate (FBP) in 
gluconeogenesis and the reverse reaction in 
glycolysis (By similarity) 
73 Rv3628 ppa 1860 inorganic pyrophosphatase 
 
Table 2.6. Most abundant cytoplasmic proteins. The top 50 most abundant cytoplasmic proteins were 
identified by PaxDB, a database calculating the relative abundance of proteins from published proteomics 
datasets (Wang et al., 2015; Wang et al., 2012). Proteins identified as abundant in PaxDB but containing 
predicted export signals (transmembrane domains and signal peptides were predicted by SignalP, TatP, 
TMHMM, (Sutcliffe & Harrington, 2004), and (McDonough et al., 2008)), or proteins known to be 
exported (e.g. EsxA and EsxB) were excluded, to generate a list of the top 50 most abundant cytoplasmic 
proteins in M. tuberculosis. These abundant cytoplasmic proteins were used as known negatives, or 
known cytoplasmic proteins, to compare to EXIT identified proteins.  
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Table 2.7 EXIT identified proteins with no in silico export signals 
Gene 
number 
Name Product MS 
Rv0518 
 
POSSIBLE EXPORTED 
PROTEIN 
CF 2, CF 3, 
MEM 8 
Rv0787 
 
HYPOTHETICAL PROTEIN 
CF 2, CF 3, 
MEM 7, MEM 9 
Rv0822c 
 
CONSERVED 
HYPOTHETICAL PROTEIN 
CF 2, CW 14 
Rv0907 
 
CONSERVED 
HYPOTHETICAL PROTEIN 
CF 2, CF 3, 
MEM 5, MEM 
8, MEM 9, CW 
14 
Rv0950c 
 
CONSERVED 
HYPOTHETICAL PROTEIN  
Rv1026 
 
CONSERVED 
HYPOTHETICAL PROTEIN  
Rv1728c 
 
CONSERVED 
HYPOTHETICAL PROTEIN  
Rv1823 
 
CONSERVED 
HYPOTHETICAL PROTEIN 
MEM 8, MEM 
9, CW 14 
Rv1832 gcvB 
Probable glycine dehydrogenase 
gcvB (Glycine decarboxylase) 
(Glycine cleavage system P-
protein) 
CF 2, MEM 4, 
MEM 8, MEM 
9, WCL 15, SOL 
16 
Rv1887 
 
HYPOTHETICAL PROTEIN CF 3, MEM 7 
Rv1891 
 
CONSERVED 
HYPOTHETICAL PROTEIN 
CF 2, CF 3, 
MEM 7, MEM 8 
Rv2088 pknJ 
PROBABLE 
TRANSMEMBRANE 
SERINE/THREONINE-
PROTEIN KINASE J PKNJ 
(PROTEIN KINASE J) (STPK J) 
MEM 8, MEM 
9, CW 14 
Rv2240c 
 
HYPOTHETICAL PROTEIN 
CF 2, CF 3, 
MEM 8, MEM 
9, CW 14 
Rv2264c 
 
conserved hypothetical proline 
rich protein 
CW 14 
Rv2300c 
 
CONSERVED 
HYPOTHETICAL PROTEIN 
MEM 8, MEM 9 
Rv2380c mbtE 
PEPTIDE SYNTHETASE MBTE 
(PEPTIDE SYNTHASE) 
MEM 4, MEM 
9, CW 13, SOL 
16 
Rv3035 
 
CONSERVED 
HYPOTHETICAL PROTEIN 
MEM 8, MEM 
9, CW 14 
Rv3067 
 
CONSERVED 
HYPOTHETICAL PROTEIN 
CF 2 
Rv3123 
 
HYPOTHETICAL PROTEIN MEM 9 
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Rv3274c fadE25 
PROBABLE ACYL-CoA 
DEHYDROGENASE FADE25 
CF 2, CF 3, 
MEM 4, MEM 
5, MEM 8, 
MEM 9, MEM 
10, CW 12, CW 
13, CW 14, 
WCL 15, SOL 
16 
Rv3343c PPE54 PPE FAMILY PROTEIN 
 
Rv3350c PPE56 PPE FAMILY PROTEIN 
 
Rv3478 
PPE60, 
mtb39c 
PE FAMILY PROTEIN 
MEM 8, MEM 
9, CW 13, CW 
14 
Rv3526 
 
POSSIBLE 
OXIDOREDUCTASE  
Rv3596c 
clpC1, 
clpC 
PROBABLE ATP-DEPENDENT 
PROTEASE ATP-BINDING 
SUBUNIT CLPC1 
CF 3, MEM 4, 
MEM 6, MEM 
8, MEM 9, 
MEM 10, CW 
12, CW 13, CW 
14, WCL 15, 
SOL 16 
Rv3654c 
 
CONSERVED 
HYPOTHETICAL PROTEIN  
Rv3667 acs 
ACETYL-COENZYME A 
SYNTHETASE ACS 
(ACETATE--CoA LIGASE) 
(ACETYL-CoA SYNTHETASE) 
(ACETYL-CoA SYNTHASE) 
(ACYL-ACTIVATING 
ENZYME) (ACETATE 
THIOKINASE) (ACETYL-
ACTIVATING ENZYME) 
(ACETATE--COENZYME A 
LIGASE) (ACETYL-
COENZYME A SYNTHASE) 
MEM 4, MEM 
9, CW 13, CW 
14, WCL 15, 
SOL 16 
Rv3691 
 
CONSERVED 
HYPOTHETICAL PROTEIN 
MEM 4, MEM 
8, MEM 9, CW 
14 
Rv3707c 
 
CONSERVED 
HYPOTHETICAL PROTEIN 
MEM 9 
Rv3811 csp 
CONSERVED 
HYPOTHETICAL PROTEIN  
Rv3822 
  
CW 14 
Rv3912 
 
HYPOTHETICAL ALANINE 
RICH PROTEIN 
MEM 9 
 
Table 2.7. EXIT identified proteins with no in silico export signals. Proteins identified as exported by 
EXIT were analyzed for export signals by SignalP, TatP, TMHMM, (McDonough et al., 2008), and 
(Sutcliffe & Harrington, 2004). 32 remained that contained no predicted export signal. Proteins are 
identified by their genome designation (column 1), name (column 2), and annotation from the H37Rv 
RefSeq genome annotation released January 9 2012. Column 4 identifies all previous in vitro MS based 
published methodologies which identified a given protein as exported, with the fractions in which the 
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protein was identified: culture filtrate (CF), membrane (MEM), cell wall (CW), soluble (SOL), or whole 
cell lysate (WCL). Mass spectrometry based approaches to identify exported proteins in fractions: CF: 1 
(Rosenkrands et al., 2000b), 2 (Malen et al., 2011), 3 (Bell et al., 2012). MEM: 4 (Gu et al., 2003), 5 
(Xiong et al., 2005), 6 (Mawuenyega et al., 2005), 7 (Malen et al., 2007), 8 (Malen et al., 2011), 9 
(Gunawardena et al., 2013), 10 (Bell et al., 2012). CW: 11 (Mawuenyega et al., 2005), 12 (Wolfe et al., 
2010), 13 (Bell et al., 2012). WCL: 15 (Bell et al., 2012). SOL: 16 (Bell et al., 2012).  
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Table 2.8 EXIT exported fusions in unannotated regions  
Strand 
location 
Upstream annotated 
gene 
Genome 
position 
Distance  in aa from 
paired site(s) 
- Rv0066c 65092 - 
- Rv0066c 65050 14 
+ Rv0397 476536 - 
+ Rv0397 476632 32 
- Rv2307A 2578951 - 
- Rv2307A 2578942 3 
- Rv2307A 2578876 22 
- Rv2307c 2575499 - 
- Rv2307c 2575451 16 
- Rv2307c 2575403 16 
- Rv2307c 2575385 6 
- Rv2307c 2575379 2 
- Rv2307c 2575358 7 
- Rv2307c 2575340 6 
+ Rv2964 3318177 - 
+ Rv2964 3318183 2 
+ Rv2964 3318189 2 
+ Rv2964 3318198 3 
+ Rv3033 3395236   
+ Rv3033 3395269 11 
+ Rv3033 3395302 11 
 
Table 2.8. EXIT exported fusions in unannotated regions. Enriched sites data located in intergenic 
non-annotated regions of the genome were identified. Regions of the genome likely to contain a non-
annotated exported protein were identified as containing at least two statistically enriched sites in frame 
of each other at a maximum distance of 100 bp apart. Six intergenic regions were identified, labeled A-F, 
containing 21 statistically enriched sites. The genome location and upstream annotated gene are 
identified, as well as the amino acid distance to additional enriched sites identified in the same region.  
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Table 2.9 EXIT exported proteins only identified in the lungs 
Gene 
number Name Product 
in silico Export 
Signal 
Rv0187   
PROBABLE O-
METHYLTRANSFERASE   
Rv0578c PE_PGRS7 PE-PGRS FAMILY PROTEIN SP, YxxxD/E 
Rv1091 PE_PGRS22 PE-PGRS FAMILY PROTEIN YxxxD/E 
Rv1371   
PROBABLE CONSERVED 
MEMBRANE PROTEIN TM 
Rv1818c PE_PGRS33 PE-PGRS FAMILY PROTEIN SP, YxxxD/E 
Rv2196 qcrB 
Probable Ubiquinol-cytochrome C 
reductase QcrB (cytochrome B subunit) TM 
Rv2490c PE_PGRS43 PE-PGRS FAMILY PROTEIN SP, YxxxD/E 
Rv3101c ftsX 
PUTATIVE CELL DIVISION 
PROTEIN FTSX (SEPTATION 
COMPONENT-TRANSPORT 
INTEGRAL MEMBRANE PROTEIN 
ABC TRANSPORTER) TM 
 
Table 2.9. EXIT exported proteins only identified in the lungs. Abundance was determined 
individually for each gene based on sequenced read counts for the most highly abundant fusion site in 
each experiment for the lungs. Genes that displayed 3.5 fold higher abundance in the lungs after in vivo β-
lactam treatment than the input in both experiments were identified as exported in vivo in the lungs. 282 
proteins were identified as exported in the lungs. The eight proteins reported above were only identified 
as exported in the lungs and not identified as exported in the spleen.  
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Table 2.10 EXIT identified proteins exported significantly more in vivo than in vitro 
Gene 
number Name Product 
in 
silico  Essential Up in vivo 
q 
value 
Rv0011c   
PROBABLE CONSERVED 
TRANSMEMBRANE PROTEIN TM     0.000 
Rv0261c narK3 
PROBABLE INTEGRAL 
MEMBRANE NITRITE 
EXTRUSION PROTEIN NARK3 
(NITRITE FACILITATOR) TM     0.003 
Rv0490 senX3 
PUTATIVE TWO COMPONENT 
SENSOR HISTIDINE KINASE 
SENX3 TM Mouse 25   0.028 
Rv0506 mmpS2 
PROBABLE CONSERVED 
MEMBRANE PROTEIN MMPS2 
SP, 
TM     0.007 
Rv0559c   
POSSIBLE CONSERVED 
SECRETED PROTEIN SP     0.008 
Rv0593 
lprL, 
mce2E 
POSSIBLE MCE-FAMILY 
LIPOPROTEIN LPRL (MCE-
FAMILY LIPOPROTEIN 
MCE2E) 
Lipo, 
TM     0.006 
Rv0615   
PROBABLE INTEGRAL 
MEMBRANE PROTEIN TM     0.017 
Rv0713   
PROBABLE CONSERVED 
TRANSMEMBRANE PROTEIN TM     0.001 
Rv0817c   
PROBABLE CONSERVED 
EXPORTED PROTEIN 
SP, 
TM 
in vitro 28, 
in vitro 29   0.005 
Rv0846c   PROBABLE OXIDASE 
SP, 
Tat 
SP, 
Lipo     0.000 
Rv0892   
PROBABLE 
MONOOXYGENASE TM   
Macrophage 
31 0.008 
Rv1026   
CONSERVED HYPOTHETICAL 
PROTEIN   in vitro 28   0.022 
Rv1145 mmpL13a 
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL13A TM     0.000 
Rv1266c pknH 
PROBABLE 
TRANSMEMBRANE 
SERINE/THREONINE-
PROTEIN KINASE H PKNH 
(PROTEIN KINASE H) (STPK 
H) TM     0.029 
Rv1508c   Probable membrane protein TM   Mouse 34 0.007 
Rv1517   
CONSERVED HYPOTHETICAL 
TRANSMEMBRANE PROTEIN 
Tat 
SP, 
TM     0.015 
Rv1639c   
CONSERVED HYPOTHETICAL 
MEMBRANE PROTEIN TM     0.007 
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Rv1737c narK2 
POSSIBLE NITRATE/NITRITE 
TRANSPORTER NARK2 TM Mouse 27 
Macrophage 
31 0.000 
Rv1739c   
PROBABLE SULPHATE-
TRANSPORT 
TRANSMEMBRANE PROTEIN 
ABC TRANSPORTER TM   
Macrophage 
31 0.043 
Rv1965 yrbE3B 
CONSERVED HYPOTHETICAL 
INTEGRAL MEMBRANE 
PROTEIN YRBE3B TM Macaque 22 
Macrophage 
31 0.001 
Rv1969 mce3D 
MCE-FAMILY PROTEIN 
MCE3D 
SP, 
TM     0.006 
Rv2138 lppL 
Probable conserved lipoprotein 
LppL 
SP, 
Lipo, 
TM 
Mouse 27, 
in vitro 28, 
in vitro 29   0.006 
Rv2144c   Probable transmembrane protein TM   Mouse 34 0.001 
Rv2273   
PROBABLE CONSERVED 
TRANSMEMBRANE PROTEIN TM   
Macrophage 
30 0.000 
Rv2284 lipM Probable esterase LipM TM   Mouse 37 0.024 
Rv2330c lppP 
PROBABLE LIPOPROTEIN 
LPPP 
SP, 
Lipo, 
TM 
Macrophage 
23 
Macrophage 
31 0.007 
Rv2380c mbtE 
PEPTIDE SYNTHETASE MBTE 
(PEPTIDE SYNTHASE)   
Mouse 27, 
in vitro 29 
Macrophage 
31 0.007 
Rv2536   
PROBABLE CONSERVED 
TRANSMEMBRANE PROTEIN TM Mouse 27   0.017 
Rv2938 drrC 
PROBABLE DAUNORUBICIN-
DIM-TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER DRRC TM Mouse 25   0.017 
Rv3343c PPE54 PPE FAMILY PROTEIN   
in vitro 28, 
in vitro 29 
Human 38, 
Human 39 0.006 
Rv3478 
PPE60, 
mtb39c PE FAMILY PROTEIN       0.017 
Rv3526   POSSIBLE OXIDOREDUCTASE     
Macrophage 
31 0.005 
Rv3554 fdxB 
POSSIBLE ELECTRON 
TRANSFER PROTEIN FDXB TM     0.001 
Rv3596c 
clpC1, 
clpC 
PROBABLE ATP-DEPENDENT 
PROTEASE ATP-BINDING 
SUBUNIT CLPC1   
Macrophage 
23, 
Macrophage 
24, in vitro 
28, in vitro 
29   0.006 
Rv3654c   
CONSERVED HYPOTHETICAL 
PROTEIN     Human 38 0.000 
Rv3701c   
CONSERVED HYPOTHETICAL 
PROTEIN   
Macrophage 
23, Mouse 
25   0.039 
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Rv3707c   
CONSERVED HYPOTHETICAL 
PROTEIN       0.039 
Rv3823c mmpL8 
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
TRANSPORT PROTEIN MMPL8 TM 
Mouse 27, 
in vitro 29   0.027 
 
Table 2.10. EXIT identified proteins exported significantly more in vivo than in vitro. 38 proteins 
were identified with export upregulated during infection. Proteins are identified by their H37Rv genome 
designation number, name, and function as annotated in the H37Rv RefSeq genome annotation released 
January 9 2012.P values were corrected due to multiple testing using the B-H correction to generate q 
values. Q values less than 0.05, representing less than 5% false discovery rate (FDR), were considered 
significant. Column 4 identifies all in silico predicted export signals: signal peptide (SP, (Petersen et al., 
2011)), twin-arginine translocation signal peptide (Tat SP, (McDonough et al., 2008)), lipoprotein signal 
peptide (Lipo, (Sutcliffe & Harrington, 2004)), or transmembrane domain (TM, (Krogh et al., 2001)). 
Column 5 identifies all large scale virulence screens that identified a given gene as essential, either in 
vitro or in models of tuberculosis infection. Column 6 identifies all studies where a given gene was 
identified as transcriptionally induced during infection. Numbers given relate to the references and 
conditions as described below.  
Genes identified as essential for virulence in models of tuberculosis: Macaque: 22 (Dutta et al., 
2010), Macrophage: 23 (Rengarajan et al., 2005), 24 (Stewart et al., 2005), Mouse: 25 (Sassetti & Rubin, 
2003), 26 (Lamichhane et al., 2005), 27 (Zhang et al., 2013). Genes identified as essential for in vitro 
growth: 28 (Sassetti et al., 2003), 29 (Sassetti et al., 2003). Genes identified as transcriptionally induced 
during infection: Macrophage: 30 (Dubnau et al., 2002), 31 (Schnappinger et al., 2003), 32 (Rohde et al., 
2007b), 33 (BCG) (Rohde et al., 2007b), Mouse: 34 (Dubnau et al., 2005), 35 (Talaat et al., 2007), 36 (60 
dpi) (Talaat et al., 2007), 37 (45 dpi) (Talaat et al., 2007), Human: 38 (granuloma) (Rachman et al., 
2006a), 39 (distant lung) (Rachman et al., 2006a).  
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CHAPTER 3: AN ORPHANED MCE-ASSOCIATED PROTEIN OF MYCOBACTERIUM 
TUBERCULOSIS IS A VIRULENCE FACTOR THAT STABILIZES MCE 
TRANSPORTERS
2
 
Introduction 
Mycobacterium tuberculosis is a human pathogen with a significant impact on world 
health. Current estimates suggest that 2 billion people worldwide have been infected with M. 
tuberculosis and 1.5 million people die per year from tuberculosis (World Health Organization, 
2014). Inside the host, M. tuberculosis survives and grows inside macrophages (Rohde et al., 
2007). Bacterial exported proteins are proteins that are transported out of cytoplasm to the 
bacterial cytoplasmic membrane, cell wall, or are fully released into the host environment. Many 
intracellular pathogens, including M. tuberculosis, survive in macrophages with the help of 
exported proteins (Ligon et al., 2012; Hicks & Galan, 2013; Isaac & Isberg, 2014). Because of 
their extracytoplasmic location, exported proteins of pathogens are ideally positioned for host 
interactions and for roles in controlling the immune response, surviving in macrophages, and 
acquiring nutrients for intracellular survival (Forrellad et al., 2013; McCann, 2009). While 
exported proteins are known to play a critical role in M. tuberculosis virulence, up to 69% of M. 
tuberculosis exported proteins have no assigned function (Appendix III). To better understand 
how M. tuberculosis interacts with the host and causes disease, it is critical to identify the 
function of unknown exported proteins. 
                                                          
2
 Adapted for this dissertation from: Perkowski EF, McCann JR, Sullivan JT, Malik S, Allen IC, Hayden JD, 
Godfrey V, Braunstein, M. An orphaned Mce-associated protein of Mycobacterium tuberculosis is a virulence factor 
that stabilizes Mce transporters. Under review. 
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In a previous study using a transposon carrying a -lactamase reporter of export, the M. 
tuberculosis Rv0199 protein was identified as an exported protein (McCann et al., 2011). 
Rv0199 is a 24 kDa protein that is predicted to be an integral membrane protein with an N-
terminal transmembrane domain (Krogh et al., 2001). The site of transposon insertion is 
consistent with the majority of the protein being exported to the periplasmic/cell wall side of the 
membrane (Figure 3.1A) (McCann et al., 2011). By testing the rv0199 transposon mutant in 
cultured macrophages, the Rv0199 protein was shown to be required for intracellular growth of 
M. tuberculosis (McCann et al., 2011). Further, the Rv0199 protein of Mycobacterium bovis 
BCG is predicted to be important for growth in macrophages (Stewart et al., 2005). The rv0199 
gene is a core mycobacterial gene (Marmiesse et al., 2004), which means that it is highly 
conserved throughout pathogenic and non-pathogenic mycobacterial species but not conserved 
outside of actinomycetes. However, the function of Rv0199 is not clear. Rv0199 is annotated as 
a membrane protein of unknown function (Lew et al., 2011), although there is limited sequence 
homology between the C-terminal region of Rv0199 and the C-terminal region of Mce-
associated (Mas) proteins of M. tuberculosis (Casali & Riley, 2007). Mas proteins are named for 
the genomic location of their corresponding genes, which are linked to mce operons encoding 
Mce transporter systems (Casali & Riley, 2007). Besides eight mas genes linked to mce operons, 
M. tuberculosis has five Open Reading Frames (ORFs) encoding proteins with low levels of 
homology to Mas proteins that are scattered elsewhere in the genome (Figure 3.1B). Rv0199 is 
one of these potential orphaned Mas proteins (Casali & Riley, 2007).  
 Mce transporters are multi-protein complexes considered to be functionally analogous to 
ABC transporters (Casali & Riley, 2007). The four Mce transporter systems in M. tuberculosis  
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Figure 3.1. Rv0199 (OmasA) is a transmembrane protein predicted to be a Mce-associated protein. 
A. OmasA is predicted to have a single N-terminal transmembrane domain (TM) at amino acid 42-64 
(Krogh et al., 2001) and C-terminal domain exposed to the cell wall side of the membrane (McCann et 
al., 2011). B. OmasA is predicted to be a Mce-associated (Mas) protein, however, rv0199 is not located in 
a mce operon. Mce operons are typically organized by two yrbE genes upstream (green), six mce genes 
(purple) and most have pairs of mas genes (red) downstream. Genes encoding putative orphaned mas 
genes are boxed. Genes encoding Omas proteins are distinguished by being distally located from mce 
operons (Casali & Riley, 2007). The mce2 operon additionally contains a small predicted pseudogene 
(grey). C. The omasAmtb gene was engineered in frame with an HA tag and expressed in M. smegmatis. 
Cells were lysed to generate whole cell lysates (WCL) and fractionated by differential ultracentrifugation 
into cell wall (CW), cell membrane (MEM), and cytoplasmic containing soluble (SOL) fractions. Results 
are representative of at least three independent replicates. D. Phyre 2, an online structural prediction 
program, predicted with high confidence (96%) that OmasA forms a NTF2-like fold, as found in the 
association domain of the calcium/calmodulin-dependent protein kinase type II alpha subunit (CAMKIIγ). 
Ribbon diagrams shown represent the Phyre 2 predicted structures of OmasA colored by secondary 
structure in Pymol. Ribbon diagrams representing the solved crystal structures of VirB8 from Brucella 
suis and Agrobacterium tumefaciens are shown for comparison. Alpha helices are colored in red, Beta-
strands in yellow, and turns in green. 
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all play roles in virulence (Gioffre et al., 2005; Shimono et al., 2003; Marjanovic et al., 2010; 
Lima et al., 2007; McCann et al., 2011; Senaratne et al., 2008; Pandey & Sassetti, 2008) and are 
thought to function in lipid uptake. The best characterized Mce transporter is Mce4. Mce4 is  
required for cholesterol uptake (Pandey & Sassetti, 2008; Mohn et al., 2008), cholesterol being 
an important nutrient during M. tuberculosis infection (Pandey & Sassetti, 2008). Emerging 
evidence suggests that Mce1 is responsible for import of mycolic acids, long chain fatty acids 
characteristic of mycobacteria (Forrellad et al., 2014; Cantrell et al., 2013). Each Mce system is 
composed of two YrbE proteins with similarity to ABC transporter permeases and six Mce 
proteins that are considered functionally similar to substrate binding proteins of ABC 
transporters (Casali & Riley, 2007). Additionally, Mce transporters are thought to share a 
common ATPase, MceG. Interestingly, the mceG gene is not located near any mce operon 
(Casali & Riley, 2007; Joshi et al., 2006). Nearly all mce operons also contain genes encoding 
Mas proteins (Figure 3.1B). Unlike the YrbE and Mce components, Mas proteins share no 
analogous features with ABC transporter components. Mas proteins are speculated to have a role 
in Mce transporter systems, but this idea is solely based on the genomic location of mas genes. 
To date, there have been no functional studies of any Mas protein. Consequently, the function of 
potential orphaned Mas proteins such as Rv0199, whose genes are distal to mce operons, is even 
less clear.  
 Here, we further characterized the role of Rv0199 in M. tuberculosis virulence using a 
low dose aerosol model of murine infection. We additionally showed that Rv0199 has a role in 
Mce lipid transport, leading us to rename Rv0199 as OmasA (orphaned Mce-associated protein 
A), and we demonstrated a role for OmasA in stabilizing Mce transporter complexes. The 
stabilization function of OmasA may be analogous to the role of VirB8 in stabilizing Type IV 
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secretion systems, as structural similarities between Mas proteins and VirB8 proteins are 
predicted by the Phyre 2 program (Kelley & Sternberg, 2009).  Our results provide important 
functional information about an exported protein with a previously unknown role in virulence 
and provide the first evidence for any Mas protein functioning with Mce transporters. Finally, 
our results suggest that OmasA, and possibly other Mas proteins as well, have a structural role 
important for the stability and/or assembly of Mce transporters.   
Results 
OmasA is important for murine infection 
Previous studies revealed a transposon insertion in the M. tuberculosis rv0199 gene, 
hereafter referred to as omasA, results in a growth defect in resting murine bone-marrow derived 
macrophages (McCann et al., 2011). To further explore the role of the OmasA protein in M. 
tuberculosis infection, we evaluated the course of murine infection with the omasA transposon 
mutant (omasA::tn) and compared it to infection with an omasA
WT
 strain, hereon referred to as 
wild type (WT) (McCann et al., 2011). Groups of C57BL/6 mice were infected by low dose 
aerosol with WT, omasA::tn, or a complemented omasA::tn +omasA strain. Mice infected with 
the omasA mutant had lower bacterial burden in the lungs at 6, 13, and 20 days post-infection 
compared to WT (Figure 3.2A). However, by 127 days post-infection there was no longer any 
difference in bacterial burden in the lungs of mice infected with the omasA mutant strain as 
compared to WT infected mice (Figure 3.2A). We also observed reduced bacterial burden in the 
spleen and liver of the omasA mutant infected mice compared to WT at 20 days post-infection 
and, like the burden in the lungs, the number of omasA mutant bacteria reached equivalent levels 
to WT by 127 days post-infection (data not shown). Importantly, all defects in bacterial burden  
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Figure 3.2. OmasA is required for early growth and virulence during murine infection. C57BL/6 
mice were infected with a low dose aerosol of WT, omasA::tn, or omasA::tn +omasA complemented 
strains. A. Groups of four mice per strain were sacrificed at various days post infection (dpi) and bacterial 
burden (colony forming units, cfu) was assessed by plating from organ homogenates. B. Groups of mice 
were monitored for survival. C. A single lung lobe from mice sacrificed for bacterial burden was fixed 
and H&E stained for histology. Average histological activity index (HAI) scores were determined by an 
experienced blinded reviewer. * indicates p<0.05 as compared to WT. tn indicates transposon insertion. 
Error bars represent standard deviation. Results are representative of two independent experiments 
comparing WT (MBTB178), omasA::tn (MBTB319), and omasA::tn + omasA (MBTB320).  
  
 155 
were fully restored in mice infected with the complemented strain. This data indicates that 
OmasA is important for early exponential phase growth in the mouse model of infection.  
We also assessed long-term survival of mice infected with the strains described above. 
Because the bacterial burden in mice infected with the omasA mutant caught up later in infection,  
we were somewhat surprised to observe that omasA mutant infected animals survived 
significantly longer (>250 days) compared to WT (193 days average) and the complemented 
strain (173 days average) (Figure 3.2B). The complemented strain not only alleviated the 
attenuated phenotype of the omasA mutant, but also appeared to potentially accelerate time to 
death in comparison to WT M. tuberculosis (p=0.05). The behavior of the complemented strain 
may be due to non-physiological levels of OmasA, as the gene is expressed off the constitutive 
hsp60 promoter on a multi-copy complementation plasmid. In a separate experiment, when 
omasA mutant infected mice were followed until they succumbed to the infection, the omasA 
mutant infected mice survived almost 50% longer than WT infected mice (data not shown). 
H&E stained lung sections demonstrated that mice infected with the omasA mutant 
displayed reduced inflammatory infiltration and increased open alveolar spaces in comparison to 
WT infected mice. The omasA mutant showed this reduced histopathology in both early (Day 
20) and late (Day 127) timepoints, and the phenotypes were fully restored in the complemented 
strain (Figure 3.3). Blinded scoring of these sections demonstrated that the omasA mutant 
infected mice had lower histopathology scores (histological activity index, HAI) early during 
infection compared to WT infected mice (Figure 3.2C). Even after the bacterial burden in omasA 
infected mice caught up to WT levels (Day 127) the HAI scores trended lower in omasA mutant 
infected mice compared to WT infected mice (p=0.07). The lower histopathology of the omasA  
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Figure 3.3. Mice infected with the omasA mutant have reduced histopathology compared to WT 
infected mice. A single lung lobe from was fixed and H&E stained for histology. Shown are 
representative images captured under 2X and 20X magnification from 20 and 127 days post infection 
comparing WT (MBTB178), omasA::tn (MBTB319), and omasA::tn + omasA (MBTB320). 
  
 157 
mutant infected mice may help account for their longer survival time in comparison to WT 
infected mice.  
A structural prediction for OmasA reveals similarities with Mce-associated proteins 
A β-lactamase reporter fusion was previously used to identify OmasA as a protein with a 
C-terminal domain exported to the extracytoplasmic space (Figure 3.1A) (McCann et al., 2011).  
A single transmembrane domain, as predicted by TMHMM (Krogh et al., 2001), maps close to 
the N-terminus of the protein. Thus, Rv0199 is a relatively small (24kDa) predicted integral 
membrane protein with the majority of the protein (155 of 219 total amino acids) located on the 
cell wall side of the membrane (McCann et al., 2011). To confirm the exported nature of 
OmasA, subcellular fractions of a Mycobacterium smegmatis strain engineered to express a C-
terminal HA tagged OmasA were prepared for immunoblot analysis. As expected, OmasA-HA 
primarily localized to the membrane and cell wall fractions of M. smegmatis, with a smaller 
fraction of OmasA-HA being detected in the soluble fraction, which includes cytoplasmic 
material (Figure 3.1C).  
Consistent with a prior bioinformatics analysis (Casali & Riley, 2007), ClustalW2 
(Goujon et al., 2010; Thompson et al., 2002) revealed the C-terminal region of OmasA to have a 
low level of sequence identity (~10-25%) with Mce-associated (Mas) proteins of actinomycetes. 
Mas proteins are uncharacterized proteins found downstream of mce operons (Casali & Riley, 
2007). However, the omasA gene is not linked to a mce operon, leading us to call it an orphaned 
mas gene (omas). ClustalW2 reveals 10-25% identity between any two Mas proteins, which is 
similar to the low homology shared between OmasA and Mas proteins (Figure 3.4). To gain 
more insight into potential functional domains of the OmasA protein, we used Phyre 2 (protein 
homology/analogy recognition engine version 2.0), an online 3D structural prediction program  
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Figure 3.4. Alignment of all Mas proteins. Alignment between all predicted M. tuberculosis Mas and 
Omas proteins in PRALINE (Bawono & Heringa, 2014). Colors represent amino acid conservation with 
blue representing no/low conservation and red indicating high level conservation.  
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Figure 3.5. Phyre 2, an online structural prediction program, predicts with high confidence that all 
Mas and Omas proteins form a NTF2-like fold. Ribbon diagrams shown represent Phyre 2 (Kelley & 
Sternberg, 2009) predicted structures of OmasA, Mas and Omas proteins colored by secondary structure 
in Pymol. Ribbon diagrams representing the solved crystal structures of the human CAMKIIγ (Rellos et 
al., 2010) as well as VirB8 from Brucella suis and Agrobacterium tumefaciens are shown for comparison 
(Smith et al., 2012; Bailey et al., 2006; Terradot et al., 2005). Alpha helices are colored in red, Beta-
strands in yellow, and turns in green.  
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(Kelley & Sternberg, 2009). Phyre 2 modeled the C-terminal domain of OmasA (aa 69-212) with 
96% confidence to the crystal structure of the protein-protein interaction domain of the 
eukaryotic protein CAMKII (Rellos et al., 2010), predicting OmasA to form a fold that is 
characteristic of NTF2 family proteins (Figure 3.5) (Chaillan-Huntington et al., 2001). Phyre 2 
also detected structural similarity between the C-terminal domain of OmasA and NTF2-like  
domains in some bacterial proteins. Notable matches were to the structures of VirB8 proteins 
from Brucella suis and Agrobacterium tumefaciens (Figure 3.1D) (Smith et al., 2012; Bailey et 
al., 2006; Terradot et al., 2005). Like OmasA, VirB8 is a small protein, 26 kDa, with an N-
terminal transmembrane domain, and the majority of the protein localized to the periplasm. 
Additionally, like OmasA, in B. abortus VirB8 plays an important role during infection of both 
mice and macrophages (den Hartigh et al., 2008). VirB8 is a component of the type IV secretion 
system, a large multi-protein transporter, and it is important to both the stability and function of 
the transporter complex (Kumar et al., 2000; Sivanesan & Baron, 2011; den Hartigh et al., 
2008). To determine whether these structural predictions for OmasA are shared with Mas family 
proteins, we used Phyre 2 to predict the structure of all M. tuberculosis Mas proteins. Strikingly, 
like OmasA, all M. tuberculosis Mas family proteins had high confidence structural alignments 
to NTF2 domain containing proteins, including VirB8 (Figure 3.5). Given the similarity between 
the structural predictions of OmasA, Mas and VirB8 proteins, we hypothesized a function of 
OmasA in Mce transporters, possibly a function analogous to that of VirB8 stabilizing multi-
protein transporter complexes.  
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Figure 3.6. Mce operons in M. smegmatis and M. leprae. A. M. smegmatis has six mce operons 
organized as shown. Mce operons are organized by two yrbE genes upstream (green), six mce genes 
(purple) and many have mas genes (red) downstream. Several genes, including msmeg0235, are predicted 
to encode Mas proteins but are not located in mce operons and thus are labeled orphaned mce-associated 
genes (omas) (Casali & Riley, 2007). B. The mce operon structure in Mycobacterium leprae which only 
contains one mce operon and two orphaned mas genes (Casali & Riley, 2007).  
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Deletion of omasA in Mycobacterium smegmatis leads to a mce mutant morphology 
phenotype  
With the goal of assigning a function to OmasA, we first explored the potential for 
OmasA to contribute to Mce transport in M. smegmatis. M. smegmatis has six mce operons with 
nine mce-associated genes (mas), and ten orphaned mce-associated (omas) genes (Casali & 
Riley, 2007) (Figure 3.6). In M. smegmatis, msmeg0235 is the ortholog of omasA, and will be 
referred to as omasAms. Like OmasAmtb, the OmasAms protein has a predicted transmembrane 
domain near the N-terminus, and OmasAms has 55% identity and 76% similarity to OmasAmtb in  
the C-terminal domain according to BLAST (Altschul et al., 1990). We constructed a deletion 
mutant of omasAms and compared phenotypes of the omasAms mutant to those of M. smegmatis 
mutants lacking mce4 or all six M. smegmatis mce operons (mce6X) (Klepp et al., 2012).  
Previous studies revealed a rugose morphology for the mce6X M. smegmatis mutant 
growing on Mueller Hinton agar plates containing Congo red (Klepp et al., 2012). Consequently, 
we tested whether the omasAms mutant displays a similar morphology. Plates were incubated at 
37C for two days and morphology was assessed by low-magnification microscopy. WT M. 
smegmatis displayed flat, shiny colonies, but mce4, mce6X, and the omasAms mutants displayed 
rugose morphology (Figure 3.7). The rugose phenotype of the omasAms mutant could be 
complemented by either expression of omasAmtb or omasAms from a plasmid (Figure 3.7). While 
the basis of the mce mutant rugose phenotype is not currently understood, the appearance of a 
similar phenotype for the omasAms M. smegmatis mutant is consistent with a role for OmasA in 
Mce transporters.  
Double mutants omasAmsmce4 and omasAmsmce6X mutants were also constructed and 
tested for possible epistatic interactions. Double mutants were spotted and compared to single  
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Figure 3.7. The omasAms mutant shares a morphology phenotype with mce operon mutants. Two µL 
spots of culture were plated on Mueller Hinton plates containing glucose and Congo red. The resulting 
colonies were visualized after 2 days at 2X and 5.6X magnification (Leica M420 macroscope). Results 
are representative of at least three independent experiments comparing WT +pMV261 (EP1182), mce4 
+pMV261 (EP1204), mce6X +pMV261 (EP1208), omasA +pMV261 (EP1193), omasA +omasAms 
(EP1194), omasA +omasAmtb (EP1203), omasAmce4 +pMV261 (EP1206), and omasAmce6X  
+pMV261 (EP1210).  pMV261 is an empty vector, omasA expression constructs are cloned in pMV261.  
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mce4 or mce6X mutants (Figure 3.7). If the rugose phenotype of the omasAms mutant is due to the 
effective loss of Mce transport, the double omasAmsmce4 and omasAmsmce6X should look like 
single mce4 or mce6X mutants. If rugosity of the omasAms mutant is independent of Mce 
transporter function, an additive effect on rugose morphology from losing both mce operons and 
omasAms may occur. The double mutant phenotype was indistinguishable from that of the single 
mutants, suggesting that OmasA functions in the Mce transporter pathway.  
OmasA is required for cholesterol utilization 
The Mce4 transporter has a demonstrated function in cholesterol import. Mycobacterial 
mutants lacking the mce4 operon are defective in cholesterol uptake and growth on cholesterol as 
a sole carbon source (Klepp et al., 2012; Pandey & Sassetti, 2008). To test whether OmasA is 
specifically important to Mce4 function, we tested the omasAms mutant for its ability to grow in 
liquid media with cholesterol as a sole carbon source. M. smegmatis strains were grown in 
minimal media supplemented with standard glucose and glycerol carbon sources or cholesterol 
as the sole carbon source. Cell number and metabolic activity in media containing different 
carbon sources was followed by resazurin reduction over time, as previously described (Hayden 
et al., 2013). Resazurin is a blue dye that converts to a pink fluorescent compound when reduced 
by metabolically active cells. In glucose and glycerol containing media, the resazurin reduction 
observed over time for the omasAms mutant was equivalent to that exhibited by WT M. 
smegmatis (Figure 3.8A). However, in media with cholesterol as a sole carbon source, resazurin 
reduction was observed with WT M. smegmatis but the omasAms mutant showed very little to no 
resazurin reduction. Strikingly, the behavior of the omasAms mutant in cholesterol media was 
equivalent to that of the mce4 M. smegmatis mutant (Figure 3.8B). The cholesterol growth defect  
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Figure 3.8. OmasA is required for M. smegmatis and M. tuberculosis to utilize cholesterol. A. 10
4
 
colony forming units (cfu) of M. smegmatis strains were added to M9 glucose/glycerol and growth was 
monitored by resazurin conversion over time. B. 10
4
 cfu of M. smegmatis were added to minimal M9 
media plus cholesterol, and growth was monitored by resazurin conversion over time. Relative 
fluorescence unit measurements in cholesterol media are reported after subtraction of the minimal signal 
from no carbon source. 10
4
 cfu of M. tuberculosis were added to minimal Sauton’s media supplemented 
with C. glycerol or D. cholesterol, and growth was monitored by resazurin conversion over time. Relative 
fluorescence unit measurements in cholesterol media are reported after subtraction of the minimal signal 
from no carbon source. Results are representative of at least three independent experiments. M. smegmatis 
strains: WT +pMV261 (EP1182), mce4 +pMV261 (EP1204), omasA +pMV261 (EP1193), omasA 
+omasAms (EP1194), and omasA +omasAmtb (EP1203).  M. tuberculosis strains: WT (MBTB178), 
omasA::tn (MBTB319), omasA::tn + omasA (MBTB320), mce2F::tn (MBTB156), mce1A::tn 
(MBTB204), mce4B::tn (MBTB329), mce4F::tn (MBTB288). 
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of the omasAms mutant could be fully complemented by expression of either omasAms or omasAmtb 
from a plasmid (Figure 3.8B).  
To determine whether OmasA is also important to Mce4 function in M. tuberculosis, we 
tested the M. tuberculosis omasA mutant for a defect in growth with cholesterol as a sole carbon 
source. Again we used resazurin reduction over time to monitor cell number and metabolic 
activity. Transposon mutants in several mce operons, including the mce4 operon (insertion 
mutants in the mce4B and mce4F genes), mce1 (mce1B), and mce2 (mce2F) were tested in  
parallel with the omasA mutant and complemented strains. The omasA mutant reduced resazurin 
to an equivalent level as WT when grown in glycerol media (Figure 3.8C). However, in 
cholesterol media, the omasA mutant and mce4 mutants with transposon insertions in mce4B or 
mce4F were unable to utilize cholesterol as a sole carbon source (Figure 3.8D). As with the M. 
smegmatis cholesterol growth experiments, the omasA and the mce4 mutants of M. tuberculosis 
exhibited the same level of defect in cholesterol media. The omasA mutant was fully 
complemented by expression of omasAmtb in the complemented strain. Transposon mutants 
interrupting mce1 and mce2 operons displayed no defect for utilization of cholesterol (Figure 
3.8D), consistent with previous reports (Pandey & Sassetti, 2008; Griffin et al., 2011). These 
data demonstrate that OmasA is required for cholesterol utilization in both M. smegmatis and M. 
tuberculosis. 
OmasA is required for cholesterol uptake 
The cholesterol growth defects of omasA mutants of M. smegmatis or M. tuberculosis 
were indistinguishable from those of mce4 mutants, suggesting a role of OmasA in Mce4 
cholesterol import. To directly test whether OmasA is required for cholesterol import, as 
opposed to playing a role in downstream cholesterol metabolism, we tested the ability of WT M. 
 167 
smegmatis, the omasAms mutant, and complemented strains to import radioactively labeled 
cholesterol. M. smegmatis strains were grown overnight in media with glucose and glycerol and 
then incubated for two hours in minimal media with C
14
 labeled cholesterol as the sole carbon 
source. After incubation, cells were washed extensively, and the level of accumulated cholesterol 
in the cells was quantified. In these experiments, the mce4 mutant exhibited a two-fold reduction 
in cholesterol uptake in comparison to WT, consistent with previous reports (Pandey & Sassetti, 
2008; Klepp et al., 2012). The omasAms mutant also revealed a defect in cholesterol uptake in 
comparison to WT, and this defect was equivalent to that observed with the M. smegmatis mce4 
mutant (Figure 3.9A). The cholesterol uptake defect of the omasA mutant could be 
complemented by either omasAmtb or omasAms (Figure 3.9A). While both the mce4 and omasAms 
mutants exhibited a significant reduction in cholesterol uptake, there remained detectable levels 
of cell-associated C
14
 cholesterol with both mutants. Previous uptake studies also report residual 
levels of cholesterol associated with mce4 mutants, leading to the suggestion that additional 
cholesterol importers may exist in mycobacteria (Pandey & Sassetti, 2008; Klepp et al., 2012). 
When we examined the double omasAmsmce4 mutant it was no more defective than single mce4 
or omasAms mutants. In fact, the double mutant showed slightly improved cholesterol uptake in 
comparison to the single mce4 and omasAms mutations alone (Figure 3.9B). The lack of an 
additive effect of the mce4 and omasAms mutations on the cholesterol uptake phenotype is 
consistent with OmasA functioning in concert with Mce4 to import cholesterol, as opposed to 
being part of an independent cholesterol uptake pathway.  
OmasA stabilizes the Mce1 transport complex  
The above studies demonstrate that OmasA is important to Mce4 cholesterol import and 
utilization. However, a function of OmasA beyond Mce4 seems likely. This is because the role  
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Figure 3.9. OmasA is required for cholesterol uptake. A. and B. M. smegmatis strains were grown 
overnight in M9 glucose/glycerol, and washed extensively in M9 no carbon source. Cells were incubated 
with 4-C
14
-cholesterol for two hours, washed extensively, and cell associated radioactivity levels were 
measured by scintillation counter. * indicates p<0.05 compared to WT. Error bars represent standard 
deviation. Results are representative of at least three independent experiments. M. smegmatis strains: WT 
+pMV261 (EP1182), mce4 +pMV261 (EP1204), omasA +pMV261 (EP1193), omasA +omasAms 
(EP1194), omasA +omasAmtb (EP1203), and omasAmce4+pMV261 (EP1206). 
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of OmasA in promoting M. tuberculosis growth in resting murine macrophages (McCann et al., 
2011) cannot be explained by an effect on Mce4, as there is no obvious role for Mce4 in 
promoting growth in resting macrophages (Pandey & Sassetti, 2008; Stewart et al., 2005; 
Rengarajan et al., 2005; McCann et al., 2011). However, because M. tuberculosis mce1 mutants 
are reported in several studies to be defective for growth in macrophages (Rengarajan et al., 
2005; Stewart et al., 2005; McCann et al., 2011), we hypothesized that OmasA is additionally 
important to Mce1 transporter function. Due to the predicted structural similarities between  
OmasA and VirB8, and the role of VirB8 in stabilizing the multi-protein type IV secretion 
complex (den Hartigh et al., 2008; Sivanesan & Baron, 2011), we further hypothesized that 
OmasA stabilizes proteins within Mce transporter complexes. Thus, to investigate the potential 
contribution of OmasA to the Mce1 transporter system and stability of the Mce1 complex we 
performed immunoblot analysis for three M. tuberculosis Mce1 proteins (Mce1A, Mce1E, and 
Mce1F) in M. tuberculosis WT, the omasA mutant, and the complemented strain. Mce1A, 
Mce1E, and Mce1F were localized to the cell wall in M. tuberculosis WT and the complemented 
strain, consistent with previous subcellular localization experiments performed in M. smegmatis 
(Forrellad et al., 2014). However, none of these Mce proteins were detected in the cell wall of 
the omasA mutant (Figure 3.10A). Further, Mce1A, Mce1E, and Mce1F were undetectable in the 
whole cell lysate of the omasA mutant, demonstrating that they were not merely mislocalized in 
the omasA mutant. Mce1 protein levels were fully restored in the complemented strain. The 
effect of the omasA mutation on Mce proteins was not due to a broad defect on cell wall proteins, 
as shown by equivalent levels of the exported 19kD lipoprotein in cell wall fractions of all three 
strains (Figure 3.10A).  
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Figure 3.10. Absence of OmasA results in Mce1 protein instability. A. M. tuberculosis cells were 
irradiated and lysed by French press to generate whole cell lysates (WCL) and fractionated by differential 
ultracentrifugation into cell wall fractions. Western blots were performed for Mce1A, Mce1E, Mce1F, 
and the 19kD lipoprotein. Results are representative of at least three independent replicates. B. RNA was 
collected from M. tuberculosis WT, omasA::tn, and omasA::tn +omasA complemented strains and 
transcript levels of mce1A, mce1F, mce4A, and mce4F were determined by Quantitative Real-Time PCR 
and normalized to expression of the housekeeping protein sigA (Manganelli et al., 1999). Reported are 
fold change values for each gene relative to expression in WT M. tuberculosis. Error bars represent 
standard deviation. Results are representative of at least three independent biological replicates of WT 
(MBTB178), omasA::tn (MBTB319), and omasA::tn + omasA (MBTB320). 
  
 171 
The immunoblot results are consistent with Mce1 proteins being unstable in the absence 
of OmasA, however; an alternate explanation is that OmasA is required for the expression of 
mce1 genes. To rule out the possibility that the absence of Mce1 proteins in the omasA mutant is 
due to a transcriptional effect, we measured the level of mce1 transcripts in WT, omasA mutant, 
and complemented strains using Quantitative Real-Time PCR. All three strains harbored 
equivalent amounts of mce1A and mce1F transcripts. Thus, the lack of Mce1 proteins in the 
omasA mutant is not a consequence of lower transcript levels. Rather, the striking reduction in 
Mce1 proteins observed in the omasA mutant is consistent with OmasA having a function,  
similar to that of VirB8, in stabilizing multi-component transporters. We similarly quantified 
mce4 transcript levels in the omasA mutant and again observed equivalent levels of mce4A and 
mce4F transcripts in the omasA mutant compared to WT and complemented strains (Figure 
3.10B).  
Discussion  
The goal of this work was to extend our previous identification of OmasA as an exported 
protein of unknown function with a role in promoting growth in macrophages. Here, we tested 
the significance of OmasA in a low-dose aerosol model of murine infection and set about 
assigning a function to the protein. While we detected low level similarity between OmasA and 
Mas proteins, the homology is limited. Further, the omasA gene is not linked to a mce operon and 
there are no prior studies assigning function to any Mas protein. By demonstrating both a role for 
OmasA during murine infection and a role in Mce1 and Mce4 transporter systems, our results 
provide the first direct evidence of any Mas protein being required for in vivo infection or 
contributing to Mce transporter function. The lack of assayable in vitro phenotypes for the Mce2 
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and Mce3 systems prevented us from testing a role for OmasA in these other transporters. Thus, 
it remains a possibility that OmasA is also involved in additional Mce transporter systems. 
When tested in mice, the omasA mutant exhibited reduced bacterial burden during the 
growth-in-vivo phase of infection (first 3 weeks), which is consistent with the role of OmasA in 
promoting M. tuberculosis growth in macrophages (McCann et al., 2011). The omasA mutant 
infected animals also exhibited reduced pathology and had an increased survival time. 
Interestingly, later in infection the organ burden of the mutant was no different than WT (as seen 
in independent experiments) indicating that the basis of the attenuated phenotype of the omasA 
mutant is complex and not simply a consequence of fewer bacteria present throughout infection. 
Because of the connection we made between OmasA and Mce systems, we compared the 
macrophage and mouse phenotypes of the omasA mutant to infection phenotypes reported for 
mce mutants. In resting macrophages, several studies report intracellular growth defects of mce1 
mutants, like that of the omasA mutant (Stewart et al., 2005; Rengarajan et al., 2005; McCann et 
al., 2011). In mice, a wide variety of models (infection route, mouse strain, etc.) have been used 
to test mce mutants making it difficult to compare studies. However, when tested in mice, 
mutants in mce1, mce2, mce3, or mce4 are generally attenuated, as demonstrated by increased 
survival time, reduced lung pathology, and/or reduced bacterial burden (Marjanovic et al., 2010; 
Senaratne et al., 2008; Rengarajan et al., 2005; Sassetti & Rubin, 2003; Gioffre et al., 2005), 
similar to the omasA mutant. For an mce4 mutant specifically, when tested in an intravenous 
infection model with a 1:1 mixture of WT:mce4, the mce4 mutant is reported to have a 
persistence defect late in infection (Joshi et al., 2006; Pandey & Sassetti, 2008; Sassetti & Rubin, 
2003). However, when tested in an aerosol infection model similar to the one used in our study, a 
mce4 mutant exhibits a subtle persistence defect (Senaratne et al., 2008), which may explain why 
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we did not observe a defect in persistence. Overall, the omasA mutant animal phenotypes are 
consistent with what has been reported for mce mutants.  
 The omasA mutant phenotypes we observed on cholesterol-containing media were 
indistinguishable from mce4 mutants. These results not only support a role for OmasA in Mce4 
transport, but they additionally reveal OmasA to be a new protein required for cholesterol 
utilization in vitro. In a Tn-seq mutagenesis study to identify M. tuberculosis genes required for 
in vitro growth on cholesterol, all genes in the mce4 operon were identified, including mas4A 
and mas4B, but omasA was not identified (Griffin et al., 2011). Interestingly, omasA only barely 
missed the cutoff for statistical significance in this study (p=0.06), consistent with a role in 
cholesterol utilization.  
It is also interesting to compare our results indicating a role for OmasA in Mce transport 
pathways to the results of a transposon mutagenesis screen conducted in mce1 or mce4 mutant 
backgrounds (Joshi et al., 2006). In this genetic interaction screen, genes that are members of the 
same Mce transport pathway or genes in redundant parallel pathways were uncovered. Once 
again, although omasA was not predicted as having genetic interactions with mce1 or mce4 in 
this earlier study, inspection of the supplemental data revealed the behavior of omasA mutations 
in mce1 and mce4 backgrounds to be consistent with omasA being part of these Mce pathways 
(Joshi et al., 2006).  
Given the many mce-linked mas genes (eight) and unlinked omas (five) genes in M. 
tuberculosis, our finding that deletion of omasA yielded phenotypes as dramatic as complete 
deletion of the mce4 operon was surprising, as was the discovery that OmasA impacted more 
than one Mce system. The dramatic phenotypes of the omasA mutant raise questions about 
whether other Mas proteins of M. tuberculosis will also have such broad effects. Data from 
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transposon mutagenesis screens predicts similar phenotypes for mutations in mas genes and the 
adjoining mce operons (Rengarajan et al., 2005; Sassetti & Rubin, 2003; Griffin et al., 2011), 
which supports the idea of mas genes functioning with their linked mce system. However, the 
function of mas genes may not extend to unlinked mce loci.  For example, the mce1-associated 
mas genes (mas1A-D) are not predicted to be required for growth on cholesterol like mce4 
mutants (Griffin et al., 2011). Additionally, it remains unclear whether all orphaned Mas proteins 
are required for multiple Mce transporters or whether they are even involved in Mce transport at 
all. Individual mas and omas mutants will need to be constructed and characterized in order to 
determine if the dramatic role of OmasA in Mce function is unique or representative of the 
overall importance of all Mas family members. 
The Mycobacterium leprae genome is highly reduced in comparison to other 
mycobacterial species and is thought to have only maintained a minimal set of genes required for 
its intracellular lifestyle (Moran, 2002; Singh & Cole, 2011). Interestingly, omasA and the 
downstream omasB are only two omas genes conserved in the M. leprae genome, which contains 
a single mce operon, mce1 (Figure 3.6). Conservation of omasA in M. leprae supports the 
importance of omasA in intracellular growth and virulence. Additionally, the conserved presence 
and arrangement of omasA and omasB suggests that the corresponding proteins may function 
together. Like omasA and omasB, Mas family proteins are usually encoded in pairs (Figure 3.1B, 
Figure 3.6) (Casali & Riley, 2007), although the significance of this arrangement is unknown. 
Future study of OmasB, the protein encoded by rv0200, could help to determine whether OmasB 
also has a broad role in Mce transport like OmasA.  
The unexpected structural similarity predicted by Phyre 2 between VirB8 and Mas 
proteins was helpful for identifying a function for OmasA. VirB8 is an essential component of 
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bacterial type IV secretion systems, helping to form the core complex of the transport machinery, 
providing stability to many proteins within the complex and potentially anchoring it to the 
cytoplasmic membrane (Paschos et al., 2006; Fronzes et al., 2009; Kumar et al., 2000; Baron, 
2006). In the absence of VirB8, many proteins within the type IV secretion apparatus become 
destabilized and degraded (den Hartigh et al., 2008; Sivanesan & Baron, 2011). Similarly, in the 
absence of OmasA all three of the Mce1 proteins we monitored by immunoblot analysis were 
degraded. These results suggest that OmasA, and Mas proteins in general, may play analogous 
roles to VirB8 in the formation and stabilization of the core Mce transport complex, resulting in 
destabilization of Mce proteins in their absence. Interestingly, VirB8 also plays a role in 
substrate transport during type IV secretion (Cascales & Christie, 2004), which raises the 
possibility that Mas proteins may also have an additional role in Mce substrate movement. Due 
to structural and functional analogies between OmasA and VirB8, we propose a model wherein 
OmasA interacts with Mce proteins, potentially driving Mce complex formation, and ultimately 
providing stability to Mce proteins within the complex (Figure 3.11). Because there are thirteen 
Mas family proteins in M. tuberculosis and only four Mce transporters, we predict that each 
transporter may be stabilized by multiple Mas family members.  
Although Mce transporters are of clear importance to M. tuberculosis virulence and a 
core component of the M. tuberculosis genome (Gioffre et al., 2005; Shimono et al., 2003; 
Marjanovic et al., 2010; Lima et al., 2007; Sassetti & Rubin, 2003; Rengarajan et al., 2005; 
Stewart et al., 2005; McCann et al., 2011; Senaratne et al., 2008; Pandey & Sassetti, 2008), there 
has yet to be a systematic genetic or biochemical analysis of the individual Mce transporter 
proteins in terms of their contribution to virulence or their function in the transport mechanism. 
Mce transporter components are assigned potential functions by analogy to classic ABC  
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Figure 3.11. OmasA is an integral membrane protein that is important to Mce transporter stability 
and function. OmasA and other Mas proteins, shown in red, are embedded in the inner membrane by an 
N-terminal transmembrane domain with the majority of the protein being localized on the cell wall side of 
the membrane. Mce permease proteins (YrbE), shown in green, are multi-membrane spanning proteins 
localized to the inner membrane. Some Mce proteins contain predicted TM domains; however, 
localization from this and other studies (Klepp et al., 2012) suggests that Mce proteins are located within 
the cell wall (shown in purple). MceG, shown in yellow, is the cytoplasmic Mkl family ATPase predicted 
to be responsible for ATP-hydrolysis that powers the transport of substrates, shown in pink, through the 
complex.  
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transporters (ex. ATPase, permease, or solute binding proteins) (Casali & Riley, 2007). 
However, Mce transporters are distinguished from ABC transporters in the multitude of 
individual proteins predicted to be involved: two YrbE permeases, six predicted Mce solute 
binding proteins, and a shared ATPase MceG. The function of all of these individual transporter 
components requires validation. Because Mas proteins share no obvious ABC transporter 
counterpart their function has been an even bigger mystery. The results of this study provide an 
essential framework for studying the role of Mas family proteins in the assembly and 
stabilization of Mce transporter systems.  
 
Experimental Procedures 
Bacterial strains and plasmids. In this study, we used the bacterial strains listed in Table 3.1 and 
plasmids as listed in Table 3.2. The M. tuberculosis omasA (rv0199) mutant was generated in a 
previous transposon mutagenesis study performed in a M. tuberculosis β-lactamase (ΔblaC) 
background (McCann et al., 2011; Flores et al., 2005). The omasA::tn mutant has a hygromycin 
resistant Tn’blaTEM-1 transposon inserted in the omasA coding sequence at amino acid position 74 
and it expresses an exported OmasA-‘BlaTEM-1 fusion protein. The omasA::tn mutant 
(omasA::tn, ΔblaC) used in this study (MBTB319) additionally carries the empty pMV261.kan 
plasmid. For mutant characterization, omasA::tn was compared to strain MBTB178 (omasA
WT
, 
ΔblaC, pJES137, pMV261.kan). Plasmid pJES137 is an integrating hygromycin resistant 
plasmid that expresses ‘blaTEM-1. MBTB178 is referred to as WT in the text. The M. 
tuberculosis complemented strain (omasA::tn, ΔblaC, pJES178) expresses omasA from the 
hsp60 promoter of the kanamycin resistant plasmid pJES178 (McCann et al., 2011). This series 
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of omasA::tn (MBTB319), omasA
WT
 (MBTB178) and complemented (MBTB320) strains are all 
hygromycin and kanamycin resistant to enable growth in identical media conditions.  
Bacterial growth. M. tuberculosis strains were grown in Middlebrook 7H9 broth (Difco) 
supplemented with 1X albumin dextrose saline (ADS), 0.5% glycerol and either 0.025% Tween 
80 (Tw) or 0.025% tyloxapol (Ty). M. smegmatis strains were grown in Middlebrook 7H9 broth 
(Difco) supplemented with 0.2% glucose, 0.5% glycerol, and either 0.05% Tween 80 (Tw) or 
0.05% Tyloxapol (Ty). Medium was supplemented with 20µg mL
-1
 kanamycin or 50µg mL
-1
 
hygromycin as needed for mycobacterial cultures. E. coli strains were grown in Luria-Bertani 
medium (Fisher) supplemented as necessary with 40µg mL
-1
 kanamycin.  
Mouse experiments. Female C57BL/6 mice aged 7-10 weeks were infected with ~200 cfu of M. 
tuberculosis by aerosol using a Madison chamber (Mechanical Engineering Workshop, Madison, 
WI), and bacterial burden was determined, as previously described (Kurtz et al., 2006). Groups 
of four mice per strain were sacrificed, organs homogenized, and diluted and plated to determine 
bacterial burden at various times after infection. The lower right lobe of the lungs was inflated 
and fixed in 10% formalin for histology.  
Histopathology. Inflammation was determined in 5 μm sections following hematoxylin and eosin 
(H&E) staining. Paraffin embedded sections were set and cut to reveal the maximum 
longitudinal visualization of the intrapulmonary main axial airway. Histopathology was 
evaluated and scored by an experienced blinded reviewer (I.C.A.) on a scale of 0 (absent) to 3 
(severe), as previously described (McElvania Tekippe et al., 2010; Allen et al., 2013; Allen et 
al., 2009). The parameters assessed included overall leukocyte infiltration, perivascular and 
peribroncheolar cuffing, extravasation, and the estimated percent of lung area involved with 
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inflammation. Each individual parameter was scored and averaged to generate the histology 
score.  
Mutant construction. M. smegmatis mutants were constructed by recombineering, as previously 
described (van Kessel & Hatfull, 2008; van Kessel & Hatfull, 2007). Briefly, upstream and 
downstream flanks were PCR amplified and cloned into pMP614 (kind gift from Martin 
Pavelka), which was then linearized to produce the final recombineering fragment, carrying a 
hygromycin resistance marker flanked by DNA sequences upstream and downstream of 
msmeg0235. Parental strains carrying a kanamycin marked plasmid expressing a recombinase, 
pJV53, (van Kessel & Hatfull, 2007; van Kessel & Hatfull, 2008) were used for recombineering. 
Following three hour induction of the recombinase with acetamide, electroporation was used to 
introduce the linear recombineering fragment. Allelic exchange recombinants were selected for 
double resistance to hygromycin and kanamycin. Strains were cured of pJV53 by passaging 3-4 
times in the absence of kanamycin. Plasmid cured strains were then transformed with the 
resolvase expressing pMP854 plasmid (kind gift from Martin Pavelka), to remove the 
hygromycin marker in the deletion cassette. Hyg
s
 strains were cured for pMP854 as described 
above to generate the final unmarked deletion strains. Mutant construction was confirmed by 
Southern blot (data not shown).  
OmasAms complementation and OmasAmtb-HA vector construction. The msmeg0235 gene 
(omasAms) was PCR amplified by msmeg0235_F1 x msmeg0235_R1, the rv0199 gene 
(omasAmtb) was PCR amplified by rv0199HA_F_MscI x rv0199HA_R_HindIII, and PCR 
fragments were cloned into pCR2.1 (Invitrogen). The resulting plasmids were sequenced to 
confirm they were error-free. The omasAms fragment was digested from pCR2.1 with EcoRI, gel 
purified, and ligated into EcoRI digested pMV261.kan (Stover et al., 1991). The omasAmtb 
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fragment was digested from pCR2.1 with MscI and HindIII, gel purified, and ligated into 
MscI/HindIII digested JSC77 (Glickman et al., 2000), containing an in-frame C-terminal HA tag. 
Primer sequences are provided (Table 3.3).  
Transformation. M. smegmatis strains were transformed by electroporation, as previously 
described (Snapper et al., 1990).  
Morphology. Congo red assays were performed, as previously described (Klepp et al., 2012). 
Mueller Hinton agar plates were supplemented with 0.2% glucose and 100µg mL
-1
 Congo red 
(Sigma). Colony morphology was analyzed by plating 2 µL spots of OD600 1.0 M. smegmatis 
strains. Plates were incubated at 37C for two days and visualized using a low-magnification 
Leica M420 macroscope with 2X and 5.6X magnification. 
Cholesterol Growth Assays for M. tuberculosis. A cholesterol stock solution was prepared by 
solubilizing cholesterol in ethanol and tyloxapol, as follows. A 1:1 solution of 200 proof 
Ethanol:Tyloxapol (Sigma) was prepared, filtered, and heated to 50C. 200mg mL-1 cholesterol 
was dissolved in 3:1 chloroform:methanol, and added dropwise to the 50C tyloxapol solution 
until reaching 20% final volume. Sauton’s media was prepared and pH adjusted to 7.4: 1L dH2O, 
4g DL asparagine, 2g sodium citrate, 0.5g K2HPO4, 0.5g MgSO4-7H2O, 0.05g ferric ammonium 
citrate, 0.025% Tyloxapol, and supplemented with either 6% glycerol or 0.5 mM cholesterol 
from stock solution. M. tuberculosis strains were diluted to 10
5 
cfu mL
-1
 in Sauton’s +Ty and 104 
cfu were aliquoted into 96 well plates with Sauton’s supplemented with glycerol or cholesterol, 
incubated shaking at 37C for seven days, then resazurin (Sigma) was added to a final 
concentration 0.0125 mg mL
-1
. Resazurin conversion was followed using fluorescence and was 
monitored daily by a Tecan Infinite 200 Pro at hv=544 nm excitation and hv=590 nm emission.  
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Cholesterol Growth Assays for M. smegmatis. A cholesterol stock solution was prepared by 
solubilizing cholesterol in cyclodextrin, as previously described (Klein et al., 1995). Briefly, 1g 
methyl-ß-cyclodextrin (C4555 Sigma) was dissolved in 11mL PBS (0.09g mL
-1
) and heated to 
80C with continuous stirring. 30 mg cholesterol (Sigma) was dissolved in 400µL 2:1 
isopropanol/chloroform. The cholesterol solution was added to the cyclodextrin in 50µL aliquots, 
stirring continuously. The solution was cooled slowly, filtered for sterility, and kept at room 
temperature. M9 minimal media was prepared as follows: 1L dH2O, 12.8g Na2HPO4, 3g 
KH2PO4, 0.5g NaCl, 1g NH4Cl, 25 µL 1M CaCl2, 500µL 1M MgSO4, and 2.5 mL 10% 
Tyloxapol (Ty, Sigma), and supplemented with 0.2% glucose and 0.5% glycerol or 0.5mM 
cholesterol from stock solution. M. smegmatis strains were grown to OD600 1.0 in M9 
supplemented with 0.2% glucose and 0.5% glycerol + 0.05% Ty. Strains were washed in M9 
+Ty three times by pelleting cells at 1,900 x g for 10 minutes at 4C, and diluted to 105 cfu mL-1 
in M9 +Ty, and 10
4 
cfu were plated into 96 well plates with M9 containing glycerol or 
cholesterol. Plates were incubated shaking at 37C overnight, after which resazurin (Sigma) was 
added to a final concentration 0.0125 mg mL
-1
. Florescence was monitored every 10 minutes by 
a Spectramax M2 using hv=544 nm excitation and hv=590 nm emission. 
Cholesterol uptake. Cholesterol uptake experiments were performed, similar to previously 
reported (Klepp et al., 2012). M. smegmatis strains were grown to OD600 1.0 in M9 
supplemented with 0.2% glucose and 0.5% glycerol + 0.05% Ty. Strains were washed in M9 + 
Ty three times by pelleting cells at 1,900 x g for 10 minutes at 4C, and then equalized to OD600 
0.5 in M9 + Ty, and incubated with 0.04µCi 4-C
14
 cholesterol (Perkin Elmer NEC018050UC) 
for 2 hours at 37C. After incubation, cells were pelleted and washed three times with M9 + Ty, 
and cell associated radioactivity was measured by scintillation counter. 
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Subcellular fractionation and Western blotting. M. tuberculosis cells were pelleted by 
centrifugation (1,900 x g) and sterilized by irradiation (JL Shephard Mark I 137Cs irradiator, 
Department of Radiobiology, University of North Carolina at Chapel Hill). After sterilization, M. 
tuberculosis cells were removed from BSL-3 containment. M. smegmatis cells were simply 
pelleted by centrifugation for 10 minutes at 1,900 x g. Subcellular fractionation was then 
performed, as previously described (Gibbons et al., 2007). Briefly, cells were resuspended in 
PBS containing protease inhibitors, lysed in a French pressure cell, and unlysed cells were 
removed by centrifugation (1,900 x g). The clarified whole cell lysates (WCL) were subjected to 
differential ultracentrifugation, 27,000 x g for 30 minutes to pellet the cell wall (CW), 100,000 x 
g for 2 hours to pellet the membrane (MEM), and remaining soluble (SOL) fraction containing 
the cytoplasm. Equal protein amounts, as determined by Bicinchonic acid assay (Pierce), for all 
fractions and strains were separated by SDS-PAGE and transferred to nitrocellulose membranes. 
Proteins were detected using the following antibodies: Mce1 antibodies (a gift from Christopher 
Sassetti, University of Massachusetts Medical School; (Feltcher et al., 2015)): anti-Mce1A 
(1:10,000), anti-Mce1E/Lprk (1:5,000), anti-Mce1F (1:10,000), anti-19kD (1:20,000) (a gift 
from Douglas Young, Imperial College, United Kingdom), and anti-HA (1:25,000) (Covance). 
Anti-mouse and Anti-rabbit IgG conjugated HRP (Biorad) were used as secondary antibodies, as 
appropriate. HRP signal was detected using Western Lighting Chemiluminescent detection 
reagent (Perkin-Elmer).  
Quantitative Real-Time PCR. Triplicate M. tuberculosis cultures were grown to OD600 of 1.0 and 
pelleted by centrifugation for 10 minutes at 1,900 x g, and qRT-PCR was performed. Bacteria 
were lysed by 3:1 chloroform methanol, mixed with Trizol (Invitrogen), and the upper phase was 
separated and RNA precipitated overnight in isopropanol. RNA samples were pelleted and 
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washed in 70% Ethanol, and resuspended in RNase-free H2O. RNA samples were treated with 
DNase (Promega), purified (Zymo RNA Clean and Concentrator Kit), and converted to cDNA 
using iScript cDNA Synthesis Kit (BioRad). Triplicate biological and triplicate technical 
replicates of cDNA from 40 ng RNA each were used for qRT-PCR using the Sensimix SYBR 
and Flourescein kit (Bioline). Transcript copy number for each gene was calculated as compared 
to known concentrations of genomic DNA, and each sample was normalized to housekeeping 
gene sigA transcript levels. Primer sequences are provided (Table 3.3).  
Statistics. Statistics were performed in SigmaPlot. Normality testing (Shapiro-Wilk) and equal 
variance testing was done to determine correct statistical methods. Comparisons passing 
normality and equal variance with two groups were performed by two-tailed Student’s t-test. 
Comparisons not passing normality with two groups were performed by Mann-Whitney rank 
sum test. Comparisons passing normality and equal variance with more than two groups used 
one way analysis of variance (ANOVA), followed by multiple comparisons with the Holm-Sidak 
method as appropriate. Comparisons not passing normality with more than two groups used 
Kruskal-Wallis one way analysis of variance on ranks, followed by multiple comparisons with 
Student-Newman-Keuls. Survival was analyzed by Log-rank test followed by multiple 
comparisons with the Holm-Sidak method.  
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Table 3.1. Bacterial strains used in this study 
M. tuberculosis 
strains 
Description Source 
PM638 M. tuberculosis H37Rv ΔblaC Flores et al., 
2005 
MBTB126 PM638 carrying integrating vector pJES137 (expressing 
'blaTEM-1). Strain is hyg
R
 
McCann et al., 
2011 
MBTB156 PM638, mce2F::tn (with a 'blaTEM-1 transposon 
inserted into mce2F at amino acid position 476). Strain is 
hyg
R
 
McCann et al., 
2011 
MBTB178 MBTB126 + pMV261.kan. Strain is hyg
R 
 and kan
R
 McCann et al., 
2011 
MBTB183 PM638, omasA(rv0199)::tn (with a 'blaTEM-1 
transposon inserted in rv0199 at amino acid position 74). 
Strain is hyg
R
 
McCann et al., 
2011 
MBTB204 PM638, mce1A::tn (with a 'blaTEM-1 transposon inserted 
in mce1A at amino acid position 449). Strain is hyg
R
 
McCann et al., 
2011 
MBTB288 PM638, mce4F::tn (with a 'blaTEM-1 transposon inserted 
in mce4F at amino acid position 539). Strain is hyg
R
 
McCann et al., 
2011 
MBTB319 MBTB183 + pMV261. Strain is hyg
R 
 and kan
R
 McCann et al., 
2011 
MBTB320 MBTB183 + pJES178 (expressing omasAmtb). Strain is 
hyg
R 
and
 
kan
R
 
McCann et al., 
2011 
MBTB329 PM638, mce4B::tn (with a 'blaTEM-1 transposon inserted 
in mce4B at amino acid position 350). Strain is hyg
R
 
McCann et al., 
2011 
   
M. smegmatis strains Description Source 
mc
2
155 M. smegmatis wild-type (WT) Snapper et. al, 
1990 
Δmce4 mutant Δmce4 Klepp et al., 
2012 
Δmce6X mutant Δmce1, Δmce2, Δmce3, Δmce4, Δmce5, Δmce6 Klepp et al., 
2012 
EP1178 ΔomasA, Δmce4 This study 
EP1179 ΔomasA This study 
EP1180 ΔomasA, Δmce6X This study 
EP1182 mc
2
155 + pMV261. Strain is kan
R
 This study 
EP1193 EP1179 + pMV261. Strain is kan
R
 This study 
EP1194 EP1179 + pEP139 (expressing omasAms). Strain is kan
R
 This study 
EP1195 EP1179 + pEP166 (expressing omasAmtbHA). Strain is 
kan
R
 
This study 
EP1203 EP1179 + pJES178 (expressing omasAmtb). Strain is kan
R
 This study 
EP1204 Δmce4 + pMV261. Strain is kanR This study 
EP1206 EP1178 + pMV261. Strain is kan
R
 This study 
EP1208 Δmce6X + pMV261. Strain is kanR This study 
EP1210 EP1180 + pMV261. Strain is kan
R
 This study 
 
Table 3.1. Bacterial Strains Used in this Study 
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Table 3.2. Plasmids used in this study 
Plasmid Antibiotic 
resistance 
Notes Source 
pMV261 kan Multicopy mycobacterial vector with 
hsp60 promoter 
Stover et al., 1991 
pJSC77 kan Multicopy mycobacterial vector, HA 
tag cloned into pMV261 
Glickman et al., 2000 
pJV53 kan Multicopy vector for recombineering, 
phage recombinase genes expressed 
from acetamide inducible promoter 
van Kessel & Hatfull, 2008; 
van Kessel & Hatfull, 2007 
pMP614 hyg res-hyg-res vector for constructing 
recombineering vectors 
Kind gift from Martin Pavelka 
pMP854 kan Resolvase plasmid to remove hyg 
resistance marker 
Kind gift from Martin Pavelka 
pJES137 hyg Integrating mycobacterial vector with 
consitituitively expressed 'blaTEM-1 
McCann et al., 2011 
pJES178 kan Phsp60-omasAmtb cloned into pMV261 McCann et al., 2011 
pEP139 kan Phsp60-omasAms cloned into pMV261 This study 
pEP166 kan Phsp60-omasAmtb cloned into pJSC77 This study 
        
Table 3.2. Plasmids Used in this Study 
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Table 3.3. Primers used in this study 
Gene Forward primer Reverse primer 
sigA GAGATCGGCCAGGTCTACGGCGTG CTGACATGGGGGCCCGCTACGTTG 
mce1A GTCTTCGCGCTCGTAGTTG ACGTGTGACCTCCGAGATG 
mce1F TCGTCTCCGTAGTCGCAATC ACATTGGCCGTCGGATACAG 
mce4A ATCCGCAGTGCTGACTTATC TGCCACGGTATTTGACCTTG 
mce4F ATCACCGTCATCACCCTGAG CGTTGGCGTTCTTGTACAGG 
msmeg02
35 
GAGAATTCCATGCCTGACGCGCCCAGCA
AG 
AGGAATTCGGTTCCTCATCGGATGGGCTC
CAGAC 
rv0199HA AAGCTTGTCGAATCGACTCCAACCGGGA
GATCA 
TTGGCCATGCCTGACGGGGAGCAGAGC 
 
Table 3.3. Primers used in this study.  
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CHAPTER 4: DISCUSSION 
Introduction 
Mycobacterium tuberculosis is responsible for the disease tuberculosis, which kills 
approximately 1.5 million people per year (WorldHealthOrganization, 2014). M. tuberculosis 
produces many proteins that are exported: transported out of the bacterial cytoplasm to the 
bacterial cell surface and out into the host environment. Exported proteins are located at the host-
pathogen interface, in an ideal location to manipulate the host response and allow for 
intracellular growth, and many exported proteins contribute significantly to virulence (Isaac & 
Isberg, 2014; Agbor & McCormick, 2011; Ligon et al., 2012). Unfortunately, the approaches to 
experimentally identify proteins as being exported by bacteria have been limited to study of 
bacteria growing in laboratory media (in vitro). Because in vitro laboratory conditions cannot 
mimic the complexity of the host environment, there are likely critical exported virulence factors 
that have been missed because they are only exported in the context of infection.  
 
Probing for Bacterial Proteins at the Host-Pathogen Interface 
The main objective of this dissertation was to develop a method to identify proteins 
exported by bacterial pathogens during infection of a host (in vivo). To accomplish this goal, we 
developed a novel method that we refer to as EXIT, EXported In vivo Technology, and applied it 
to identify M. tuberculosis proteins exported during murine infection.  
 194 
The Comprehensive EXIT Approach 
EXIT utilizes the ‘BlaTEM reporter, a reporter originally developed and used in other 
pathogens (Broome-Smith & Spratt, 1986) and more recently adapted successfully for use in M. 
tuberculosis (McCann et al., 2007; McCann et al., 2011). While the ‘BlaTEM reporter was 
developed around the same time as the alkaline phosphatase (‘PhoA) reporter, the ‘BlaTEM 
reporter is often overlooked and it is the ‘PhoA reporter that is routinely used as a genetic 
reporter of bacterial protein export (Manoil & Beckwith, 1985; Broome-Smith & Spratt, 1986). 
Like the ‘BlaTEM reporter, the ‘PhoA reporter is only enzymatically active when exported 
(Manoil & Beckwith, 1985). ‘PhoA reporter constructs are screened with a colorimetric assay, 
where negative colonies are white and colonies expressing exported ‘PhoA constructs are blue 
(Manoil & Beckwith, 1985). However, the ‘BlaTEM reporter is even more powerful than the 
‘PhoA reporter because it can be used as a selectable marker. For EXIT it was critical that we 
used a reporter that could be selected for in vivo. Only with a selectable reporter were we able to 
select for and pool bacteria actively producing exported fusions during in vivo β-lactam 
treatment, and use next-generation sequencing to identify exported fusion proteins.  
We built a multi-copy plasmid carrying the ‘BlaTEM reporter, constructed a 
comprehensive library of fusions between M. tuberculosis genomic DNA and the ‘BlaTEM 
reporter, and transformed these plasmids into M. tuberculosis. The EXIT library was planned and 
built on a scale suitable for comprehensive genome-wide analysis (Appendix I), containing 
5x10
6
 M. tuberculosis clones that included at least one in frame fusion for 99% of M. 
tuberculosis genes. While none of the library construction steps were novel, genetic reporters 
have rarely been used on such a truly genome-wide scale.  
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The comprehensive EXIT library was the foundation for genome-wide identification of in 
vivo exported proteins. We infected mice with the EXIT library, and conducted in vivo β-lactam 
selection for clones producing in vivo exported proteins. Plasmids from clones recovered after in 
vivo β-lactam selection were analyzed by next-generation sequencing to identify the fusion 
proteins that had promoted survival and in vivo β-lactam resistance. EXIT identified 593 proteins 
exported by M. tuberculosis during infection, including 100 proteins that were never before 
demonstrated to be exported by any experimental method, 32 proteins that have no in silico 
predicted export signal, and 9 proteins that lack both a predicted export signal and have never 
been previously identified as exported in vitro. Additionally, EXIT identified 6 intergenic 
unannotated regions that seem to encode entirely new exported proteins.  
Many previous studies have applied genetic reporters to study exported proteins. The two 
most ambitious studies prior to EXIT were conducted by Lewenza et al. in Pseudomonas 
aeruginosa (Lewenza et al., 2005) and McCann et al. in M. tuberculosis (McCann et al., 2011). 
Each of these studies identified a large number of exported proteins, 310 in P. aeruginosa and 
111 in M. tuberculosis, and represented significant advances to prior smaller scale 
identifications. To our knowledge, the identification of 593 proteins as exported in EXIT 
represents the largest number of exported proteins identified by a genetic reporter, to date, as 
well as the first ever attempt at genome-wide identification of proteins exported in vivo. 
Although we used EXIT in vivo, the more general approach could also be useful for 
identifying proteins exported during in vitro growth. Libraries of ‘BlaTEM fusions can be plated 
on β-lactam containing agar to select for colonies producing exported fusions in vitro, and the 
colonies that survive and grow after β-lactam selection can then be pooled and next-generation 
sequencing used to identify in vitro exported fusion sites. Because of the selective nature of the 
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‘BlaTEM reporter this methodology represents a significant advance from traditional ‘PhoA 
based screens where individual reporter positive clones would be identified from screening a 
large number of colonies, and then isolated, grown, and sequenced individually (Manoil et al., 
1990). 
Prior to the development of EXIT there were very few attempts to study bacterial protein 
export during infection. Of the few studies that had been performed previously, they focused on 
directly testing export of a single protein previously shown to be exported in vitro or predicted to 
be exported due to genomic proximity to a secretion system (Danelishvili et al., 2010; Pechous et 
al., 2013; Danelishvili et al., 2014; Ge et al., 2009; Broms et al., 2012). Therefore, the EXIT 
methodology represents a fundamental advance in the ability to study protein export during 
infection, and is the first available method to identify in vivo exported proteins on a genome-
wide scale.  
Genetic reporters such as ‘PhoA, ‘BlaTEM, and GFP are not only useful for identifying 
proteins as being exported but also for providing evidence to support a specific orientation in the 
membrane (topology). Therefore, information on the location of exported fusion sites in 
membrane proteins can be used to identify exported domains and bolster in silico topology 
predictions (McCann et al., 2011; Manoil, 1991; Rapp et al., 2004). The EXIT methodology also 
represents a significant advance from traditional methods of protein topology determination, 
which traditionally consist of individual construction and testing of C-terminal fusions of 
membrane proteins engineered in frame with a reporter (Manoil, 1991; Daley et al., 2005). 
Because of the laborious process of constructing individual in-frame reporter fusions, to our 
knowledge there is only one example of an attempt at a genome-wide topology study in bacteria 
(Daley et al., 2005). Towards the goal of better understanding integral membrane protein 
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topology, Daley et al. constructed a library of 1,166 protein fusions to ‘PhoA or GFP reporters 
and identified the orientation (periplasmic or cytoplasmic) of the C-terminus of 502 membrane 
proteins in E. coli (Daley et al., 2005). EXIT identified 1,293 exported fusions in 337 integral 
membrane proteins (defined as containing a predicted TM domain but no predicted signal 
peptide). On average each membrane protein was identified by four fusions spread throughout 
the length of the protein. In this way EXIT provided a more complete picture of the exported 
domains of each integral membrane protein than could be generated by C-terminal orientation 
information alone. Thus, the EXIT methodology is also valuable for its ability to 
comprehensively determine the topology of membrane proteins, which could vastly increase our 
knowledge about the 3-dimensional structure of integral membrane proteins. 
Identification of in vivo Exported Proteins 
Statistical modeling was used to identify a population of highly abundant clones which 
produced in vivo exported fusion proteins. EXIT identified 593 proteins as exported during 
infection in the spleen, and 282 proteins predicted to be exported during infection in the lungs. 
The vast majority of proteins identified as exported in the lungs were also exported in the spleen 
(97%), suggesting that M. tuberculosis uses a similar strategy to survive in both organs. A large 
bottleneck in infection greatly limited the number of clones reaching the lungs resulting in 
incomplete testing of the library in that organ. Therefore, we expect that many of the 311 
proteins only identified in the spleen are also exported in the lungs. The eight proteins only 
identified by EXIT in the lungs and not found as highly abundant in the spleens (including four 
PE/PPE family proteins) are a very interesting group of proteins for further study. These proteins 
may reflect organ-specific virulence requirements and could assist in the understanding of how 
M. tuberculosis is able to infect and cause disease in a wide variety of organ systems.  
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Unpredicted and Unannotated Exported proteins  
The 593 proteins exported by M. tuberculosis during infection included 32 proteins that 
had no annotated export signal (transmembrane domain or signal peptide), and 6 intergenic 
unannotated regions that appeared to encode new exported proteins. Three of the proteins with 
no annotated export signal and no known function were chosen for follow-up study, and all three 
proteins were shown to localize to the M. tuberculosis cell wall, validating the new proteins 
identified by EXIT as real exported proteins. An additional protein chosen for follow-up based 
on a pilot experiment was Rv0990c, a small virulence factor with no predicted export signal and 
unknown function whose expression is known to be highly induced during infection (Talaat et 
al., 2004; Abomoelak et al., 2011). Rv0990c was validated as exported in M. smegmatis (data 
not shown). However, Rv0990c was not as highly abundant as many of the other proteins we 
identified in our large scale experiments, and it did not meet our stringent statistics and is, 
therefore, not included on the list of 593 EXIT identified proteins. We expect there are other 
proteins, like Rv0990c, that are exported in vivo but were not identified by the stringent 
statistical analysis we employed in EXIT. 
A subset of the 32 proteins with no in silico predicted export signal may have been 
misannotated, and an upstream start site may produce a translated protein with an export signal. 
In the study described above, Lewenza et al. identified 14 proteins with no in silico predicted 
export signal of which 3 proteins possessed signal peptides when translation was initiated at an 
alternate upstream start site (Lewenza et al., 2005). In light of this, we examine the 32 proteins 
for potential alternate start sites, and found that the start site was likely misannotated for Rv3035 
such that if translation began at the upstream start site the protein would possess an N-terminal 
transmembrane domain. Mistakes in genome annotation also appear to explain the six intergenic 
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regions that are predicted to encode exported ORFs in EXIT but do not contain any annotated 
genes. However, the remaining 31 exported proteins with no predicted export signal do not 
appear to be explained by annotation mistakes. The four proteins validated as exported were 
exogenously expressed using the annotated start site and were still exported, suggesting 
additional reasons that these proteins are not predicted as exported by in silico programs. Some 
proteins could have been missed simply because their export signal deviates enough from 
standard that it is not recognized by in silico prediction algorithms. Or, perhaps they do not 
possess conventional export signals at all, and may be examples of proteins exported in an 
unconventional manner. Further study of these proteins may uncover additional specialized 
export pathways in M. tuberculosis. Identification of these new proteins as exported provides 
important information that could direct future studies of their function in M. tuberculosis cellular 
physiology and virulence. 
Topology of membrane proteins 
Integral membrane proteins are notoriously difficult to purify and study by biochemical 
means, thus membrane proteins are highly underrepresented in comparison to soluble proteins in 
crystallography databases. The lack of 3-dimensional structural data limits functional analyses of 
these proteins. In Chapter 2, we highlighted specific instances where EXIT provided clarity on 
the topology for polytopic membrane proteins of particular interest in M. tuberculosis virulence 
and drug resistance. While we chose only a few examples for presenting topology models, the 
EXIT dataset could be mined to provide topology information for all 337 EXIT identified 
transmembrane proteins. Information gleaned from individual exported fusion sites provides a 
valuable resource for future functional studies of membrane proteins, and the exported fusion site 
database generated by EXIT will be a valuable resource to the M. tuberculosis community. 
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Combining even a small amount of experimental topology data with in silico transmembrane 
prediction programs highly increases the accuracy of the topology model generated (Rapp et al., 
2004). In the study described above, Daley et al. were able to broaden their results by using 
experimental C-terminal topology information to constrain the in silico transmembrane 
prediction program TMHMM and generate improved topology models for additional membrane 
proteins (Daley et al., 2005). One future direction for the EXIT dataset would be to partner with 
bioinformatics collaborators who could use it to constrain and improve prediction algorithms and 
provide improved topology models for all M. tuberculosis membrane proteins.  
In vivo induced export  
Bacterial pathogens encounter and must respond to a variety of conditions during 
infection, and 25% of the M. tuberculosis genome has been identified as transcriptionally 
induced in vivo during infection of cultured macrophages, mice, and humans, compared to in 
vitro growth (Dubnau et al., 2002; Schnappinger et al., 2003; Rohde et al., 2007b; Dubnau et al., 
2005; Talaat et al., 2007; Rachman et al., 2006a). The original impetus for identifying proteins 
exported during infection was the hypothesis that some proteins would only be exported, and 
thus only identified as exported, in vivo. We imagine several situations that could result in a 
protein exported significantly more in vivo than in vitro: transcriptional and post-transcriptional 
regulation of protein abundance or direct regulation of protein export. EXIT provided evidence 
for 38 proteins being in vivo induced exported proteins (i.e. proteins that are exported to higher 
levels during infection than during in vitro growth, regardless of mechanism). Of the 38 in vivo 
induced proteins identified, 14 (37%) are known to be transcriptionally induced during infection 
(Dubnau et al., 2005; Dubnau et al., 2002; Schnappinger et al., 2003; Rachman et al., 2006b ; 
Talaat et al., 2007; Rohde et al., 2007a; Rohde et al., 2007b; Sharma et al., 2006; Srivastava et 
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al., 2007; Rodriguez et al., 2013). However, the mechanism of transcriptional control for most of 
these 14 genes has yet to be identified. Additionally, the mechanism for increased export remains 
unclear for the 23 proteins that have not been shown to be transcriptionally induced. One future 
direction of EXIT is to study the mechanism of regulation for these proteins to learn more about 
how M. tuberculosis controls its response to infection.  
The 38 in vivo induced exported proteins include 21 proteins of unknown function, which 
represent potentially unidentified and underappreciated virulence factors. The remaining in vivo 
induced exported proteins have predicted or demonstrated functions (regulation, host defense, 
myco-membrane synthesis, and nutrient acquisition) that can teach us about the pressures facing 
pathogens in the host environment. In particular, many nutrient transporters identified as in vivo 
induced exported proteins are poorly understood, and future study of these transport systems 
could help identify nutritional requirements and availability in vivo. Improved knowledge of the 
host environment could be applied to design improved in vitro growth media that better mimics 
in vivo growth conditions. Manipulation of in vitro media conditions has been vital to the study 
of many virulence strategies including iron acquisition, resistance to oxidative and nitrosative 
stress, anaerobic growth, and non-replicating persistence. Generation of an improved in vitro 
growth media could facilitate characterization for many in vivo induced exported proteins. 
Application of EXIT to new systems 
 The EXIT methodology is theoretically compatible for use in any bacteria that is either 
naturally, or can be made genetically, β-lactam sensitive. Therefore, EXIT could be used in the 
future to study the in vivo exported proteome for a variety of pathogens, in diverse models of 
infection, and could lead to a better understanding of host-pathogen interactions for multiple 
bacterial diseases. In particular, the EXIT methodology could be easily translated to study 
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bacterial pathogens that are already treated with β-lactam antibiotics and pathogens that 
demonstrate significant bacterial expansion during infection. Additionally, the EXIT 
methodology can be further applied to M. tuberculosis to identify proteins exported during the 
persistence phase of infection in vivo. Application of EXIT to studying persistence in M. 
tuberculosis, or study of bacterial infections where the bacteria are not growing exponentially, is 
theoretically possible because β-lactam antibiotics are bactericidal and can kill non-replicating 
bacteria. In Chapter 2, EXIT was only applied to studying M. tuberculosis during the acute phase 
of infection, and β-lactam treatment was begun one day after inoculation. In order to identify 
proteins exported during persistence phase, β-lactam treatment would be delayed until after 
bacterial expansion has ceased (~21 days post infection). However, adapting EXIT to study of 
latent non-replicating M. tuberculosis during persistence would require additional optimization 
to ensure adequate selection for β-lactam resistant bacteria.  
 
Characterization of in vivo exported proteins 
70% of exported proteins in M. tuberculosis have no known function which reflects the 
unique complexity of the mycobacterial cell envelope, evolutionary divergence of mycobacteria 
from more extensively studied bacterial pathogens, and unique virulence strategies used by M. 
tuberculosis during infection.  
New exported proteins as virulence factors 
 Proteins identified by EXIT as in vivo induced exported proteins are particularly 
intriguing virulence candidates, especially the 21 in vivo induced exported proteins of unknown 
function. 13 of the 38 in vivo induced exported proteins (34%) have demonstrated or predicted 
roles in virulence (Reddy et al., 2013; Danelishvili et al., 2010; Chuang et al., 2015; 
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Papavinasasundaram et al., 2005; Rifat et al., 2014; Tischler et al., 2013; Marjanovic et al., 
2010; McCann et al., 2011; Gioffre et al., 2005; Senaratne et al., 2008; Dutta et al., 2010; Hu et 
al., 2010; Sassetti & Rubin, 2003; Stewart et al., 2005; Rengarajan et al., 2005). Most of these 
predictions are from large scale virulence screens (TraSH, TnSeq, DeADMAn) where the whole 
genome is tested for genes required for virulence. However, we expect that the list of 25 in vivo 
induced proteins that are not predicted to be important for virulence include additional virulence 
factors missed by these methods. Large scale virulence screens are highly valuable, but they have 
limits, and there are many published examples of proteins shown to be individually important to 
virulence that were not predicted to be virulence factors (Forrellad et al., 2013). In particular, 
secreted and surface associated proteins are most likely to be trans-complemented when tested in 
a large pool of mutants (e.g. large virulence screens), because their phenotypes could be rescued 
by exported proteins of surrounding bacteria resulting in a false-negative prediction. Because M. 
tuberculosis regulates in vivo induced exported proteins in a spatial or temporal manner, and 
these proteins are positioned at the host-pathogen interface, we predict the in vivo induced 
exported proteins will include additional unpredicted virulence factors.  
 To begin to test this hypothesis we obtained ten mutants from a library of transposon 
mutants (generated by (Lamichhane et al., 2005; Lamichhane et al., 2003) and available through 
BEI Resources) in genes that encode in vivo induced proteins that had not been predicted by 
virulence screens as virulence factors or individually studied for roles in M. tuberculosis 
virulence. The first mutant we were able to obtain was in eccD2, a gene encoding the predicted 
membrane channel for the ESX-2 secretion system and highlighted in topology models shown in 
Chapter 2 (Figure 2.12). ESX-1 and ESX-5 secretion systems are known to be important for M. 
tuberculosis virulence (Bottai et al., 2012; Guinn et al., 2004); however, ESX-2 was not 
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predicted as important for virulence by large scale virulence screens (Dutta et al., 2010; 
Rengarajan et al., 2005; Stewart et al., 2005; Sassetti & Rubin, 2003; Lamichhane et al., 2005; 
Zhang et al., 2013). EccD2 was initially chosen for follow-up because it behaved like an in vivo 
induced exported protein, although it did not end up reaching our stringent statistical cutoff for 
being an in vivo induced exported protein, in the end. Preliminary study determined that mice 
infected with an eccD2::tn mutant survive longer than mice infected with wild type M. 
tuberculosis (data not shown), suggesting that ESX-2 secretion plays an important virulence role 
during infection.  
 Nine additional transposon mutants were obtained in genes that encode in vivo induced 
exported proteins. Eight of these mutants are in genes of unknown function. We are currently 
testing these mutants for intracellular growth defects during infection of murine bone marrow 
derived macrophages. Preliminary results suggest that some of these in vivo induced exported 
proteins not previously predicted to be virulence factors may be required for M. tuberculosis 
growth in macrophages (data not shown). The function of these proteins remains unknown (for 
eight) and understudied (for one), and future studies will focus on further characterizing the 
function and virulence role for these exported proteins.  
Construction of a functional genomics database for M. tuberculosis  
In many regards EXIT represents a new tool for functional genomics. EXIT was a 
genome-wide attempt to identify exported proteins as way to better understand the function of 
each individual identified protein. In fact, 70% of the EXIT identified exported proteins have 
unknown function, and knowledge about their subcellular localization will further their 
functional characterization. Identification of in vivo induced exported proteins provides 
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additional functional clues, and highlights the 38 in vivo induced proteins as particularly 
interesting candidates for future studies.  
In an effort to consolidate a vast wealth of data on export, virulence predictions, and in 
vivo expression data we built a functional genomics database that could become a valuable 
resource to the M. tuberculosis community. We combined information from previous 
publications studying in vitro protein export, large scale virulence studies (e.g. TraSH, TnSeq, 
DeADMAn), and in vivo expression data (e.g. microarray, IVET) (Rosenkrands et al., 2000; 
Malen et al., 2011; Bell et al., 2012; Gu et al., 2003; Xiong et al., 2005; Mawuenyega et al., 
2005; Malen et al., 2007; Gunawardena et al., 2013; Wolfe et al., 2010; Gomez et al., 2000; 
Braunstein et al., 2000; McDonough et al., 2008; McCann et al., 2011; Dutta et al., 2010; 
Rengarajan et al., 2005; Stewart et al., 2005; Sassetti & Rubin, 2003; Lamichhane et al., 2005; 
Zhang et al., 2013; Sassetti et al., 2003; Dubnau et al., 2002; Schnappinger et al., 2003; Rohde et 
al., 2007b; Dubnau et al., 2005; Talaat et al., 2007; Rachman et al., 2006a). We supplemented 
this previously published data with data generated by submitting the M. tuberculosis proteome to 
in silico prediction programs for export, structure, and function. We first analyzed the entire 
proteome of M. tuberculosis for export signals using online bioinformatics tools to predict 
transmembrane domains (TMHMM, TMPred), or signal peptides (SignalP). We combined this 
with previous whole genome analyses of Tat signal peptides and lipoprotein signal peptides 
(McDonough et al., 2008; Sutcliffe & Harrington, 2004). Because of its usefulness in predicting 
a function for Rv0199/OmasA (Chapter 3), we analyzed the entire M. tuberculosis proteome in 
Phyre (Kelley & Sternberg, 2009) to generate additional functional predictions, and included 
these hypothetical function predictions alongside annotated functional information from the 
H37Rv RefSeq genome (released January 9 2012). In this way, we built a database of 
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information for each protein coding gene that can be mined to identify and predict the function of 
exported proteins and shed light on M. tuberculosis pathogenesis. A table representing portions 
of this database is included in Appendix III.  
Orphaned Mce-associated protein A (OmasA) 
One of the in vivo exported proteins identified by EXIT, Rv0199/OmasA, was 
functionally characterized in Chapter 3. Rv0199 is a 24 kDa protein that is predicted to be an 
integral membrane protein of unknown function (Krogh et al., 2001). In Chapter 3, we 
characterized the role of Rv0199 in M. tuberculosis virulence using a low dose aerosol model of 
murine infection, and demonstrated that OmasA plays a crucial role in lipid transport by Mce 
transporters leading us to rename Rv0199 as OmasA (orphaned Mce-associated protein A).  
In mice, the omasA mutant displays reduced bacterial burden early during infection, 
reduced tissue pathology, and delayed mouse mortality (Figure 3.2, Figure 3.3). Unfortunately, 
discrepancies in the literature surrounding mce mutant phenotypes in mice (in particular mce1 
phenotypes) distracts from our ability to directly compare mce mutants to the omasA mutant. 
Direct comparison of different mce mutants in the same background and same infection model 
would go far to improve our understanding of the role of Mce transport during infection. Thus, 
one future direction for the OmasA project could be side-by-side comparison of the omasA 
mutant to mce mutants in a murine infection model. Additionally, the interaction or cross-talk 
between different Mce systems is poorly understood and worth exploring further. The evidence 
that OmasA impacts multiple mce systems warrants side-by-side comparison of the omasA 
mutant and mutants missing multiple mce operons. However, given the difficulty in making even 
single mutants in M. tuberculosis, it would not be easy to construct such a strain.  
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While the mce mutant phenotypes in mice are controversial, the picture is much clearer in 
macrophages. Mutants in mce1 are defective for intracellular growth; however, mce4 is not 
required for growth in macrophages (McCann et al., 2011; Miner et al., 2009; Rengarajan et al., 
2005; Stewart et al., 2005). Therefore, we hypothesize that the intracellular growth defect of the 
omasA mutant can be attributed to loss of Mce1 transporter function during growth in 
macrophages. 
Due to structural and functional analogies identified between OmasA and VirB8 (den 
Hartigh et al., 2008; Sivanesan & Baron, 2011; Paschos et al., 2006; Fronzes et al., 2009; Kumar 
et al., 2000; Baron, 2006; Kelley & Sternberg, 2009), we proposed a model wherein OmasA 
interacts with Mce proteins, potentially driving Mce complex formation, and ultimately 
providing stability to Mce proteins within the complex (Figure 3.11). However, many questions 
remain: Is the function of OmasA actually in stabilizing the Mce complex? What proteins does 
OmasA interact with (the channel itself, or perhaps just the Mce proteins in the cell wall)? Is 
OmasA responsible for assembling the multi-protein complex? And what distinguishes different 
Mas/Omas proteins from one another?  
The question of whether OmasA really functions to stabilize the complex is the most 
pressing. While we have demonstrated that loss of OmasA results in loss of Mce1 proteins and 
Mce4 transport function but does not affect transcript levels of mce operons, we have not directly 
shown that the lack of Mce proteins is due to their instability. Because of the structural 
homology between OmasA and VirB8, we hypothesize that the function of OmasA is stability of 
the Mce complex. However, we have not ruled out a potential role for OmasA in translation of 
Mce proteins. If OmasA is directly interacting with Mce proteins and providing a scaffold for 
stabilizing the Mce complex, we would expect to see an enhanced degradation rate and reduced 
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half-life of Mce proteins in an omasA mutant as compared to WT. Preliminary evidence supports 
this hypothesis and our current model, and suggests that Mce proteins do have a reduced half-life 
in an omasA mutant as compared to WT M. smegmatis (data not shown).  
We hypothesize that OmasA directly interacts with the Mce complex, either through 
interaction with the channel (YrbE proteins), other Mas family proteins, or Mce proteins 
themselves. If OmasA physically interacts with the Mce complex proteins, we may be able to 
perform co-immunoprecipitation experiments or bacterial two-hybrid (Karimova et al., 2000) 
experiments confirming these interactions. Previous attempts to screen OmasA for interacting 
proteins using the bacterial two-hybrid system were unsuccessful due to an apparent high false 
positive rate (data not shown). This can potentially be explained because we attempted to use the 
entire OmasA protein instead of producing OmasA without its N-terminal transmembrane 
domain (Gueguen et al., 2011). However, this warrants revisiting, especially now that we have 
candidate interacting proteins to directly test and better available negative controls. Preliminary 
studies have shown that OmasA-HA appears to localize properly in M. smegmatis, and can be 
successfully isolated by immunoprecipitation (Figure 3.1, data not shown), suggesting that co-
immunoprecipitation could be potentially be used to identify proteins directly interacting with 
OmasA.  
Evidence from study of Type IV complexes in Agrobacterium tumefaciens suggests that 
VirB8 is responsible for assembly of the multi-protein complex (Kumar et al., 2000), and we 
hypothesize that OmasA may perform a similar function. For A. tumefaciens the role of VirB8 in 
complex assembly was shown by localizing VirB9 and VirB10 by immuno-electron microscopy 
and immuno-fluorescence microscopy in WT and ΔvirB8 strains. In the presence of VirB8, 
VirB9 and VirB10 formed clusters, suggesting complex formation; however, VirB9 and VirB10 
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were more randomly localized in the ΔvirB8 mutant. A similar approach could be utilized to 
study Mce complex assembly in mycobacteria.  
Mce proteins localize to the cell wall in mycobacteria (Forrellad et al., 2014); however, 
the method by which they localize there is not fully understood. One possibility is that OmasA 
could play a role in assembling the Mce complex by directing localization of Mce proteins to the 
cell wall. Therefore, we could perform subcellular fractionation and determine whether Mce 
proteins localize differently in the ΔomasA mutant than in WT M. smegmatis. This would be 
difficult to study with endogenous proteins because Mce proteins are almost completely 
undetectable in the ΔomasA mutant; however, we now have strains of M. smegmatis that 
conditionally overexpress Mce proteins, such that we can detect robust levels of Mce proteins 
even in the ΔomasA mutant ((Forrellad et al., 2014), data not shown).  
Aside from the eight mas genes located within mce operons, M. tuberculosis encodes five 
potential orphaned mas genes located outside of mce operons, including rv0199/omasA (Casali 
& Riley, 2007). As well as identifying structural homology between OmasA and VirB8, Phyre 2 
(Kelley & Sternberg, 2009) predicted structural similarity between all Mas family proteins and 
VirB8. Therefore, we hypothesize that all Mas and Omas proteins may perform similar functions 
to OmasA in stability and/or assembly of Mce transporters. Given that M. tuberculosis possesses 
thirteen Mas family proteins it is perhaps surprising that the loss of a single one of these proteins, 
OmasA, results in a dramatic reduction in Mce1 protein levels and Mce4 transport function. If 
Mas family proteins are functionally analogous, why does M. tuberculosis produce so many 
different varieties and why is there no compensation for loss of OmasA? One potential 
explanation is that each separate system (Mce1-4) requires multiple individualized Mas family 
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proteins that provide compatible but not functionally redundant roles. Alternatively, OmasA may 
play a more critical role than most Mas family proteins.  
Several avenues could be explored to address these questions. One possibility for why 
alternate Mas and Omas proteins did not compensate for the loss of OmasA is that they are not 
produced in the conditions we tested in sufficient amount to make up for the loss of OmasA. 
Therefore, we overexpressed Rv0199-like Mas and Omas proteins in the omasA mutant 
background of M. tuberculosis to test for functional complementation. Preliminary studies of 
these overexpression strains in the omasA mutant have not shown any evidence of compensation 
for the loss of omasA (data not shown). An alternate strategy to address this question may be to 
generate additional mutants in mas and omas genes to directly compare their phenotypes. If 
physical interaction studies with OmasA are successful, it would also be valuable to identify and 
compare the proteins that interact with different Mas and Omas proteins. Alignments or Phyre 
structural predictions of Mas and Omas proteins do not suggest any obvious differences (primary 
amino acid alignments have very low conservation across the board), or any domains possessed 
by OmasA that are missing from the other proteins. However, if crystal structures of Mas family 
proteins could be solved, comparisons could reveal unique structural differences required for 
their individual function. Overall, future studies are necessary to determine whether the function 
of OmasA is representative of all Mas proteins, and to functionally characterize other proteins 
within the Mce transport complex. We are just beginning to understand the function of OmasA, 
and future studies promise to refine our understanding of Mce complex assembly and stability. 
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Conclusion 
Prior to this work new exported proteins could only be identified in vitro; however, we 
have developed a method to identify exported proteins in vivo in the context of infection. In its 
first application, EXIT successfully identified in vivo exported proteins in M. tuberculosis, 
including proteins not previously demonstrated as exported in vitro, not predicted to be exported, 
and in vivo induced exported proteins. However, identification of exported proteins is a proximal 
goal. Each of these categories of proteins provides new and exciting avenues to study M. 
tuberculosis virulence and interaction with the host immune system. With the knowledge that 
exported proteins are critical to M. tuberculosis virulence we seek to better understand the roles 
of individual exported proteins during infection and assign function to these exported proteins. 
OmasA is just the beginning, the characterization of one in vivo exported protein of unknown 
function with a previously unknown role in virulence. Having completed an extensive project 
designed to identify in vivo exported proteins and constructed a functional genomics database to 
help identify the most interesting proteins for future study, the focus will now shift to applying 
the EXIT dataset to uncover novel virulence strategies of M. tuberculosis and extend our 
understanding of the host-pathogen interface.  
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APPENDIX I: CALCULATIONS TO DETERMINE GENOMIC LIBRARY DENSITY 
AND MOUSE NUMBERS 
Determine size for genomic DNA Library 
Original calculations to determine the number of plasmids required for full genome 
coverage in the EXIT Input library were made using an equation from the Molecular Cloning 2
nd 
Edition (Sambrook et al., 1989). This equation determines the probability that a given DNA 
sequence is represented within a plasmid or cosmid library. P represented the probability of 
representation, and f was the fractional proportion of the genome in a single plasmid or cosmid. 
N was the required number of plasmids or cosmids in the library to reach given probability (P) of 
a single gene of interest being represented P. 
𝑁 =  
ln (1 − 𝑃)
ln (1 − 𝑓)
 
The equation above was solved separately for three different scenarios where different sizes of 
genomic DNA fragments were inserted into the library plasmid backbone (pDW31): 500 bp 
fragments, 1,000 bp fragments, and 5,000 bp fragments. To reach 99% probability of a given 
gene of interest being represented in the library, the following library sizes (i.e. number of 
plasmids) were necessary:  
𝑁 =
ln (1 − 0.99)
ln (1 − [
500
4,411,532])
=
−4.61
−1.13 ∗ 10−4
= 40,629 𝑝𝑙𝑎𝑠𝑚𝑖𝑑𝑠 
𝑁 =
ln (1 − 0.99)
ln (1 − [
1,000
4,411,532])
= 20,313 
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𝑁 =
ln (1 − 0.99)
ln (1 − [
5,000
4,411,532])
= 4,061 
This equation is intended to calculate how many cosmids or plasmids are necessary for 
complete coverage of a genome; however, the EXIT library is additionally constrained in that 
only plasmids containing a given gene of interest fused in frame with the reporter are capable of 
producing functional reporter constructs. Therefore, six times more plasmids were required in the 
EXIT library than would be required in a standard plasmid/cosmid library, and complete 
coverage of the M. tuberculosis genome in frame with the reporter was calculated to require 
approximately 2.5x10
5 
plasmids. By these calculations, the final EXIT library of 5x10
6
 plasmids 
represented 20 (500 bp fragments) to 200 fold (5,000 bp fragments) above minimal requirements 
for 99% probability of genome coverage.  
Another way to evaluate the required size of our library, using a cumulative binomial 
equation, is more appropriate for this calculation. Cumulative binomial calculations are made far 
less challenging with the use of an online calculator (e.g. http://stattrek.com/online-
calculator/binomial.aspx). In the cumulative binomial calculator a trial (n) represented a single 
plasmid. The number of successes (x) was 1, representing a goal of at least one representative 
plasmid in the library in frame with a given gene of interest. The probability that a single plasmid 
contained an in frame fusion to a given gene of interest was calculated as: 
𝑠𝑖𝑧𝑒 𝑜𝑓 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑔𝑒𝑛𝑒
𝑔𝑒𝑛𝑜𝑚𝑒 𝑠𝑖𝑧𝑒
∗  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑛 𝑓𝑟𝑎𝑚𝑒 𝑓𝑢𝑠𝑖𝑜𝑛𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑢𝑡 𝑜𝑓 𝑓𝑟𝑎𝑚𝑒 𝑎𝑛𝑑 𝑜𝑝𝑝𝑜𝑠𝑖𝑡𝑒 𝑜𝑟𝑖𝑒𝑛𝑡𝑎𝑡𝑖𝑜𝑛 𝑓𝑢𝑠𝑖𝑜𝑛𝑠
 
1,006 𝑏𝑝
4,411,532 𝑏𝑝
∗ 
1
6
= 3.8 ∗ 10−5  
Given a sufficiently large n value, or number of plasmids containing fusions to the 
reporter, it was possible to achieve a very high probability of complete genome coverage. For 
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example, given a library of 2.5x10
5
 plasmids, the probability of an average size gene (1006 bp) 
represented in frame by at least one fusion, P(x ≥ 1), was 99.9%. 99.9% representation for genes 
as small as 100 bp, or 1/10
th
 the average size, required a library of 2x10
6
 plasmids. Therefore, the 
final EXIT library of 5x10
6
 plasmids theoretically had saturating coverage of genes as small as 
55 bp in frame with the reporter.  
Determine the number of mice required for comprehensive library testing 
In mice, several routes of tuberculosis infection are regularly utilized. A low dose aerosol 
model is the most similar to natural infection, where humans are thought to be infected by 
inhalation of as few as one bacterium. However, the low aerosol dosage is not compatible with 
screening a large library. Further, using aerosol delivery we were unable to increase the 
pulmonary dosage to a sufficient level to survey the EXIT library in a comprehensive manner 
(data not shown). We therefore adopted the strategy used for screening M. tuberculosis 
transposon insertion libraries for virulence defects, and infected mice by intravenous infection 
and focused on comprehensively screening the library in the mouse spleens (Sassetti & Rubin, 
2003; Zhang et al., 2013). One day after intravenous infection, approximately 20% of the M. 
tuberculosis inoculum established in the spleen and 1% in the lungs (data not shown), consistent 
with previous studies (Orme & Gonzalez-Juarrero, 2007).  
We calculated the number of animals that would be required in order to comprehensively 
screen the EXIT library in mouse spleens prior to conducting the large-scale experiments. Using 
the modified binomial calculation described below we determined that infection of 24 mice with 
5x10
6
 bacteria from the EXIT library would result in a 99.5% probability of any individual clone 
in the library establishing infection in the spleen of at least one mouse. For the modified 
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binomial calculation n was the number of mice/trials, Q was the probability of failure on a given 
mouse/trial, and P
 
was the probability of success overall.  
1 − 𝑃 =  (𝑄)𝑛 
 To comprehensively test the EXIT input library in the spleen (5x10
6
 individual clones) 
we determined that it would be easiest if each mouse was infected with effectively the entire 
library, and aimed for infection with 5x10
6 
cfu per mouse. Therefore, an individual library clone 
injected into a single mouse would have a 20% chance of reaching the spleen (because 20% of 
the inoculum establishes in the spleen). For this inoculum, there would be a failure rate (i.e. not 
reaching the spleen) of Q=0.8 or 80%. For a lower inoculum dosage, for example 5x10
5
, there 
would be compounding factors resulting in a higher failure rate, Q. An individual library clone 
would only have a 10% chance of being in the inoculum that is injected into the mouse, and then 
only 20% chance of reaching the spleen, so only a 2% chance of successfully establishing in the 
spleen. For this more stringent scenario Q=0.98, or 98% chance of failure, and a much higher 
number of mice would have been required to comprehensively test the EXIT library at this lower 
initial dosage. 
We used the modified binomial equation and solved for the value of n to get the required 
number of mice for the comprehensive testing of the EXIT Input library in the spleen 
(probability P=99.5%) where Q=0.8 (24 mice).  
1 − 0.995 =  (0.8)𝑛 
Alternatively, comprehensive testing of the EXIT input library in the lung, where only 
1% of the inoculum established after intravenous injection (Q=0.99 and P=0.995) would have 
required 530 mice. 
1 − 0.995 =  (0.99)𝑛 
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Therefore, infection of 24 mice with 5x10
6
 bacteria from the EXIT library resulted in a 
99.5% probability of any individual clone in the library establishing infection in the spleen of at 
least one of the mice. We screened the EXIT library in two independent experiments, each 
consisting of 24 mice, which resulted in a 99.5% confidence for complete coverage of the library 
in each independent replicate. Unfortunately, we were unable to comprehensively evaluate the 
library in the lungs due to the unnecessarily high number of mice (530) that would have been 
required. Therefore, the analysis in Chapter 2 was primarily focused on the robust and 
comprehensive dataset from the spleens.  
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APPENDIX II: EXIT RESULTS 
Table 6.1 EXIT results  
ORF 
number Name Product 
Exported 
fusion 
junctions 
ID in 
Lung 
in 
silico 
MS ID as 
exported 
GR ID as 
exported 
Predicted to 
be essential 
in vitro or 
during 
infection 
Rv0011c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 83   TM 
MEM 8, MEM 9, 
CW 14     
Rv0012   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
39, 46, 93, 
102   TM 
MEM 6, MEM 7, 
MEM 9, CW 14   Mouse 27 
Rv0014c pknB 
TRANSMEMBRANE 
SERINE/THREONINE-
PROTEIN KINASE B PKNB 
(PROTEIN KINASE B) 
(STPK B) 
404, 421, 
445, 446, 
594   TM 
CF 2, CF 3, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
13, CW 14, SOL 
16   
in vitro 28, in 
vitro 29 
Rv0015c pknA 
TRANSMEMBRANE 
SERINE/THREONINE-
PROTEIN KINASE A PKNA 
(PROTEIN KINASE A) 
(STPK A) 362   TM 
MEM 7, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv0016c pbpA 
PROBABLE PENICILLIN-
BINDING PROTEIN PBPA 29, 51   
SP, 
TM 
MEM 8, MEM 9, 
CW 14   Mouse 27 
Rv0017c 
rodA, 
ftsW 
PROBABLE CELL DIVISION 
PROTEIN RODA 412   TM MEM 9, CW 14   
Macrophage 
23, Mouse 27 
Rv0037c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
122, 349, 
377   TM 
MEM 8, MEM 9, 
CW 14   
Macrophage 
23 
Rv0039c   
POSSIBLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
45, 50, 51, 
58, 60, 95 Yes 
SP, 
TM       
Rv0040c mtc28 
SECRETED PROLINE RICH 
PROTEIN MTC28 (PROLINE 
RICH 28 KDA ANTIGEN) 
61, 85, 
102, 178, 
275, 283 Yes 
SP, 
TM 
CF 2, CF 3, MEM 
7, CW 14   Mouse 27 
Rv0048c   
POSSIBLE MEMBRANE 
PROTEIN 
123, 148, 
201   TM 
CF 3, MEM 4, 
MEM 5, MEM 8, 
MEM 9, MEM 10, 
CW 12, CW 13, 
CW 14     
Rv0062 
celA1, 
celA 
POSSIBLE CELLULASE 
CELA1 
(ENDOGLUCANASE) 
(ENDO-1,4-BETA-
GLUCANASE) (FI-CMCASE) 
(CARBOXYMETHYL 
CELLULASE) 
91, 99, 
106, 168, 
173, 183, 
191, 268, 
308 Yes TM 
CF 2, MEM 7, 
CW 14     
Rv0064   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
275, 316, 
423, 529 Yes TM MEM 7, CW 12 
PhoA 18, 
BlaTEM 
20   
Rv0072   
PROBABLE GLUTAMINE-
TRANSPORT 
TRANSMEMBRANE 
PROTEIN ABC 
TRANSPORTER 
33, 59, 80, 
83, 165, 
275 Yes TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14 
BlaTEM 
20   
Rv0076c   
PROBABLE MEMBRANE 
PROTEIN 125   TM       
Rv0083   PROBABLE 303, 368,   TM MEM 9     
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OXIDOREDUCTASE 385, 493, 
498 
Rv0084 
hycD, 
hevD 
POSSIBLE FORMATE 
HYDROGENLYASE HYCD 
(FHL) 
86, 174, 
248, 250, 
253, 306 Yes TM     Macaque 22 
Rv0086 hycQ 
POSSIBLE HYDROGENASE 
HYCQ 
58, 184, 
189, 480 Yes TM     
Mouse 27, in 
vitro 28 
Rv0092 ctpA 
PROBABLE CATION 
TRANSPORTER P-TYPE 
ATPASE A CTPA 
127, 374, 
379, 444 Yes TM 
MEM 9, CW 12, 
CW 14 
BlaTEM 
20 
Macrophage 
23 
Rv0093c   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
161, 189, 
191, 214 Yes TM 
MEM 8, MEM 9, 
CW 12     
Rv0102   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
52, 71, 75, 
136, 150, 
156, 198, 
213, 331, 
416 Yes TM 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv0103c ctpB 
PROBABLE CATION-
TRANSPORTER P-TYPE 
ATPASE B CTPB 
130, 140, 
213, 221 Yes TM MEM 9, CW 14     
Rv0110   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 72, 191   TM MEM 8     
Rv0111   
POSSIBLE 
TRANSMEMBRANE 
ACYLTRANSFERASE 
70, 125, 
428, 439, 
457 Yes TM 
MEM 6, CW 11, 
CW 12     
Rv0116c   
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 
18, 26, 82, 
120, 192   
SP, 
TM CF 2, MEM 7 
BlaTEM 
20   
Rv0125 
pepA, 
mtb32a 
PROBABLE SERINE 
PROTEASE PEPA (SERINE 
PROTEINASE) (MTB32A) 
45, 77, 
109, 132, 
134, 144, 
186, 204, 
266, 299, 
304 Yes 
SP, 
Tat 
SP, 
TM 
CF 2, CF 3, MEM 
7, MEM 8, MEM 
9, CW 12, CW 13, 
CW 14, WCL 15, 
SOL 16 
PhoA 18, 
BlaTEM 
20 Mouse 27 
Rv0128   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 39, 195   TM       
Rv0143c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
94, 97, 
245, 334, 
342 Yes TM MEM 8, MEM 9     
Rv0157 pntB 
PROBABLE NAD(P) 
TRANSHYDROGENASE 
(SUBUNIT BETA) PNTB 
[INTEGRAL MEMBRANE 
PROTEIN] (PYRIDINE 
NUCLEOTIDE 
TRANSHYDROGENASE 
SUBUNIT BETA) 
(NICOTINAMIDE 
NUCLEOTIDE 
TRANSHYDROGENASE 
SUBUNIT BETA) 
63, 190, 
192, 253, 
260 Yes TM 
MEM 4, MEM 5, 
MEM 9, MEM 10, 
CW 13, CW 14, 
WCL 15   Mouse 27 
Rv0167 
yrbE1
A 
CONSERVED 
HYPOTHETICAL 
INTEGRAL MEMBRANE 
PROTEIN YRBE1A 
88, 90, 
110, 112, 
183, 194 Yes TM 
MEM 4, MEM 8, 
MEM 9, CW 14     
Rv0168 yrbE1B 
CONSERVED 
HYPOTHETICAL 
INTEGRAL MEMBRANE 
PROTEIN YRBE1B 86, 108   TM 
MEM 8, MEM 9, 
CW 14     
Rv0169 
mce1A, 
mce1 
MCE-FAMILY PROTEIN 
MCE1A 
37, 50, 59, 
116, 179, 
400 Yes TM 
MEM 8, MEM 9, 
CW 12, CW 13, 
CW 14 
BlaTEM 
20 
Macrophage 
23, 
Macrophage 
24, Mouse 25 
Rv0170 
mce1B, 
mceD 
MCE-FAMILY PROTEIN 
MCE1B 
39, 46, 
154   TM 
MEM 4, MEM 7, 
MEM 8, MEM 9, 
CW 13, CW 14, 
WCL 15 
BlaTEM 
20 
Macrophage 
23, 
Macrophage 
24, Mouse 25 
Rv0171 mce1C MCE-FAMILY PROTEIN 48, 49, 60, Yes SP, MEM 8, MEM 9, BlaTEM Macrophage 
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MCE1C 146, 242, 
338, 372, 
449, 461, 
489, 503, 
504 
TM CW 13, CW 14 20 23, Mouse 25 
Rv0172 mce1D 
MCE-FAMILY PROTEIN 
MCE1D 472   TM 
CF 2, CF 3, MEM 
5, MEM 7, MEM 
8, MEM 9, CW 
12, CW 13, CW 
14, WCL 15 
BlaTEM 
20 
Macrophage 
23 
Rv0173 
lprK, 
mce1E 
POSSIBLE MCE-FAMILY 
LIPOPROTEIN LPRK (MCE-
FAMILY LIPOPROTEIN 
MCE1E) 
30, 33, 41, 
42 Yes 
Lipo, 
TM 
MEM 5, MEM 7, 
MEM 8, MEM 9, 
CW 12, CW 13, 
CW 14, WCL 15 
BlaTEM 
20 
Macaque 22, 
Macrophage 
23, Mouse 25 
Rv0174 mce1F 
MCE-FAMILY PROTEIN 
MCE1F 
46, 60, 
161 Yes TM 
CF 2, CF 3, MEM 
6, MEM 7, MEM 
8, MEM 9, CW 
12, CW 13, CW 
14, WCL 15 
BlaTEM 
20 
Macrophage 
23 
Rv0175   
PROBABLE CONSERVED 
MCE ASSOCIATED 
MEMBRANE PROTEIN 66   TM 
CF 3, MEM 5, 
MEM 9, MEM 10, 
CW 13, CW 14, 
WCL 15 
PhoA 18, 
BlaTEM 
20 
Macrophage 
23, Mouse 25 
Rv0176   
PROBABLE CONSERVED 
MCE ASSOCIATED 
TRANSMEMBRANE 
PROTEIN 279   TM 
MEM 4, MEM 8, 
MEM 9, CW 14   
Macrophage 
23, 
Macrophage 
24, Mouse 25 
Rv0177   
PROBABLE CONSERVED 
MCE ASSOCIATED 
PROTEIN 115   TM 
MEM 4, MEM 8, 
MEM 9, CW 14   
Macrophage 
23, 
Macrophage 
24, Mouse 27 
Rv0178   
PROBABLE CONSERVED 
MCE ASSOCIATED 
MEMBRANE PROTEIN 
119, 162, 
177 Yes TM 
CF 3, MEM 4, 
MEM 5, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15 
BlaTEM 
20 
Macrophage 
23 
Rv0179c lprO 
POSSIBLE LIPOPROTEIN 
LPRO 
36, 40, 43, 
67, 124, 
159, 169, 
183, 199, 
273, 277, 
296 Yes 
SP, 
Lipo, 
TM CW 14 PhoA 18 
Macaque 22, 
Macrophage 
23 
Rv0180c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
40, 45, 66, 
68, 79, 
153, 180, 
181, 191, 
211 Yes TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15   Mouse 27 
Rv0191   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
113, 310, 
318, 382 Yes TM MEM 9     
Rv0192A   
CONSERVED SECRETED 
PROTEIN 40, 46   
SP, 
Tat 
SP, 
TM       
Rv0199   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
64, 70, 82, 
155, 157 Yes TM 
MEM 5, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15 
BlaTEM 
20 
Mouse 25, 
Mouse 27 
Rv0200   
POSSIBLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
22, 129, 
145, 161, 
172, 195   TM 
MEM 4, MEM 9, 
CW 14   
Macrophage 
24 
Rv0202c 
mmpL
11 
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL11 
37, 39, 44, 
166, 168, 
407, 432, 
433, 436 Yes 
SP, 
TM 
MEM 9, CW 12, 
CW 14   
Macrophage 
24 
Rv0203   
POSSIBLE EXPORTED 
PROTEIN 
23, 34, 
119 Yes 
SP, 
Tat 
SP, 
TM 
CF 2, CF 3, MEM 
7     
Rv0205   
PROBABLE CONSERVED 
TRANSMEMBRANE 
87, 114, 
127, 262, Yes TM MEM 8, MEM 9   
Mouse 27, in 
vitro 28 
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PROTEIN 324, 348 
Rv0206c 
mmpL
3 
POSSIBLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL3 
25, 40, 65, 
76, 108, 
117, 121, 
163, 173, 
205, 419, 
444, 479 Yes TM 
CF 3, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15 PhoA 18 in vitro 29 
Rv0218   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
64, 81, 90, 
162, 179, 
295   
Tat 
SP, 
TM MEM 8   Mouse 25 
Rv0219   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 130   TM MEM 7, MEM 9     
Rv0226c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
22, 169, 
311, 343, 
348 Yes 
Tat 
SP, 
TM MEM 8, MEM 9   
in vitro 28, in 
vitro 29 
Rv0227c   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
79, 219, 
236, 326 Yes 
SP, 
TM 
CF 3, MEM 4, 
MEM 5, MEM 6, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15   
in vitro 28, in 
vitro 29 
Rv0228   
PROBABLE INTEGRAL 
MEMBRANE 
ACYLTRANSFERASE 212, 351   TM     
in vitro 28, in 
vitro 29 
Rv0236c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
24, 36, 
191, 248, 
329, 346, 
425, 452, 
510, 597, 
1365 Yes 
SP, 
TM MEM 6, MEM 9   
in vitro 28, in 
vitro 29 
Rv0237 lpqI 
PROBABLE CONSERVED 
LIPOPROTEIN LPQI 
22, 26, 32, 
36, 88, 
111 Yes 
SP, 
Lipo 
CF 2, CF 3, MEM 
5, MEM 7, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
13, CW 14     
Rv0249c   
PROBABLE SUCCINATE 
DEHYDROGENASE 
[MEMBRANE ANCHOR 
SUBUNIT] (SUCCINIC 
DEHYDROGENASE) 80, 180 Yes TM 
MEM 8, MEM 9, 
MEM 10, CW 13, 
WCL 15   
Mouse 25, 
Mouse 27, in 
vitro 29 
Rv0261c narK3 
PROBABLE INTEGRAL 
MEMBRANE NITRITE 
EXTRUSION PROTEIN 
NARK3 (NITRITE 
FACILITATOR) 62, 331   TM       
Rv0283 eccB3 
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 
111, 154, 
422, 526 Yes TM 
CF 3, MEM 4, 
MEM 5, MEM 7, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15, SOL 16   
in vitro 28, in 
vitro 29 
Rv0291 mycP3 
PROBABLE MEMBRANE-
ANCHORED MYCOSIN 
MYCP3 (SERINE 
PROTEASE) (SUBTILISIN-
LIKE PROTEASE) 
(SUBTILASE-LIKE) 
(MYCOSIN-3) 433   
SP, 
TM 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM 
9, MEM 10, CW 
12, CW 13, CW 
14, WCL 15, SOL 
16   
in vitro 28, in 
vitro 29 
Rv0309   
POSSIBLE CONSERVED 
EXPORTED PROTEIN 
48, 49, 61, 
63, 70, 
101, 105   
SP, 
TM 
CF 2, MEM 7, 
MEM 8, CW 12, 
CW 14     
Rv0312   
CONSERVED 
HYPOTHETICAL PROLINE 
AND THREONINE RICH 
PROTEIN 
479, 486, 
551   TM MEM 9, CW 14 
BlaTEM 
20 
Mouse 27, in 
vitro 28 
Rv0314c   
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 
132, 139, 
192, 211   TM 
MEM 8, MEM 9, 
CW 14     
Rv0338c   PROBABLE IRON-SULFUR- 119, 203   TM MEM 4, MEM 5,   in vitro 28, in 
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BINDING REDUCTASE MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15 
vitro 29 
Rv0344c lpqJ 
PROBABLE LIPOPROTEIN 
LPQJ 
50, 68, 71, 
90, 126   
SP, 
Lipo MEM 9, CW 14     
Rv0346c 
ansP2, 
aroP2 
POSSIBLE L-ASPARAGINE 
PERMEASE ANSP2 (L-
ASPARAGINE TRANSPORT 
PROTEIN) 
52, 118, 
234, 273, 
312, 376   TM 
MEM 8, MEM 9, 
CW 14 
BlaTEM 
20 
Macrophage 
24 
Rv0359   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 42, 112   TM MEM 8, MEM 9     
Rv0361   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 182, 186 Yes TM 
CF 3, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15, SOL 16 
BlaTEM 
20 Mouse 27 
Rv0398c   
POSSIBLE SECRETED 
PROTEIN 
20, 24, 30, 
41, 50, 
206   
SP, 
TM 
CF 2, CF 3, MEM 
7, SOL 16     
Rv0399c lpqK 
POSSIBLE CONSERVED 
LIPOPROTEIN LPQK 24   
SP, 
Lipo 
MEM 8, MEM 9, 
CW 14   in vitro 28 
Rv0402c 
mmpL
1 
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL1 
123, 788, 
864   TM 
MEM 7, MEM 8, 
MEM 9, CW 12, 
CW 14 
BlaTEM 
20   
Rv0403c mmpS1 
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
MMPS1 40   
SP, 
TM CF 2, MEM 9   Mouse 27 
Rv0411c glnH 
PROBABLE GLUTAMINE-
BINDING LIPOPROTEIN 
GLNH (GLNBP) 25, 68 Yes 
SP, 
Tat 
SP, 
Lipo 
CF 2, MEM 7, 
MEM 8, MEM 9, 
MEM 10, CW 14   
in vitro 28, in 
vitro 29 
Rv0412c   
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 
65, 90, 94, 
103, 269   TM 
MEM 5, MEM 8, 
MEM 9, CW 14 
BlaTEM 
20 
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv0418 lpqL 
PROBABLE LIPOPROTEIN 
AMINOPEPTIDASE LPQL 
38, 105, 
165, 188, 
278, 459 Yes 
SP, 
Lipo, 
TM 
CF 3, MEM 4, 
MEM 5, MEM 8, 
MEM 9, CW 14 
BlaTEM 
20   
Rv0420c   
POSSIBLE 
TRANSMEMBRANE 
PROTEIN 
65, 92, 
113, 131 Yes 
Tat 
SP, 
TM       
Rv0426c   
POSSIBLE 
TRANSMEMBRANE 
PROTEIN 83 Yes 
SP, 
TM 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15   
Macrophage 
23 
Rv0431 AT103 
PUTATIVE TUBERCULIN 
RELATED PEPTIDE 
71, 89, 
100, 131, 
155 Yes TM 
CF 2, CF 3, MEM 
5, MEM 8, MEM 
9, MEM 10, CW 
12, CW 13, CW 
14   in vitro 29 
Rv0432 sodC 
PROBABLE PERIPLASMIC 
SUPEROXIDE DISMUTASE 
[CU-ZN] SODC 
50, 53, 66, 
85, 102, 
109, 130, 
131, 134, 
139, 140, 
153, 164, 
189, 224, 
233 Yes 
SP, 
Lipo 
CF 3, MEM 4, 
MEM 5, MEM 8, 
MEM 9, MEM 10, 
CW 12, CW 13, 
CW 14, WCL 15 
BlaTEM 
20 Mouse 27 
Rv0446c   
POSSIBLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 120, 123   TM MEM 7, MEM 9     
Rv0450c 
mmpL
4 
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL4 
149, 182, 
185, 188, 
239, 248, 
301, 420, 
427, 500   TM 
CF 3, MEM 6, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 14 
PhoA 18, 
BlaTEM 
20 
in vitro 28, in 
vitro 29 
Rv0451c mmpS4 
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
25, 60, 
138 Yes TM MEM 9     
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MMPS4 
Rv0455c   
CONSERVED 
HYPOTHETICAL PROTEIN 19, 138   
SP, 
TM 
CF 2, CF 3, MEM 
7, MEM 9, CW 
13, CW 14, WCL 
15, SOL 16 PhoA 18 in vitro 29 
Rv0461   
PROBABLE 
TRANSMEMBRANE 
PROTEIN 105, 149   TM MEM 8, MEM 9     
Rv0476   
POSSIBLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 27, 67   
SP, 
TM MEM 8, MEM 9     
Rv0477   
POSSIBLE CONSERVED 
SECRETED PROTEIN 28   SP, 
CF 2, CF 3, MEM 
7     
Rv0479c   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
125, 155, 
180   TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15   
in vitro 28, in 
vitro 29 
Rv0490 senX3 
PUTATIVE TWO 
COMPONENT SENSOR 
HISTIDINE KINASE SENX3 121   TM 
MEM 7, MEM 9, 
CW 14   Mouse 25 
Rv0497   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 244   TM 
MEM 8, MEM 9, 
CW 12, CW 14   
Macrophage 
24, Mouse 
27, in vitro 
29 
Rv0506 mmpS2 
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
MMPS2 145   
SP, 
TM 
CF 2, MEM 7, 
MEM 8, MEM 9, 
CW 14 
BlaTEM 
20   
Rv0507 
mmpL
2 
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL2 188, 410   TM 
CF 2, CW 12, CW 
14   in vitro 29 
Rv0517   
POSSIBLE MEMBRANE 
ACYLTRANSFERASE 
152, 248, 
294, 299   TM MEM 9, CW 14 
BlaTEM 
20   
Rv0518   
POSSIBLE EXPORTED 
PROTEIN 
48, 53, 61, 
85, 90, 
101 Yes   
CF 2, CF 3, MEM 
8     
Rv0522 gabP 
PROBABLE GABA 
PERMEASE GABP (4-
AMINO BUTYRATE 
TRANSPORT CARRIER) 
(GAMA-AMINOBUTYRATE 
PERMEASE) 
149, 251, 
271, 400   TM       
Rv0526   
POSSIBLE THIOREDOXIN 
PROTEIN (THIOL-
DISULFIDE INTERCHANGE 
PROTEIN) 
31, 39, 47, 
48 Yes 
SP, 
Tat 
SP, 
Lipo 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM 
9, CW 14   
in vitro 28, in 
vitro 29 
Rv0528   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
34, 42, 
190   
SP, 
TM MEM 9, CW 14   
in vitro 28, in 
vitro 29 
Rv0529 
ccsA, 
ccsB 
POSSIBLE CYTOCHROME 
C-TYPE BIOGENESIS 
PROTEIN CCSA 
39, 41, 50, 
78, 151, 
159, 188 Yes TM MEM 9, CW 14   
in vitro 28, in 
vitro 29 
Rv0534c menA 
1,4-DIHYDROXY-2-
NAPHTHOATE 
OCTAPRENYLTRANSFERA
SE MENA (DHNA-
OCTAPRENYLTRANSFERA
SE) 
65, 102, 
123, 243, 
251, 256 Yes TM MEM 9, CW 14   in vitro 29 
Rv0537c   
PROBABLE INTEGRAL 
MEMBRANE PROTEIN 
65, 98, 
104, 116, 
158, 177, 
266 Yes 
Tat 
SP, 
TM 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15     
Rv0541c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
45, 47, 
111   TM     
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv0545c pitA 
PROBABLE LOW-AFFINITY 
INORGANIC PHOSPHATE 
TRANSPORTER INTEGRAL 
MEMBRANE PROTEIN 
26, 36, 
128, 161, 
170, 174 Yes TM MEM 9   Mouse 27 
 231 
PITA 
Rv0559c   
POSSIBLE CONSERVED 
SECRETED PROTEIN 79   SP, 
CF 2, CF 3, MEM 
7, MEM 8, CW 
12, CW 13     
Rv0583c lpqN 
PROBABLE CONSERVED 
LIPOPROTEIN LPQN 
79, 104, 
111, 128, 
133, 141, 
148, 215 Yes 
SP, 
Lipo 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM 
9, MEM 10, CW 
12, CW 13, CW 
14, WCL 15, SOL 
16 
BlaTEM 
20   
Rv0585c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
622, 642, 
713   TM MEM 8     
Rv0587 
yrbE2
A 
CONSERVED 
HYPOTHETICAL 
INTEGRAL MEMBRANE 
PROTEIN YRBE2A 88, 90   TM       
Rv0588 yrbE2B 
CONSERVED 
HYPOTHETICAL 
INTEGRAL MEMBRANE 
PROTEIN YRBE2B 114   TM     
Mouse 27, in 
vitro 28 
Rv0590 mce2B 
MCE-FAMILY PROTEIN 
MCE2B 36, 39, 50 Yes TM MEM 9   Mouse 27 
Rv0593 
lprL, 
mce2E 
POSSIBLE MCE-FAMILY 
LIPOPROTEIN LPRL (MCE-
FAMILY LIPOPROTEIN 
MCE2E) 261   
Lipo, 
TM       
Rv0594 mce2F 
MCE-FAMILY PROTEIN 
MCE2F 48, 141   TM MEM 9 
BlaTEM 
20   
Rv0601c   
PROBABLE TWO 
COMPONENT SENSOR 
KINASE [FIRST PART] 18, 29, 36 Yes TM       
Rv0603   
POSSIBLE EXPORTED 
PROTEIN 
20, 35, 44, 
54, 55, 62, 
66, 101   
SP, 
TM CF 3     
Rv0604 lpqO 
PROBABLE CONSERVED 
LIPOPROTEIN LPQO 
20, 34, 59, 
88, 128, 
129, 134, 
153, 177, 
182, 191, 
201, 206, 
267 Yes 
SP, 
Lipo 
MEM 4, MEM 8, 
MEM 9, CW 14     
Rv0615   
PROBABLE INTEGRAL 
MEMBRANE PROTEIN 47, 63 Yes TM       
Rv0621   
POSSIBLE MEMBRANE 
PROTEIN 
108, 112, 
260 Yes TM MEM 9     
Rv0622   
POSSIBLE MEMBRANE 
PROTEIN 144, 164   TM CW 12   Mouse 27 
Rv0625c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 50 Yes TM MEM 8, CW 14     
Rv0658c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
38, 45, 53, 
59, 60, 
109, 118 Yes TM       
Rv0671 lpqP 
POSSIBLE CONSERVED 
LIPOPROTEIN LPQP 
41, 65, 
104, 111, 
203, 258   
SP, 
Lipo, 
TM CW 14   
Macaque 22, 
Mouse 27 
Rv0676c 
mmpL
5 
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL5 
179, 243, 
272, 421, 
432, 758   TM 
MEM 5, MEM 8, 
MEM 9, CW 14 
PhoA 18, 
BlaTEM 
20   
Rv0677c mmpS5 
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 
MMPS5 
20, 60, 62, 
140 Yes TM 
CF 2, CF 3, MEM 
7, MEM 8, MEM 
9, CW 14 
BlaTEM 
20 
Macrophage 
23 
Rv0679c   
CONSERVED 
HYPOTHETICAL 
THREONINE RICH 
PROTEIN 
45, 47, 58, 
65, 70, 87 Yes 
SP, 
Lipo 
CF 3, MEM 8, 
MEM 9, CW 14     
 232 
Rv0680c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 21, 37   
SP, 
TM 
CF 2, MEM 7, 
MEM 8, CW 14     
Rv0713   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 136, 178   TM MEM 9, CW 14     
Rv0732 secY 
PROBABLE PREPROTEIN 
TRANSLOCASE SECY 
31, 36, 55, 
66, 67, 85, 
140, 212, 
295, 398 Yes TM 
MEM 7, MEM 8, 
MEM 9, MEM 10, 
CW 13, CW 14, 
WCL 15   
in vitro 28, in 
vitro 29 
Rv0774c   
PROBABLE CONSERVED 
EXPORTED PROTEIN 40   
SP, 
Tat 
SP, 
TM CF 2, MEM 7 BlaC 19   
Rv0779c   
POSSIBLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
48, 60, 65, 
85, 95, 97, 
105 Yes TM MEM 9, CW 14     
Rv0783c emrB 
POSSIBLE MULTIDRUG 
RESISTANCE INTEGRAL 
MEMBRANE EFFLUX 
PROTEIN EMRB 
352, 395, 
520, 538 Yes TM MEM 9 
BlaTEM 
20   
Rv0787   HYPOTHETICAL PROTEIN 136     
CF 2, CF 3, MEM 
7, MEM 9     
Rv0817c   
PROBABLE CONSERVED 
EXPORTED PROTEIN 
83, 140, 
151   
SP, 
TM 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv0822c   
CONSERVED 
HYPOTHETICAL PROTEIN 
188, 218, 
235, 243, 
250, 471, 
565 Yes   CF 2, CW 14     
Rv0835 lpqQ 
POSSIBLE LIPOPROTEIN 
LPQQ 33, 60   SP, 
CF 2, MEM 7, 
MEM 9   Mouse 27 
Rv0838 lpqR 
PROBABLE CONSERVED 
LIPOPROTEIN LPQR 
50, 63, 69, 
75, 88, 95, 
241, 243 Yes 
SP, 
Lipo 
CF 2, MEM 7, 
MEM 8     
Rv0846c   PROBABLE OXIDASE 
41, 43, 44, 
47   
SP, 
Tat 
SP, 
Lipo 
MEM 8, MEM 9, 
CW 14 BlaC 19   
Rv0870c   
POSSIBLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
60, 61, 63, 
88   TM 
MEM 8, MEM 9, 
CW 14     
Rv0875c   
POSSIBLE CONSERVED 
EXPORTED PROTEIN 
19, 21, 28, 
101   
SP, 
TM 
MEM 4, MEM 9, 
CW 14   
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv0879c   
POSSIBLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 53, 70   TM MEM 8, MEM 9     
Rv0888   
PROBABLE EXPORTED 
PROTEIN 
30, 53, 75, 
143, 146   
SP, 
TM 
CF 2, MEM 8, 
MEM 9, CW 14   
Macrophage 
24 
Rv0892   
PROBABLE 
MONOOXYGENASE 41   TM 
MEM 9, CW 12, 
CW 14     
Rv0899 ompA 
OUTER MEMBRANE 
PROTEIN A OMPA 
56, 59, 86, 
100, 142, 
287 Yes TM 
CF 2, CF 3, MEM 
5, MEM 8, MEM 
9, MEM 10, CW 
12, CW 14     
Rv0902c prrB 
TWO COMPONENT 
SENSOR HISTIDINE 
KINASE PRRB 110   
SP, 
TM 
MEM 5, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15   in vitro 29 
Rv0907   
CONSERVED 
HYPOTHETICAL PROTEIN 
24, 35, 51, 
73, 76, 85 Yes   
CF 2, CF 3, MEM 
5, MEM 8, MEM 
9, CW 14   
Mouse 27, in 
vitro 29 
Rv0912   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
31, 118, 
119, 120, 
135 Yes TM       
Rv0917 betP 
POSSIBLE GLYCINE 
BETAINE TRANSPORT 
INTEGRAL MEMBRANE 
PROTEIN BETP 
53, 228, 
315   TM   
BlaTEM 
20   
 233 
Rv0924c 
mntH, 
Nramp, 
Mramp 
DIVALENT CATION-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN 
MNTH (BRAMP) (MRAMP) 
183, 275, 
426   TM MEM 9   Macaque 22 
Rv0928 
pstS3, 
phoS2 
PERIPLASMIC 
PHOSPHATE-BINDING 
LIPOPROTEIN PSTS3 (PBP-
3) (PSTS3) (PHOS1) 
20, 29, 44, 
74, 118, 
165, 202, 
280, 285, 
304 Yes 
SP, 
Lipo 
CF 2, CF 3, MEM 
5, MEM 7, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
13, CW 14, WCL 
15   
Macrophage 
23, Mouse 27 
Rv0931c 
pknD, 
mbk 
TRANSMEMBRANE 
SERINE/THREONINE-
PROTEIN KINASE D PKND 
(PROTEIN KINASE D) 
(STPK D) 
411, 419, 
593, 653   TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15, SOL 16 
BlaTEM 
20   
Rv0932c pstS2 
PERIPLASMIC 
PHOSPHATE-BINDING 
LIPOPROTEIN PSTS2 (PBP-
2) (PSTS2) 
22, 34, 98, 
151, 172, 
190, 280, 
326 Yes 
SP, 
Lipo 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM 
9, MEM 10, CW 
13, CW 14, WCL 
15, SOL 16     
Rv0934 
pstS1, 
phoS1, 
phoS 
PERIPLASMIC 
PHOSPHATE-BINDING 
LIPOPROTEIN PSTS1 (PBP-
1) (PSTS1) 
29, 36, 38, 
45, 55, 
170, 188, 
210, 235 Yes 
SP, 
Lipo 
CF 1, CF 2, CF 3, 
MEM 4, MEM 5, 
MEM 7, MEM 8, 
MEM 9, MEM 10, 
CW 12, CW 13, 
CW 14, WCL 15, 
SOL 16 
PhoA 18, 
BlaTEM 
20   
Rv0935 pstC1 
PHOSPHATE-TRANSPORT 
INTEGRAL MEMBRANE 
ABC TRANSPORTER PSTC1 172, 184   TM 
MEM 8, MEM 9, 
MEM 10     
Rv0936 pstA2 
PHOSPHATE-TRANSPORT 
INTEGRAL MEMBRANE 
ABC TRANSPORTER PSTA2 239 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv0950c   
CONSERVED 
HYPOTHETICAL PROTEIN 143, 222 Yes       
Mouse 25, 
Mouse 27 
Rv0954   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
73, 90, 
129, 159   TM 
MEM 5, MEM 8, 
MEM 9, MEM 10, 
CW 12, CW 13, 
WCL 15   Macaque 22 
Rv0961   
PROBABLE INTEGRAL 
MEMBRANE PROTEIN 31   TM       
Rv0962c lprP 
POSSIBLE LIPOPROTEIN 
LPRP 33   
SP, 
Lipo       
Rv0969 ctpV 
PROBABLE METAL 
CATION TRANSPORTER P-
TYPE ATPASE CTPV 169   TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15, SOL 16     
Rv0982 mprB 
PROBABLE TWO 
COMPONENT SENSOR 
KINASE MPRB 
48, 82, 94, 
100, 186 Yes 
SP, 
TM 
MEM 7, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv0983 
pepD, 
mtb32b 
PROBABLE SERINE 
PROTEASE PEPD (SERINE 
PROTEINASE) (MTB32B) 
116, 119, 
130, 146, 
245, 292, 
313, 316, 
370, 398, 
402 Yes TM 
CF 2, CF 3, MEM 
8, MEM 9, MEM 
10, CW 13, CW 
14, WCL 15, SOL 
16 
BlaTEM 
20 Mouse 27 
Rv0987   
PROBABLE ADHESION 
COMPONENT TRANSPORT 
TRANSMEMBRANE 
PROTEIN ABC 
TRANSPORTER 
58, 62, 73, 
92, 533, 
537   TM 
MEM 6, MEM 9, 
CW 14   in vitro 29 
Rv0988   
POSSIBLE CONSERVED 
EXPORTED PROTEIN 45 Yes 
SP, 
TM 
CF 2, MEM 8, 
MEM 9, CW 14   
Mouse 27, in 
vitro 29 
Rv0999   HYPOTHETICAL PROTEIN 
57, 60, 89, 
93, 169, 
201, 208 Yes SP, 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM 
9, CW 14     
 234 
Rv1002c   
CONSERVED MEMBRANE 
PROTEIN 
75, 149, 
285, 328, 
483   TM 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv1004c   
PROBABLE MEMBRANE 
PROTEIN 
44, 49, 64, 
71, 113, 
119, 122, 
168, 172, 
192, 211, 
218, 230, 
237, 245, 
287, 408 Yes 
SP, 
TM MEM 8 
BlaTEM 
20   
Rv1006   HYPOTHETICAL PROTEIN 
33, 56, 72, 
81, 128, 
219, 263, 
286, 305, 
361, 400, 
504 Yes SP, 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15 PhoA 18   
Rv1009 rpfB 
Probable resuscitation-
promoting factor rpfB 
15, 21, 33, 
63, 65, 98, 
117, 128, 
145, 165, 
177, 247, 
271, 288, 
292, 300 Yes 
SP, 
Lipo, 
TM   
BlaTEM 
20 
in vitro 
growth-
defect 28 
Rv1016c lpqT 
PROBABLE CONSERVED 
LIPOPROTEIN LPQT 69   
SP, 
Lipo 
CF 2, CF 3, MEM 
5, MEM 8, MEM 
9, MEM 10, CW 
12, CW 14   
Macrophage 
23, Mouse 25 
Rv1022 lpqU 
PROBABLE CONSERVED 
LIPOPROTEIN LPQU 39, 51, 54 Yes 
SP, 
TM 
MEM 8, MEM 9, 
CW 14     
Rv1024   
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 
187, 209, 
225 Yes 
Tat 
SP 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv1026   
CONSERVED 
HYPOTHETICAL PROTEIN 245         in vitro 28 
Rv1029 kdpA 
Probable Potassium-
transporting ATPase A chain 
KDPA (Potassium-
translocating ATPase A chain) 
(ATP phosphohydrolase 
[potassium-transporting] A 
chain) (Potassium binding and 
translocating subunit A) 
37, 220, 
236, 244, 
327, 369, 
443, 451, 
483 Yes TM CW 12     
Rv1030 kdpB 
Probable Potassium-
transporting P-type ATPase B 
chain KDPB (Potassium-
translocating ATPase B chain) 
(ATP phosphohydrolase 
[potassium-transporting] B 
chain) (Potassium binding and 
translocating subunit B) 
88, 262, 
263   TM 
MEM 8, MEM 9, 
CW 14     
Rv1031 kdpC 
Probable Potassium-
transporting ATPase C chain 
KDPC (Potassium-
translocating ATPase C chain) 
(ATP phosphohydrolase 
[potassium-transporting] C 
chain) (Potassium binding and 
translocating subunit C) 27, 52, 60   TM 
MEM 8, MEM 9, 
CW 14     
Rv1032c trcS 
TWO COMPONENT 
SENSOR HISTIDINE 
KINASE TRCS 51, 82   TM       
Rv1064c lpqV 
POSSIBLE LIPOPROTEIN 
LPQV 
23, 27, 33, 
40, 53, 62   
SP, 
Lipo       
Rv1072   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
137, 200, 
210   TM 
MEM 8, MEM 9, 
CW 14 PhoA 18 in vitro 29 
Rv1081c   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 54 Yes TM MEM 9   in vitro 29 
Rv1085c   POSSIBLE HEMOLYSIN- 63, 181 Yes TM MEM 9     
 235 
LIKE PROTEIN 
Rv1096   
POSSIBLE GLYCOSYL 
HYDROLASE 
31, 84, 87, 
119, 133, 
143, 144, 
154, 284   TM 
CF 2, CF 3, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
13, CW 14 
BlaTEM 
20 
Macrophage 
23, Mouse 
27, in vitro 
growth-
defect 28 
Rv1097c   
PROBABLE MEMBRANE 
GLYCINE AND PROLINE 
RICH PROTEIN 114, 207   TM 
CF 2, CF 3, MEM 
5, MEM 8, MEM 
9, MEM 10, CW 
12, CW 13, CW 
14   Mouse 27 
Rv1100   
CONSERVED 
HYPOTHETICAL PROTEIN 
67, 101, 
107, 110, 
122, 230 Yes TM 
CF 3, MEM 8, 
MEM 9, CW 12, 
CW 14   
Mouse 27, in 
vitro growth-
defect 28 
Rv1111c   
CONSERVED 
HYPOTHETICAL PROTEIN 34, 44, 56   TM MEM 9, CW 14   
Mouse 25, 
Mouse 27, in 
vitro 29 
Rv1132   
CONSERVED MEMBRANE 
PROTEIN 
166, 180, 
318   TM 
MEM 8, MEM 9, 
CW 14     
Rv1140   
PROBABLE INTEGRAL 
MEMBRANE PROTEIN 101, 135 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv1145 
mmpL
13a 
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL13A 39, 63   TM MEM 9     
Rv1158c   
CONSERVED 
HYPOTHETICAL ALA-, 
PRO-RICH PROTEIN 23   
SP, 
TM MEM 7     
Rv1159 pimE 
CONSERVED 
TRANSMEMBRANE 
PROTEIN 277, 288   TM     
Mouse 27, in 
vitro 29 
Rv1166 lpqW 
PROBABLE CONSERVED 
LIPOPROTEIN LPQW 
25, 63, 78, 
99, 112, 
160, 161, 
174, 187, 
211, 251, 
297, 485 Yes 
SP, 
Lipo 
CF 2, MEM 7, 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv1174c TB8.4 
LOW MOLECULAR 
WEIGHT T-CELL ANTIGEN 
TB8.4 26, 55, 83 Yes SP, 
CF 2, CF 3, MEM 
7, MEM 10, CW 
13, WCL 15, SOL 
16 
BlaTEM 
20   
Rv1183 
mmpL
10 
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL10 
50, 329, 
862, 932   
SP, 
TM 
MEM 6, MEM 7, 
MEM 8, MEM 9, 
CW 14   Mouse 25 
Rv1184c   
POSSIBLE EXPORTED 
PROTEIN 
16, 21, 28, 
48, 88, 89, 
134, 174, 
190, 218, 
253, 255, 
354, 357   
SP, 
TM 
MEM 8, CW 12, 
CW 14   Mouse 25 
Rv1200   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
TRANSPORT PROTEIN 
42, 102, 
269, 323   TM     Macaque 22 
Rv1217c   
PROBABLE TETRONASIN-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER 
67, 70, 
102, 174, 
227, 352, 
448, 513, 
518 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv1223 
htrA, 
degP 
PROBABLE SERINE 
PROTEASE HTRA (DEGP 
PROTEIN) 
191, 194, 
225, 254, 
261, 294, 
386, 387, 
402, 403, 
466, 470 Yes TM 
CF 2, CF 3, MEM 
5, MEM 8, MEM 
9, MEM 10, CW 
12, CW 13, CW 
14, WCL 15   
in vitro 28, in 
vitro 29 
Rv1226c   
PROBABLE 
TRANSMEMBRANE 
PROTEIN 
197, 206, 
210 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv1228 lpqX PROBABLE LIPOPROTEIN 37, 56, 68, Yes Lipo CF 2, MEM 9,     
 236 
LPQX 74 CW 14 
Rv1230c   
POSSIBLE MEMBRANE 
PROTEIN 
53, 69, 74, 
118, 130, 
270, 271, 
275, 305 Yes 
SP, 
TM CW 12 
BlaTEM 
20   
Rv1234   
PROBABLE 
TRANSMEMBRANE 
PROTEIN 112, 116   TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15   
Macaque 22, 
Mouse 27 
Rv1236 sugA 
PROBABLE SUGAR-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER SUGA 146, 246   
Tat 
SP, 
TM MEM 8, MEM 9   
Macrophage 
23, 
Macrophage 
24, Mouse 
25, Mouse 27 
Rv1237 sugB 
PROBABLE SUGAR-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER SUGB 
212, 219, 
228, 237   TM 
MEM 8, MEM 9, 
CW 14   
Macrophage 
23, Mouse 25 
Rv1244 lpqZ 
PROBABLE LIPOPROTEIN 
LPQZ 
26, 47, 65, 
85, 123, 
137, 154, 
249, 274, 
275   
SP, 
Lipo 
MEM 8, MEM 9, 
CW 12, CW 14   
Macrophage 
23, Mouse 25 
Rv1250   
PROBABLE DRUG-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN 
104, 106, 
111, 120, 
386, 396, 
438, 440, 
441   TM       
Rv1252c lprE 
PROBABLE LIPOPROTEIN 
LPRE 
61, 72, 
130, 157, 
199, 200 Yes 
SP, 
Lipo 
CF 2, MEM 7, 
MEM 8, MEM 9, 
CW 14     
Rv1258c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
TRANSPORT PROTEIN 372   TM       
Rv1266c pknH 
PROBABLE 
TRANSMEMBRANE 
SERINE/THREONINE-
PROTEIN KINASE H PKNH 
(PROTEIN KINASE H) 
(STPK H) 603 Yes TM 
MEM 9, MEM 10, 
CW 12, CW 13, 
CW 14, WCL 15     
Rv1269c   
CONSERVED PROBABLE 
SECRETED PROTEIN 29, 34, 44 Yes 
SP, 
Tat 
SP 
CF 2, CF 3, MEM 
7, MEM 8, MEM 
9, MEM 10, CW 
12, CW 13, CW 
14, WCL 15 PhoA 17   
Rv1270c lprA 
POSSIBLE LIPOPROTEIN 
LPRA 
22, 30, 36, 
60, 93, 
123, 161, 
238 Yes 
SP, 
Lipo, 
TM 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM 
9, MEM 10, CW 
12, CW 13, CW 
14, WCL 15, SOL 
16     
Rv1271c   
CONSERVED 
HYPOTHETICAL 
SECRETED PROTEIN 28, 30   
SP, 
TM CF 3     
Rv1273c   
PROBABLE DRUGS-
TRANSPORT 
TRANSMEMBRANE ATP-
BINDING PROTEIN ABC 
TRANSPORTER 38, 50, 64   
SP, 
TM 
MEM 8, MEM 9, 
CW 12   
Macrophage 
23, Mouse 27 
Rv1274 lprB 
POSSIBLE LIPOPROTEIN 
LPRB 
27, 55, 69, 
74, 86, 
127 Yes 
SP, 
Lipo 
 MEM 8, MEM 9, 
MEM 10, CW 13, 
WCL 15   in vitro 28 
Rv1275 lprC 
POSSIBLE LIPOPROTEIN 
LPRC 18, 27 Yes 
SP, 
Lipo 
CF 2, MEM 4, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15     
Rv1280c oppA PROBABLE PERIPLASMIC 49, 54, 81, Yes Tat MEM 5, MEM 8,     
 237 
OLIGOPEPTIDE-BINDING 
LIPOPROTEIN OPPA 
252, 267, 
400, 469 
SP, 
Lipo, 
TM 
MEM 9, MEM 10, 
CW 14 
Rv1283c oppB 
PROBABLE 
OLIGOPEPTIDE-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER OPPB 
82, 111, 
169, 174, 
177, 178, 
258, 262, 
282 Yes TM MEM 9, CW 14     
Rv1290c   
CONSERVED 
HYPOTHETICAL PROTEIN 
94, 184, 
194 Yes 
Tat 
SP, 
TM MEM 9, CW 14     
Rv1302 
rfe, 
wecA 
PROBABLE 
UNDECAPAPRENYL-
PHOSPHATE ALPHA-N-
ACETYLGLUCOSAMINYLT
RANSFERASE RFE (UDP-
GlcNAc TRANSFERASE) 
106, 109, 
114, 237, 
360, 371, 
382 Yes TM MEM 8, MEM 9   in vitro 29 
Rv1304 atpB 
PROBABLE ATP 
SYNTHASE A CHAIN ATPB 
(PROTEIN 6) 145   TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
WCL 15   
Mouse 25, in 
vitro 29 
Rv1320c   
POSSIBLE ADENYLATE 
CYCLASE (ATP 
PYROPHOSPHATE-LYASE) 
(ADENYLYL CYCLASE) 151, 237 Yes TM MEM 9, CW 14     
Rv1348   
PROBABLE DRUGS-
TRANSPORT 
TRANSMEMBRANE ATP-
BINDING PROTEIN ABC 
TRANSPORTER 322, 342 Yes TM MEM 4, MEM 9   
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv1352   
CONSERVED 
HYPOTHETICAL PROTEIN 31, 36   
SP, 
TM 
CF 2, CF 3, MEM 
7     
Rv1362c   
POSSIBLE MEMBRANE 
PROTEIN 
95, 97, 
103, 126, 
132, 159   TM 
MEM 4, MEM 9, 
CW 14     
Rv1363c   
POSSIBLE MEMBRANE 
PROTEIN 
119, 122, 
139, 144, 
173, 214, 
228 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv1368 lprF 
PROBABLE CONSERVED 
LIPOPROTEIN LPRF 
38, 50, 
136, 226 Yes 
SP, 
Lipo, 
TM 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
13, CW 14 
BlaTEM 
20   
Rv1411c 
lprG, 
P27 
PROBABLE CONSERVED 
LIPOPROTEIN LPRG 
24, 33, 
168, 198   
SP, 
Lipo 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
13, CW 14, WCL 
15, SOL 16   
Macrophage 
23, 
Macrophage 
24, Mouse 
25, Mouse 27 
Rv1418 lprH 
PROBABLE LIPOPROTEIN 
LPRH 
43, 48, 
208 Yes 
SP, 
Lipo, 
TM 
MEM 8, MEM 9, 
CW 14     
Rv1419   HYPOTHETICAL PROTEIN 85, 130   SP, 
CF 2, CF 3, MEM 
7 
BlaTEM 
20   
Rv1424c   
POSSIBLE MEMBRANE 
PROTEIN 
65, 67, 
191, 217, 
223 Yes SP, 
MEM 8, MEM 9, 
CW 12, CW 14     
Rv1431   
CONSERVED MEMBRANE 
PROTEIN 
65, 164, 
175, 177 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv1433   
POSSIBLE CONSERVED 
EXPORTED PROTEIN 
44, 84, 
124   
SP, 
TM     Macaque 22 
Rv1435c   
Probable conserved Proline, 
Glycine, Valine-rich secreted 
protein 
71, 117, 
167, 180 Yes SP, CF 2, MEM 7 
BlaTEM 
20   
Rv1451 ctaB 
PROBABLE CYTOCHROME 
C OXIDASE ASSEMBLY 
FACTOR CTAB 
47, 61, 65, 
67, 87, 
271 Yes TM MEM 9, CW 12   in vitro 29 
Rv1456c   PROBABLE UNIDENTIFIED 30, 37, Yes TM MEM 9   in vitro 28, in 
 238 
ANTIBIOTIC-TRANSPORT 
INTEGRAL MEMBRANE 
ABC TRANSPORTER 
261, 270, 
282, 291 
vitro 29 
Rv1457c   
PROBABLE UNIDENTIFIED 
ANTIBIOTIC-TRANSPORT 
INTEGRAL MEMBRANE 
ABC TRANSPORTER 71, 163   TM     
in vitro 28, in 
vitro 29 
Rv1459c   
POSSIBLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
158, 190, 
388, 400, 
418, 520   TM 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv1477   
HYPOTHETICAL INVASION 
PROTEIN 
46, 279, 
360, 373 Yes SP, 
CF 2, CF 3, MEM 
7, MEM 9, CW 
13, CW 14   
in vitro 28, in 
vitro 29 
Rv1478   
HYPOTHETICAL INVASION 
PROTEIN 27, 32, 48 Yes SP,       
Rv1487   
CONSERVED MEMBRANE 
PROTEIN 20, 29, 34 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv1490   
PROBABLE MEMBRANE 
PROTEIN 
160, 342, 
426   TM     
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv1491c   
CONSERVED MEMBRANE 
PROTEIN 
92, 110, 
123, 202, 
204 Yes TM       
Rv1508c   Probable membrane protein 232   TM 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15     
Rv1510   
conserved probable membrane 
protein 
205, 272, 
349   TM       
Rv1517   
CONSERVED 
HYPOTHETICAL 
TRANSMEMBRANE 
PROTEIN 69   
Tat 
SP, 
TM       
Rv1522c 
mmpL
12 
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL12 
48, 449, 
517, 953 Yes 
SP, 
TM MEM 9, CW 12   in vitro 29 
Rv1539 lspA 
PROBABLE LIPOPROTEIN 
SIGNAL PEPTIDASE LSPA 59, 86 Yes TM MEM 9   
in vitro 28, in 
vitro 29 
Rv1541c lprI Possible lipoprotein lprI 27, 28, 60 Yes 
SP, 
Lipo MEM 7     
Rv1554 frdC 
PROBABLE FUMARATE 
REDUCTASE [MEMBRANE 
ANCHOR SUBUNIT] FRDC 
(FUMARATE 
DEHYDROGENASE) 
(FUMARIC 
HYDROGENASE) 48   TM       
Rv1565c   
CONSERVED 
HYPOTHETICAL 
MEMBRANE PROTEIN 
71, 151, 
226, 263, 
440   TM MEM 9   
Mouse 27, in 
vitro 29 
Rv1566c   Possible inv protein 
22, 24, 48, 
60, 69, 71, 
83, 93   
SP, 
TM MEM 8, CW 14 
PhoA 17, 
PhoA 18 Mouse 27 
Rv1607 chaA 
Probable ionic transporter 
integral membrane protein 
chaA 
83, 84, 
166, 168, 
244 Yes TM MEM 9     
Rv1610   
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 57, 117   TM 
MEM 8, MEM 9, 
CW 14   in vitro 28 
Rv1616   
CONSERVED MEMBRANE 
PROTEIN 51   TM       
Rv1619   
CONSERVED MEMBRANE 
PROTEIN 65, 134   TM MEM 9     
Rv1622c cydB 
Probable integral membrane 
cytochrome D ubiquinol 
oxidase (subunit II) cydB 
(Cytochrome BD-I oxidase 
subunit II) 172   TM MEM 8, MEM 9   
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv1623c 
cydA, 
appC 
Probable integral membrane 
cytochrome D ubiquinol 
44, 67, 
138, 161, Yes TM 
MEM 8, MEM 9, 
CW 12, CW 14   
Mouse 27, in 
vitro 29 
 239 
oxidase (subunit I) cydA 
(Cytochrome BD-I oxidase 
subunit I) 
177, 242, 
389, 408, 
425 
Rv1625c cya 
MEMBRANE-ANCHORED 
ADENYLYL CYCLASE CYA 
(ATP PYROPHOSPHATE-
LYASE) (ADENYLATE 
CYCLASE) 
70, 82, 
132, 188   TM MEM 9, CW 14     
Rv1635c   
Probable conserved 
transmembrane protein 
242, 397, 
432, 446   TM   
BlaTEM 
20   
Rv1639c   
CONSERVED 
HYPOTHETICAL 
MEMBRANE PROTEIN 
77, 146, 
153, 227, 
239, 265, 
338, 379, 
422, 484 Yes TM       
Rv1640c lysX 
Possible lysyl-tRNA synthetase 
2 lysX 
162, 168, 
171, 262   TM 
MEM 6, MEM 9, 
CW 12, CW 14   
Macrophage 
23, Mouse 25 
Rv1648   
Probable transmembrane 
protein 113   
SP, 
TM CW 14 
BlaTEM 
20   
Rv1672c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
TRANSPORT PROTEIN 
53, 57, 59, 
72, 125, 
172, 175, 
271, 275, 
386, 393, 
404 Yes TM MEM 8     
Rv1677 dsbF 
PROBABLE CONSERVED 
LIPOPROTEIN DSBF 
32, 36, 48, 
96   
SP, 
Lipo 
CF 3, MEM 9, 
MEM 10     
Rv1678   
PROBABLE INTEGRAL 
MEMBRANE PROTEIN 
202, 220, 
235, 256, 
270, 275   TM MEM 9, CW 14     
Rv1686c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN ABC 
TRANSPORTER 23, 27, 31 Yes TM MEM 8, MEM 9     
Rv1704c cycA 
PROBABLE D-
SERINE/ALANINE/GLYCIN
E TRANSPORTER PROTEIN 
CYCA 
120, 436, 
438   TM MEM 9   Macaque 22 
Rv1707   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 28, 30, 46   TM 
MEM 8, MEM 9, 
CW 14 
BlaTEM 
20   
Rv1728c   
CONSERVED 
HYPOTHETICAL PROTEIN 
183, 234, 
239 Yes     
BlaTEM 
20 
Macrophage 
24 
Rv1733c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
59, 62, 64, 
83, 85, 
100, 146   
SP, 
TM       
Rv1736c narX 
PROBABLE NITRATE 
REDUCTASE NARX 492, 587   TM MEM 9, CW 14     
Rv1737c narK2 
POSSIBLE 
NITRATE/NITRITE 
TRANSPORTER NARK2 247, 248   TM MEM 8, MEM 9   Mouse 27 
Rv1739c   
PROBABLE SULPHATE-
TRANSPORT 
TRANSMEMBRANE 
PROTEIN ABC 
TRANSPORTER 
158, 238, 
261   TM       
Rv1743 pknE 
PROBABLE 
TRANSMEMBRANE 
SERINE/THREONINE-
PROTEIN KINASE E PKNE 
(PROTEIN KINASE E) (STPK 
E)     TM 
CF 3, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15, 
SOL 16 
BlaTEM 
20   
Rv1747   
PROBABLE CONSERVED 
TRANSMEMBRANE ATP-
BINDING PROTEIN ABC 
TRANSPORTER 
722, 781, 
820   TM 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15, SOL 16     
Rv1749c   
POSSIBLE INTEGRAL 
MEMBRANE PROTEIN 
86, 89, 
113 Yes TM 
MEM 8, MEM 9, 
MEM 10, CW 13, 
WCL 15     
 240 
Rv1754c   
CONSERVED 
HYPOTHETICAL PROTEIN 
95, 98, 
129, 301, 
394 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv1779c   
HYPOTHETICAL 
INTEGRAL MEMBRANE 
PROTEIN 
128, 174, 
200, 278 Yes TM MEM 8, MEM 9 
BlaTEM 
20   
Rv1782 eccB5 
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
92, 116, 
135, 154, 
380 Yes TM 
CF 2, MEM 4, 
MEM 8, MEM 9, 
CW 12, CW 14   in vitro 29 
Rv1804c   
CONSERVED 
HYPOTHETICAL PROTEIN 24   SP, MEM 7   Macaque 22 
Rv1810   
CONSERVED 
HYPOTHETICAL PROTEIN 
31, 41, 45, 
50, 63, 89 Yes 
SP, 
TM 
CF 2, CF 3, MEM 
7   Macaque 22 
Rv1811 mgtC 
POSSIBLE Mg2+ 
TRANSPORT P-TYPE 
ATPASE C MGTC 75, 117   TM MEM 9     
Rv1813c   
CONSERVED 
HYPOTHETICAL PROTEIN 47   
SP, 
Tat 
SP, 
TM 
CF 3, MEM 9, 
CW 14     
Rv1814 erg3 
MEMBRANE-BOUND C-5 
STEROL DESATURASE 
ERG3 (STEROL-C5-
DESATURASE) 86   TM       
Rv1823   
CONSERVED 
HYPOTHETICAL PROTEIN 
79, 94, 98, 
112, 188, 
264, 292     
MEM 8, MEM 9, 
CW 14   Mouse 27 
Rv1824   
CONSERVED 
HYPOTHETICAL 
MEMBRANE PROTEIN 29, 45, 96   TM MEM 9   
in vitro 
growth-
defect 28 
Rv1825   
CONSERVED 
HYPOTHETICAL PROTEIN 
92, 135, 
163, 176, 
276 Yes TM 
CF 2, CF 3, MEM 
5, MEM 8, MEM 
9, MEM 10, CW 
14 PhoA 18 Mouse 27 
Rv1832 gcvB 
Probable glycine 
dehydrogenase gcvB (Glycine 
decarboxylase) (Glycine 
cleavage system P-protein) 257     
CF 2, MEM 4, 
MEM 8, MEM 9, 
WCL 15, SOL 16   
in vitro 28, in 
vitro 29 
Rv1842c   
CONSERVED 
HYPOTHETICAL 
MEMBRANE PROTEIN 30, 42   TM MEM 9, CW 14     
Rv1845c   
CONSERVED 
HYPOTHETICAL 
TRANSMEMBRANE 
PROTEIN 51, 62, 76 Yes 
SP, 
TM MEM 7, MEM 9   
Mouse 27, in 
vitro growth-
defect 28, in 
vitro 29 
Rv1857 modA 
PROBABLE MOLYBDATE-
BINDING LIPOPROTEIN 
MODA 
26, 31, 87, 
96, 109, 
124, 187 Yes 
SP, 
Lipo MEM 8     
Rv1860 
apa, 
mpt32, 
modD 
ALANINE AND PROLINE 
RICH SECRETED PROTEIN 
APA (FIBRONECTIN 
ATTACHMENT PROTEIN) 
(Immunogenic protein MPT32) 
(Antigen MPT-32) (45-kDa 
glycoprotein) (45/47 kDa 
antigen) 
35, 50, 73, 
146 Yes 
SP, 
TM 
CF 1, CF 2, CF 3, 
MEM 7, MEM 8, 
CW 13, CW 14, 
WCL 15, SOL 16 
BlaTEM 
20 Mouse 27 
Rv1861   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 74   TM MEM 9     
Rv1863c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
59, 125, 
148 Yes TM       
Rv1877   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
128, 134, 
234   TM       
Rv1884c rpfC 
PROBABLE 
RESUSCITATION-
PROMOTING FACTOR 
RPFC 
66, 80, 88, 
94, 107, 
139, 141, 
153   SP, 
CF 2, CF 3, MEM 
7, MEM 8, MEM 
9, WCL 15, SOL 
16     
 241 
Rv1885c   
CONSERVED 
HYPOTHETICAL PROTEIN 44   
SP, 
TM 
CF 2, CF 3, MEM 
8, CW 14     
Rv1887   HYPOTHETICAL PROTEIN 280, 331     CF 3, MEM 7 
PhoA 18, 
BlaTEM 
20   
Rv1891   
CONSERVED 
HYPOTHETICAL PROTEIN 
58, 77, 
102   
Tat 
SP 
CF 2, CF 3, MEM 
7, MEM 8 
BlaTEM 
20   
Rv1902c nanT 
PROBABLE SIALIC ACID-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN 
NANT 
246, 253, 
259   TM     
Macrophage 
24 
Rv1903   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 28, 84 Yes TM MEM 9     
Rv1906c   
CONSERVED 
HYPOTHETICAL PROTEIN 
29, 62, 
123 Yes 
SP, 
TM 
CF 2, CF 3, MEM 
7 PhoA 17   
Rv1911c lppC 
PROBABLE LIPOPROTEIN 
LPPC 
25, 27, 51, 
88, 189 Yes Lipo 
CF 2, CF 3, MEM 
7, MEM 10, CW 
12, WCL 15 PhoA 18 Mouse 27 
Rv1921c lppF 
PROBABLE CONSERVED 
LIPOPROTEIN LPPF 30 Yes 
SP, 
Lipo MEM 9     
Rv1922   
PROBABLE CONSERVED 
LIPOPROTEIN 25   
SP, 
Lipo 
CF 2, MEM 9, 
CW 14     
Rv1926c 
mpt63, 
mpb63 
IMMUNOGENIC PROTEIN 
MPT63 (ANTIGEN 
MPT63/MPB63) (16 kDa 
IMMUNOPROTECTIVE 
EXTRACELLULAR 
PROTEIN) 
33, 66, 85, 
90, 99, 
118, 129, 
137 Yes 
SP, 
TM 
CF 1, CF 2, CF 3, 
MEM 7, MEM 8, 
MEM 9, CW 12, 
CW 13, CW 14, 
WCL 15, SOL 16 PhoA 18 Mouse 27 
Rv1965 yrbE3B 
CONSERVED 
HYPOTHETICAL 
INTEGRAL MEMBRANE 
PROTEIN YRBE3B 90, 104   TM     Macaque 22 
Rv1968 mce3C 
MCE-FAMILY PROTEIN 
MCE3C 
42, 48, 49, 
53, 60 Yes TM       
Rv1969 mce3D 
MCE-FAMILY PROTEIN 
MCE3D 
27, 30, 
110   
SP, 
TM CW 12     
Rv1973   
POSSIBLE CONSERVED 
MCE ASSOCIATED 
MEMBRANE PROTEIN 35, 51 Yes TM       
Rv1979c   
POSSIBLE CONSERVED 
PERMEASE 374   TM       
Rv1980c 
mpt64, 
mpb64 
IMMUNOGENIC PROTEIN 
MPT64 (ANTIGEN 
MPT64/MPB64) 
22, 36, 
119, 210   
SP, 
TM 
CF 1, CF 2, CF 3, 
MEM 7, MEM 8, 
CW 12, CW 13, 
CW 14, WCL 15, 
SOL 16     
Rv1984c cfp21 
PROBABLE CUTINASE 
PRECURSOR CFP21 
23, 24, 25, 
28, 43, 67, 
132, 157, 
184, 186, 
215 Yes SP, 
CF 1, CF 2, CF 3, 
MEM 7, MEM 8, 
CW 12, CW 13, 
CW 14 
BlaTEM 
20   
Rv1986   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 74, 76 Yes TM       
Rv1987   POSSIBLE CHITINASE 
51, 110, 
116, 123   
SP, 
TM 
CF 2, MEM 8, 
MEM 9     
Rv1997 ctpF 
PROBABLE METAL 
CATION TRANSPORTER P-
TYPE ATPASE A CTPF 278, 318 Yes TM 
MEM 5, MEM 9, 
MEM 10, CW 13, 
CW 14     
Rv1999c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
172, 399, 
400   
Tat 
SP, 
TM       
Rv2025c   
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 70, 127   TM       
Rv2046 lppI Probable lipoprotein lppI 
20, 34, 45, 
65, 103, 
128, 142 Yes 
SP, 
Lipo 
MEM 4, MEM 8, 
MEM 9   Macaque 22 
Rv2051c ppm1 
Polyprenol-
monophosphomannose 93, 306 Yes TM 
MEM 4, MEM 8, 
MEM 9, CW 11,   
Mouse 27, in 
vitro 29 
 242 
synthase Ppm1 CW 14 
Rv2053c fxsA 
PROBABLE 
TRANSMEMBRANE 
PROTEIN 106   TM MEM 9     
Rv2060   
Possible conserved integral 
membrane protein 70   
SP, 
TM MEM 7     
Rv2080 lppJ Possible lipoprotein lppJ 37, 47, 69   
SP, 
Lipo, 
TM 
CF 2, MEM 7, 
MEM 8, MEM 9 
BlaTEM 
20   
Rv2088 pknJ 
PROBABLE 
TRANSMEMBRANE 
SERINE/THREONINE-
PROTEIN KINASE J PKNJ 
(PROTEIN KINASE J) (STPK 
J) 399, 435     
MEM 8, MEM 9, 
CW 14     
Rv2091c   Probable membrane protein 161, 176   TM 
CF 3, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15   
Macaque 22, 
Mouse 27 
Rv2093c tatC 
Probable Sec-independent 
protein translocase 
transmembrane protein tatC 
110, 241, 
249 Yes TM MEM 8   
in vitro 28, in 
vitro 29 
Rv2113   
Probable integral membrane 
protein 67, 197 Yes TM 
MEM 5, MEM 8, 
MEM 9, CW 14 
BlaTEM 
20   
Rv2120c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
16, 30, 96, 
118   
SP, 
TM 
MEM 8, MEM 9, 
MEM 10     
Rv2127 ansP1 
Probable L-asparagine 
permease ansP1 
183, 193, 
202, 236, 
272, 276, 
293, 364   TM 
MEM 8, MEM 9, 
CW 14 
BlaTEM 
20 
Macrophage 
24 
Rv2128   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 48 Yes TM       
Rv2138 lppL 
Probable conserved lipoprotein 
LppL 35   
SP, 
Lipo, 
TM 
CF 2, MEM 8, 
MEM 9, CW 14   
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv2144c   
Probable transmembrane 
protein 86   TM       
Rv2151c ftsQ 
POSSIBLE CELL DIVISION 
PROTEIN FTSQ 144, 230   TM 
CF 3, MEM 5, 
MEM 9, MEM 10, 
CW 13, CW 14   
in vitro 28, in 
vitro 29 
Rv2154c ftsW FtsW-like protein FtsW 
149, 273, 
388   TM CW 14   
in vitro 28, in 
vitro 29 
Rv2156c murX 
Probable phospho-N-
acetylmuramoyl-
pentappeptidetransferase MurX 
46, 191, 
237   TM 
MEM 9, MEM 10, 
CW 13   
in vitro 28, in 
vitro 29 
Rv2171 lppM 
Probable conserved lipoprotein 
lppM 
22, 40, 45, 
104, 105, 
143 Yes 
SP, 
Lipo, 
TM 
CF 2, MEM 8, 
MEM 9, CW 12, 
CW 14     
Rv2174   
Possible conserved integral 
membrane protein 
175, 199, 
263, 290, 
339, 347   TM MEM 8, MEM 9   
in vitro 28, in 
vitro 29 
Rv2181   
Probable conserved integral 
membrane protein 
64, 285, 
401, 417   TM MEM 8, MEM 9     
Rv2190c   
CONSERVED 
HYPOTHETICAL PROTEIN 
27, 107, 
174, 229, 
238, 258, 
269 Yes 
SP, 
TM 
MEM 7, MEM 9, 
CW 14   in vitro 29 
Rv2193 ctaE 
PROBABLE CYTOCHROME 
C OXIDASE (SUBUNIT III) 
CTAE 
53, 143, 
151, 152 Yes TM MEM 9   
in vitro 28, in 
vitro 29 
Rv2194 qcrC 
Probable Ubiquinol-
cytochrome C reductase 
QcrC(cytochrome C subunit) 
111, 139, 
180, 197, 
243 Yes 
SP, 
TM 
CF 3, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15   
in vitro 28, in 
vitro 29 
Rv2198c mmpS3 
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
130, 208, 
218, 235   TM 
CF 2, CF 3, MEM 
5, MEM 8, MEM   
Mouse 27, in 
vitro growth-
 243 
MMPS3 9, MEM 10, CW 
12, CW 13, CW 
14 
defect 28, in 
vitro 29 
Rv2199c ctaF 
Possible conserved integral 
membrane protein 
30, 44, 45, 
115, 125 Yes TM MEM 10     
Rv2200c ctaC 
PROBABLE 
TRANSMEMBRANE 
CYTOCHROME C OXIDASE 
(SUBUNIT II) CTAC 
92, 287, 
353   TM 
CF 3, MEM 4, 
MEM 5, MEM 7, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15 
BlaTEM 
20 
in vitro 28, in 
vitro 29 
Rv2203   
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 
114, 137, 
195, 225 Yes TM 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15 
BlaTEM 
20   
Rv2209   
Probable conserved integral 
membrane protein 110, 187   TM MEM 9     
Rv2219   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 68   TM 
MEM 5, MEM 8, 
MEM 9, MEM 10, 
CW 13, CW 14   
in vitro 28, in 
vitro 29 
Rv2223c   Probable exported protease 
31, 37, 39, 
84 Yes 
SP, 
TM 
CF 2, MEM 9, 
CW 12 PhoA 17   
Rv2224c   Probable exported protease 
64, 65, 
110, 113, 
141, 325, 
360, 383, 
478 Yes 
SP, 
Lipo, 
TM 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM 
9, MEM 10, CW 
13, CW 14   
Macrophage 
23, Mouse 
25, Mouse 
26, Mouse 27 
Rv2235   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
80, 112, 
145, 198, 
210   TM 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv2240c   HYPOTHETICAL PROTEIN 
128, 177, 
185, 262 Yes   
CF 2, CF 3, MEM 
8, MEM 9, CW 14 
BlaTEM 
20   
Rv2262c   
CONSERVED 
HYPOTHETICAL PROTEIN 
88, 89, 
227, 239, 
244   
Tat 
SP, 
TM       
Rv2264c   
conserved hypothetical proline 
rich protein 497, 535     CW 14 
BlaTEM 
20   
Rv2265   
Possible conserved integral 
membrane protein 
180, 188, 
189, 191   TM       
Rv2270 lppN 
PROBABLE LIPOPROTEIN 
LPPN 27   
SP, 
Lipo       
Rv2272   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
52, 70, 
120   TM MEM 9, CW 14     
Rv2273   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 102   TM       
Rv2281 pitB 
Putative phosphate-transport 
permease PitB 
62, 131, 
137, 195   TM MEM 9     
Rv2284 lipM Probable esterase LipM 62, 105   TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14 
BlaTEM 
20   
Rv2287 yjcE 
Probable conserved integral 
membrane transport protein 
YjcE 
122, 196, 
301 Yes TM MEM 9, CW 14     
Rv2289 cdh 
Probable CDP-diacylglycerol 
pyrophosphatase Cdh (CDP-
diacylglycerol diphosphatase) 
(CDP-diacylglycerol 
phosphatidylhydrolase) 
99, 115, 
121   
SP, 
TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
CW 14 PhoA 18   
Rv2290 lppO 
Probable conserved lipoprotein 
lppO 44, 46, 59   
SP, 
Lipo 
CF 2, CF 3, MEM 
9, CW 14 
PhoA 17, 
BlaTEM 
20   
Rv2300c   
CONSERVED 
HYPOTHETICAL PROTEIN 210     MEM 8, MEM 9     
Rv2301 
cut2, 
cfp25 
PROBABLE CUTINASE 
CUT2 
30, 31, 34, 
59, 118, 
119, 147, 
174, 208   
SP, 
Tat 
SP, 
TM 
CF 1, CF 2, CF 3, 
MEM 7, MEM 8, 
CW 14 
BlaTEM 
20   
Rv2307c   CONSERVED 49, 50 Yes SP, CW 12, CW 14     
 244 
HYPOTHETICAL PROTEIN TM 
Rv2316 uspA 
PROBABLE SUGAR-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER USPA 
71, 231, 
252   
Tat 
SP, 
TM       
Rv2317 uspB 
PROBABLE SUGAR-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER USPB 36, 63   TM     
Mouse 27, in 
vitro 29 
Rv2318 uspC 
PROBABLE PERIPLASMIC 
SUGAR-BINDING 
LIPOPROTEIN USPC 
30, 35, 
133   
SP, 
TM     in vitro 29 
Rv2320c rocE 
PROBABLE CATIONIC 
AMINO ACID TRANSPORT 
INTEGRAL MEMBRANE 
PROTEIN ROCE 
227, 231, 
296, 297, 
395, 450 Yes TM MEM 8 
BlaTEM 
20   
Rv2325c   
CONSERVED 
HYPOTHETICAL PROTEIN 
67, 100, 
109, 125 Yes TM 
MEM 4, MEM 9, 
CW 14   in vitro 28 
Rv2326c   
POSSIBLE 
TRANSMEMBRANE ATP-
BINDING PROTEIN ABC 
TRANSORTER 
59, 69, 99, 
114, 147 Yes TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
CW 12, CW 14     
Rv2329c narK1 
PROBABLE NITRITE 
EXTRUSION PROTEIN 1 
NARK1 (NITRITE 
FACILITATOR 1) 
154, 251, 
380, 446 Yes TM       
Rv2330c lppP 
PROBABLE LIPOPROTEIN 
LPPP 28, 52   
SP, 
Lipo, 
TM 
MEM 8, MEM 9, 
CW 14   
Macrophage 
23 
Rv2333c stp 
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
TRANSPORT PROTEIN 
99, 290, 
297, 388, 
450, 503 Yes TM       
Rv2339 
mmpL
9 
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL9 
72, 193, 
202, 406, 
422, 877 Yes TM 
MEM 8, MEM 9, 
CW 12, CW 14 
BlaTEM 
20 in vitro 29 
Rv2345   
POSSIBLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
15, 22, 45, 
48, 74, 
103 Yes 
SP, 
TM 
CF 2, MEM 4, 
MEM 5, MEM 6, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15     
Rv2376c 
cfp2, 
mtb12 
LOW MOLECULAR 
WEIGHT ANTIGEN CFP2 
(LOW MOLECULAR 
WEIGHT PROTEIN 
ANTIGEN 2) (CFP-2) 21, 29, 51   
SP, 
TM 
CF 1, CF 2, CF 3, 
MEM 7, MEM 8, 
CW 12, CW 13, 
WCL 15, SOL 16     
Rv2380c mbtE 
PEPTIDE SYNTHETASE 
MBTE (PEPTIDE 
SYNTHASE)       
MEM 4, MEM 9, 
CW 13, SOL 16   
Mouse 27, in 
vitro 29 
Rv2387   
CONSERVED 
HYPOTHETICAL PROTEIN 55, 146 Yes TM 
MEM 8, MEM 9, 
CW 14   
Macaque 22, 
Mouse 25 
Rv2389c rpfD 
PROBABLE 
RESUSCITATION-
PROMOTING FACTOR 
RPFD 61   
SP, 
TM       
Rv2390c   
CONSERVED 
HYPOTHETICAL PROTEIN 45, 50, 64 Yes TM       
Rv2394 ggtB 
PROBABLE GAMMA-
GLUTAMYLTRANSPEPTID
ASE PRECURSOR GGTB 
(GAMMA-
GLUTAMYLTRANSFERASE
) (GLUTAMYL 
TRANSPEPTIDASE) 
18, 21, 31, 
65, 121, 
124, 126, 
151, 213, 
259, 266, 
270, 271, 
278, 396, 
525, 578 Yes 
SP, 
Tat 
SP, 
Lipo 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
8, MEM 9, MEM 
10, CW 13, CW 
14 
BlaTEM 
20   
Rv2395   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
95, 342, 
346, 347, 
485, 515   TM       
 245 
Rv2399c cysT 
PROBABLE SULFATE-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER CYST 
52, 143, 
145   TM MEM 9, CW 14   
in vitro 28, in 
vitro 29 
Rv2400c subI 
PROBABLE SULFATE-
BINDING LIPOPROTEIN 
SUBI 
74, 99, 
218, 232, 
354   Lipo 
CF 2, CF 3, MEM 
5, MEM 8, MEM 
9, CW 14   
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv2403c lppR 
PROBABLE CONSERVED 
LIPOPROTEIN LPPR 24   
SP, 
Lipo, 
TM MEM 9, CW 14     
Rv2434c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 143   TM       
Rv2435c   
PROBABLE CYCLASE 
(ADENYLYL-OR 
GUANYLYL-
)(ADENYLATE-OR 
GUANYLATE-) 
69, 148, 
155 Yes TM MEM 9     
Rv2437   
CONSERVED 
HYPOTHETICAL PROTEIN 91   TM     
Mouse 25, in 
vitro 28 
Rv2443 dctA 
PROBABLE C4-
DICARBOXYLATE-
TRANSPORT 
TRANSMEMBRANE 
PROTEIN DCTA 
46, 130, 
135   TM MEM 8, MEM 9 
BlaTEM 
20   
Rv2450c rpfE 
PROBABLE 
RESUSCITATION-
PROMOTING FACTOR 
RPFE 
22, 38, 
108, 116, 
127, 128 Yes SP, MEM 7 PhoA 17   
Rv2459   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
TRANSPORT PROTEIN 222, 306   TM     Macaque 22 
Rv2473   
POSSIBLE ALANINE AND 
PROLINE RICH 
MEMBRANE PROTEIN 115, 133 Yes 
SP, 
TM 
MEM 8, MEM 9, 
CW 14     
Rv2507   
POSSIBLE CONSERVED 
PROLINE RICH 
MEMBRANE PROTEIN 
148, 167, 
175, 183, 
207, 234 Yes TM MEM 8   
in vitro 28, in 
vitro 29 
Rv2508c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
LEUCINE AND ALANINE 
RICH PROTEIN 
117, 179, 
224, 232, 
297, 348 Yes TM MEM 8, MEM 9     
Rv2518c lppS 
PROBABLE CONSERVED 
LIPOPROTEIN LPPS 
34, 38, 81, 
157, 402 Yes 
SP, 
Lipo, 
TM 
MEM 8, MEM 9, 
CW 12, CW 14   
Mouse 27, in 
vitro 29 
Rv2519 PE26 PE FAMILY PROTEIN 255, 333   SP,       
Rv2536   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
32, 82, 86, 
102, 116   TM 
CF 3, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15   Mouse 27 
Rv2543 lppA 
PROBABLE CONSERVED 
LIPOPROTEIN LPPA 45   Lipo     Mouse 27 
Rv2544 lppB 
PROBABLE CONSERVED 
LIPOPROTEIN LPPB 45   Lipo MEM 7   Mouse 27 
Rv2553c   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
76, 78, 89, 
127 Yes TM 
CF 3, MEM 9, 
CW 14   
Mouse 25, 
Mouse 27, in 
vitro 29 
Rv2560   
PROBABLE PROLINE AND 
GLYCINE RICH 
TRANSMEMBRANE 
PROTEIN 
135, 170, 
174   TM MEM 8, MEM 9     
Rv2563   
PROBABLE GLUTAMINE-
TRANSPORT 
TRANSMEMBRANE 
PROTEIN ABC 
TRANSPORTER 
33, 59, 88, 
108, 117, 
165 Yes TM 
MEM 4, MEM 5, 
MEM 7, MEM 8, 
MEM 9, MEM 10, 
CW 13, CW 14   Mouse 27 
Rv2571c   
PROBABLE 
TRANSMEMBRANE 94 Yes TM MEM 9, CW 14     
 246 
ALANINE AND VALINE 
AND LEUCINE RICH 
PROTEIN 
Rv2575   
POSSIBLE CONSERVED 
MEMBRANE GLYCINE 
RICH PROTEIN 
46, 63, 72, 
100, 116, 
154, 287 Yes 
Tat 
SP, 
TM 
CF 2, CF 3, MEM 
7, MEM 8, CW 
14, SOL 16     
Rv2576c   
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 
95, 102, 
115, 117, 
144 Yes 
SP, 
TM 
CF 2, CF 3, MEM 
7, CW 12     
Rv2582 
ppiB, 
ppi 
PROBABLE PEPTIDYL-
PROLYL CIS-TRANS 
ISOMERASE B PPIB 
(CYCLOPHILIN) (PPIASE) 
(ROTAMASE) 
(PEPTIDYLPROLYL 
ISOMERASE) 
93, 95, 
130, 204, 
234, 242, 
284, 287 Yes TM 
CF 3, MEM 4, 
MEM 5, MEM 8, 
MEM 9, MEM 10, 
CW 13, CW 14, 
WCL 15   
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv2586c secF 
PROBABLE PROTEIN-
EXPORT MEMBRANE 
PROTEIN SECF 94, 130 Yes TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 14   in vitro 29 
Rv2587c secD 
PROBABLE PROTEIN-
EXPORT MEMBRANE 
PROTEIN SECD 
30, 35, 45, 
52, 83, 99, 
144, 268, 
304, 348 Yes TM 
MEM 5, MEM 8, 
MEM 9, MEM 10, 
CW 12, CW 13, 
CW 14, WCL 15 PhoA 18 in vitro 29 
Rv2599   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
108, 129, 
136   
SP, 
TM 
CF 2, MEM 8, 
MEM 9, CW 14 
BlaTEM 
20   
Rv2615c 
PE_PG
RS45 PE-PGRS FAMILY PROTEIN 303   SP,       
Rv2617c   
PROBABLE 
TRANSMEMBRANE 
PROTEIN 109, 111   TM 
MEM 8, MEM 9, 
CW 14     
Rv2639c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
62, 70, 
107   TM   
BlaTEM 
20   
Rv2643 arsC 
PROBABLE ARSENIC-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN 
ARSC 
121, 256, 
326   TM CW 14     
Rv2668   
POSSIBLE EXPORTED 
ALANINE AND VALINE 
RICH PROTEIN 
28, 44, 70, 
107, 129   SP, 
CF 2, CF 3, MEM 
7     
Rv2672   
POSSIBLE SECRETED 
PROTEASE 
89, 135, 
209, 223, 
230, 327, 
330, 334, 
369, 373, 
526 Yes 
SP, 
Lipo, 
TM 
CF 2, CF 3, MEM 
5, MEM 7, MEM 
8, MEM 9, MEM 
10, CW 13, CW 
14   Mouse 27 
Rv2684 arsA 
PROBABLE ARSENIC-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN 
ARSA 50   TM MEM 9     
Rv2686c   
PROBABLE ANTIBIOTIC-
TRANSPORT INTEGRAL 
MEMBRANE LEUCINE 
AND ALANINE AND 
VALINE RICH PROTEIN 
ABC TRANSPORTER 135   TM     Macaque 22 
Rv2690c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
ALANINE AND VALINE 
AND LEUCINE RICH 
PROTEIN 
205, 283, 
394, 463 Yes TM MEM 9, CW 14   
Macaque 22, 
Mouse 27, in 
vitro 29 
Rv2698   
PROBABLE CONSERVED 
ALANINE RICH 
TRANSMEMBRANE 
PROTEIN 58 Yes TM 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv2700   
POSSIBLE CONSERVED 
SECRETED ALANINE RICH 
PROTEIN 
84, 120, 
128, 196, 
204   TM 
CF 3, MEM 5, 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv2719c   POSSIBLE CONSERVED 93, 94, Yes TM       
 247 
MEMBRANE PROTEIN 104 
Rv2721c   
POSSIBLE CONSERVED 
TRANSMEMBRANE 
ALANINE AND GLYCINE 
RICH PROTEIN 
46, 77, 78, 
87, 104, 
133, 152, 
222, 235, 
250, 269, 
315, 334, 
339, 370, 
387, 395, 
413 Yes 
SP, 
TM 
CF 2, CF 3, MEM 
5, MEM 7, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
13, CW 14 
BlaTEM 
20   
Rv2723   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
59, 122, 
231, 287, 
313   TM MEM 8     
Rv2729c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
ALANINE VALINE AND 
LEUCINE RICH PROTEIN 
127, 226, 
287, 288   TM       
Rv2732c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
53, 57, 68, 
130 Yes 
Tat 
SP, 
TM 
MEM 8, MEM 9, 
CW 14     
Rv2746c pgsA3 
PROBABLE PGP 
SYNTHASE PGSA3 (CDP-
DIACYLGLYCEROL--
GLYCEROL-3-PHOSPHATE 
3-
PHOSPHATIDYLTRANSFER
ASE) 
(PHOSPHATIDYLGLYCERO
PHOSPHATE SYNTHASE) 
50, 55, 67, 
179 Yes TM 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv2748c ftsK 
POSSIBLE CELL DIVISION 
TRANSMEMBRANE 
PROTEIN FTSK 168, 246 Yes TM 
MEM 9, CW 11, 
CW 12, CW 14 PhoA 18 
in vitro 28, in 
vitro 29 
Rv2772c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 41, 64   
Tat 
SP, 
TM 
MEM 8, MEM 9, 
CW 14     
Rv2784c lppU 
PROBABLE LIPOPROTEIN 
LPPU 165, 166   
SP, 
Lipo MEM 8, MEM 9     
Rv2796c lppV 
PROBABLE CONSERVED 
LIPOPROTEIN LPPV 18, 27, 86   
SP, 
Lipo MEM 9, CW 14   Macaque 22 
Rv2799   
PROBABLE MEMBRANE 
PROTEIN 
47, 48, 57, 
140, 144   TM 
CF 2, CF 3, MEM 
7, CW 14     
Rv2806   
POSSIBLE MEMBRANE 
PROTEIN 38   TM       
Rv2835c ugpA 
PROBABLE Sn-GLYCEROL-
3-PHOSPHATE TRANSPORT 
INTEGRAL MEMBRANE 
PROTEIN ABC 
TRANSPORTER UGPA 247, 271   TM       
Rv2843   
PROBABLE CONSERVED 
TRANSMEMBRANE 
ALANINE RICH PROTEIN 44, 65   
SP, 
Tat 
SP, 
Lipo, 
TM 
MEM 8, MEM 9, 
CW 14 BlaC 19   
Rv2846c efpA 
POSSIBLE INTEGRAL 
MEMBRANE EFFLUX 
PROTEIN EFPA 
87, 94, 
160, 186   TM MEM 8, MEM 9   
in vitro 28, in 
vitro 29 
Rv2856 nicT 
POSSIBLE NICKEL-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN 
NICT 
51, 57, 
152, 328 Yes TM     in vitro 28 
Rv2864c   
POSSIBLE PENICILLIN-
BINDING LIPOPROTEIN 
31, 40, 47, 
49 Yes 
SP, 
Lipo MEM 9, CW 12     
Rv2869c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
155, 165, 
223, 238, 
250, 259, 
285, 392   TM 
CF 2, MEM 8, 
MEM 9, CW 14   
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv2873 
mpt83, 
mpb83 
CELL SURFACE 
LIPOPROTEIN MPT83 
(LIPOPROTEIN P23) 
54, 118, 
198   
SP, 
Lipo 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM     
 248 
9, MEM 10, CW 
13, CW 14, WCL 
15 
Rv2874 dipZ 
POSSIBLE INTEGRAL 
MEMBRANE C-TYPE 
CYTOCHROME 
BIOGENESIS PROTEIN 
DIPZ 
143, 353, 
362, 396, 
406, 412, 
545, 583 Yes TM MEM 7     
Rv2877c , merT 
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 75, 158   TM MEM 8, MEM 9     
Rv2903c lepB 
PROBABLE SIGNAL 
PEPTIDASE I LEPB (SPASE 
I) (LEADER PEPTIDASE I). 179, 229   TM 
MEM 5, MEM 8, 
MEM 9, CW 14 PhoA 18 
in vitro 28, in 
vitro 29 
Rv2905 lppW 
PROBABLE CONSERVED 
ALANINE RICH 
LIPOPROTEIN LPPW 
85, 115, 
166, 212   
SP, 
Lipo MEM 7, CW 14 
BlaTEM 
20   
Rv2911 
dacB2, 
dacB 
PROBABLE D-ALANYL-D-
ALANINE 
CARBOXYPEPTIDASE 
DACB2 (PENICILLIN-
BINDING PROTEIN) (DD-
PEPTIDASE) (DD-
CARBOXYPEPTIDASE) 
(PBP) (DD-
TRANSPEPTIDASE) 
(SERINE-TYPE D-ALA-D-
ALA 
CARBOXYPEPTIDASE) (D-
AMINO ACID 
HYDROLASE) 
21, 31, 51, 
56, 66, 
127, 168, 
169, 171, 
243, 246 Yes 
SP, 
Tat 
SP 
CF 2, CF 3, MEM 
7, CW 13, CW 14, 
SOL 16   Macaque 22 
Rv2914c pknI 
PROBABLE 
TRANSMEMBRANE 
SERINE/THREONINE-
PROTEIN KINASE I PKNI 
(PROTEIN KINASE I) (STPK 
I) (PHOSPHORYLASE B 
KINASE KINASE) 
(HYDROXYALKYL-
PROTEIN KINASE) 376, 582 Yes TM MEM 9, CW 14     
Rv2920c amt 
PROBABLE AMMONIUM-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN 
AMT 
79, 105, 
175, 179, 
192, 195, 
201, 257, 
382, 428 Yes TM MEM 8   Macaque 22 
Rv2938 drrC 
PROBABLE 
DAUNORUBICIN-DIM-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER DRRC 235   TM 
MEM 8, MEM 9, 
CW 12, CW 14 
BlaTEM 
20 Mouse 25 
Rv2942 
mmpL
7 
CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 
MMPL7 
95, 276, 
420, 438, 
487 Yes TM 
MEM 5, MEM 8, 
MEM 9, MEM 10, 
CW 14   
Macrophage 
23, Mouse 25 
Rv2945c lppX 
PROBABLE CONSERVED 
LIPOPROTEIN LPPX 47 Yes 
SP, 
Lipo, 
TM 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM 
9, MEM 10, CW 
12, CW 13, CW 
14, WCL 15, SOL 
16 
PhoA 18, 
BlaTEM 
20 
Mouse 25, 
Mouse 27 
Rv2963   
PROBABLE INTEGRAL 
MEMBRANE PROTEIN 127, 347   TM MEM 8, MEM 9     
Rv2968c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 64   TM MEM 6   
in vitro 28, in 
vitro 29 
Rv2969c   
POSSIBLE CONSERVED 
MEMBRANE OR 
SECRETED PROTEIN 
56, 71, 91, 
96 Yes TM 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
8, MEM 9, MEM   
in vitro 28, in 
vitro 29 
 249 
10, CW 12, CW 
13, CW 14, WCL 
15 
Rv2972c   
POSSIBLE CONSERVED 
MEMBRANE OR 
EXPORTED PROTEIN 35, 45, 51 Yes 
SP, 
Tat 
SP, 
TM MEM 9     
Rv2994   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
42, 113, 
114, 120, 
248, 331, 
392 Yes TM 
MEM 7, MEM 8, 
MEM 9, CW 14     
Rv2999 lppY 
PROBABLE CONSERVED 
LIPOPROTEIN LPPY 
36, 68, 95, 
160, 194, 
246 Yes 
SP, 
Lipo 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
CW 14   in vitro 28 
Rv3005c   
CONSERVED 
HYPOTHETICAL PROTEIN 166, 171 Yes TM MEM 9, CW 14   Mouse 27 
Rv3006 lppZ 
PROBABLE CONSERVED 
LIPOPROTEIN LPPZ 
21, 95, 
118, 198, 
232, 343 Yes 
SP, 
Lipo 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM 
9, MEM 10, CW 
12, CW 13, CW 
14, WCL 15   in vitro 29 
Rv3016 lpqA 
PROBABLE LIPOPROTEIN 
LPQA 
24, 32, 55, 
57, 129   
SP, 
Lipo 
CF 2, MEM 7, 
CW 14     
Rv3033   HYPOTHETICAL PROTEIN 
46, 52, 53, 
167   SP, 
CF 2, CF 3, MEM 
4, MEM 7, MEM 
8, MEM 9, CW 
13, CW 14   
Macrophage 
23 
Rv3035   
CONSERVED 
HYPOTHETICAL PROTEIN 
2, 9, 20, 
44, 48, 
133, 149, 
224, 254, 
259, 285, 
307, 328 Yes   
MEM 8, MEM 9, 
CW 14   in vitro 29 
Rv3036c TB22.2 
PROBABLE CONSERVED 
SECRETED PROTEIN 
TB22.2 
27, 30, 35, 
100, 148, 
168, 172, 
178 Yes SP, 
CF 1, CF 2, CF 3, 
MEM 7, CW 14, 
WCL 15, SOL 16 
BlaTEM 
20 Mouse 27 
Rv3043c ctaD 
PROBABLE CYTOCHROME 
C OXIDASE POLYPEPTIDE 
I CTAD (CYTOCHROME 
AA3 SUBUNIT 1) 
66, 68, 
137, 143, 
165, 371   TM 
MEM 5, MEM 8, 
MEM 9, MEM 10, 
CW 13, CW 14, 
WCL 15   
in vitro 28, in 
vitro 29 
Rv3044 fecB 
PROBABLE FEIII-
DICITRATE-BINDING 
PERIPLASMIC 
LIPOPROTEIN FECB 
40, 60, 
113, 135, 
179, 195, 
208, 276   
SP, 
Lipo 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 9, MEM 
10, CW 13, CW 
14, WCL 15   
Mouse 27, in 
vitro 29 
Rv3063 cstA 
PROBABLE CARBON 
STARVATION PROTEIN A 
HOMOLOG CSTA 
269, 348, 
357, 441, 
464, 477, 
478, 578 Yes 
Tat 
SP, 
TM       
Rv3064c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 52, 56   TM       
Rv3067   
CONSERVED 
HYPOTHETICAL PROTEIN 
29, 41, 44, 
67, 76 Yes   CF 2     
Rv3090   
HYPOTHETICAL ALANINE 
AND VALINE RICH 
PROTEIN 
71, 119, 
133, 166, 
188, 197   TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, SOL 16 
BlaTEM 
20   
Rv3092c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
113, 123, 
134, 144   TM 
MEM 8, MEM 9, 
CW 14     
Rv3103c   
HYPOTHETICAL PROLINE-
RICH PROTEIN 127   TM   
BlaTEM 
20 Mouse 25 
Rv3123   HYPOTHETICAL PROTEIN 145     MEM 9     
Rv3152 nuoH 
PROBABLE NADH 
DEHYDROGENASE I 
(CHAIN H) NUOH (NADH- 280, 289 Yes 
Tat 
SP, 
TM 
MEM 8, MEM 9, 
CW 14     
 250 
UBIQUINONE 
OXIDOREDUCTASE CHAIN 
H) 
Rv3156 nuoL 
PROBABLE NADH 
DEHYDROGENASE I 
(CHAIN L) NUOL (NADH-
UBIQUINONE 
OXIDOREDUCTASE CHAIN 
L) 
75, 76, 77, 
211, 233, 
354, 414, 
422   TM 
MEM 8, MEM 9, 
CW 14     
Rv3157 nuoM 
PROBABLE NADH 
DEHYDROGENASE I 
(CHAIN M) NUOK (NADH-
UBIQUINONE 
OXIDOREDUCTASE CHAIN 
M) 
74, 218, 
233, 530 Yes 
SP, 
Tat 
SP, 
TM 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15   in vitro 29 
Rv3158 nuoN 
PROBABLE NADH 
DEHYDROGENASE I 
(CHAIN N) NUON (NADH-
UBIQUINONE 
OXIDOREDUCTASE CHAIN 
N) 
368, 447, 
450, 451   TM 
MEM 5, MEM 7, 
MEM 8, MEM 9, 
CW 14     
Rv3165c   HYPOTHETICAL PROTEIN 29 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv3166c   
CONSERVED 
HYPOTHETICAL PROTEIN 
29, 43, 44, 
58, 137 Yes TM MEM 9, CW 14   Mouse 27 
Rv3193c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
142, 239, 
300, 328, 
451, 529, 
531, 678 Yes TM 
CF 3, MEM 4, 
MEM 5, MEM 7, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15, SOL 16   
Mouse 27, in 
vitro 29 
Rv3194c   
POSSIBLE CONSERVED 
SECRETED PROTEIN 
33, 111, 
119, 152, 
171, 194, 
238, 264 Yes 
SP, 
TM 
CF 3, MEM 5, 
MEM 7, MEM 8, 
MEM 9, CW 14   Mouse 27 
Rv3207c   
CONSERVED 
HYPOTHETICAL PROTEIN 
33, 50, 58, 
120, 152, 
204   
SP, 
TM 
CF 2, MEM 9, 
CW 14   Mouse 27 
Rv3209   
CONSERVED 
HYPOTHETICAL 
THREONIN AND PROLINE 
RICH PROTEIN 70, 81 Yes SP,   
BlaTEM 
20 Mouse 27 
Rv3217c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
47, 55, 60, 
61 Yes TM       
Rv3236c , kefB 
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
TRANSPORT PROTEIN 51, 53, 59   TM MEM 8, CW 14   Mouse 25 
Rv3239c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
TRANSPORT PROTEIN 446   
Tat 
SP, 
TM       
Rv3244c lpqB 
PROBABLE CONSERVED 
LIPOPROTEIN LPQB 
174, 232, 
336   
SP, 
Lipo 
CF 2, CF 3, MEM 
5, MEM 7, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
14, SOL 16   
in vitro 28, in 
vitro 29 
Rv3245c mtrB 
TWO COMPONENT 
SENSORY TRANSDUCTION 
HISTIDINE KINASE MTRB 
88, 116, 
154, 175   TM MEM 9, CW 14   
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv3252c alkB 
PROBABLE 
TRANSMEMBRANE 
ALKANE 1-
MONOOXYGENASE ALKB 
(ALKANE 1-
HYDROXYLASE) (LAURIC 
ACID OMEGA-
HYDROXYLASE) (OMEGA-
HYDROXYLASE) (FATTY 
ACID OMEGA- 55   TM MEM 9     
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HYDROXYLASE) (ALKANE 
HYDROXYLASE-
RUBREDOXIN) 
Rv3253c   
POSSIBLE CATIONIC 
AMINO ACID TRANSPORT 
INTEGRAL MEMBRANE 
PROTEIN 
49, 52, 
199, 215, 
227, 241, 
314, 325, 
334, 413, 
453, 468 Yes TM MEM 9 
BlaTEM 
20   
Rv3267   
CONSERVED 
HYPOTHETICAL PROTEIN 
(CPSA-RELATED PROTEIN) 28, 87 Yes 
SP, 
TM 
CF 2, CF 3, MEM 
7, MEM 9, MEM 
10, CW 13, CW 
14 
PhoA 18, 
BlaTEM 
20 
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv3271c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
62, 68, 83, 
89, 120, 
203 Yes TM MEM 9, CW 14   in vitro 28 
Rv3273   
PROBABLE 
TRANSMEMBRANE 
CARBONIC ANHYDRASE 
(CARBONATE 
DEHYDRATASE) 
(CARBONIC 
DEHYDRATASE) 
55, 61, 69, 
73, 366 Yes TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15     
Rv3274c fadE25 
PROBABLE ACYL-CoA 
DEHYDROGENASE FADE25 316     
CF 2, CF 3, MEM 
4, MEM 5, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
13, CW 14, WCL 
15, SOL 16   Mouse 27 
Rv3278c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 42 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv3289c   
POSSIBLE 
TRANSMEMBRANE 
PROTEIN 52   TM       
Rv3298c lpqC 
POSSIBLE ESTERASE 
LIPOPROTEIN LPQC 
19, 49, 53, 
63, 65, 67, 
81, 120, 
131, 137, 
252 Yes 
SP, 
Lipo 
MEM 5, MEM 8, 
MEM 9, CW 14     
Rv3310   
POSSIBLE ACID 
PHOSPHATASE (ACID 
PHOSPHOMONOESTERASE
) 
(PHOSPHOMONOESTERAS
E) 
(GLYCEROPHOSPHATASE) 
78, 118, 
131, 186, 
258   
SP, 
TM 
CF 2, CF 3, MEM 
7, MEM 8     
Rv3312A mtp 
SECRETED PROTEIN 
ANTIGEN 32, 48, 77   
SP, 
TM 
CF 3, WCL 15, 
SOL 16     
Rv3316 sdhC 
PROBABLE SUCCINATE 
DEHYDROGENASE 
(CYTOCHROME B-556 
SUBUNIT) SDHC 
(SUCCINIC 
DEHYDROGENASE) 
(FUMARATE REDUCTASE) 
(FUMARATE 
DEHYDROGENASE) 
(FUMARIC 
HYDROGENASE) 24   TM MEM 8, MEM 9   Mouse 27 
Rv3330 dacB1 
PROBABLE PENICILLIN-
BINDING PROTEIN DACB1 
(D-ALANYL-D-ALANINE 
CARBOXYPEPTIDASE) 
(DD-PEPTIDASE) (DD-
CARBOXYPEPTIDASE) 
(PBP) (DD-
TRANSPEPTIDASE) 
(SERINE-TYPE D-ALA-D-
24, 26, 31, 
52, 54, 69, 
76, 80, 88, 
108, 141, 
158, 192, 
215 Yes 
SP, 
TM 
CF 2, MEM 9, 
CW 14     
 252 
ALA 
CARBOXYPEPTIDASE) (D-
AMINO ACID 
HYDROLASE) 
Rv3331 sugI 
PROBABLE SUGAR-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN 
SUGI 
200, 212, 
312, 332 Yes TM MEM 9, CW 14     
Rv3343c PPE54 PPE FAMILY PROTEIN 555         
in vitro 28, in 
vitro 29 
Rv3350c PPE56 PPE FAMILY PROTEIN 3387         in vitro 29 
Rv3354   
CONSERVED 
HYPOTHETICAL PROTEIN 
26, 40, 45, 
113, 126   
SP, 
TM MEM 7     
Rv3365c   
CONSERVED 
HYPOTHETICAL PROTEIN 
79, 104, 
116, 145, 
203, 215, 
232, 370 Yes TM MEM 9, CW 14     
Rv3390 lpqD 
PROBABLE CONSERVED 
LIPOPROTEIN LPQD 
25, 57, 59, 
95, 96, 
100, 118, 
154, 164 Yes 
SP, 
Lipo, 
TM 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14 
BlaTEM 
20   
Rv3395A   
PROBABLE MEMBRANE 
PROTEIN 
28, 30, 60, 
103 Yes 
SP, 
TM CF 2   Mouse 27 
Rv3413c   
HYPOTHETICAL ALANINE 
AND PROLINE RICH 
PROTEIN 
110, 200, 
277 Yes TM 
CF 2, CF 3, MEM 
7 
BlaTEM 
20   
Rv3434c   
POSSIBLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 44, 191   TM     Mouse 27 
Rv3435c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
27, 106, 
116, 119 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv3451 cut3 
PROBABLE CUTINASE 
PRECURSOR CUT3 
52, 54, 58, 
87, 134, 
169, 198, 
203, 227, 
241 Yes 
SP, 
TM CF 2, MEM 8     
Rv3452 cut4 
PROBABLE CUTINASE 
PRECURSOR CUT4 
36, 55, 57, 
124, 137, 
142, 152, 
159, 172 Yes 
SP, 
TM       
Rv3476c kgtP 
PROBABLE 
DICARBOXYLIC ACID 
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN 
KGTP (DICARBOXYLATE 
TRANSPORTER) 284   TM MEM 8 
BlaTEM 
20   
Rv3478 
PPE60, 
mtb39c PE FAMILY PROTEIN 155, 177     
MEM 8, MEM 9, 
CW 13, CW 14     
Rv3481c   
PROBABLE INTEGRAL 
MEMBRANE PROTEIN 
62, 69, 73, 
147, 158   TM MEM 8, MEM 9     
Rv3482c   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 104, 109   TM 
MEM 5, MEM 9, 
CW 14     
Rv3483c   
CONSERVED 
HYPOTHETICAL PROTEIN 
52, 70, 
126, 154   TM 
MEM 5, MEM 8, 
MEM 9, CW 14     
Rv3484 cpsA 
POSSIBLE CONSERVED 
PROTEIN CPSA 
39, 51, 67, 
105, 193, 
206, 216, 
231, 236, 
237, 321, 
348, 384, 
395, 401, 
452, 487 Yes TM 
CF 2, MEM 7, 
MEM 8 
BlaTEM 
20 
Macrophage 
24, Mouse 
25, Mouse 
27, in vitro 
29 
Rv3491   HYPOTHETICAL PROTEIN 
24, 44, 47, 
54, 101   
SP, 
TM CF 2, MEM 7   Mouse 27 
Rv3492c   
CONSERVED 
HYPOTHETICAL MCE 
ASSOCIATED PROTEIN 19, 21 Yes 
SP, 
TM MEM 9, CW 14     
Rv3493c   CONSERVED 118, 150,   TM MEM 5, MEM 9,   Mouse 27 
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HYPOTHETICAL MCE 
ASSOCIATED ALANINE 
AND VALINE RICH 
PROTEIN 
180, 230 CW 14 
Rv3494c mce4F 
MCE-FAMILY PROTEIN 
MCE4F 
31, 48, 60, 
171, 354, 
363 Yes TM 
CF 3, MEM 9, 
CW 14 
BlaTEM 
20 
Macaque 22, 
Mouse 27 
Rv3496c mce4D 
MCE-FAMILY PROTEIN 
MCE4D 
35, 418, 
448   TM 
MEM 9, CW 12, 
CW 14 
BlaTEM 
20 Mouse 27 
Rv3497c mce4C 
MCE-FAMILY PROTEIN 
MCE4C 
53, 58, 78, 
120, 303, 
305, 316 Yes TM 
MEM 5, MEM 8, 
MEM 9, CW 14 
BlaTEM 
20 
Mouse 25, 
Mouse 27 
Rv3498c mce4B 
MCE-FAMILY PROTEIN 
MCE4B 
27, 63, 
137, 302 Yes 
SP, 
TM MEM 9, CW 14 
BlaTEM 
20 Mouse 27 
Rv3499c 
mce4A, 
mce4 
MCE-FAMILY PROTEIN 
MCE4A 
24, 49, 87, 
102, 171, 
196, 215, 
216 Yes 
SP, 
TM 
MEM 6, MEM 9, 
CW 14   Mouse 25 
Rv3500c yrbE4B 
CONSERVED 
HYPOTHETICAL 
INTEGRAL MEMBRANE 
PROTEIN YRBE4B 
78, 99, 
193, 272   TM 
MEM 8, MEM 9, 
CW 14     
Rv3501c 
yrbE4
A 
CONSERVED 
HYPOTHETICAL 
INTEGRAL MEMBRANE 
PROTEIN YRBE4A 
74, 78, 80, 
159, 160, 
184, 244 Yes TM 
MEM 8, MEM 9, 
CW 14   Mouse 25 
Rv3507 
PE_PG
RS53 PE-PGRS FAMILY PROTEIN 820, 1320   
SP, 
Tat 
SP       
Rv3524   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
122, 132, 
149, 174, 
248, 257, 
274, 275, 
300, 311   TM MEM 9, CW 14     
Rv3526   
POSSIBLE 
OXIDOREDUCTASE 381           
Rv3554 fdxB 
POSSIBLE ELECTRON 
TRANSFER PROTEIN FDXB 65   TM MEM 9, CW 14     
Rv3572   HYPOTHETICAL PROTEIN 
24, 74, 
129, 139 Yes SP, 
CF 2, CF 3, MEM 
7, MEM 8, CW 14     
Rv3576 
lppH, 
pknM 
POSSIBLE CONSERVED 
LIPOPROTEIN LPPH 
18, 27, 34, 
59, 102, 
135, 163, 
168, 190 Yes 
SP, 
Lipo 
CF 3, MEM 8, 
MEM 9, CW 14     
Rv3578 arsB2 
POSSIBLE ARSENICAL 
PUMP INTEGRAL 
MEMBRANE PROTEIN 
ARSB2 
293, 297, 
302, 307   
SP, 
TM     Mouse 27 
Rv3584 lpqE 
POSSIBLE CONSERVED 
LIPOPROTEIN LPQE 
27, 106, 
112, 114, 
163 Yes 
SP, 
Lipo, 
TM 
CF 2, CF 3, MEM 
4, MEM 5, MEM 
7, MEM 8, MEM 
9, MEM 10, CW 
12, CW 13, CW 
14, WCL 15 
BlaTEM 
20   
Rv3587c   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
44, 95, 
156 Yes 
SP, 
TM 
CF 2, CF 3, MEM 
7, MEM 8, MEM 
9, CW 14   in vitro 29 
Rv3593 lpqF 
PROBABLE CONSERVED 
LIPOPROTEIN LPQF 
38, 82, 
104, 186, 
231 Yes 
SP, 
Lipo     
in vitro 28, in 
vitro 29 
Rv3596c 
clpC1, 
clpC 
PROBABLE ATP-
DEPENDENT PROTEASE 
ATP-BINDING SUBUNIT 
CLPC1 598     
CF 3, MEM 4, 
MEM 6, MEM 8, 
MEM 9, MEM 10, 
CW 12, CW 13, 
CW 14, WCL 15, 
SOL 16   
Macrophage 
23, 
Macrophage 
24, in vitro 
28, in vitro 
29 
Rv3604c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN RICH IN 33 Yes TM 
MEM 6, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
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ALANINE AND ARGININE 
AND PROLINE 
Rv3610c ftsH 
MEMBRANE-BOUND 
PROTEASE FTSH (CELL 
DIVISION PROTEIN) 30, 84   TM 
MEM 4, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15   
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv3623 lpqG 
PROBABLE CONSERVED 
LIPOPROTEIN LPQG 
42, 61, 
112, 116, 
144, 145, 
214, 223   
SP, 
Lipo 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15, SOL 16     
Rv3627c   
CONSERVED 
HYPOTHETICAL PROTEIN 
27, 62, 68, 
72, 96, 
139, 140, 
163, 200, 
228, 260, 
335, 381, 
401, 408, 
438 Yes 
SP, 
TM 
CF 2, MEM 5, 
MEM 7, MEM 8, 
MEM 9, CW 14   
in vitro 28, in 
vitro 29 
Rv3629c   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 
27, 89, 
124, 200, 
333 Yes TM MEM 7     
Rv3635   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
43, 64, 
397, 423   TM MEM 9   
in vitro 28, in 
vitro 29 
Rv3654c   
CONSERVED 
HYPOTHETICAL PROTEIN 16, 18, 23           
Rv3655c   
CONSERVED 
HYPOTHETICAL PROTEIN 42   
SP, 
TM       
Rv3664c dppC 
PROBABLE DIPEPTIDE-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER DPPC 38   
SP, 
TM     
Macrophage 
24, Mouse 27 
Rv3665c dppB 
PROBABLE DIPEPTIDE-
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER DPPB 
30, 70, 
129   TM     
Mouse 27, in 
vitro 29 
Rv3666c dppA 
PROBABLE PERIPLASMIC 
DIPEPTIDE-BINDING 
LIPOPROTEIN DPPA 
22, 25, 38, 
48, 64, 97, 
154, 215, 
254, 261, 
288 Yes 
SP, 
Lipo, 
TM 
CF 2, MEM 8, 
CW 12, CW 14   
Mouse 27, in 
vitro 28 
Rv3667 acs 
ACETYL-COENZYME A 
SYNTHETASE ACS 
(ACETATE--CoA LIGASE) 
(ACETYL-CoA 
SYNTHETASE) (ACETYL-
CoA SYNTHASE) (ACYL-
ACTIVATING ENZYME) 
(ACETATE THIOKINASE) 
(ACETYL-ACTIVATING 
ENZYME) (ACETATE--
COENZYME A LIGASE) 
(ACETYL-COENZYME A 
SYNTHASE)       
MEM 4, MEM 9, 
CW 13, CW 14, 
WCL 15, SOL 16     
Rv3668c   POSSIBLE PROTEASE 
25, 35, 92, 
144 Yes 
SP, 
TM 
CF 2, CF 3, MEM 
7 PhoA 17 Mouse 27 
Rv3671c   
POSSIBLE MEMBRANE-
ASSOCIATED SERINE 
PROTEASE 
63, 166, 
296, 305, 
391 Yes TM 
CF 2, CF 3, MEM 
5, MEM 7, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
13, CW 14, WCL 
15, SOL 16   
Mouse 27, in 
vitro 29 
Rv3673c   
POSSIBLE MEMBRANE-
ANCHORED 
THIOREDOXIN-LIKE 
PROTEIN (THIOL-
DISULFIDE INTERCHANGE 
RELATED PROTEIN) 44, 53, 92   TM 
MEM 8, MEM 9, 
CW 14   in vitro 29 
Rv3682 ponA2 PROBABLE 33, 117, Yes SP, CF 2, CF 3, MEM   Macrophage 
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BIFUNCTIONAL 
MEMBRANE-ASSOCIATED 
PENICILLIN-BINDING 
PROTEIN 1A/1B PONA2 
(MUREIN POLYMERASE) 
[INCLUDES: PENICILLIN-
INSENSITIVE 
TRANSGLYCOSYLASE 
(PEPTIDOGLYCAN TGASE) 
+ PENICILLIN-SENSITIVE 
TRANSPEPTIDASE (DD-
TRANSPEPTIDASE)] 
124, 130, 
285, 290, 
317, 335, 
346, 379, 
395, 405, 
432, 466, 
597, 613, 
734, 746 
TM 4, MEM 7, MEM 
8, MEM 9, MEM 
10, CW 12, CW 
14 
23, Mouse 27 
Rv3691   
CONSERVED 
HYPOTHETICAL PROTEIN 2     
MEM 4, MEM 8, 
MEM 9, CW 14     
Rv3694c   
POSSIBLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
128, 153, 
197   TM 
MEM 8, MEM 9, 
CW 14     
Rv3695   
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 
45, 56, 
123   TM 
MEM 8, MEM 9, 
CW 14     
Rv3701c   
CONSERVED 
HYPOTHETICAL PROTEIN       MEM 9, CW 14   
Macrophage 
23, Mouse 25 
Rv3705A   
CONSERVED 
HYPOTHETICAL PROLINE 
RICH PROTEIN 
82, 93, 94, 
103, 123 Yes TM MEM 9     
Rv3705c   
CONSERVED 
HYPOTHETICAL PROTEIN 
29, 153, 
169, 194, 
197, 199, 
205 Yes SP, 
CF 2, CF 3, MEM 
7, MEM 8, SOL 
16     
Rv3706c   
CONSERVED 
HYPOTHETICAL PROLINE 
RICH PROTEIN 
43, 51, 54, 
78, 90, 
100, 103   TM       
Rv3707c   
CONSERVED 
HYPOTHETICAL PROTEIN 42     MEM 9     
Rv3717   
CONSERVED 
HYPOTHETICAL PROTEIN 15, 24, 48 Yes SP, CF 2, CW 14   
Mouse 25, 
Mouse 27 
Rv3723   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
35, 97, 
108, 109 Yes TM 
MEM 5, MEM 8, 
MEM 9, MEM 10, 
CW 13, CW 14, 
WCL 15   
Macrophage 
23, Mouse 25 
Rv3724A cut5a 
PROBABLE CUTINASE 
PRECURSOR [FIRST PART] 
CUT5A 33   SP,       
Rv3732   
CONSERVED 
HYPOTHETICAL PROTEIN 
34, 90, 
117, 122, 
127, 149   
SP, 
TM 
CF 3, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, WCL 15     
Rv3737   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
228, 233, 
238, 292 Yes TM MEM 9     
Rv3756c proZ 
POSSIBLE 
OSMOPROTECTANT 
(GLYCINE 
BETAINE/CARNITINE/CHO
LINE/L-PROLINE) 
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER PROZ 109   TM MEM 8     
Rv3757c proW 
POSSIBLE 
OSMOPROTECTANT 
(GLYCINE 
BETAINE/CARNITINE/CHO
LINE/L-PROLINE) 
TRANSPORT INTEGRAL 
MEMBRANE PROTEIN ABC 
TRANSPORTER PROW 167, 180   TM     
Macrophage 
24, Mouse 27 
Rv3759c proX 
POSSIBLE 
OSMOPROTECTANT 
(GLYCINE 
BETAINE/CARNITINE/CHO
36, 46, 
126, 146, 
149, 165, 
181, 205, Yes 
SP, 
Lipo 
CF 2, CF 3, MEM 
7, MEM 9, CW 14   Mouse 27 
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LINE/L-PROLINE) BINDING 
LIPOPROTEIN PROX 
248 
Rv3760   
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 44   TM 
MEM 7, MEM 9, 
CW 14     
Rv3763 lpqH 
19 KDA LIPOPROTEIN 
ANTIGEN PRECURSOR 
LPQH 
19, 30, 35, 
43, 45, 47, 
61, 68, 70, 
78, 82, 
134 Yes 
SP, 
Lipo 
CF 1, CF 2, CF 3, 
MEM 4, MEM 5, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15, SOL 16 PhoA 18   
Rv3779   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN ALANINE AND 
LEUCINE RICH 
61, 64, 
303, 360, 
439, 546, 
561, 657 Yes TM MEM 9, CW 14 
BlaTEM 
20   
Rv3789   
POSSIBLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 103   TM MEM 8   in vitro 29 
Rv3792   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
141, 338, 
491 Yes TM 
MEM 6, MEM 8, 
MEM 9, CW 12, 
CW 14   
in vitro 28, in 
vitro 29 
Rv3793 embC 
INTEGRAL MEMBRANE 
INDOLYLACETYLINOSITO
L 
ARABINOSYLTRANSFERA
SE EMBC 
(ARABINOSYLINDOLYLAC
ETYLINOSITOL 
SYNTHASE) 
55, 437, 
662, 794, 
819, 1028   TM 
CF 3, MEM 8, 
MEM 9, MEM 10, 
CW 13, CW 14   
Macaque 22, 
in vitro 28, in 
vitro 29 
Rv3794 embA 
INTEGRAL MEMBRANE 
INDOLYLACETYLINOSITO
L 
ARABINOSYLTRANSFERA
SE EMBA 
(ARABINOSYLINDOLYLAC
ETYLINOSITOL 
SYNTHASE) 
39, 49, 58, 
63, 82, 
144, 145, 
156, 158, 
182, 198, 
319, 577, 
587, 656, 
727 Yes TM 
MEM 5, MEM 8, 
MEM 9, MEM 10, 
CW 13, CW 14 PhoA 18 
Macrophage 
23, Mouse 
25, in vitro 
29 
Rv3795 embB 
INTEGRAL MEMBRANE 
INDOLYLACETYLINOSITO
L 
ARABINOSYLTRANSFERA
SE EMBB 
(ARABINOSYLINDOLYLAC
ETYLINOSITOL 
SYNTHASE) 
79, 197, 
599   TM 
MEM 8, MEM 9, 
CW 14   
in vitro 28, in 
vitro 29 
Rv3796 atsH 
CONSERVED 
HYPOTHETICAL PROTEIN 67, 68   
Tat 
SP 
CF 2, MEM 8, 
MEM 9, CW 14     
Rv3802c   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
36, 290, 
291   
SP, 
TM 
CF 2, CF 3, MEM 
5, MEM 8, MEM 
9, MEM 10, CW 
14 
BlaTEM 
20 
Mouse 27, in 
vitro 28, in 
vitro 29 
Rv3804c 
fbpA, 
mpt44, 
85A 
SECRETED ANTIGEN 85-A 
FBPA (MYCOLYL 
TRANSFERASE 85A) 
(FIBRONECTIN-BINDING 
PROTEIN A) (ANTIGEN 85 
COMPLEX A) 
39, 76, 
127, 129, 
160, 288, 
330 Yes 
SP, 
Tat 
SP, 
TM 
CF 1, CF 2, CF 3, 
MEM 4, MEM 7, 
MEM 8, MEM 9, 
MEM 10, CW 12, 
CW 13, CW 14, 
WCL 15, SOL 16 PhoA 18 
Mouse 27, in 
vitro 29 
Rv3805c   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 417   TM MEM 9, CW 14   
Mouse 25, in 
vitro 28, in 
vitro 29 
Rv3811 csp 
CONSERVED 
HYPOTHETICAL PROTEIN 
15, 38, 
178           
Rv3821   
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
PROTEIN 62, 74   
Tat 
SP, 
TM       
Rv3822     
72, 74, 90, 
152, 185, 
249, 325, 
341, 358, 
362, 368 Yes   CW 14     
 257 
Rv3823c 
mmpL
8 
PROBABLE CONSERVED 
INTEGRAL MEMBRANE 
TRANSPORT PROTEIN 
MMPL8 89, 440   TM CW 12   
Mouse 27, in 
vitro 29 
Rv3831   HYPOTHETICAL PROTEIN 29, 67, 74 Yes TM       
Rv3835   
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
62, 72, 
133, 146, 
182, 202, 
226, 255, 
375, 425 Yes TM 
CF 2, CF 3, MEM 
6, MEM 7, MEM 
8, MEM 9, CW 
12, CW 14 
BlaTEM 
20   
Rv3851   
POSSIBLE MEMBRANE 
PROTEIN 48   
SP, 
TM MEM 8     
Rv3869 eccB1 
POSSIBLE CONSERVED 
MEMBRANE PROTEIN 
70, 88, 
130, 463, 
476 Yes TM 
CF 2, CF 3, MEM 
8, MEM 9, CW 
12, CW 14, WCL 
15, SOL 16 
BlaTEM 
20 Mouse 25 
Rv3877 eccD1 
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 223, 234   TM 
MEM 8, MEM 9, 
CW 12, CW 14   Mouse 25 
Rv3883c mycP1 
MEMBRANE-ANCHORED 
MYCOSIN MYCP1 (SERINE 
PROTEASE) (SUBTILISIN-
LIKE PROTEASE) 
(SUBTILASE-LIKE) 
(MYCOSIN-1) 
17, 79, 
188, 201, 
252, 256, 
392 Yes 
SP, 
TM 
CF 2, MEM 8, 
MEM 9, CW 14     
Rv3886c mycP2 
PROBABLE ALANINE AND 
PROLINE RICH 
MEMBRANE-ANCHORED 
MYCOSIN MYCP2 (SERINE 
PROTEASE) (SUBTILISIN-
LIKE PROTEASE) 
(SUBTILASE-LIKE) 
(MYCOSIN-2) 170, 510 Yes 
SP, 
TM 
CF 3, MEM 5, 
MEM 9, MEM 10, 
CW 13, CW 14     
Rv3887c eccD2 
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 172, 445   TM MEM 9, CW 14     
Rv3895c eccB2 
PROBABLE CONSERVED 
MEMBRANE PROTEIN 
65, 79, 98, 
103, 122 Yes TM 
MEM 8, MEM 9, 
CW 14     
Rv3901c   
POSSIBLE MEMBRANE 
PROTEIN 54, 67   
SP, 
TM   
BlaTEM 
20   
Rv3909   
CONSERVED 
HYPOTHETICAL PROTEIN 
76, 243, 
420 Yes SP, 
MEM 6, MEM 8, 
MEM 9, CW 14   in vitro 29 
Rv3910   
PROBABLE CONSERVED 
TRANSMEMBRANE 
PROTEIN 
70, 353, 
372, 430, 
1022, 
1033, 
1049 Yes 
Tat 
SP, 
TM 
CF 3, MEM 4, 
MEM 5, MEM 6, 
MEM 8, MEM 9, 
MEM 10, CW 13, 
CW 14, SOL 16 
BlaTEM 
20 
Mouse 25, in 
vitro 29 
Rv3912   
HYPOTHETICAL ALANINE 
RICH PROTEIN 177     MEM 9   
Macrophage 
24 
 
Table 6.1. EXIT Results: all exported proteins and all exported fusion sites. Proteins identified as 
exported in EXIT in the spleen (Chapter 2) are identified by their genome identification number, name, 
and function from the NCBI genome annotation (H37Rv RefSeq genome annotation released January 9 
2012). Column 4 identifies all statistically enriched fusion sites identified by EXIT as exported in the 
spleen by the amino acid position of fusion to the ‘BlaTEM reporter. Column 5 identifies whether a given 
protein was also identified as exported in the lungs. Column 6 identifies all in silico predicted export 
signals: signal peptide (SP, (Petersen et al., 2011)), twin-arginine translocation signal peptide (Tat SP, 
(McDonough et al., 2008)), lipoprotein signal peptide (Lipo, (Sutcliffe & Harrington, 2004)), or 
transmembrane domain (TM, (Krogh et al., 2001)). Column 7 identifies all previous in vitro MS based 
published methodologies which identified a given protein as exported, with the fractions in which the 
protein was identified: culture filtrate (CF), membrane (MEM), cell wall (CW), soluble (SOL), or whole 
cell lysate (WCL). Column 8 identifies all previous genetic reporter based experiments that identified a 
given protein as exported, with the genetic reporter identified. Column 9 identifies all studies where a 
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given gene was identified as transcriptionally induced during infection. Numbers given relate to the 
references and conditions as described below.  
Mass spectrometry based approaches to identify exported proteins in fractions: CF: 1 
(Rosenkrands et al., 2000), 2 (Malen et al., 2011), 3 (Bell et al., 2012). MEM: 4 (Gu et al., 2003), 5 
(Xiong et al., 2005), 6 (Mawuenyega et al., 2005), 7 (Malen et al., 2007), 8 (Malen et al., 2011), 9 
(Gunawardena et al., 2013), 10 (Bell et al., 2012). CW: 11 (Mawuenyega et al., 2005), 12 (Wolfe et al., 
2010), 13 (Bell et al., 2012). WCL: 15 (Bell et al., 2012). SOL: 16 (Bell et al., 2012). Genetic reporter 
based approaches to identify exported proteins: 17 (Gomez et al., 2000), 18 (Braunstein et al., 2000), 19 
(McDonough et al., 2008), 20 (McCann et al., 2011), 21 (Chapter 2). Genes identified as transcriptionally 
induced during infection: Macrophage: 30 (Dubnau et al., 2002), 31 (Schnappinger et al., 2003), 32 
(Rohde et al., 2007), 33 (BCG) (Rohde et al., 2007), Mouse: 34 (Dubnau et al., 2005), 35 (Talaat et al., 
2007), 36 (60 dpi) (Talaat et al., 2007), 37 (45 dpi) (Talaat et al., 2007), Human: 38 (granuloma) 
(Rachman et al., 2006), 39 (distant lung) (Rachman et al., 2006). 
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APPENDIX III: FUNCTIONAL GENOMICS DATABASE FOR MYCOBACTERIUM 
TUBERCULOSIS 
 In an effort to consolidate a vast wealth of data on proteins of M. tuberculosis we built a 
functional genomics database that could become a valuable resource to the M. tuberculosis 
community (https://www.med.unc.edu/microimm/braunsteinlab/research/exported-proteins). 
Data was compiled for each annotated protein coding gene in the M. tuberculosis genome (H37Rv RefSeq 
genome annotation released January 9 2012) from previous studies identifying exported proteins, in 
silico predicted export signals, essentiality predictions for growth in vitro and during infection, 
and expression data for genes transcriptionally induced during infection.  
 To aid in predicting the subcellular localization of each protein, data was compiled for 
previous in vitro studies using MS or GR based approaches to identify a given protein as 
exported, with the fractions in which the protein was identified: culture filtrate (CF), membrane 
(MEM), cell wall (CW), soluble (SOL), or whole cell lysate (WCL) (Rosenkrands et al., 2000; 
Malen et al., 2011; Bell et al., 2012; Gu et al., 2003; Xiong et al., 2005; Mawuenyega et al., 
2005; Gunawardena et al., 2013; Wolfe et al., 2010; Gomez et al., 2000; Braunstein et al., 2000; 
McDonough et al., 2008; McCann et al., 2011; Chapter 2). We supplemented this previously 
published data with data generated by submitting the M. tuberculosis proteome to in silico 
prediction programs for export. In silico predicted export signals were identified using online 
prediction programs: signal peptide (Petersen et al., 2011), twin-arginine translocation signal 
peptide (McDonough et al., 2008), lipoprotein signal peptide (Sutcliffe & Harrington, 2004), or 
transmembrane domain (Krogh et al., 2001).  
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 To aid in identification of predicted virulence factors results from the multiple high-
throughput screens to identify genes essential for in vitro growth or virulence in various models 
of tuberculosis have been included (Dutta et al., 2010; Rengarajan et al., 2005; Stewart et al., 
2005; Sassetti & Rubin, 2003; Lamichhane et al., 2005; Zhang et al., 2013; Sassetti et al., 2003). 
Additionally, results from high-throughput screens to identify genes transcriptionally induced 
during infection were included (Dubnau et al., 2002; Schnappinger et al., 2003; Rohde et al., 
2007; Dubnau et al., 2005; Talaat et al., 2007; Talaat et al., 2007; Rachman et al., 2006). 
Because of its usefulness in predicting a function for Rv0199/OmasA (Chapter 3), we 
analyzed the entire M. tuberculosis proteome in Phyre 2.0 (Kelley & Sternberg, 2009) to 
generate additional functional predictions, and included these hypothetical function predictions 
alongside annotated functional information from the H37Rv RefSeq genome (released January 9 
2012). In this way, we built a database of information for each protein coding gene that can be 
mined to identify and predict the function of exported proteins and shed light on M. tuberculosis 
pathogenesis. This database can be found at 
https://www.med.unc.edu/microimm/braunsteinlab/research/exported-proteins.  
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